<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

<meta charset="utf-8">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="generator" content="pandoc" />



<title>Covid-19 trials</title>

<meta property="og:title" content="Covid-19 trials" />

<meta name='viewport' content='width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no' />

<link rel="icon" href="data:image/x-icon;" type="image/x-icon">


<script type="text/javascript">
window.FlexDashboardComponents = [];
</script>

<script src="site_libs/header-attrs-2.1/header-attrs.js"></script>
<script src="site_libs/jquery-1.12.4/jquery.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<script src="site_libs/stickytableheaders-0.1.19/jquery.stickytableheaders.min.js"></script>
<script src="site_libs/htmlwidgets-1.5.1/htmlwidgets.js"></script>
<link href="site_libs/datatables-css-0.0.0/datatables-crosstalk.css" rel="stylesheet" />
<script src="site_libs/datatables-binding-0.13/datatables.js"></script>
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.min.css" rel="stylesheet" />
<link href="site_libs/dt-core-1.10.20/css/jquery.dataTables.extra.css" rel="stylesheet" />
<script src="site_libs/dt-core-1.10.20/js/jquery.dataTables.min.js"></script>
<link href="site_libs/crosstalk-1.0.0/css/crosstalk.css" rel="stylesheet" />
<script src="site_libs/crosstalk-1.0.0/js/crosstalk.min.js"></script>
<script src="site_libs/jszip-1.10.20/jszip.min.js"></script>
<link href="site_libs/dt-ext-buttons-1.10.20/css/buttons.dataTables.min.css" rel="stylesheet" />
<script src="site_libs/dt-ext-buttons-1.10.20/js/dataTables.buttons.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.flash.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.html5.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.colVis.min.js"></script>
<script src="site_libs/dt-ext-buttons-1.10.20/js/buttons.print.min.js"></script>
<style type="text/css">

/*
 Dashboard CSS from Keen IO Dashboards
 (https://github.com/keen/dashboards)
*/

body {
  background: #f2f2f2;
  padding: 60px 0 0 8px; /* padding-top overridden by theme */
}

body hr {
  border-color: #d7d7d7;
  margin: 10px 0;
}

.navbar-inverse .navbar-nav > li > a,
.navbar .navbar-brand {
  text-decoration: none;
}

.navbar-logo {
  margin-top: 1px;
}

.navbar-logo img {
  margin-right: 12px;
}

.navbar-author {
  margin-left: 10px;
  font-size: 15px;
}

.navbar .dropdown-menu .fa {
  min-width: 20px;
}

.navbar .dropdown-menu {
  min-width: 150px;
  max-height: 500px;
  overflow: auto;
}

.chart-wrapper,
.nav-tabs-custom,
.sbframe-commentary
{
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  margin-bottom: 8px;
  margin-right: 8px;
}

.chart-title {
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  padding: 7px 10px 4px;
}

.chart-wrapper .chart-title:empty {
  display: none;
}

.chart-wrapper .chart-stage {
  overflow: hidden;
  padding: 5px 10px;
  position: relative;
}

.chart-wrapper .chart-notes {
  background: #fbfbfb;
  border-top: 1px solid #e2e2e2;
  color: #808080;
  font-size: 12px;
  padding: 8px 10px 5px;
}

/*
 CSS for handling flexbox layout
*/

#dashboard-container {
  visibility: hidden;
}

.tab-content>.dashboard-page-wrapper.active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.dashboard-page-wrapper {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.dashboard-row {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-row-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
}

.dashboard-column-orientation {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: horizontal;
  -webkit-box-direction: normal;
  -webkit-flex-direction: row;
      -ms-flex-direction: row;
          flex-direction: row;
}

.dashboard-column {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-wrapper-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
  -webkit-box-orient: vertical;
  -webkit-box-direction: normal;
  -webkit-flex-direction: column;
      -ms-flex-direction: column;
          flex-direction: column;
}

.chart-stage-flex {
  -webkit-box-flex: 1;
  -webkit-flex: 1;
      -ms-flex: 1;
          flex: 1;
  position: relative;
}

.chart-shim {
  position: absolute;
  left: 8px; top: 8px; right: 8px; bottom: 8px;
}

.no-padding .chart-shim {
  left: 0; top: 0; right: 0; bottom: 0;
}

.flowing-content-shim {
  overflow: auto;
  left: 0; top: 0; right: 0; bottom: 0;
  padding-left: 8px;
  padding-right: 8px;
}

.flowing-content-container {
  padding-top: 8px;
  padding-bottom: 8px;
}

.chart-stage .table-bordered {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > th,
.chart-stage .table-bordered > tfoot > tr > th,
.chart-stage .table-bordered > tbody > tr > td,
.chart-stage .table-bordered > tfoot > tr > td {
  border: none;
}

.chart-stage .table-bordered > tbody > tr > td {
  border-top: 1px solid #dddddd;
}

.chart-stage .table-bordered > thead > tr > th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.bootstrap-table table>thead {
  background-color: #fff;
}

.bootstrap-table table.data,
.bootstrap-table table.shiny-table {
  width: inherit !important;
}

.bootstrap-table table.data>tbody>tr>th,
.bootstrap-table table.shiny-table>tbody>tr>th {
  border-top: none;
  border-bottom: 2px solid #dddddd;
  padding: 5px;
}

.bootstrap-table .data td[align=right] {
  font-family: inherit;
}

.chart-wrapper form {
  padding-left: 5px;
  padding-right: 5px;
}

.shiny-input-container label {
  font-weight: normal;
}

.chart-stage .html-widget {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .html-widget-static-bound {
  width: 100% !important;
  height: 100% !important;
}

.chart-stage .shiny-bound-output {
  width: 100% !important;
  height: 100% !important;
}

/* Omit display of empty paragraphs */

.chart-shim>p:empty {
  display: none;
}

.chart-stage>p:empty {
  display: none;
}

/* Omit display of special knitr options div*/

.chart-stage .knitr-options {
  display: none;
}

/* Automatically resizing images */

.image-container {
  position: absolute;
  top: 0;
  left: 0;
  right: 0;
  bottom: 0;
  margin: 0;
}

.image-container img {
  opacity: 0;
  overflow: hidden;
}

/* Value box */

.value-box {
  border-radius: 2px;
  position: relative;
  display: block;
  margin-right: 8px;
  margin-bottom: 8px;
  box-shadow: 0 1px 1px rgba(0, 0, 0, 0.1);
}

.value-box > .inner {
  padding: 10px;
  padding-left: 20px;
  padding-right: 20px;
}

.value-box .value {
  font-size: 38px;
  font-weight: bold;
  margin: 0 0 3px 0;
  white-space: nowrap;
  padding: 0;
}

.value-box .caption {
  font-size: 15px;
}
.value-box .caption > small {
  display: block;
  font-size: 13px;
  margin-top: 5px;
}

.value-box .icon i {
  position: absolute;
  top: 15px;
  right: 15px;
  font-size: 80px;
  color: rgba(0, 0, 0, 0.15);
}

.linked-value:hover {
  cursor: pointer;
}

.value-box.linked-value:hover {
  box-shadow: 0 2px 2px rgba(0, 0, 0, 0.3);
}

/* STORYBOARD */

.storyboard-nav button {
  background: transparent;
  border: 0;
  opacity: .3;
  outline: none;
  padding: 0;
}

.storyboard-nav button:hover,
.storyboard-nav button:hover {
  opacity: .5;
}

.storyboard-nav button:disabled,
.storyboard-nav button:disabled {
  opacity: .1;
}

.storyboard-nav .sbnext,
.storyboard-nav .sbprev {
  float: left;
  width: 2%;
  height: 120px;
  font-size: 50px;
}

.storyboard-nav .sbprev {
  text-align: left;
  width: 2%;
}

.storyboard-nav .sbnext {
  float: right;
  text-align: right;
  margin-right: 8px;
}

.storyboard-nav .sbframelist {
  margin: 0 auto;
  width: 94%;
  height: 120px;
  overflow: hidden;
  text-shadow: none;
  margin-bottom: 8px;
}

.storyboard-nav .sbframelist ul {
  list-style: none;
  margin: 0;
  padding: 0;
  height: 100%;
}

.storyboard-nav .sbframelist ul li {
  float: left;
  width: 270px;
  height: 100%;
  padding: 10px 10px 10px 10px;
  margin-right: 8px;
  background: #fff;
  border: 1px solid #e2e2e2;
  border-radius: 3px;
  color: #3a3c47;
  text-align: left;
  font-size: 14px;
  cursor: pointer;
}

.storyboard-nav .sbframelist ul li:last-child {
  margin-right: 0px;
}

.storyboard-nav .sbframelist ul li.active {
  color: #fff;
  background: #B8B8B8;
}

.sbframe-commentary {
  width: 300px;
  background: #fbfbfb;
  font-size: 14px;
}

.sbframe-commentary ul {
  padding-left: 22px;
}

.sbframe.active {
  display: flex;
}

.sbframe:not(.active) {
  display: none;
}

/* NAV TABS */

.nav-tabs-custom > .nav-tabs {
  margin: 0;
  border-bottom: 1px solid #d7d7d7;
  color: #666;
  font-size: 14px;
  font-weight: 300;
  border-top-right-radius: 3px;
  border-top-left-radius: 3px;
}
.nav-tabs-custom > .nav-tabs > li {
  border-top: 3px solid transparent;
  margin-bottom: -1px;
  margin-right: 5px;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  color: #666;
  font-weight: 300;
  font-size: 14px;
  border-radius: 0;
  padding: 3px 10px 5px;
  text-transform: none;
}

.nav-tabs-custom > .nav-tabs > li:not(.active) > a {
  border-bottom-color: transparent;
}

.nav-tabs-custom > .nav-tabs > li > a.text-muted {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:hover {
  background: transparent;
  margin: 0;
}
.nav-tabs-custom > .nav-tabs > li > a:hover {
  color: #999;
}
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:hover,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:focus,
.nav-tabs-custom > .nav-tabs > li:not(.active) > a:active {
  border-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: #3c8dbc;
}
.nav-tabs-custom > .nav-tabs > li.active > a,
.nav-tabs-custom > .nav-tabs > li.active:hover > a {
  background-color: #fff;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.active > a {
  border-top-color: transparent;
  border-left-color: #d7d7d7;
  border-right-color: #d7d7d7;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type {
  margin-left: 0;
}
.nav-tabs-custom > .nav-tabs > li:first-of-type.active > a {
  border-left-color: transparent;
}
.nav-tabs-custom > .nav-tabs.pull-right {
  float: none !important;
}
.nav-tabs-custom > .nav-tabs.pull-right > li {
  float: right;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type {
  margin-right: 0;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type > a {
  border-left-width: 1px;
}
.nav-tabs-custom > .nav-tabs.pull-right > li:first-of-type.active > a {
  border-left-color: #d7d7d7;
  border-right-color: transparent;
}
.nav-tabs-custom > .nav-tabs > li.header {
  line-height: 35px;
  padding: 0 10px;
  font-size: 20px;
  color: #666;
}
.nav-tabs-custom > .nav-tabs > li.header > .fa,
.nav-tabs-custom > .nav-tabs > li.header > .glyphicon,
.nav-tabs-custom > .nav-tabs > li.header > .ion {
  margin-right: 5px;
}
.nav-tabs-custom > .tab-content {
  background: #fff;
  padding: 0;
  border-bottom-right-radius: 3px;
  border-bottom-left-radius: 3px;
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom > .tab-content > .chart-wrapper {
  background: #fff;
  border: none;
  margin: 0;
}


.nav-tabs-custom > .tab-content > .active {
  display: -webkit-box;
  display: -webkit-flex;
  display: -ms-flexbox;
  display: flex;
}

.nav-tabs-custom .dropdown.open > a:active,
.nav-tabs-custom .dropdown.open > a:focus {
  background: transparent;
  color: #999;
}


@media (max-width: 767px) {
  .value-box {
    text-align: center;
    margin-right: 8px;
  }
  .value-box .icon {
    display: none;
  }
}

/* Fixed position sidebar */

.section.sidebar {
  position: fixed;
  top: 51px; /* overridden by theme */
  left: 0;
  bottom: 0;
  border-right: 1px solid #e2e2e2;
  background-color: white; /* overridden by theme */
  padding-left: 10px;
  padding-right: 10px;
  visibility: hidden;
  overflow: auto;
}

.section.sidebar form p:first-child {
  margin-top: 10px;
}

/* Embedded source code */

#flexdashboard-source-code {
  display: none;
}

.featherlight-content #flexdashboard-source-code {
  display: inline-block;
}

.featherlight-content {
  width: 80%;
  max-width: 800px;
  padding: 0 !important;
  border-bottom: none !important;
}

.featherlight:last-of-type {
  background: rgba(0, 0, 0, 0.7);
}

.featherlight-inner {
  width: 100%;
}

.featherlight-content pre {
  margin: 0;
  border: 0;
  background: #fff;
  font-size: 12px;
}

.unselectable {
  -ms-user-select: none;
  -webkit-user-select: none;
  -khtml-user-select: none;
  -moz-user-select: -moz-none;
  -o-user-select: none;
  user-select: none;
}

#flexdashboard-source-code code {
  -ms-user-select: text;
  -webkit-user-select: text;
  -khtml-user-select: text;
  -moz-user-select: text;
  -o-user-select: text;
  user-select: text;
}

/* DataTables Tweaks */

.dataTables_filter input[type="search"] {
  -webkit-appearance: searchfield;
  outline: none;
}

.dataTables_wrapper.no-footer
.dataTables_info {
  padding-top: 0;
}


table.dataTable thead th {
  border-bottom: 1px solid #d7d7d7;
}

.dataTables_wrapper.no-footer .dataTables_scrollBody {
  border-bottom: 1px solid #d7d7d7;
}

/* Mobile phone only CSS */

.desktop-layout div.section.mobile {
  display: none;
}

.mobile-layout div.section.no-mobile {
  display: none;
}

.mobile-figure {
  display: none;
}



body {
  padding-top: 60px;
}

.section.sidebar {
  top: 51px;
  background-color: rgba(39, 128, 227, 0.1);
}

.value-box {
  color: #f9f9f9;
}

.bg-primary {
  background-color: rgba(39, 128, 227, 0.7);
}

.storyboard-nav .sbframelist ul li.active {
  background-color: rgba(39, 128, 227, 0.7);
}

.nav-tabs-custom > .nav-tabs > li.active {
  border-top-color: rgba(39, 128, 227, 0.7);
}

.bg-info {
  background-color: rgba(153, 84, 187, 0.7);
}

.bg-warning {
  background-color: rgba(255, 117, 24, 0.7);
}

.bg-danger {
  background-color: rgba(255, 0, 57, 0.7);
}

.bg-success {
  background-color: rgba(63, 182, 24, 0.7);
}

.chart-title {
  font-weight: 500;
}

.nav-tabs-custom > .nav-tabs > li > a,
.nav-tabs-custom > .nav-tabs > li > a:active {
  font-weight: 500;
}

@media only screen and (min-width: 768px) {
html, body {
  height: 100%;
}

#dashboard-container {
  height: 100%;
}
}
</style>



</head>

<body>

<div class="navbar navbar-inverse navbar-fixed-top" role="navigation">
<div class="container-fluid">
<div class="navbar-header">

<button id="navbar-button" type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>

<span class="navbar-logo pull-left">
  
</span>
<span class="navbar-brand">
  Covid-19 trials
  <span class="navbar-author">
        </span>
</span>

</div>
<div id="navbar" class="navbar-collapse collapse">
<ul class="nav navbar-nav navbar-left">
</ul>
<ul class="nav navbar-nav navbar-right">
</ul>
</div><!--/.nav-collapse-->
</div><!--/.container-->
</div><!--/.navbar-->

<script type="text/javascript">


var FlexDashboard = (function () {

  // initialize options
  var _options = {};

  var FlexDashboard = function() {

    // default options
    _options = $.extend(_options, {
      theme: "cosmo",
      fillPage: false,
      orientation: 'columns',
      storyboard: false,
      defaultFigWidth: 576,
      defaultFigHeight: 461,
      defaultFigWidthMobile: 360,
      defaultFigHeightMobile: 461,
      isMobile: false,
      isPortrait: false
    });
  };

  function init(options) {

    // extend default options
    $.extend(true, _options, options);

    // add ids to sections that don't have them (pandoc won't assign ids
    // to e.g. sections with titles consisting of only chinese characters)
    var nextId = 1;
    $('.level1:not([id]),.level2:not([id]),.level3:not([id])').each(function() {
      $(this).attr('id', 'dashboard-' + nextId++);
    });

    // find navbar items
    var navbarItems = $('#flexdashboard-navbar');
    if (navbarItems.length)
      navbarItems = JSON.parse(navbarItems.html());
    addNavbarItems(navbarItems);

    // find the main dashboard container
    var dashboardContainer = $('#dashboard-container');

    // resolve mobile classes
    resolveMobileClasses(dashboardContainer);

    // one time global initialization for components
    componentsInit(dashboardContainer);

    // look for a global sidebar
    var globalSidebar = dashboardContainer.find(".section.level1.sidebar");
    if (globalSidebar.length > 0) {

      // global layout for fullscreen displays
      if (!isMobilePhone()) {

         // hoist it up to the top level
         globalSidebar.insertBefore(dashboardContainer);

         // lay it out (set width/positions)
         layoutSidebar(globalSidebar, dashboardContainer);

      // tuck sidebar into first page for mobile phones
      } else {

        // convert it into a level3 section
        globalSidebar.removeClass('sidebar');
        globalSidebar.removeClass('level1');
        globalSidebar.addClass('level3');
        var h1 = globalSidebar.children('h1');
        var h3 = $('<h3></h3>');
        h3.html(h1.html());
        h3.insertBefore(h1);
        h1.remove();

        // move it into the first page
        var page = dashboardContainer.find('.section.level1').first();
        if (page.length > 0)
          page.prepend(globalSidebar);
      }
    }

    // look for pages to layout
    var pages = $('div.section.level1');
    if (pages.length > 0) {

        // find the navbar and collapse on clicked
        var navbar = $('#navbar');
        navbar.on("click", "a[data-toggle!=dropdown]", null, function () {
           navbar.collapse('hide');
        });

        // envelop the dashboard container in a tab content div
        dashboardContainer.wrapInner('<div class="tab-content"></div>');

        pages.each(function(index) {

          // lay it out
          layoutDashboardPage($(this));

          // add it to the navbar
          addToNavbar($(this), index === 0);

        });

    } else {

      // remove the navbar and navbar button if we don't
      // have any navbuttons
      if (navbarItems.length === 0) {
        $('#navbar').remove();
        $('#navbar-button').remove();
      }

      // add the storyboard class if requested
      if (_options.storyboard)
        dashboardContainer.addClass('storyboard');

      // layout the entire page
      layoutDashboardPage(dashboardContainer);
    }

    // if we are in shiny we need to trigger a window resize event to
    // force correct layout of shiny-bound-output elements
    if (isShinyDoc())
      $(window).trigger('resize');

    // make main components visible
    $('.section.sidebar').css('visibility', 'visible');
    dashboardContainer.css('visibility', 'visible');

    // handle location hash
    handleLocationHash();

    // intialize prism highlighting
    initPrismHighlighting();

    // record mobile and orientation state then register a handler
    // to refresh if it changes
    _options.isMobile = isMobilePhone();
    _options.isPortrait = isPortrait();
    $(window).on('resize', function() {
      if (_options.isMobile !== isMobilePhone() ||
          _options.isPortrait !== isPortrait()) {
        window.location.reload();
      }
    });

    // trigger layoutcomplete event
    dashboardContainer.trigger('flexdashboard:layoutcomplete');
  }

  function resolveMobileClasses(dashboardContainer) {
     // add top level layout class
    dashboardContainer.addClass(isMobilePhone() ? 'mobile-layout' :
                                                  'desktop-layout');

    // look for .mobile sections and add .no-mobile to their peers
    var mobileSections = $('.section.mobile');
    mobileSections.each(function() {
       var id = $(this).attr('id');
       var nomobileId = id.replace(/-\d+$/, '');
       $('#' + nomobileId).addClass('no-mobile');
    });
  }

  function addNavbarItems(navbarItems) {

    var navbarLeft = $('ul.navbar-left');
    var navbarRight = $('ul.navbar-right');

    for (var i = 0; i<navbarItems.length; i++) {

      // get the item
      var item = navbarItems[i];

      // determine the container
      var container = null;
      if (item.align === "left")
        container = navbarLeft;
      else
        container = navbarRight;

      // navbar menu if we have multiple items
      if (item.items) {
        var menu = navbarMenu(null, item.icon, item.title, container);
        for (var j = 0; j<item.items.length; j++) {
          var subItem = item.items[j];
          var li = $('<li></li>');
          li.append(navbarLink(subItem.icon, subItem.title, subItem.href, subItem.target));
          menu.append(li);
        }
      } else {
        var li = $('<li></li>');
        li.append(navbarLink(item.icon, item.title, item.href, item.target));
        container.append(li);
      }
    }
  }

  // create or get a reference to an existing dropdown menu
  function navbarMenu(id, icon, title, container) {
    var existingMenu = [];
    if (id)
      existingMenu = container.children('#' + id);
    if (existingMenu.length > 0) {
      return existingMenu.children('ul');
    } else {
      var li = $('<li></li>');
      if (id)
        li.attr('id', id);
      li.addClass('dropdown');
      // auto add "Share" title on mobile if necessary
      if (!title && icon && (icon === "fa-share-alt") && isMobilePhone())
        title = "Share";
      if (title) {
        title = title + ' <span class="caret"></span>';
      }
      var a = navbarLink(icon, title, "#");
      a.addClass('dropdown-toggle');
      a.attr('data-toggle', 'dropdown');
      a.attr('role', 'button');
      a.attr('aria-expanded', 'false');
      li.append(a);
      var ul = $('<ul class="dropdown-menu"></ul>');
      ul.attr('role', 'menu');
      li.append(ul);
      container.append(li);
      return ul;
    }
  }

  function addToNavbar(page, active) {

    // capture the id and data-icon attribute (if any)
    var id = page.attr('id');
    var icon = page.attr('data-icon');
    var navmenu = page.attr('data-navmenu');

    // get hidden state (transfer this to navbar)
    var hidden = page.hasClass('hidden');
    page.removeClass('hidden');

    // sanitize the id for use with bootstrap tabs
    id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
    page.attr('id', id);

    // get the wrapper
    var wrapper = page.closest('.dashboard-page-wrapper');

    // move the id to the wrapper
    page.removeAttr('id');
    wrapper.attr('id', id);

    // add the tab-pane class to the wrapper
    wrapper.addClass('tab-pane');
    if (active)
      wrapper.addClass('active');

    // get a reference to the h1, discover it's id and title, then remove it
    var h1 = wrapper.find('h1').first();
    var title = h1.html();
    h1.remove();

    // create a navbar item
    var li = $('<li></li>');
    var a = navbarLink(icon, title, '#' + id);
    a.attr('data-toggle', 'tab');
    li.append(a);

    // add it to the navbar (or navbar menu if specified)
    var container = $('ul.navbar-left');
    if (navmenu) {
      var menuId = navmenu.replace(/\s+/g, '');
      var menu = navbarMenu(menuId, null, navmenu, container);
      menu.append(li);
    } else {
      container.append(li);
    }

    // hide it if requested
    if (hidden)
      li.addClass('hidden');
  }

  function navbarLink(icon, title, href, target) {

    var a = $('<a></a>');
    if (icon) {

      // get the name of the icon set and icon
      var dashPos = icon.indexOf("-");
      var iconSet = icon.substring(0, dashPos);
      var iconName = icon.substring(dashPos + 1);

      // create the icon
      var iconElement = $('<span class="' + iconSet + ' ' + icon + '"></span>');
      if (title)
        iconElement.css('margin-right', '7px');
      a.append(iconElement);
      // if href is null see if we can auto-generate based on icon (e.g. social)
      if (!href)
        maybeGenerateLinkFromIcon(iconName, a);
    }
    if (title)
      a.append(title);

    // add the href.
    if (href) {
      if (href === "source_embed") {
        a.attr('href', '#');
        a.attr('data-featherlight', "#flexdashboard-source-code");
        a.featherlight({
            beforeOpen: function(event){
              $('body').addClass('unselectable');
            },
            afterClose: function(event){
              $('body').removeClass('unselectable');
            }
        });
      } else {
        a.attr('href', href);
      }
    }

    // add the arget
    if (target)
      a.attr('target', target);

    return a;
  }

  // auto generate a link from an icon name (e.g. twitter) when possible
  function maybeGenerateLinkFromIcon(iconName, a) {

     var serviceLinks = {
      "twitter": "https://twitter.com/share?text=" + encodeURIComponent(document.title) + "&url="+encodeURIComponent(location.href),
      "facebook": "https://www.facebook.com/sharer/sharer.php?s=100&p[url]="+encodeURIComponent(location.href),
      "google-plus": "https://plus.google.com/share?url="+encodeURIComponent(location.href),
      "linkedin": "https://www.linkedin.com/shareArticle?mini=true&url="+encodeURIComponent(location.href) + "&title=" + encodeURIComponent(document.title),
      "pinterest": "https://pinterest.com/pin/create/link/?url="+encodeURIComponent(location.href) + "&description=" + encodeURIComponent(document.title)
    };

    var makeSocialLink = function(a, href) {
      a.attr('href', '#');
      a.on('click', function(e) {
        e.preventDefault();
        window.open(href);
      });
    };

    $.each(serviceLinks, function(key, value) {
      if (iconName.indexOf(key) !== -1)
        makeSocialLink(a, value);
    });
  }

  // layout a dashboard page
  function layoutDashboardPage(page) {

    // use a page wrapper so that free form content above the
    // dashboard appears at the top rather than the side (as it
    // would without the wrapper in a column orientation)
    var wrapper = $('<div class="dashboard-page-wrapper"></div>');
    page.wrap(wrapper);

    // if there are no level2 or level3 headers synthesize a level3
    // header to contain the (e.g. frame it, scroll container, etc.)
    var headers = page.find('h2,h3');
    if (headers.length === 0)
      page.wrapInner('<div class="section level3"></div>');

    // hoist up any content before level 2 or level 3 headers
    var children = page.children();
    children.each(function(index) {
      if ($(this).hasClass('level2') || $(this).hasClass('level3'))
        return false;
      $(this).insertBefore(page);
    });

    // determine orientation and fillPage behavior for distinct media
    var orientation, fillPage, storyboard;

    // media: mobile phone
    if (isMobilePhone()) {

      // if there is a sidebar we need to ensure it's content
      // is properly framed as an h3
      var sidebar = page.find('.section.sidebar');
      sidebar.removeClass('sidebar');
      sidebar.wrapInner('<div class="section level3"></div>');
      var h2 = sidebar.find('h2');
      var h3 = $('<h3></h3>');
      h3.html(h2.html());
      h3.insertBefore(h2);
      h2.remove();

      // wipeout h2 elements then enclose them in a single h2
      var level2 = page.find('div.section.level2');
      level2.each(function() {
        level2.children('h2').remove();
        level2.children().unwrap();
      });
      page.wrapInner('<div class="section level2"></div>');

      // substitute mobile images
      if (isPortrait()) {
        var mobileFigures = $('img.mobile-figure');
        mobileFigures.each(function() {
          // get the src (might be base64 encoded)
          var src = $(this).attr('src');

          // find it's peer
          var id = $(this).attr('data-mobile-figure-id');
          var img = $('img[data-figure-id=' + id + "]");
          img.attr('src', src)
             .attr('width', _options.defaultFigWidthMobile)
             .attr('height', _options.defaultFigHeightMobile);
        });
      }

      // hoist storyboard commentary into it's own section
      if (page.hasClass('storyboard')) {
        var commentaryHR = page.find('div.section.level3 hr');
        commentaryHR.each(function() {
          var commentary = $(this).nextAll().detach();
          var commentarySection = $('<div class="section level3"></div>');
          commentarySection.append(commentary);
          commentarySection.insertAfter($(this).closest('div.section.level3'));
          $(this).remove();
        });
      }

      // force a non full screen layout by columns
      orientation = _options.orientation = 'columns';
      fillPage = _options.fillPage = false;
      storyboard = _options.storyboard = false;

    // media: desktop
    } else {

      // determine orientation
      orientation = page.attr('data-orientation');
      if (orientation !== 'rows' && orientation != 'columns')
        orientation = _options.orientation;

      // determine storyboard mode
      storyboard = page.hasClass('storyboard');

      // fillPage based on options (force for storyboard)
      fillPage = _options.fillPage || storyboard;

      // handle sidebar
      var sidebar = page.find('.section.level2.sidebar');
      if (sidebar.length > 0)
        layoutSidebar(sidebar, page);
    }

    // give it and it's parent divs height: 100% if we are in fillPage mode
    if (fillPage) {
      page.addClass('vertical-layout-fill');
      page.css('height', '100%');
      page.parents('div').css('height', '100%');
    } else {
      page.addClass('vertical-layout-scroll');
    }

    // perform the layout
    if (storyboard)
      layoutPageAsStoryboard(page);
    else if (orientation === 'rows')
      layoutPageByRows(page, fillPage);
    else if (orientation === 'columns')
      layoutPageByColumns(page, fillPage);
  }

  function layoutSidebar(sidebar, content) {

    // get it out of the header hierarchy
    sidebar = sidebar.first();
    if (sidebar.hasClass('level1')) {
      sidebar.removeClass('level1');
      sidebar.children('h1').remove();
    } else if (sidebar.hasClass('level2')) {
      sidebar.removeClass('level2');
      sidebar.children('h2').remove();
    }

    // determine width
    var sidebarWidth = isTablet() ? 220 : 250;
    var dataWidth = parseInt(sidebar.attr('data-width'));
    if (dataWidth)
      sidebarWidth = dataWidth;

    // set the width and shift the page right to accomodate the sidebar
    sidebar.css('width', sidebarWidth + 'px');
    content.css('padding-left', sidebarWidth + 'px');

    // wrap it's contents in a form
    sidebar.wrapInner($('<form></form>'));
  }

  function layoutPageAsStoryboard(page) {

    // create storyboard navigation
    var nav = $('<div class="storyboard-nav"></div>');

    // add navigation buttons
    var prev = $('<button class="sbprev"><i class="fa fa-angle-left"></i></button>');
    nav.append(prev);
    var next= $('<button class="sbnext"><i class="fa fa-angle-right"></i></button>');
    nav.append(next);

    // add navigation frame
    var frameList = $('<div class="sbframelist"></div>');
    nav.append(frameList);
    var ul = $('<ul></ul>');
    frameList.append(ul);

     // find all the level3 sections (those are the storyboard frames)
    var frames = page.find('div.section.level3');
    frames.each(function() {

      // mark it
      $(this).addClass('sbframe');

      // divide it into chart content and (optional) commentary
      $(this).addClass('dashboard-column-orientation');

      // stuff the chart into it's own div w/ flex
      $(this).wrapInner('<div class="sbframe-component"></div>');
      setFlex($(this), 1);
      var frame = $(this).children('.sbframe-component');

      // extract the title from the h3
      var li = $('<li></li>');
      var h3 = frame.children('h3');
      li.html(h3.html());
      h3.remove();
      ul.append(li);

      // extract commentary
      var hr = frame.children('hr');
      if (hr.length) {
        var commentary = hr.nextAll().detach();
        hr.remove();
        var commentaryFrame = $('<div class="sbframe-commentary"></div>');
        commentaryFrame.addClass('flowing-content-shim');
        commentaryFrame.addClass('flowing-content-container');
        commentaryFrame.append(commentary);
        $(this).append(commentaryFrame);

        // look for a data-commentary-width attribute
        var commentaryWidth = $(this).attr('data-commentary-width');
        if (commentaryWidth)
          commentaryFrame.css('width', commentaryWidth + 'px');
      }

      // layout the chart (force flex)
      var result = layoutChart(frame, true);

      // ice the notes if there are none
      if (!result.notes)
        frame.find('.chart-notes').remove();

      // set flex on chart
      setFlex(frame, 1);
    });

    // create a div to hold all the frames
    var frameContent = $('<div class="sbframe-content"></div>');
    frameContent.addClass('dashboard-row-orientation');
    frameContent.append(frames.detach());

    // row orientation to stack nav and frame content
    page.addClass('dashboard-row-orientation');
    page.append(nav);
    page.append(frameContent);
    setFlex(frameContent, 1);

    // initialize sly
    var sly = new Sly(frameList, {
    		horizontal: true,
    		itemNav: 'basic',
    		smart: true,
    		activateOn: 'click',
    		startAt: 0,
    		scrollBy: 1,
    		activatePageOn: 'click',
    		speed: 200,
    		moveBy: 600,
    		dragHandle: true,
    		dynamicHandle: true,
    		clickBar: true,
    		keyboardNavBy: 'items',
    		next: next,
    		prev: prev
    	}).init();

    // make first frame active
    frames.removeClass('active');
    frames.first().addClass('active');

    // subscribe to frame changed events
    sly.on('active', function (eventName, itemIndex) {
      frames.removeClass('active');
      frames.eq(itemIndex).addClass('active')
                          .trigger('shown');
    });
  }

  function layoutPageByRows(page, fillPage) {

    // row orientation
    page.addClass('dashboard-row-orientation');

    // find all the level2 sections (those are the rows)
    var rows = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (rows.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      rows = page.find('div.section.level2');
    }

    rows.each(function () {

      // flags
      var haveNotes = false;
      var haveFlexHeight = true;

      // remove the h2
      $(this).children('h2').remove();

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // give it row layout semantics if it's not a tabset
      if (!isTabset)
        $(this).addClass('dashboard-row');

      // find all of the level 3 subheads
      var columns = $(this).find('div.section.level3');

      // determine figureSizes sizes
      var figureSizes = chartFigureSizes(columns);

      // fixup the columns
      columns.each(function(index) {

        // layout the chart (force flex if we are in a tabset)
        var result = layoutChart($(this), isTabset);

        // update flexHeight state
        if (!result.flex)
          haveFlexHeight = false;

        // update state
        if (result.notes)
          haveNotes = true;

        // set the column flex based on the figure width
        // (value boxes will just get the default figure width)
        var chartWidth = figureSizes[index].width;
        setFlex($(this), chartWidth + ' ' + chartWidth + ' 0px');

      });

      // remove empty chart note divs
      if (isTabset)
        $(this).find('.chart-notes').filter(function() {
            return $(this).html() === "&nbsp;";
        }).remove();
      if (!haveNotes)
        $(this).find('.chart-notes').remove();

       // make it a flexbox row
      if (haveFlexHeight)
        $(this).addClass('dashboard-row-flex');

      // now we can set the height on all the wrappers (based on maximum
      // figure height + room for title and notes, or data-height on the
      // container if specified). However, don't do this if there is
      // no flex on any of the constituent columns
      var flexHeight = null;
      var dataHeight = parseInt($(this).attr('data-height'));
      if (dataHeight)
        flexHeight = adjustedHeight(dataHeight, columns.first());
      else if (haveFlexHeight)
        flexHeight = maxChartHeight(figureSizes, columns);
      if (flexHeight) {
        if (fillPage)
          setFlex($(this), flexHeight + ' ' + flexHeight + ' 0px');
        else {
          $(this).css('height', flexHeight + 'px');
          setFlex($(this), '0 0 ' + flexHeight + 'px');
        }
      }

    });
  }

  function layoutPageByColumns(page, fillPage) {

    // column orientation
    page.addClass('dashboard-column-orientation');

    // find all the level2 sections (those are the columns)
    var columns = page.find('div.section.level2');

    // if there are no level2 sections then treat the
    // entire page as if it's a level 2 section
    if (columns.length === 0) {
      page.wrapInner('<div class="section level2"></div>');
      columns = page.find('div.section.level2');
    }

    // layout each column
    columns.each(function (index) {

      // remove the h2
      $(this).children('h2').remove();

      // make it a flexbox column
      $(this).addClass('dashboard-column');

      // check for a tabset
      var isTabset = $(this).hasClass('tabset');
      if (isTabset)
        layoutTabset($(this));

      // find all the h3 elements
      var rows = $(this).find('div.section.level3');

      // get the figure sizes for the rows
      var figureSizes = chartFigureSizes(rows);

      // column flex is the max row width (or data-width if specified)
      var flexWidth;
      var dataWidth = parseInt($(this).attr('data-width'));
      if (dataWidth)
        flexWidth = dataWidth;
      else
        flexWidth = maxChartWidth(figureSizes);
      setFlex($(this), flexWidth + ' ' + flexWidth + ' 0px');

      // layout each chart
      rows.each(function(index) {

        // perform the layout
        var result = layoutChart($(this), false);

        // ice the notes if there are none
        if (!result.notes)
          $(this).find('.chart-notes').remove();

        // set flex height based on figHeight, then adjust
        if (result.flex) {
          var chartHeight = figureSizes[index].height;
          chartHeight = adjustedHeight(chartHeight, $(this));
          if (fillPage)
            setFlex($(this), chartHeight + ' ' + chartHeight + ' 0px');
          else {
            $(this).css('height', chartHeight + 'px');
            setFlex($(this), chartHeight + ' ' + chartHeight + ' ' + chartHeight + 'px');
          }
        }
      });
    });
  }

  function chartFigureSizes(charts) {

    // sizes
    var figureSizes = new Array(charts.length);

    // check each chart
    charts.each(function(index) {

      // start with default
      figureSizes[index] = {
        width: _options.defaultFigWidth,
        height: _options.defaultFigHeight
      };

      // look for data-height or data-width then knit options
      var dataWidth = parseInt($(this).attr('data-width'));
      var dataHeight = parseInt($(this).attr('data-height'));
      var knitrOptions = $(this).find('.knitr-options:first');
      var knitrWidth, knitrHeight;
      if (knitrOptions) {
        knitrWidth = parseInt(knitrOptions.attr('data-fig-width'));
        knitrHeight =  parseInt(knitrOptions.attr('data-fig-height'));
      }

      // width
      if (dataWidth)
        figureSizes[index].width = dataWidth;
      else if (knitrWidth)
        figureSizes[index].width = knitrWidth;

      // height
      if (dataHeight)
        figureSizes[index].height = dataHeight;
      else if (knitrHeight)
        figureSizes[index].height = knitrHeight;
    });

    // return sizes
    return figureSizes;
  }

  function maxChartHeight(figureSizes, charts) {

    // first compute the maximum height
    var maxHeight = _options.defaultFigHeight;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].height > maxHeight)
        maxHeight = figureSizes[i].height;

    // now add offests for chart title and chart notes
    if (charts.length)
      maxHeight = adjustedHeight(maxHeight, charts.first());

    return maxHeight;
  }

  function adjustedHeight(height, chart) {
    if (chart.length > 0) {
      var chartTitle = chart.find('.chart-title');
      if (chartTitle.length)
        height += chartTitle.first().outerHeight();
      var chartNotes = chart.find('.chart-notes');
      if (chartNotes.length)
        height += chartNotes.first().outerHeight();
    }
    return height;
  }

  function maxChartWidth(figureSizes) {
    var maxWidth = _options.defaultFigWidth;
    for (var i = 0; i<figureSizes.length; i++)
      if (figureSizes[i].width > maxWidth)
        maxWidth = figureSizes[i].width;
    return maxWidth;
  }

  // layout a chart
  function layoutChart(chart, forceFlex) {

    // state to return
    var result = {
      notes: false,
      flex: false
    };

    // extract the title
    var title = extractTitle(chart);

    // find components that apply to this container
    var components = componentsFind(chart);

    // if it's a custom component then call it and return
    var customComponents = componentsCustom(components);
    if (customComponents.length) {
      componentsLayout(customComponents, title, chart);
      result.notes = false;
      result.flex = forceFlex || componentsFlex(customComponents);
      return result;
    }

    // put all the content in a chart wrapper div
    chart.addClass('chart-wrapper');
    chart.wrapInner('<div class="chart-stage"></div>');
    var chartContent = chart.children('.chart-stage');

    // flex the content if appropriate
    result.flex = forceFlex || componentsFlex(components);
    if (result.flex) {
      // add flex classes
      chart.addClass('chart-wrapper-flex');
      chartContent.addClass('chart-stage-flex');

      // additional shim to break out of flexbox sizing
      chartContent.wrapInner('<div class="chart-shim"></div>');
      chartContent = chartContent.children('.chart-shim');
    }

    // set custom data-padding attribute
    var pad = chart.attr('data-padding');
    if (pad) {
      if (pad === "0")
        chart.addClass('no-padding');
      else {
        pad = pad + 'px';
        chartContent.css('left', pad)
                    .css('top', pad)
                    .css('right', pad)
                    .css('bottom', pad)
      }
    }

    // call compoents
    componentsLayout(components, title, chartContent);

    // also activate components on shiny output
    findShinyOutput(chartContent).on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {

          // see if we opted out of flex based on our output (for shiny
          // we can't tell what type of output we have until after the
          // value is bound)
          var components = componentsFind(element);
          var flex = forceFlex || componentsFlex(components);
          if (!flex) {
            chart.css('height', "");
            setFlex(chart, "");
            chart.removeClass('chart-wrapper-flex');
            chartContent.removeClass('chart-stage-flex');
            chartContent.children().unwrap();
          }

          // perform layout
          componentsLayout(components, title, element.parent());
        }, 10);
      });

    // add the title
    var chartTitle = $('<div class="chart-title"></div>');
    chartTitle.html(title);
    chart.prepend(chartTitle);

    // add the notes section
    var chartNotes = $('<div class="chart-notes"></div>');
    chartNotes.html('&nbsp;');
    chart.append(chartNotes);

    // attempt to extract notes if we have a component
    if (components.length)
      result.notes = extractChartNotes(chartContent, chartNotes);

    // return result
    return result;
  }

  // build a tabset from a section div with the .tabset class
  function layoutTabset(tabset) {

    // check for fade option
    var fade = tabset.hasClass("tabset-fade");
    var navClass = "nav-tabs";

    // determine the heading level of the tabset and tabs
    var match = tabset.attr('class').match(/level(\d) /);
    if (match === null)
      return;
    var tabsetLevel = Number(match[1]);
    var tabLevel = tabsetLevel + 1;

    // find all subheadings immediately below
    var tabs = tabset.find("div.section.level" + tabLevel);
    if (!tabs.length)
      return;

    // create tablist and tab-content elements
    var tabList = $('<ul class="nav ' + navClass + '" role="tablist"></ul>');
    $(tabs[0]).before(tabList);
    var tabContent = $('<div class="tab-content"></div>');
    $(tabs[0]).before(tabContent);

    // build the tabset
    tabs.each(function(i) {

      // get the tab div
      var tab = $(tabs[i]);

      // get the id then sanitize it for use with bootstrap tabs
      var id = tab.attr('id');

      // sanitize the id for use with bootstrap tabs
      id = id.replace(/[.\/?&!#<>]/g, '').replace(/\s/g, '_');
      tab.attr('id', id);

      // get the heading element within it and grab it's text
      var heading = tab.find('h' + tabLevel + ':first');
      var headingText = heading.html();

      // build and append the tab list item
      var a = $('<a role="tab" data-toggle="tab">' + headingText + '</a>');
      a.attr('href', '#' + id);
      a.attr('aria-controls', id);
      var li = $('<li role="presentation"></li>');
      li.append(a);
      if (i === 0)
        li.attr('class', 'active');
      tabList.append(li);

      // set it's attributes
      tab.attr('role', 'tabpanel');
      tab.addClass('tab-pane');
      tab.addClass('tabbed-pane');
      tab.addClass('no-title');
      if (fade)
        tab.addClass('fade');
      if (i === 0) {
        tab.addClass('active');
        if (fade)
          tab.addClass('in');
      }

      // move it into the tab content div
      tab.detach().appendTo(tabContent);
    });

    // add nav-tabs-custom
    tabset.addClass('nav-tabs-custom');

    // internal layout is dashboard-column with tab-content flexing
    tabset.addClass('dashboard-column');
    setFlex(tabContent, 1);
  }

  // one time global initialization for components
  function componentsInit(dashboardContainer) {
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.init)
        component.init(dashboardContainer);
    }
  }

  // find components that apply within a container
  function componentsFind(container) {

    // look for components
    var components = [];
    for (var i=0; i<window.FlexDashboardComponents.length; i++) {
      var component = window.FlexDashboardComponents[i];
      if (component.find(container).length)
        components.push(component);
    }

    // if there were none then use a special flowing content component
    // that just adds a scrollbar in fillPage mode
    if (components.length == 0) {
      components.push({
        find: function(container) {
          return container;
        },

        flex: function(fillPage) {
          return fillPage;
        },

        layout: function(title, container, element, fillPage) {
          if (fillPage) {
            container.addClass('flowing-content-shim');
            container.addClass('flowing-content-container');
          }
        }
      });
    }

    return components;
  }

  // if there is a custom component then pick it out
  function componentsCustom(components) {
    var customComponent = [];
    for (var i=0; i<components.length; i++)
      if (components[i].type === "custom") {
        customComponent.push(components[i]);
        break;
      }
    return customComponent;
  }

  // query all components for flex
  function componentsFlex(components) {

    // no components at all means no flex
    if (components.length === 0)
      return false;

    // otherwise query components (assume true unless we see false)
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++)
      if (components[i].flex && !components[i].flex(_options.fillPage))
        return false;
    return true;
  }

  // layout all components
  function componentsLayout(components, title, container) {
    var isMobile = isMobilePhone();
    for (var i=0; i<components.length; i++) {
      var element = components[i].find(container);
      if (components[i].layout) {
        // call layout (don't call other components if it returns false)
        var result = components[i].layout(title, container, element, _options.fillPage);
        if (result === false)
          return;
      }
    }
  }

  // get a reference to the h3, discover it's inner html, and remove it
  function extractTitle(container) {
    var h3 = container.children('h3').first();
    var title = '';
    if (!container.hasClass('no-title'))
      title = h3.html();
    h3.remove();
    return title;
  }

  // extract chart notes
  function extractChartNotes(chartContent, chartNotes) {
    // look for a terminating blockquote or image caption
    var blockquote = chartContent.children('blockquote:last-child');
    var caption = chartContent.children('div.image-container')
                              .children('p.caption');
    if (blockquote.length) {
      chartNotes.html(blockquote.children('p:first-child').html());
      blockquote.remove();
      return true;
    } else if (caption.length) {
      chartNotes.html(caption.html());
      caption.remove();
      return true;
    } else {
      return false;
    }
  }

  function findShinyOutput(chartContent) {
    return chartContent.find('.shiny-text-output, .shiny-html-output');
  }

  // safely detect rendering on a mobile phone
  function isMobilePhone() {
    try
    {
      return ! window.matchMedia("only screen and (min-width: 768px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  function isFillPage() {
    return _options.fillPage;
  }

  // detect portrait mode
  function isPortrait() {
    return ($(window).width() < $(window).height());
  }

  // safely detect rendering on a tablet
  function isTablet() {
    try
    {
      return window.matchMedia("only screen and (min-width: 769px) and (max-width: 992px)").matches;
    }
    catch(e) {
      return false;
    }
  }

  // test whether this is a shiny doc
  function isShinyDoc() {
    return (typeof(window.Shiny) !== "undefined" && !!window.Shiny.outputBindings);
  }

  // set flex using vendor specific prefixes
  function setFlex(el, flex) {
    el.css('-webkit-box-flex', flex)
      .css('-webkit-flex', flex)
      .css('-ms-flex', flex)
      .css('flex', flex);
  }

  // support bookmarking of pages
  function handleLocationHash() {

    // restore tab/page from bookmark
    var hash = window.location.hash;
    if (hash.length > 0)
      $('ul.nav a[href="' + hash + '"]').tab('show');
    FlexDashboardUtils.manageActiveNavbarMenu();

    // navigate to a tab when the history changes
    window.addEventListener("popstate", function(e) {
      var hash = window.location.hash;
      var activeTab = $('ul.nav a[href="' + hash + '"]');
      if (activeTab.length) {
        activeTab.tab('show');
      } else {
        $('ul.nav a:first').tab('show');
      }
      FlexDashboardUtils.manageActiveNavbarMenu();
    });

    // add a hash to the URL when the user clicks on a tab/page
    $('.navbar-nav a[data-toggle="tab"]').on('click', function(e) {
      var baseUrl = FlexDashboardUtils.urlWithoutHash(window.location.href);
      var hash = FlexDashboardUtils.urlHash($(this).attr('href'));
      var href = baseUrl + hash;
      FlexDashboardUtils.setLocation(href);
    });

    // handle clicks of other links that should activate pages
    var navPages = $('ul.navbar-nav li a[data-toggle=tab]');
    navPages.each(function() {
      var href =  $(this).attr('href');
      var links = $('a[href="' + href + '"][data-toggle!=tab]');
      links.each(function() {
        $(this).on('click', function(e) {
          window.FlexDashboardUtils.showPage(href);
        });
      });
    });
  }

  // tweak Prism highlighting
  function initPrismHighlighting() {

    if (window.Prism) {
      Prism.languages.insertBefore('r', 'comment', {
        'heading': [
          {
            // title 1
        	  // =======

        	  // title 2
        	  // -------
        	  pattern: /\w+.*(?:\r?\n|\r)(?:====+|----+)/,
            alias: 'operator'
          },
          {
            // ### title 3
            pattern: /(^\s*)###[^#].+/m,
            lookbehind: true,
            alias: 'operator'
          }
        ]
      });

      // prism highlight
      Prism.highlightAll();
    }
  }


  // get theme color
  var themeColors = {
    bootstrap: {
      primary: "rgba(51, 122, 183, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cerulean: {
      primary: "rgb(47, 164, 231)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    journal: {
      primary: "rgba(235, 104, 100, 0.70)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    flatly: {
      primary: "rgba(44, 62, 80, 0.70)",
      info: "rgba(52, 152, 219, 0.70)",
      success: "rgba(24, 188, 156, 0.70)",
      warning: "rgba(243, 156, 18, 0.70)",
      danger: "rgba(231, 76, 60, 0.70)"
    },
    readable: {
      primary: "rgba(69, 130, 236, 0.4)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    spacelab: {
      primary: "rgba(68, 110, 155, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    united: {
      primary: "rgba(221, 72, 20, 0.30)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    cosmo: {
      primary: "rgba(39, 128, 227, 0.7)",
      info: "rgba(153, 84, 187, 0.7)",
      success: "rgba(63, 182, 24, 0.7)",
      warning: "rgba(255, 117, 24, 0.7)",
      danger: "rgba(255, 0, 57, 0.7)"
    },
    lumen: {
      primary: "rgba(21, 140, 186, 0.70)",
      info: "rgba(117, 202, 235, 0.90)",
      success: "rgba(40, 182, 44, 0.70)",
      warning: "rgba(255, 133, 27, 0.70)",
      danger: "rgba(255, 65, 54, 0.70)"
    },
    paper: {
      primary: "rgba(33, 150, 243, 0.35)",
      info: "rgb(225, 190, 231)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(255, 224, 178)",
      danger: "rgb(249, 189, 187)"
    },
    sandstone: {
      primary: "rgba(50, 93, 136, 0.3)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    simplex: {
      primary: "rgba(217, 35, 15, 0.25)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    },
    yeti: {
      primary: "rgba(0, 140, 186, 0.298039)",
      info: "rgb(217, 237, 247)",
      success: "rgb(223, 240, 216)",
      warning: "rgb(252, 248, 227)",
      danger: "rgb(242, 222, 222)"
    }
  }
  function themeColor(color) {
    return themeColors[_options.theme][color];
  }

  FlexDashboard.prototype = {
    constructor: FlexDashboard,
    init: init,
    isMobilePhone: isMobilePhone,
    isFillPage: isFillPage,
    themeColor: themeColor
  };

  return FlexDashboard;

})();

// utils
window.FlexDashboardUtils = {
  resizableImage: function(img) {
    var src = img.attr('src');
    var url = 'url("' + src + '")';
    img.parent().css('background', url)
                .css('background-size', 'contain')
                .css('background-repeat', 'no-repeat')
                .css('background-position', 'center')
                .addClass('image-container');
  },
  setLocation: function(href) {
    if (history && history.pushState) {
      history.pushState(null, null, href);
    } else {
      window.location.replace(href);
    }
    setTimeout(function() {
        window.scrollTo(0, 0);
    }, 10);
    this.manageActiveNavbarMenu();
  },
  showPage: function(href) {
    $('ul.navbar-nav li a[href="' + href + '"]').tab('show');
    var baseUrl = this.urlWithoutHash(window.location.href);
    var loc = baseUrl + href;
    this.setLocation(loc);
  },
  showLinkedValue: function(href) {
    // check for a page link
    if ($('ul.navbar-nav li a[data-toggle=tab][href="' + href + '"]').length > 0)
      this.showPage(href);
    else
      window.open(href);
  },
  urlWithoutHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(0, hashLoc);
    else
      return url;
  },
  urlHash: function(url) {
    var hashLoc = url.indexOf('#');
    if (hashLoc != -1)
      return url.substring(hashLoc);
    else
      return "";
  },
  manageActiveNavbarMenu: function () {
    // remove active from anyone currently active
    $('.navbar ul.nav').find('li').removeClass('active');
    // find the active tab
    var activeTab = $('.dashboard-page-wrapper.tab-pane.active');
    if (activeTab.length > 0) {
      var tabId = activeTab.attr('id');
      if (tabId)
        $(".navbar ul.nav a[href='#" + tabId + "']").parents('li').addClass('active');
    }
  }
};

window.FlexDashboard = new FlexDashboard();

// empty content
window.FlexDashboardComponents.push({
  find: function(container) {
    if (container.find('p').length == 0)
      return container;
    else
      return $();
  }
})

// plot image
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('p')
                    .children('img:only-child');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// plot image (figure style)
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.figure').children('img');
  },

  layout: function(title, container, element, fillPage) {
    FlexDashboardUtils.resizableImage(element);
  }
});

// htmlwidget
window.FlexDashboardComponents.push({

  init: function(dashboardContainer) {
    // trigger "shown" after initial layout to force static htmlwidgets
    // in runtime: shiny to be resized after the dom has been transformed
    dashboardContainer.on('flexdashboard:layoutcomplete', function(event) {
      setTimeout(function() {
        dashboardContainer.trigger('shown');
      }, 200);
    });
  },

  find: function(container) {
    return container.children('div[id^="htmlwidget-"],div.html-widget');
  }
});

// gauge
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.children('div.html-widget.gauge');
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {


  }

});

// shiny output
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.children('div[class^="shiny-"]');
  }
});

// datatables
window.FlexDashboardComponents.push({
  find: function(container) {
    return container.find('.datatables');
  },
  flex: function(fillPage) {
    return fillPage;
  }
});

// bootstrap table
window.FlexDashboardComponents.push({

  find: function(container) {
    var bsTable = container.find('table.table');
    if (bsTable.length !== 0)
      return bsTable;
    else
      return container.find('tr.header').parent('thead').parent('table');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var bsTable = element;

    // fixup xtable generated tables with a proper thead
    var headerRow = bsTable.find('tbody > tr:first-child > th').parent();
    if (headerRow.length > 0) {
      var thead = $('<thead></thead>');
      bsTable.prepend(thead);
      headerRow.detach().appendTo(thead);
    }

    // improve appearance
    container.addClass('bootstrap-table');

    // for fill page provide scrolling w/ sticky headers
    if (fillPage) {
      // force scrollbar on overflow
      container.addClass('flowing-content-shim');

      // stable table headers when scrolling
      bsTable.stickyTableHeaders({
        scrollableArea: container
      });
    }
  }
});

// embedded shiny app
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('iframe.shiny-frame');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage) {
      element.attr('height', '100%');
    } else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (!height)
        height = element.attr('height');
      if (!height)
        element.attr('height', 500);
    }
  }
});

// shiny fillRow or fillCol
window.FlexDashboardComponents.push({

  find: function(container) {
    return container.find('.flexfill-container');
  },

  flex: function(fillPage) {
    return fillPage;
  },

  layout: function(title, container, element, fillPage) {
    if (fillPage)
      element.css('height', '100%');
    else {
      // provide default height if necessary
      var height = element.get(0).style.height;
      if (height === "100%" || height === "auto" || height === "initial" ||
          height === "inherit" || !height) {
        element.css('height', 500);
      }
    }
  }
});

// valueBox
window.FlexDashboardComponents.push({

  type: "custom",

  find: function(container) {
    if (container.find('span.value-output, .shiny-valuebox-output').length)
      return container;
    else
      return $();
  },

  flex: function(fillPage) {
    return false;
  },

  layout: function(title, container, element, fillPage) {

    // alias variables
    var chartTitle = title;
    var valueBox = element;

    // add value-box class to container
    container.addClass('value-box');

    // value paragraph
    var value = $('<p class="value"></p>');

    // if we have shiny-text-output then just move it in
    var valueOutputSpan = [];
    var shinyOutput = valueBox.find('.shiny-valuebox-output').detach();
    if (shinyOutput.length) {
      valueBox.children().remove();
      shinyOutput.html("&mdash;");
      value.append(shinyOutput);
    } else {
      // extract the value (remove leading vector index)
      var chartValue = valueBox.text().trim();
      chartValue = chartValue.replace("[1] ", "");
      valueOutputSpan = valueBox.find('span.value-output').detach();
      valueBox.children().remove();
      value.text(chartValue);
    }

    // caption
    var caption = $('<p class="caption"></p>');
    caption.html(chartTitle);

    // build inner div for value box and add it
    var inner = $('<div class="inner"></div>');
    inner.append(value);
    inner.append(caption);
    valueBox.append(inner);

    // add icon if specified
    var icon = $('<div class="icon"><i></i></div>');
    valueBox.append(icon);
    function setIcon(chartIcon) {
      var iconLib = "";
      var components = chartIcon.split("-");
      if (components.length > 1)
        iconLib = components[0];
      icon.children('i').attr('class', iconLib + ' ' + chartIcon);
    }
    var chartIcon = valueBox.attr('data-icon');
    if (chartIcon)
      setIcon(chartIcon);

    // set color based on data-background if necessary
    var dataBackground = valueBox.attr('data-background');
    if (dataBackground)
      valueBox.css('background-color', bgColor);
    else {
      // default to bg-primary if no other background is specified
      if (!valueBox.hasClass('bg-primary') &&
          !valueBox.hasClass('bg-info') &&
          !valueBox.hasClass('bg-warning') &&
          !valueBox.hasClass('bg-success') &&
          !valueBox.hasClass('bg-danger')) {
        valueBox.addClass('bg-primary');
      }
    }

    // handle data attributes in valueOutputSpan
    function handleValueOutput(valueOutput) {

      // caption
      var dataCaption = valueOutput.attr('data-caption');
      if (dataCaption)
        caption.html(dataCaption);

      // icon
      var dataIcon = valueOutput.attr('data-icon');
      if (dataIcon)
        setIcon(dataIcon);

      // color
      var dataColor = valueOutput.attr('data-color');
      if (dataColor) {
        if (dataColor.indexOf('bg-') === 0) {
          valueBox.css('background-color', '');
          if (!valueBox.hasClass(dataColor)) {
             valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
             valueBox.addClass(dataColor);
          }
        } else {
          valueBox.removeClass('bg-primary bg-info bg-warning bg-danger bg-success');
          valueBox.css('background-color', dataColor);
        }
      }

      // url
      var dataHref = valueOutput.attr('data-href');
      if (dataHref) {
        valueBox.addClass('linked-value');
        valueBox.off('click.value-box');
        valueBox.on('click.value-box', function(e) {
          window.FlexDashboardUtils.showLinkedValue(dataHref);
        });
      }
    }

    // check for a valueOutputSpan
    if (valueOutputSpan.length > 0) {
      handleValueOutput(valueOutputSpan);
    }

    // if we have a shinyOutput then bind a listener to handle
    // new valueOutputSpan values
    shinyOutput.on('shiny:value',
      function(event) {
        var element = $(event.target);
        setTimeout(function() {
          var valueOutputSpan = element.find('span.value-output');
          if (valueOutputSpan.length > 0)
            handleValueOutput(valueOutputSpan);
        }, 10);
      }
    );
  }
});


</script>

<div id="dashboard-container">

<div id="column" class="section level2 sidebar">
<h2 class="sidebar">Column</h2>
<div id="ltima-atualizao" class="section level3">
<h3>ltima atualizao</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">2020-05-13 14:25</span>
<!-- ------------------------------------- -->
<!-- ### Trials na base americana -->
<!-- ```{r} -->
<!-- valueBox(nrow(eua)) -->
<!-- ``` -->
<hr />
</div>
<div id="total-de-trials-na-base-da-oms" class="section level3">
<h3>Total de trials na base da OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<span class="value-output">2369</span>
<p>Link para dados completos: <a href="https://www.who.int/ictrp/COVID19-web.csv" class="uri">https://www.who.int/ictrp/COVID19-web.csv</a></p>
<hr />
</div>
<div id="trials-intervencionais-na-base-da-oms" class="section level3">
<h3>Trials intervencionais na base da OMS</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<p><span class="value-output">1292</span> <!-- ### Trials na base da China --> <!-- ```{r} --> <!-- valueBox(nrow(china)) --> <!-- ``` --></p>
<!-- Extraidos da base da OMS + busca por outros mais recentes  -->
<!-- ### Protocolos na base da Unio Europeia -->
<!-- ```{r} -->
<!-- valueBox(nrow(eu_data)) -->
<!-- ``` -->
<!-- Um trial pode ter protocolos diferentes em cada pas participante -->
</div>
</div>
<div id="column-1" class="section level2 tabset tabset-fade">
<h2 class="tabset tabset-fade">Column</h2>
<div id="grupos" class="section level3">
<h3>Grupos</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-aa7846b7e9b97b143c72" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-aa7846b7e9b97b143c72">{"x":{"filter":"none","caption":"<caption>Grupos<\/caption>","fillContainer":true,"data":[["1","2","3","4"],["Drogas","Outros tratamentos","No identificado","Preveno"],[681,346,257,202],[30,63,56,27],[47,39,10,16],[305,81,32,46],[227,31,20,46],[91,25,26,21],[56,133,117,59],[78,28,7,16]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>total<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>multiplas_fases<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":[2,3,4,5,6,7,8,9]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="categorias" class="section level3">
<h3>Categorias</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-76812f00a5dbb90d5b7c" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-76812f00a5dbb90d5b7c">{"x":{"filter":"none","caption":"<caption>Categorias<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19"],[null,"Drogas","Drogas","Drogas","Outros tratamentos","Preveno","Outros tratamentos","Drogas","Preveno","Outros tratamentos","Drogas","Outros tratamentos","Outros tratamentos","Drogas","Preveno","Drogas","Drogas","Outros tratamentos","Drogas"],["No identificado","Outras drogas","Antimalrico","Antivirais","Ventilao Pulmonar","Outras formas de preveno","Plasma de pessoas curadas","Anticorpos monoclonais","Testes","Medicina Tradicional Chinesa","Antibiticos","Comportamental ou atividade fsica","Clulas-Tronco","Corticides","Vacinas","Inibidores de enzimas do tipo quinases","Anti-inflamatrio","NK cells","Imunomoduladores"],[257,253,242,135,109,97,80,78,76,68,64,53,47,36,34,31,28,7,3],[56,5,4,20,7,14,8,1,13,32,0,4,11,1,0,1,4,4,0],[10,33,10,5,7,2,11,1,0,1,4,1,20,0,15,1,0,3,0],[32,138,82,32,24,27,40,55,7,0,26,0,19,11,12,21,8,1,2],[20,72,108,40,16,31,11,20,7,1,32,1,2,14,11,10,11,0,1],[26,24,47,28,13,8,2,5,10,11,4,0,0,7,3,1,2,0,1],[117,19,17,23,46,17,17,4,41,23,5,46,8,6,2,1,4,0,0],[7,38,27,14,5,3,9,9,3,0,7,0,13,3,10,5,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>categoria<\/th>\n      <th>total<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>multiplas_fases<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":[3,4,5,6,7,8,9,10]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="substncias" class="section level3">
<h3>Substncias</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-afe75a2d5f081173b36c" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-afe75a2d5f081173b36c">{"x":{"filter":"none","caption":"<caption>Substncias (apenas trials do grupo \"Drogas\")<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18"],["Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas"],["Antimalrico","Outras drogas","Antibiticos","Anticorpos monoclonais","Antivirais","Antivirais","Outras drogas","Corticides","Inibidores de enzimas do tipo quinases","Anti-inflamatrio","Antivirais","Anticorpos monoclonais","Antivirais","Antivirais","Outras drogas","Antivirais","Imunomoduladores","Antibiticos"],["cloroquina ou hidroxicloroquina","Outras drogas","azithromycin","tocilizumab ou sarilumab","lopinavir/ritonavir","outros antivirais","Interferon","corticides","Inibidores de enzimas do tipo quinases","Anti-inflamatrio","favipiravir","outros anticorpos monoclonais","remdesivir","arbidol (Umifenovir)","Anakinra","azvudine","Imunomoduladores","outros antibiticos"],[242,199,64,60,51,51,43,36,31,28,24,22,17,14,13,4,3,2],[4,0,0,1,6,8,5,1,1,4,5,0,0,4,0,3,0,0],[10,29,4,0,2,3,4,0,1,0,0,1,0,0,0,0,0,0],[82,119,26,38,16,8,13,11,21,8,8,19,4,0,8,0,2,0],[108,60,32,18,14,9,6,14,10,11,10,4,13,0,7,0,1,1],[47,12,4,5,12,11,12,7,1,2,2,0,1,8,0,0,1,1],[17,12,5,3,8,12,7,6,1,4,3,1,1,2,0,1,0,0],[27,33,7,6,7,1,4,3,5,1,4,3,2,0,2,0,1,0]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>categoria<\/th>\n      <th>substancia<\/th>\n      <th>total<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>multiplas_fases<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":[4,5,6,7,8,9,10,11]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="pases" class="section level3">
<h3>Pases</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-031fae5596dfdfd11730" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-031fae5596dfdfd11730">{"x":{"filter":"none","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75"],["China","United States","No identificado","France","Spain","United Kingdom","Italy","Germany","Canada","Netherlands","Denmark","Australia","Brazil","Belgium","Egypt","Iran","Austria","Israel","Japan","Mexico","Greece","India","Switzerland","Hong Kong","Norway","Korea, Republic of, Republic of","Russian Federation","South Africa","Sweden","Ireland","Pakistan","Colombia","Nigeria","Poland","Singapore","Thailand","Turkey","Argentina","New Zealand","Taiwan","Cuba","Hungary","Indonesia","Jordan","Luxembourg","Malaysia","Peru","Saudi Arabia","Bahrain","Czech Republic","Finland","Monaco","Romania","Tunisia","Zambia","Bosnia and Herzegovina","Chile","Croatia","French Guiana","Ghana","Gibraltar","Honduras","Iceland","Iraq","Kenya","KOREA","Lebanon","Philippines","Portugal","Puerto Rico","Qatar","Serbia","Slovenia","United States of America","Vietnam"],[383,197,180,127,110,49,47,42,38,32,27,25,21,20,18,17,15,14,14,14,12,12,12,9,9,8,8,8,8,7,7,6,6,6,6,6,6,5,5,5,3,3,3,3,3,3,3,3,2,2,2,2,2,2,2,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>Countries<\/th>\n      <th>n<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tpi","columnDefs":[{"className":"dt-right","targets":2},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="dados" class="section level3">
<h3>Dados</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-3b99973c8eed0ac4779e" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-3b99973c8eed0ac4779e">{"x":{"filter":"none","extensions":["Buttons"],"caption":"<caption>Variveis selecionadas; apenas trials intervencionais<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26","27","28","29","30","31","32","33","34","35","36","37","38","39","40","41","42","43","44","45","46","47","48","49","50","51","52","53","54","55","56","57","58","59","60","61","62","63","64","65","66","67","68","69","70","71","72","73","74","75","76","77","78","79","80","81","82","83","84","85","86","87","88","89","90","91","92","93","94","95","96","97","98","99","100","101","102","103","104","105","106","107","108","109","110","111","112","113","114","115","116","117","118","119","120","121","122","123","124","125","126","127","128","129","130","131","132","133","134","135","136","137","138","139","140","141","142","143","144","145","146","147","148","149","150","151","152","153","154","155","156","157","158","159","160","161","162","163","164","165","166","167","168","169","170","171","172","173","174","175","176","177","178","179","180","181","182","183","184","185","186","187","188","189","190","191","192","193","194","195","196","197","198","199","200","201","202","203","204","205","206","207","208","209","210","211","212","213","214","215","216","217","218","219","220","221","222","223","224","225","226","227","228","229","230","231","232","233","234","235","236","237","238","239","240","241","242","243","244","245","246","247","248","249","250","251","252","253","254","255","256","257","258","259","260","261","262","263","264","265","266","267","268","269","270","271","272","273","274","275","276","277","278","279","280","281","282","283","284","285","286","287","288","289","290","291","292","293","294","295","296","297","298","299","300","301","302","303","304","305","306","307","308","309","310","311","312","313","314","315","316","317","318","319","320","321","322","323","324","325","326","327","328","329","330","331","332","333","334","335","336","337","338","339","340","341","342","343","344","345","346","347","348","349","350","351","352","353","354","355","356","357","358","359","360","361","362","363","364","365","366","367","368","369","370","371","372","373","374","375","376","377","378","379","380","381","382","383","384","385","386","387","388","389","390","391","392","393","394","395","396","397","398","399","400","401","402","403","404","405","406","407","408","409","410","411","412","413","414","415","416","417","418","419","420","421","422","423","424","425","426","427","428","429","430","431","432","433","434","435","436","437","438","439","440","441","442","443","444","445","446","447","448","449","450","451","452","453","454","455","456","457","458","459","460","461","462","463","464","465","466","467","468","469","470","471","472","473","474","475","476","477","478","479","480","481","482","483","484","485","486","487","488","489","490","491","492","493","494","495","496","497","498","499","500","501","502","503","504","505","506","507","508","509","510","511","512","513","514","515","516","517","518","519","520","521","522","523","524","525","526","527","528","529","530","531","532","533","534","535","536","537","538","539","540","541","542","543","544","545","546","547","548","549","550","551","552","553","554","555","556","557","558","559","560","561","562","563","564","565","566","567","568","569","570","571","572","573","574","575","576","577","578","579","580","581","582","583","584","585","586","587","588","589","590","591","592","593","594","595","596","597","598","599","600","601","602","603","604","605","606","607","608","609","610","611","612","613","614","615","616","617","618","619","620","621","622","623","624","625","626","627","628","629","630","631","632","633","634","635","636","637","638","639","640","641","642","643","644","645","646","647","648","649","650","651","652","653","654","655","656","657","658","659","660","661","662","663","664","665","666","667","668","669","670","671","672","673","674","675","676","677","678","679","680","681","682","683","684","685","686","687","688","689","690","691","692","693","694","695","696","697","698","699","700","701","702","703","704","705","706","707","708","709","710","711","712","713","714","715","716","717","718","719","720","721","722","723","724","725","726","727","728","729","730","731","732","733","734","735","736","737","738","739","740","741","742","743","744","745","746","747","748","749","750","751","752","753","754","755","756","757","758","759","760","761","762","763","764","765","766","767","768","769","770","771","772","773","774","775","776","777","778","779","780","781","782","783","784","785","786","787","788","789","790","791","792","793","794","795","796","797","798","799","800","801","802","803","804","805","806","807","808","809","810","811","812","813","814","815","816","817","818","819","820","821","822","823","824","825","826","827","828","829","830","831","832","833","834","835","836","837","838","839","840","841","842","843","844","845","846","847","848","849","850","851","852","853","854","855","856","857","858","859","860","861","862","863","864","865","866","867","868","869","870","871","872","873","874","875","876","877","878","879","880","881","882","883","884","885","886","887","888","889","890","891","892","893","894","895","896","897","898","899","900","901","902","903","904","905","906","907","908","909","910","911","912","913","914","915","916","917","918","919","920","921","922","923","924","925","926","927","928","929","930","931","932","933","934","935","936","937","938","939","940","941","942","943","944","945","946","947","948","949","950","951","952","953","954","955","956","957","958","959","960","961","962","963","964","965","966","967","968","969","970","971","972","973","974","975","976","977","978","979","980","981","982","983","984","985","986","987","988","989","990","991","992","993","994","995","996","997","998","999","1000","1001","1002","1003","1004","1005","1006","1007","1008","1009","1010","1011","1012","1013","1014","1015","1016","1017","1018","1019","1020","1021","1022","1023","1024","1025","1026","1027","1028","1029","1030","1031","1032","1033","1034","1035","1036","1037","1038","1039","1040","1041","1042","1043","1044","1045","1046","1047","1048","1049","1050","1051","1052","1053","1054","1055","1056","1057","1058","1059","1060","1061","1062","1063","1064","1065","1066","1067","1068","1069","1070","1071","1072","1073","1074","1075","1076","1077","1078","1079","1080","1081","1082","1083","1084","1085","1086","1087","1088","1089","1090","1091","1092","1093","1094","1095","1096","1097","1098","1099","1100","1101","1102","1103","1104","1105","1106","1107","1108","1109","1110","1111","1112","1113","1114","1115","1116","1117","1118","1119","1120","1121","1122","1123","1124","1125","1126","1127","1128","1129","1130","1131","1132","1133","1134","1135","1136","1137","1138","1139","1140","1141","1142","1143","1144","1145","1146","1147","1148","1149","1150","1151","1152","1153","1154","1155","1156","1157","1158","1159","1160","1161","1162","1163","1164","1165","1166","1167","1168","1169","1170","1171","1172","1173","1174","1175","1176","1177","1178","1179","1180","1181","1182","1183","1184","1185","1186","1187","1188","1189","1190","1191","1192","1193","1194","1195","1196","1197","1198","1199","1200","1201","1202","1203","1204","1205","1206","1207","1208","1209","1210","1211","1212","1213","1214","1215","1216","1217","1218","1219","1220","1221","1222","1223","1224","1225","1226","1227","1228","1229","1230","1231","1232","1233","1234","1235","1236","1237","1238","1239","1240","1241","1242","1243","1244","1245","1246","1247","1248","1249","1250","1251","1252","1253","1254","1255","1256","1257","1258","1259","1260","1261","1262","1263","1264","1265","1266","1267","1268","1269","1270","1271","1272","1273","1274","1275","1276","1277","1278","1279","1280","1281","1282","1283","1284","1285","1286","1287","1288","1289","1290","1291","1292"],["NCT04246242","ChiCTR2000029935","ChiCTR2000029850","ChiCTR2000029947","ChiCTR2000029814","ChiCTR2000029811","ChiCTR2000029789","NCT04260594","NCT04261426","ChiCTR2000029778","ChiCTR2000029656","ChiCTR2000029777","NCT04252885","ChiCTR2000029776","ChiCTR2000029601","ChiCTR2000029742","ChiCTR2000029569","NCT04261907","ChiCTR2000029941","ChiCTR2000029542","ChiCTR2000029741","ChiCTR2000029939","ChiCTR2000029539","ChiCTR2000029438","ChiCTR2000029869","ChiCTR2000029636","ChiCTR2000029436","ChiCTR2000029867","ChiCTR2000029589","ChiCTR2000029855","ChiCTR2000029849","ChiCTR2000029418","ChiCTR2000029578","ChiCTR2000029853","ChiCTR2000029822","ChiCTR2000030173","ChiCTR2000029518","ChiCTR2000029517","ChiCTR2000030166","ChiCTR2000029813","ChiCTR2000029495","ChiCTR2000030118","ChiCTR2000029819","ChiCTR2000029806","ChiCTR2000030116","ChiCTR2000029493","ChiCTR2000029769","ChiCTR2000029790","ChiCTR2000030093","ChiCTR2000029768","ChiCTR2000029788","ChiCTR2000030084","ChiCTR2000029765","ChiCTR2000030043","ChiCTR2000029763","ChiCTR2000030041","ChiCTR2000030034","ChiCTR2000029756","ChiCTR2000029621","ChiCTR2000029747","ChiCTR2000030016","ChiCTR2000029609","ChiCTR2000029739","ChiCTR2000030007","ChiCTR2000029606","ChiCTR2000030000","ChiCTR2000029605","ChiCTR2000029956","ChiCTR2000029639","ChiCTR2000029603","ChiCTR2000029781","ChiCTR2000029558","ChiCTR2000029740","ChiCTR2000029548","ChiCTR2000029461","ChiCTR2000029602","ChiCTR2000029460","ChiCTR2000029600","ChiCTR2000029459","ChiCTR2000029572","ChiCTR2000029432","ChiCTR2000029439","ChiCTR2000029559","ChiCTR2000030420","ChiCTR2000029381","ChiCTR2000029544","ChiCTR2000029541","ChiCTR2000029431","NCT04269525","ChiCTR2000030188","ChiCTR2000029468","ChiCTR2000030170","ChiCTR2000030314","ChiCTR2000030138","ChiCTR2000030260","ChiCTR2000030255","ChiCTR2000029435","ChiCTR2000030136","ChiCTR2000030219","ChiCTR2000029400","ChiCTR2000030102","ChiCTR2000030091","ChiCTR2000030167","ChiCTR2000030089","ChiCTR2000030165","ChiCTR2000030088","ChiCTR2000029975","ChiCTR2000030117","ChiCTR2000029762","ChiCTR2000029760","ChiCTR2000030054","NCT04286503","ChiCTR2000030090","ChiCTR2000030039","ChiCTR2000030058","NCT04268537","ChiCTR2000030033","ChiCTR2000030020","ChiCTR2000030540","ChiCTR2000030490","ChiCTR2000030006","ChiCTR2000030003","ChiCTR2000030481","ChiCTR2000030001","ChiCTR2000030467","ChiCTR2000030002","ChiCTR2000029999","ChiCTR2000030465","ChiCTR2000030014","ChiCTR2000029992","ChiCTR2000029989","ChiCTR2000029580","ChiCTR2000029990","ChiCTR2000029988","ChiCTR2000030179","NCT04295551","ChiCTR2000029974","ChiCTR2000029972","ChiCTR2000029803","ChiCTR2000029954","ChiCTR2000029780","NCT04296643","ChiCTR2000030433","ChiCTR2000030418","ChiCTR2000030897","ChiCTR2000030113","ChiCTR2000030892","ChiCTR2000030386","NCT04275245","NCT04275388","NCT04279197","NCT04280588","ChiCTR2000030333","ChiCTR2000030432","ChiCTR2000030849","ChiCTR2000030317","ChiCTR2000030398","ChiCTR2000030046","ChiCTR2000030265","ChiCTR2000030029","ChiCTR2000030261","ChiCTR2000030215","ChiCTR2000030218","ChiCTR2000030196","ChiCTR2000030022","ChiCTR2000030013","ChiCTR2000029761","ChiCTR2000030773","ChiCTR2000029991","ChiCTR2000029759","ChiCTR2000029755","ChiCTR2000029386","ChiCTR2000029387","ChiCTR2000030027","ChiCTR2000030744","ChiCTR2000030010","ChiCTR2000029996","ChiCTR2000030703","ChiCTR2000029994","NCT04276987","ChiCTR2000030545","ChiCTR2000029978","NCT04281693","NCT04282902","ChiCTR2000030388","NCT04285190","ChiCTR2000030627","ChiCTR2000030082","ChiCTR2000030518","ChiCTR2000029984","ChiCTR2000030578","ChiCTR2000029817","ChiCTR2000029812","ChiCTR2000030484","ChiCTR2000030480","NCT04302519","ChiCTR2000030479","ChiCTR2000030475","ChiCTR2000031138","ChiCTR2000030477","ChiCTR2000031090","ChiCTR2000030996","ChiCTR2000029993","ChiCTR2000029757","ChiCTR2000029960","ChiCTR2000029638","EUCTR2018-004318-16-DK","NCT04293887","ChiCTR2000029308","ChiCTR2000030853","ChiCTR2000030864","ChiCTR2000030929","ChiCTR2000030920","ChiCTR2000030836","ChiCTR2000030855","ChiCTR2000030835","ChiCTR2000029851","ChiCTR2000030841","EUCTR2020-000890-25-FR","ChiCTR2000030832","NCT04276896","NCT04291053","NCT04293692","NCT04273529","NCT04273581","ChiCTR2000030804","NCT04310865","ChiCTR2000030779","ChiCTR2000030442","ChiCTR2000030751","ChiCTR2000030718","ChiCTR2000030761","ChiCTR2000030424","NCT04316728","ChiCTR2000031271","ChiCTR2000030701","ChiCTR2000030700","ChiCTR2000030720","ChiCTR2000030940","ChiCTR2000030702","ChiCTR2000030681","ChiCTR2000030937","ChiCTR2000030704","ChiCTR2000030483","ChiCTR2000030478","ChiCTR2000030028","EUCTR2020-001243-15-BE","ChiCTR2000030031","ChiCTR2000030509","ChiCTR2000030324","ChiCTR2000030476","NCT04307693","ChiCTR2000030417","ChiCTR2000030381","ChiCTR2000031023","ChiCTR2000030135","ChiCTR2000030946","ChiCTR2000029818","ChiCTR2000030933","ChiCTR2000029816","NCT04299724","ChiCTR2000029658","ChiCTR2000029573","ChiCTR2000030259","ChiCTR2000031139","ChiCTR2000029496","ChiCTR2000031089","NCT04251767","NCT04254874","NCT04319900","NCT04323514","ChiCTR2000030987","NCT04323631","NCT04255017","NCT04261270","ChiCTR2000030944","ChiCTR2000030225","ChiCTR2000031494","NCT04264858","NCT04278963","ChiCTR2000031454","ChiCTR2000030539","ChiCTR2000029868","JPRN-jRCTs041190120","EUCTR2020-001271-33-FR","EUCTR2020-001281-11-FR","NCT04304313","ChiCTR2000031328","NCT04320238","NCT04326452","ChiCTR2000031272","ChiCTR2000031196","ChiCTR2000030162","NCT04331613","NCT04333251","ChiCTR2000030988","ChiCTR2000029899","NCT04334967","ChiCTR2000030288","ChiCTR2000029898","ChiCTR2000031203","NCT04335201","ChiCTR2000030198","ACTRN12620000448943","EUCTR2020-000919-69-NL","ChiCTR2000030535","EUCTR2020-001023-14-GB","ChiCTR2000030522","ChiCTR2000031734","NCT04305106","NCT04321928","ChiCTR2000030503","NCT04290871","NCT04324996","ChiCTR2000030328","ChiCTR2000030487","EUCTR2020-001381-11-FR","NCT04322344","EUCTR2020-001435-27-FR","ChiCTR2000031630","EUCTR2020-001366-11-ES","EUCTR2020-000936-23-FR","EUCTR2020-001409-21-ES","NCT04275414","NCT04315298","ChiCTR2000031540","EUCTR2020-001492-33-FR","EUCTR2020-001194-69-ES","NCT04325867","EUCTR2020-001565-37-ES","NCT04326075","NCT04326114","ChiCTR2000031453","NCT04291729","NCT04330144","NCT04303299","NCT04305457","NCT04330586","ChiCTR2000030472","NCT04306393","NCT04310228","NCT04315480","ACTRN12620000454976","NCT04324021","EUCTR2020-001236-10-NL","NCT04331470","EUCTR2020-001010-38-NO","ChiCTR2000031781","ChiCTR2000030471","NCT04331834","NCT04332094","NCT04333407","NCT04334005","NCT04337216","NCT04326036","NCT04337996","NCT04338698","EUCTR2020-001301-23-FR","NCT04327349","EUCTR2020-001335-28-NL","ChiCTR2000030469","NCT04338906","NCT04339660","EUCTR2020-001188-96-FR","NCT04340544","EUCTR2020-001373-70-FR","NCT04331600","NCT04333472","EUCTR2020-001457-43-FR","EUCTR2020-001445-39-ES","ACTRN12620000447954","EUCTR2020-001442-19-ES","NCT04341610","NCT04341935","NCT04343677","ACTRN12620000473965","EUCTR2020-001385-11-ES","ChiCTR2000031834","EUCTR2020-001307-16-ES","ChiCTR2000031735","ChiCTR2000031955","NCT04306055","ChiCTR2000031944","NCT04323800","NCT04328467","ChiCTR2000029976","EUCTR2020-001333-13-FR","EUCTR2020-001303-16-FR","NCT04329832","EUCTR2020-001160-28-ES","EUCTR2020-001421-31-ES","NCT04334512","EUCTR2020-001602-34-FR","EUCTR2020-001606-33-ES","NCT04336254","EUCTR2020-001321-31-ES","NCT04252274","NCT04261517","NCT04337541","EUCTR2020-001413-20-ES","NCT04317092","NCT04325672","EUCTR2020-001765-37-ES","NCT04328012","NCT04338828","NCT04340349","EUCTR2020-001466-11-GR","NCT04341038","NCT04334382","EUCTR2020-001379-34-ES","NCT04344080","NCT04337788","NCT04344951","NCT04338802","ACTRN12620000468921","ACTRN12620000480987","NCT04340414","NCT04341207","EUCTR2020-001324-33-FR","NCT04341415","EUCTR2020-001257-51-DK","EUCTR2020-001320-34-NL","NCT04341922","EUCTR2020-001290-74-ES","ACTRN12620000478910","EUCTR2020-001406-27-FR","ChiCTR2000032098","EUCTR2020-001530-35-ES","EUCTR2020-001587-29-ES","ChiCTR2000030300","EUCTR2020-001634-36-ES","EUCTR2020-001420-34-DK","EUCTR2020-001689-12-ES","EUCTR2019-002688-89-ES","EUCTR2020-001511-25-ES","EUCTR2020-001262-11-ES","EUCTR2020-001553-48-FR","CTRI/2020/04/024479","EUCTR2020-001437-12-ES","EUCTR2020-001682-36-ES","CTRI/2020/04/024659","EUCTR2020-001266-11-ES","EUCTR2020-001448-24-GB","CTRI/2020/03/024402","ChiCTR2000030312","ChiCTR2000029550","JPRN-jRCT2031190264","JPRN-jRCTs031190269","ChiCTR2000029549","ChiCTR2000029479","PACTR202004801273802","ChiCTR2000030896","RBR-6m69fc","RBR-8969zg","ChiCTR2000030894","PACTR202004693933092","NCT03891420","NCT04257656","PACTR202004761408382","NCT04299152","NCT04315987","RBR-3cbs3w","NCT04322565","NCT04325061","RBR-9d8z6m","TCTR20200404004","NCT04328129","PER-010-20","NCT04329611","NCT04331054","NCT04244591","NCT04333628","NCT04334044","NCT04252664","NCT04273321","NCT04334148","TCTR20200409006","NCT04276688","NCT04280224","NCT04338568","NCT04342663","NCT04304690","NCT04315896","NCT04343183","NCT04343690","NCT04252118","NCT04273646","NCT04344015","NCT04318015","NCT04321174","NCT04304053","NCT04320953","NCT04344756","NCT04344782","NCT04321616","NCT04323228","NCT04324073","NCT04324190","NCT04345549","NCT04323345","NCT04327401","NCT04345887","NCT04329533","NCT04331366","NCT04326426","NCT04328961","NCT04346329","NCT04346355","NCT04329650","NCT04346420","NCT04346628","NCT04341285","NCT04347538","NCT04343248","NCT04343755","NCT04347980","NCT04340050","NCT04343794","NCT04341142","NCT04348513","NCT04348695","NCT04342728","NCT04343144","NCT04344288","NCT04344535","NCT04349371","NCT04350671","ChiCTR2000030810","NCT04344106","NCT04351347","NCT04345406","NCT04351763","NCT04344210","NCT04344236","NCT04344444","NCT04344548","NCT04354155","NCT04344730","NCT04346693","NCT04354805","NCT04345445","NCT04346927","NCT04346953","NCT04355247","ChiCTR2000030759","NCT04345653","NCT04347382","NCT04355676","NCT04355767","NCT04345991","NCT04346017","NCT04356534","NCT04346199","NCT04348461","ACTRN12620000492954","NCT04347174","NCT04348864","NCT04348877","NCT04347941","NCT04350593","NCT04348383","NCT04348500","NCT04351295","NCT04351490","ChiCTR2000032237","NCT04349241","NCT04350450","NCT04350684","NCT04351243","NCT04352803","NCT04351542","ISRCTN14326006","NCT04353206","NCT04352400","NCT04352933","NCT04356495","NCT04356508","ISRCTN16912075","NCT04352959","NCT04353284","NCT04356937","ACTRN12620000445976","EUCTR2020-001391-15-IE","EUCTR2017-001100-30-DE","ACTRN12620000457943","EUCTR2020-001366-11-IT","NCT04355026","NCT04357340","ChiCTR2000032214","ChiCTR2000032205","EUCTR2020-001622-64-ES","ChiCTR2000032165","EUCTR2020-001072-15-GB","EUCTR2020-001417-21-BE","EUCTR2020-001244-26-AT","NCT04318444","EUCTR2020-001440-26-ES","EUCTR2020-001469-35-PL","EUCTR2020-001459-42-DK","NCT04320056","NCT04321421","EUCTR2020-001270-29-GB","NCT04324463","EUCTR2020-001310-38-DE","EUCTR2020-001327-13-AT","EUCTR2020-001614-38-BE","NCT04326920","NCT04331899","NCT03648372","NCT04321278","NCT04333654","NCT04317040","NCT04322682","NCT04335097","NCT04336410","NCT04330638","NCT04319445","NCT04321993","NCT04337918","NCT04341675","NCT04331808","NCT04333589","NCT04327505","NCT04329572","NCT04345601","NCT04345679","NCT04332380","NCT04332835","NCT04335084","NCT04335123","NCT04347512","NCT04332991","NCT04334980","NCT04335279","NCT04335032","NCT04337008","NCT04348929","NCT04338009","NCT04343092","NCT04339712","NCT04342689","NCT04353037","NCT04343976","NCT04344431","NCT04344184","NCT04353128","NCT04353518","NCT04351724","NCT04353596","NCT04354389","NCT04345861","NCT04347681","NCT04352348","NCT04354714","NCT04355351","NCT04352608","NCT04354870","NCT04350580","NCT04352946","NCT04357613","ChiCTR2000030580","NCT04355052","NCT04355429","NCT04357782","NCT04357808","NCT04358549","ChiCTR2000030329","NCT04355754","NCT04358783","NCT04359290","NCT04356677","NCT04359316","NCT04359615","NCT04359095","ChiCTR2000030187","NCT04357457","ChiCTR2000029895","NCT04358406","NCT04359329","NCT04359537","NCT04359875","NCT04358614","NCT04359953","ChiCTR2000029837","NCT04358809","NCT04358835","NCT04360096","NCT04361474","NCT04359251","NCT04359264","NCT04360811","NCT04361916","NCT04359680","ChiCTR2000029826","NCT04362124","NCT04362332","NCT04361253","NCT04359901","NCT04362358","NCT04363541","NCT04363749","NCT04361838","NCT04360356","NCT04360551","NCT04363346","NCT04363866","NCT04360759","NCT04360980","NCT04365699","NCT04264533","NCT04363463","NCT04363528","NCT04361422","NCT04361435","NCT04361448","NCT04366050","ACTRN12620000516987","NCT04363853","NCT04365738","NCT04361461","NCT04362085","ISRCTN43900695","ChiCTR2000032573","NCT04362111","ChiCTR2000032487","ACTRN12620000517976","ISRCTN13311119","NCT04363372","ChiCTR2000032632","ChiCTR2000031174","NCT04363385","NCT04363606","EUCTR2020-001686-36-FR","NCT04363840","NCT04364022","EUCTR2020-001717-20-ES","ChiCTR2000030989","EUCTR2020-001172-15-DK","NCT04364893","EUCTR2020-001770-30-BE","NCT04365101","NCT04365127","ChiCTR2000032459","EUCTR2020-001408-41-DE","NCT04365153","ChiCTR2000032135","EUCTR2020-001367-88-DK","EUCTR2020-001198-55-DK","NCT04365582","NCT02765191","NCT04251871","EUCTR2020-001823-15-FR","NCT04292899","NCT04312009","EUCTR2020-001640-26-GB","ISRCTN17898730","NCT04322123","NCT04280705","NCT04326790","EUCTR2020-001678-31-FR","NCT04327206","NCT04328285","EUCTR2020-001734-36-FR","ChiCTR2000030939","NCT04328480","NCT04328441","NCT04330690","EUCTR2020-001722-66-ES","NCT04329923","NCT04331795","NCT04332107","EUCTR2020-001505-22-ES","NCT04332081","NCT04334629","EUCTR2020-001541-39-ES","NCT04333355","NCT04333550","NCT04334928","EUCTR2020-001618-39-ES","NCT04335786","NCT04336332","NCT04338958","NCT04283461","NCT04292730","NCT04340232","NCT04341116","NCT04342182","NCT04312997","NCT04313023","NCT04342897","NCT04343729","NCT04343261","NCT04343768","NCT04315948","NCT04345614","NCT04344457","NCT04345419","NCT04321096","NCT04346589","NCT04348071","NCT04345848","NCT04346615","NCT04328493","NCT04333225","NCT04349098","NCT04351152","NCT04346667","NCT04351906","NCT04352751","NCT04335071","NCT04335136","NCT04347954","NCT04351191","NCT04353674","ChiCTR2000030922","NCT04358068","NCT04355533","NCT04355637","NCT04343989","NCT04358926","NCT04359277","NCT04356690","NCT04356833","NCT04344041","NCT04346082","NCT04358939","NCT04359511","NCT04359797","NCT04346147","NCT04346446","NCT04359810","NCT04360837","NCT04361643","NCT04348370","NCT04348435","NCT04361396","NCT04361942","NCT04362059","NCT04348656","NCT04350320","ChiCTR2000030254","NCT04350476","NCT04350736","NCT04363814","NCT04364009","NCT04363437","NCT04352465","NCT04354428","NCT04364737","NCT04364763","ChiCTR2000030224","NCT04363827","NCT04354597","NCT04354610","NCT04365517","NCT04355728","NCT04356482","NCT04366115","NCT04365972","NCT04357730","NCT04357990","NCT04366180","NCT04366245","NCT04366063","NCT04366089","NCT04358003","NCT04366232","NCT04366791","NCT04366856","NCT04359654","NCT04366960","NCT04366323","NCT04366817","NCT04360824","NCT04367545","NCT04366947","NCT04362813","NCT04363450","NCT04367636","NCT04363502","NCT04363593","NCT04367662","NCT04368013","NCT04366141","NCT04368000","NCT04366739","NCT04263402","NCT04368260","NCT04287686","NCT04308317","NCT04368988","NCT04369469","NCT04368676","NCT04369742","NCT04369794","NCT04313322","NCT04367077","NCT04369456","NCT04370223","ChiCTR2000031319","NCT04368156","NCT04370834","NCT04370288","NCT04370938","NCT04368377","NCT04371393","NCT04371419","ChiCTR2000031204","NCT04371510","NCT04371601","NCT04368845","NCT04371406","NCT04371523","NCT04369066","NCT04369274","ChiCTR2000030923","NCT04371640","NCT04371822","NCT04371926","NCT04371952","EUCTR2020-001162-12-FR","NCT04371965","NCT04370782","NCT04372082","NCT04323332","NCT04372030","NCT04371029","NCT04372589","NCT04323592","NCT04373382","ISRCTN14966673","NCT04372186","ChiCTR2000031639","NCT04373824","NCT04372602","NCT04372628","ChiCTR2000031503","NCT04372693","NCT04373044","NCT04374032","NCT04373135","NCT04373161","ChiCTR2000031501","NCT04372979","NCT04373005","NCT04374149","NCT04373200","NCT04374474","NCT04374539","NCT04373460","NCT04374565","NCT04374019","NCT04374084","NCT04375098","NCT04375124","ChiCTR2000031430","NCT04375774","NCT04374279","NCT04374461","NCT04374552","NCT04376515","NCT04374487","NCT04374526","NCT04374942","EUCTR2020-001386-37-IT","NCT04374786","NCT04374903","NCT04375202","NCT03331445","NCT04298060","NCT04375397","NCT04376476","NCT04375735","NCT04378257","NCT04312243","NCT04316377","NCT04376684","NCT04324528","NCT04328272","NCT04379531","NCT04377477","NCT04377503","NCT04377100","NCT04377308","NCT04380532","NCT04377620","NCT04332666","NCT04377334","NCT04377568","NCT04380948","NCT04377711","NCT04377737","NCT04334850","ACTRN12620000443998","ACTRN12620000555954","ChiCTR2000031772","NCT04377802","NCT04378244","NCT04377750","NCT04377789","ACTRN12620000557932","NCT04378712","NCT04377997","NCT04378803","NCT04378920","ChiCTR2000032717","NCT04379037","NCT04379076","NCT04379336","NCT04379453","ISRCTN44152751","NCT04379271","NCT04379661","NCT04380402","NCT04380519","NCT04379479","ISRCTN50189673","NCT04379492","NCT04379518","NCT04380961","NCT04380376","ChiCTR2000031672","NCT04381052","NCT04380818","NCT04381000","NCT04381013","ACTRN12620000524998","ChiCTR2000032716","ChiCTR2000030750","EUCTR2020-001250-21-FR","NL8547","NL8521","EUCTR2020-001039-29-GR","NL8538","NCT03680274","NCT04288102","NL8490","NCT04322773","NCT04325893","NCT04330300","EUCTR2020-001709-21-FR","NCT04330495","NCT04331665","EUCTR2020-001598-66-FR","EUCTR2020-001632-10-DE","NCT04335851","EUCTR2020-001721-31-GB","EUCTR2020-001825-29-ES","EUCTR2020-001768-27-FR","NCT04336462","EUCTR2020-001643-13-GB","EUCTR2020-002032-69-ES","EUCTR2020-001635-27-FR","EUCTR2020-001411-25-AT","NCT04336904","EUCTR2020-001335-28-DE","EUCTR2020-001827-15-ES","EUCTR2020-001736-95-GB","EUCTR2020-001909-22-FR","EUCTR2020-001395-15-DK","EUCTR2020-001449-38-GB","EUCTR2020-001684-89-GB","EUCTR2020-001994-66-ES","EUCTR2020-001786-36-GB","EUCTR2020-001783-28-HU","EUCTR2020-001296-33-DK","NCT04338074","EUCTR2020-001777-71-GB","EUCTR2020-001882-36-GR","EUCTR2020-001206-35-AT","NCT04339816","EUCTR2020-001891-14-ES","EUCTR2020-001662-11-DE","NCT04342221","EUCTR2020-001697-30-ES","EUCTR2020-001603-16-ES","ACTRN12620000477921","EUCTR2020-001474-29-ES","ACTRN12620000472976","EUCTR2020-001696-32-ES","ACTRN12620000470998","EUCTR2020-001953-36-ES","ChiCTR2000032013","ChiCTR2000032011","ChiCTR2000031888","ChiCTR2000029434","ChiCTR2000029433","EUCTR2020-001156-18-ES","EUCTR2020-001331-26-GB","EUCTR2015-002340-14-NL","EUCTR2020-001254-22-BE","JPRN-jRCTs031190226","JPRN-jRCTs031190227","NCT03042143","NCT04313127","NCT04320277","NCT04322396","NCT04325633","NCT04333420","NCT04334434","NCT04339426","NCT04341584","NCT04342156","NCT04342169","NCT04342650","NCT04343001","NCT04343963","NCT04345276","NCT04345289","NCT04345523","NCT04345692","NCT04346368","NCT04347889","NCT04347915","NCT04349410","NCT04349618","NCT04350086","NCT04350281","NCT04350931","NCT04351620","NCT04351789","NCT04353336","NCT04354441","ACTRN12620000417987","ACTRN12620000482965","ACTRN12620000501943","ACTRN12620000500954","ChiCTR2000032400","ChiCTR2000032399","ChiCTR2000032367","ChiCTR2000032346","ChiCTR2000032314","ChiCTR2000032313","ChiCTR2000032242","ISRCTN86534580","EUCTR2020-001329-30-AT","EUCTR2020-001527-14-NL","EUCTR2020-001363-85-DK","EUCTR2020-001255-40-ES","EUCTR2020-001659-42-ES","EUCTR2020-001536-98-ES","EUCTR2020-001531-27-ES","EUCTR2020-001224-33-DE","EUCTR2020-001500-41-BE","NCT04303507","NCT04311697","NCT04320615","NCT04325906","NCT04333914","NCT04334265","NCT04335305","NCT04341389","NCT04341493","NCT04346797","NCT04348409","NCT04348474","NCT04350073","NCT04354259","NCT04354831","NCT04355234","NCT04355897","NCT04355936","NCT04355962","NCT04357106","NCT04357327","NCT04357366","NCT04357860","NCT04358081","NCT04360876","NCT04361318","NCT04361344","NCT04361526","NCT04361552","NCT04362189","NCT04363736","NCT04364594","NCT04364802","NCT04365439","ISRCTN83971151","ChiCTR2000032456","ChiCTR2000032455","ChiCTR2000030262","RPCEC00000306","RPCEC00000307","RPCEC00000308","EUCTR2020-001571-32-FR","EUCTR2020-001723-13-FR","EUCTR2020-001364-29-ES","EUCTR2020-001888-90-DK","EUCTR2020-001345-38-GR","EUCTR2020-000982-18-NO","NCT04273763","NCT04308668","NCT04311177","NCT04324489","NCT04324606","NCT04327388","NCT04333732","NCT04334460","NCT04336774","NCT04341441","NCT04341688","NCT04341870","NCT04343651","NCT04344561","NCT04344587","NCT04347226","NCT04347239","NCT04349631","NCT04351516","NCT04351581","NCT04353180","NCT04353271","NCT04355143","NCT04355364","NCT04357028","NCT04359225","NCT04360122","NCT04361032","NCT04361214","NCT04362176","NCT04363060","NCT04363203","NCT04363216","NCT04364815","NCT04364828","NCT04365231","NCT04365257","NCT04365309","NCT04365608","NCT04365985","NCT04366271","NCT04366297","NCT04366882","NCT04366908","NCT04367831","NCT04368299","NCT04368728","NCT04368923","NCT04369365","NCT04369378","NCT04369599","NCT04369820","NCT04370015","NCT04370236","NCT04370262","NCT04370886","NCT04371367","NCT04371978","NCT04372004","NCT04372017","NCT04372680","NCT04373096","NCT04373291","NCT04374591","NCT04375046","NCT04376593","NCT04376788","NCT04376814","NCT04377646","NCT04377659","NCT04377672","NCT04379154","NCT04379375","NCT04380688","NCT04380909","NCT04380935","NCT04381338","NCT04381364","NCT04381377","ChiCTR2000032769","ChiCTR2000032737","ChiCTR2000032635","NL8523","NL8577","NL8578","NL8483","NL8491","NL8504","EUCTR2020-001700-42-FR","EUCTR2020-001784-88-FI","EUCTR2020-001766-11-FR","EUCTR2020-001370-30-DE","EUCTR2020-001370-30-GB","EUCTR2020-001228-32-GB","EUCTR2020-001740-26-GB","EUCTR2020-000705-86-ES","EUCTR2020-001302-30-AT","EUCTR2020-001275-32-DK","EUCTR2020-001375-32-NL","EUCTR2020-001934-37-ES","EUCTR2020-002123-11-ES"],["A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With 2019 Novel Coronavirus (2019-nCoV)","A Single-arm Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","Effecacy and safty of convalescent plasma treatment for severe patients with novel coronavirus pneumonia (COVID-19): a prospective cohort study","A Randomized Controlled Trial for Qingyi No. 4 Compound in the treatment of Convalescence Patients of Novel Coronavirus Pneumonia (COVID-19)","Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Randomized controlled trial for TCM syndrome differentiation treatment impacting quality of life of post-discharge patients with novel coronavirus pneumonia (COVID-19)","Randomized, Open, Multicenter Study on the Efficacy and Safety of Arbidol Hydrochloride Tablets in Treating Pneumonia in Patients Infected With Novel Coronavirus (2019-ncov).","A Randomized, Open-label, Controlled, Single-center Study to Evaluate the Efficacy of Intravenous Immunoglobulin Therapy in Patients With Severe 2019- nCoV Pneumonia","Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the 'Truncated Torsion' strategy","A Randomized, Open-label, Controlled Study of the Efficacy of Lopinavir Plus Ritonavir and Arbidol for Treating With Patients With Novel Coronavirus Infection","A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19)","Community based prevention and control for Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in the isolated population","A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19)","Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A Randomized, Open-label, Multi-centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Pneumonia Caused by Novel Coronavirus Infection","A randomized controlled trial for Traditional Chinese Medicine in the treatment for Novel Coronavirus Pneumonia (COVID-19)","A prospective cohort study for the efficacy and safety of chloroquine in hospitalized patients with novel coronavirus pneumonia (COVID-19)","Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study","A Single-blind, Randomized, Controlled Clinical Trial for Chloroquine Phosphate in the treatment of Novel Coronavirus Pneumonia 2019 (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19)","A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, controlled trial for integrated Chinese and western medicine in the treatment of ordinary novel coronavirus pneumonia (COVID-19) based on the ' Internal and External Relieving -Truncated Torsion' strategy","Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial","The evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","The efficacy and safety of carrimycin treatment in patients with novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open and controlled clinical trial for traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Application of Regulating Intestinal Flora in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for honeysuckle decoction in the treatment of patients with novel coronavirus (COVID-19) infection","Key techniques of umbilical cord mesenchymal stem cells for the treatment of novel coronavirus pneumonia (COVID-19) and clinical application demonstration","A prospective randomized double-blind placebo-controlled study of traditional Chinese medicine staging regimen in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19)","Randomized, parallel control, open trial for Qing-Wen Bai-Du-Yin combined with antiviral therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese Medicine, Psychological Intervention and Investigation of Mental Health for Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period","A clinical study for ''Huo-Shen'' particles in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the pharmacodynamics and mechanism of traditional Chinese medicine in the treatment of novel coronavirus infection (COVID-19) based on inflammatory factor network","Optimization of treatment and diagnosis plan for critically ill patients","Safety and effectiveness of human umbilical cord mesenchymal stem cells in the treatment of acute respiratory distress syndrome of severe novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial","Babaodan Capsule used for the adjuvant treatment of severe novel coronavirus pneumonia (COVID-19)","Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Study for application of simplified cognitive-behavioral therapy for related emergency psychological stress reaction of medical providers working in the position of treatment and control of novel coronavirus pneumonia (COVID-19)","A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency","Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial","A multicenter study for efficacy of intelligent psychosomatic adjustment system intervention in the treatment of novel coronavirus pneumonia (COVID-19) patients with mild to moderate anxiety and depression","A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)","Shen-Fu injection in the treatment of severe novel coronavirus pneumonia (COVID-19): a multicenter, randomized, open-label, controlled trial","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","A single-arm, single-center clinical trial for Azivudine tablets in the treatment of adult novel coronavirus pneumonia (COVID-19)","Traditional Chinese Medicine in the treatment of novel coronavirus pneumonia (COVID-19): a multicentre, randomized controlled trial","Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19)","Multicenter, randomized, open-label, controlled trial for the efficacy and safety of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19)","Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19)","Efficacy evaluation of inhalation of mycobacterium vaccae injection for treating Novel coronavirus pneumonia (COVID-19) and the mechanism study of prevention and treatment of respiratory virus infection","A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with novel coronavirus pneumonia (COVID-19)","A Multicenter, Randomized, Parallel Controlled Clinical Study of Hydrogen-Oxygen Nebulizer to Improve the Symptoms of Patients With Novel Coronavirus Pneumonia (COVID-19)","Multicenter randomized controlled trial for rhG-CSF in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study for Human Menstrual Blood-derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","An open, controlled clinical trial for evaluation of ganovo combined with ritonavir and integrated traditional Chinese and Western medicine in the treatment of novel coronavirus infection (COVID-19)","A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of novel coronavirus pneumonia (COVID-19)","Chinese Medicine Promotes Rehabilitation Recommendations after 2019 Novel Coronavirus Infection (COVID-19)","Mental health and psychological interventions on doctors, nurses and patients at the novel coronavirus pneumonia (COVID-19) designated hospitals: a prospective, open, single-center clinical study","A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19)","A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19)","Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province","Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial)","Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients","A Randomized Controlled Trial for Integrated Traditional Chinese Medicine and Western Medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19)","Clinical study for community based prevention and control strategy of novel coronavirus pneumonia (COVID-19) in the isolate suspected and confirmed population","The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Clinical study on safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19)","Pulmonary rehabilitation to improve pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period","Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial","A Real World Study For the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19)","Combination of traditional chinese medicne and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19)","Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19)","A Clinical Trial Study for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy","A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical study of type I macrophages therapy in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection","Clinical Study on Syndrome Differentiation of TCM in Treating Severe and Critical novel coronavirus pneumonia (COVID-19)","The early use of lopinavir/litonavir (LPV/r) and emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of the novel coronavirus pneumonia (COVID-19): a real-world study","Study for safety and efficacy of Jakotinib hydrochloride tablets in the treatment severe and acute exacerbation patients of novel coronavirus pneumonia (COVID-19)","Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San in the treatment of children with novel coronavirus pneumonia (COVID-19)","Clinical Trial for Human Mesenchymal Stem Cells in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Clinical study on novel coronavirus pneumonia (COVID-19) patients in Tibetan Plateau promoted by individualized nutritional assessment and supportive treatment","Efficacy and Safety of Jing-Yin Granule in the treatment of novel coronavirus pneumonia (COVID-19) wind-heat syndrome","Randomized controlled trial for traditional Chinese medicine in the prevention of novel coronavirus pneumonia (COVID-19) in high risk population","The Therapeutic Efficacy of Psychological and Physical Rehabilitation Based Humanistic Care in Patients With  Novel Coronavirus Pneumonia (COVID-19)","Study for evaluation of integrated traditional Chinese and Western Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19)","A multicenter randomized controlled trial for ozone autohemotherapy in the treatment of novel coronavirus pneumonia (COVID-19)","A prospective randomized controlled trial for the home exercise prescription intervention in nursing students during epidemic of novel coronary pneumonia (COVID-19)","Clinical Trial for Recombinant Human Interleukin-2 in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of  Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","Clinical study for ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Umbilical cord Wharton's Jelly derived mesenchymal stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","Single arm study for exploration of chloroquine phosphate aerosol inhalation in the treatment of novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open, parallel controlled trial for the evaluation of the effectiveness and safety of Xiyanping injection in the treatment of common type novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","A randomized controlled study to evaluate the efficacy and safety of hydroxychloroquine for mild and moderate COVID-19 Infectious diseases","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of mild and common novel coronavirus pneumonia (COVID-19)","The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study","A Prospective Randomized Controlled Trial for Home Exercise Prescription Intervention During Epidemic of Novel Coronary Pneumonia (COVID-19) in College Students","Clinical study for infusing convalescent plasma to treat patients with new coronavirus pneumonia (COVID-19)","A multicenter, randomized, double-blind, controlled clinical trial for leflunomide in the treatment of novel coronavirus pneumonia (COVID-19)","Immunoregulatory Therapy for 2019-nCoV-induced Severe Pneumonia Patients","A study for the intervention of Xiangxue antiviral oral solution and Wu-Zhi-Fang-Guan-Fang on close contacts of novel coronavirus pneumonia (COVID-19)","The clinical application and basic research related to mesenchymal stem cells to treat novel coronavirus pneumonia (COVID-19)","Research for the mechanism of improvement of novel coronavirus pneumonia (COVID-19) patients' pulmonary exudation by continuous renal replacement therapy","To evaluate the efficacy and safety of diammonium glycyrrhizinate enteric-coated capsules combined with hydrogen-rich water in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the efficacy of ozonated autohemotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Optimization Protocal of Integrated Traditional Chinese and Western Medicine Treatment for Novel Coronavirus Pneumonia (COVID-19)","The clinical value of corticosteroid therapy timing in the treatment of novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","The efficacy and safety of Triazavirin for 2019 novel coronary pneumonia (COVID-19): a multicenter, randomized, double blinded, placebo-controlled trial","A Randomized  Controlled Trial  for the Influence of TCM Psychotherapy on Negative Emotion of Patients with Novel Coronavirus Pneumonia (COVID-19) Based on Network Platform","Clinical study for novel NLRP Inflammasome inhibitor (Tranilast) in the treatment of novel coronavirus (COVID-19)","A clinical study for probiotics in the regulation of intestinal function and microflora structure of novel coronavirus pneumonia (COVID-19)","Influence of nasal high-fow preoxygenation on video laryngoscope for emergency intubation in patients with critical novel coronavirus pneumonia (COVID-19)","Effect of early pulmonary training on lung function and quality of life for novel coronavirus pneumonia (COVID-19) patients","An open randomized controlled trial for Chloroquine phosphate and Hydroxychloroquine sulfate in the treatment of severe novel coronavirus pneumonia (COVID-19)","A randomized controlled Trial for therapeutic efficacy of Recombinant Human Interferon alpha 1b Eye Drops in the treatment of elderly with novel coronavirus pneumonia (COVID-19)","Severe novel coronavirus pneumonia (COVID-19) patients treated with ruxolitinib in combination with mesenchymal stem cells: a prospective, single blind, randomized controlled clinical trial","Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of Severe Novel Coronavirus Pneumonia (COVID-19)","Experimental study of novel coronavirus pneumonia rehabilitation plasma therapy severe novel coronavirus pneumonia (COVID-19)","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)","A prospective, multicenter, open-label, randomized, parallel-controlled trial for probiotics to evaluate efficacy and safety in patients infected with 2019 novel coronavirus pneumonia (COVID-19)","A randomized controlled trial for the Efficacy of Ultra Short Wave Electrotherapy in the treatment of Novel Coronavirus Pneumonia (COVID-19)","A prospective, randomized, open-label, controlled clinical study to evaluate the preventive effect of hydroxychloroquine on close contacts after exposure to the Novel Coronavirus Pneumonia (COVID-19)","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19)","Medical Masks Versus N95 Respirators to Prevent 2019 Novel Coronavirus Disease (COVID-19) in Healthcare Workers: A Randomized Trial","The Application of Rehabilitation and Lung Eight-segment Exercise in  Home Rehabilitation of Survivors from novel coronavirus pneumonia (COVID-19)","Application of rehabilitation lung exercise eight-segment exercise in patients with novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking Newgen beta-gluten probiotic composite powder to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19)","Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19) with poorly responsive ritonavir/ritonavir","Efficacy and Safety of Pirfenidone in the Treatment of Severe Post-Novel Coronavirus Pneumonia (COVID-19)) Fibrosis:a prospective exploratory experimental medical study","Study for moxibustion in the preventing of novel coronavirus pneumonia (COVID-19)","Single Center, Single Arm, Open Clinical Study to Access Safety and Initial Efficacy of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia","A Prospective, Randomized, Open, Parallel Controlled, Multicenter Clinical Study of Xiyanping Injection in Combination With Conventional Treatment for the Evaluation of the Effectiveness and Safety of Novel Coronavirus Infection Pneumonia","A Randomized, Placebo-Controlled, Multi-Center Study on the Efficacy and Safety of Fuzheng Huayu on Pulmonary Fibrosis Due to 2019-nCoV","Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)","A randomized, open-label study to evaluate the efficacy and safety of Pirfenidone in patients with severe and critical novel coronavirus infection (COVID-19)","Application of rehabilitation and Lung eight-segment exercise in front-line nurses in the prevention of novel coronavirus pneumonia (COVID-19) epidemic","Investigation on psychological status of COVID-19 rehabilitation patients in Zhengzhou City and research on coping strategies","A prospective randomized controlled trial for a Self-made Gastroscope isolation mask for preventing and controlling the novel coronavirus pneumonia (COVID-19) Epidemic period","A randomized, double-blind, placebo-controlled trial for evaluation of  the efficacy and safety of bismuth potassium citrate capsules in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A single arm trial to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of novel coronavirus pneumonia patient (COVID-19)","Clinical research program of continuous renal replacement therapy with adsorption filter for the treatment of the novel coronavirus pneumonia (COVID-19)","A multi-center study on the efficacy and safety of suramin sodium in adult patients with novel coronavirus pneumonia (COVID-19)","A study for the key technology of mesenchymal stem cells exosomes atomization in the treatment of novel coronavirus pneumonia (COVID-19)","Study for the efficacy of Kangguan No. 1-3 prescription in the treatment of novel coronavirus pneumonia (COVID19)","Study of Pinavir / Ritonavir Tablets (Trade Name: Kelizhi) Combined with Xiyanping Injection for Novel Coronavirus Pneumonia (COVID-19)","A multicenter, single arm, open label trial for the efficacy and safety of CMAB806 in the treatment of cytokine release syndrome of novel coronavirus pneumonia (COVID-19)","A parallel, randomized controlled clinical trial for the efficacy and safety of Pediatric Huatanzhike granules (containing ipecacuanha tincture) in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A study on the efficacy and safety of recombinant human interferon alpha 1b spray in preventing novel coronavirus (COVID-19) infection in highly exposed medical staffs.","Multicenter, randomized, open clinical study of Hydroxychloroquine Sulfate tablets in the treatment of common patients with novel coronavirus pneumonia (COVID-19)","Application of blood purification in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled trial for the safety and efficiency of Kesuting syrup and Keqing capsule in the treatment of mild and moderate novel coronavirus pneumonia (COVID-19)","A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19)","A study on treatment strategies of novel coronavirus pnueumonia patients","Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia","Traditional Chinese medicine cooperative therapy for patients with Novel coronavirus pneumonia (COVID-19) and its effect on spermatogenesis: a randomized controlled trial","Clinical Application of ECMO(or Ultra-Protective Lung Mechanical Ventilation) in the Treatment of Patients with ARDS due to novel Coronavirus Pneumonia (COVID-19)","A randomized, double-blind, parallel-controlled, trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia patients (COVID-19)","A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)","A randomized, blinded, controlled, multicenter clinical trial to evaluate the efficacy and safety of Ixekizumab combined with conventional antiviral drugs in patients with novel coronavirus pneumonia (COVID-19)","Liu-Zi-Jue Qigong and Acupressure Therapy for Pulmonary Function and Quality of Life in Patient with Severe novel coronavirus pneumonia (COVID-19): A Randomized Controlled Trial","A Pilot Clinical Study on Aerosol Inhalation of the Exosomes Derived From Allogenic Adipose Mesenchymal Stem Cells in the Treatment of Severe Patients With Novel Coronavirus Pneumonia","Efficacy and safety of honeysuckle oral liquid in the treatment of novel coronavirus pneumonia (COVID-19): a multicenter, randomized, controlled, open clinical trial","A randomized controlled trial for the efficacy of Dao-Yin in the prevention and controlling novel coronavirus pneumonia (COVID-19)","Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection","A Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection","Efficacy and safety of Xue-Bi-Jing injection in the treatment of severe cases of novel coronavirus pneumonia (COVID-19)","A Clinical Study to Investigate the Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With Coronavirus Disease 2019 (COVID-19)","Study on the application of convalescent plasma therapy in severe COVID-19","Randomized controlled trial for the efficacy of dihydroartemisinine piperaquine in the treatment of mild/common novel coronavirus pneumonia (COVID-19)","Zedoary Turmeric Oil for Injection in the treatment of Novel Coronavirus Pneumonia (COVID-19): a randomized, open, controlled trial","Study on the effect of human placenta biological preparation on the defense of immune function against novel coronavirus pneumonia (COVID-19)","Clinical Prediction and Intervention of Pulmonary Function Impairment in Patients with Novel Coronavirus Pneumonia (COVID-19)","Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (NCP)","HUMSCs and Exosomes Treating Patients with Lung Injury following Novel Coronavirus Pneumonia (COVID-19)","Randomized, open, blank controlled trial for the efficacy and safety of recombinant human interferon alpha 1beta in the treatment of Wuhan patients with novel coronavirus pneumonia (COVID-19)","Clinical Study of Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells","Study for the Effectiveness and Safety of Yi-Qi Hua-shi Jie-Du-Fang in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","The Effect and Safety of cytokine removal therapy in Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19) adult patients: a Prospective Open-label Study","Prospective exploratory clinical research on the efficacy and safety of pirfenidone capsules in the treatment of severe novel coronavirus pneumonia (COVID-19)","The Effect and Safety of oXiris Membrane Treating Critically Ill Hospitalized Adult Patients with novel coronavirus pneumonia (COVID-19): a Single Center Prospective Open-label Study","Psychological Support for Diagnosed Patients with novel coronavirus pneumonia (COVID-19)","Effect of Auricular point pressing on insomnia of 2019 new coronavirus pneumonia patients: a randomized controlled trial.","A multicenter, randomized, open-label, parallel controlled trial for the safety and efficacy of Integrated Chinese and Western Medicine in treatment of non-critical novel coronavirus pneumonia (COVID-19): pilot study","Convalescent plasma for the treatment of severe and critical novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial","Comparative study for integrate Chinese and conventional medicine the the treatment of novel coronavirus pneumonia (COVID-19) in Hu'nan province","A Multicenter, Randomized, Controlled trial for Recombinant Super-Compound Interferon (rSIFN-co) in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects - STOP PIV - Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects","Randomized, Open, Blank Control Study on the Efficacy and Safety of Recombinant Human Interferon a1 in the Treatment of Patients With New Type of Coronavirus Infection in Wuhan","A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with 2019-nCoV infection","Evaluation of the protective effect of dexmedetomidine on patients with severe new coronavirus pneumonia","Clinical study for TCM Decoction in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19)","Evaluation of the effect of taking tricholoma matsutake, cannabis sativa capsule and dendrobium candidum to nutrition intervention of patients with novel coronavirus pneumonia (COVID-19) during convalescence.","Novel covid-19 pneumonia combined with Chinese and Western medicine based on ''Internal and External Relieving -Truncated Torsion'' strategy","Study for the effect of external diaphragmatic pacing assisted invasive ventilation and weaning in patients with severe new coronavirus pneumonia","Clinical study on the efficacy of Mesenchymal stem cells (MSC) in the treatment of severe novel coronavirus pneumonia (COVID-19)","A multicenter, randomized controlled trial for the efficacy and safety of Alpha lipoic acid (iv) in the treatment of patients of severe novel coronavirus pneumonia (COVID-19)","Treatment of Acute Severe COVID-19 With Immunoglobulin From Cured COVID-19 Patients","Treatment of Coronavirus SARS-Cov2 Respiratory Infections with Hydroxychloroquine - SARS-CoV2quine","Study on the pathogenesis and effective intervention of mood disorders caused by the novel coronavirus pneumonia (COVID-19)","Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19: a Prospective, Multicenter, Randomized, Parallel Controlled Clinical Study","Human Umbilical Cord Mesenchymal Stem Cells Treatment for Pneumonia Patients Infected by 2019 Novel Coronavirus","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study","Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial","An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19","A randomized, open-label, controlled trial for the efficacy and safety of  Ulinastatin Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID-19)","The therapeutic efficacy of combination of Tocilizumab, IVIG and CRRT in sever patients with novel coronavirus pneumonia (COVID-19)","Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Study of Chloroquine Phosphate in the Treatment of 2019-nCoV Infection","Continuous renal replacement therapy (CRRT) alleviating inflammatory response in severe patients with novel coronavirus pneumonia (COVID-19) associated with renal injury: A Prospective study","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical Performance of the VivaDiag  COVID-19 lgM / IgG Rapid Test in a Cohort of Negative Patients for Coronavirus Infection for the Early Detection of Positive Antibodies for COVID-19","Metabolic abnormalities and rearrangement reversal treatment of patient with novel coronavirus pneumonia (COVID-19)","A randomized, parallel controlled open-label trial to evaluate the efficacy and safety of Prolongin (Enoxaparin Sodium Injection) in adult hospitalized patients with novel coronavirus pneumonia (COVID-19)","An evaluative clinical study: efficacy and safety of of Prolongin (Enoxaparin Sodium Injection) in treatment of hospitalized adult patients with common novel coronavirus pneumonia (COVID-19)","Prognosis Investigation and Intervention Study on Patients with novel coronavirus pneumonia (COVID-19) in recovery period Based on Community Health Management","Study for ''Bai-Du Duan Fang'' application on the acupoint in the treatment of general type novel coronavirus pneumonia (COVID-19)","Convalescent plasma for the treatment of common COVID-19: a prospective randomized controlled trial","An anaesthesia procedure and extubation strategy for reducing patient agitation and cough after extubation that can be used to prevent the spread of SARS-CoV-2 and other infectious viruses in the operating Room","Gu-Shen Ding-Chuan-Wan used in the recovery phase of 2019-nCoV pneumonia(FeiPiQiXuZheng): a randomized, open-label, controlled clinical trial","Observation Of Clinical Efficacy And Safety Of Bufonis Venenum Injection In The Treatment Of Severe Novel Coronavirus Pneumonia (COVID-19)","A multicentre, randomized, controlled trial for the Ba-Duan-Jin in the adjunctive treatment of patients with common type novel coronavirus pneumonia (COVID-19)","Positively Controlled Clinical Study of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)","Clinical comparative study of PD-1 mAb in the treatment of severe and critical patients with novel coronavirus disease (COVID-19)","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumonia (COVID-19)","Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)","Traditional Chinese Medicine 'Zang-Fu Point-pressing' massage for children with novel coronavirus pneumonia (COVID-19)","Study for meditation assists for the rehabilitation of patients with novel coronaviruse pneumonia (COVID-19)","Randomized Controlled Clinical Trials of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)","Efficacy and safety of chloroquine phosphate inhalation combined with standard therapy in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, controlled and single-center trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Perioperative immune prediction and intervention of tumor patients undergoing surgery during the novel coronavirus pneumonia (COVID-19) outbreak period","A randomized controlled trial for high-dose Vitamin C in the treatment of severe and critical novel coronavirus pneumonia (COVID-19) patients","Effects of different VTE prevention methods on the prognosis of hospitalized patients with novel coronavirus pneumonia","Clinical Study for Umbilical Cord Blood Plasma in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Effectiveness of ''Liu-Zi-Jue'' combined with respiratory muscle training for respiratory function in COVID-19 patients: a demonstration study for the key techniques","Clinical Study of  Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19)","Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine","Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19): a randomized clinical trial","A multicenter, randomized, open, controlled clinical study to evaluate the efficacy and safety of recombinant cytokine gene-derived protein injection in combination with standard therapy in patients with novel coronavirus infection","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel coronavirus infection (COVID-19): a randomized, open and controlled trial","Safety and Effectiveness of Human embryonic stem cell-derived M cells (CAStem) for Pulmonary Fibrosis Correlated with novel coronavirus pneumonia(COVID-19)","A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection on clearing novel coronavirus in patients with novel coronavirus pneumonia (COVID-19)","Clinical Research on Treatment of COVID-19 (mild and moderate cases) with Toujiequwen Granules","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection: a Randomized, Double-blind, Placebo-controlled Study","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Two Therapeutic Schemes(Abidol Hydrochloride,Abidol Hydrochloride Combined With Interferon Atomization)in the Treatment of 2019-nCoV Pneumonia.","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia","Use of Ascorbic Acid in Patients With COVID 19","Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of novel coronavirus pneumonia (COVID-19)","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Three Antiviral Drugs(Abidol Hydrochloride, Oseltamivir and Lopinavir/Ritonavir) in the Treatment of 2019-nCoV Pneumonia.","A Randomized,Open,Controlled Small Sample Clinical Study to Evaluate the Efficacy and Safety of ASC09/Ritonavir Compound Tablets and Ritonavir for 2019-nCoV Pneumonia","An open, multi-center, control, exploratory clinical study of human NK cells and UC-MSCs transplantation for severe novel coronavirus pneumonia","Clinical Reseach of Acupuncture in the treatment of Novel Coronavirus Pneumonia (COVID-19)","Clinical study for stem cells in the treatment of severe novel coronavirus pneumonia (COVID-19)","An Exploratory Clinical Study on the Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured 2019-nCoV Pneumonia Patients","Adaptive, Randomized, Single-blind, Three-arm Parallel Controlled Clinical Trial of Yinhu Qingwen Decoction in the Treatment of Mild / Common CoVID-19","Clinical study for prevention and treatment of digestive tract lesions caused by novel coronavirus pneumonia (COVID-19)","Study for the effect of 3% hydrogen peroxide gargle on the Intraoral novel coronavirus of the patients with novel coronavirus pneumonia (COVID-19)","Hydroxychloroquine treating novel coronavirus pneumonia (COVID-19): a randomized controlled, open label, multicenter trial","Multicenter, open-label, randomized trial of favipiravir in asymptomatic and minimally symptomatic patients infected with SARS-CoV2 to evaluate viral load reduction","HYCOVID - Hydroxychloroquine versus placebo chez les patients ayant une infection COVID-19  risque daggravation secondaire : tude prospective multicentrique randomise en double aveugle - HYCOVID","Evaluation of the concentration/viral effect relationship of hydroxychloroquine in COVID-19 patients in the intensive care unit.","A Pilot Study of Sildenafi in the Treatment of COVID-19","The protective effect of sleep psychology and music therapy in patients with new coronary pneumonia (mild and moderate type)","An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area","The Use of a Bidirectional Oxygenation Valve in the Management of Respiratory Failure Due to COVID-19 Infection","The effectiveness of mindfulness intervention in improving people's psychological and physical well-being during novel coronavirus pneumonia (COVID-19) outbreak","Clinical efficacy of novel coronavirus infection treated by combination of interferon regimen and Ritonavir Tablets","Cancelled                         Study for the water extract of soybean in the treatment of patients with novel coronavirus pneumonia (COVID-19)","Safety and Efficacy Study of Human Embryonic Stem Cells Derived M Cells (CAStem) for the Treatment of Severe COVID-19 Associated With or Without Acute Respiratory Distress Syndrome (ARDS)","Evaluating Convalescent Plasma to Decrease Coronavirus Associated Complications. A Phase I Study Comparing the Efficacy and Safety of High-titer Anti-Sars-CoV-2 Plasma vs Best Supportive Care in Hospitalized Patients With Interstitial Pneumonia Due to COVID-19","Efficacy and safety of Chinese Herb Medicine Hua-Shi Bai-Du granules in patients with novel coronavirus pneumonia (COVID-19) in Wuhan, China: a prospective, randomized, controlled, open-label trial","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Mild and Commen Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-label, Parallel, Controlled Trial","Randomized Study to Evaluate the Safety and Antiviral Efficacy of Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care Treatment","Study on Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19) With Traditional Chinese Medicine","Evaluation the Efficacy and Safety of Hydroxychloroquine Sulfate in Comparison with Phosphate Chloroquine in Severe Patients with Novel Coronavirus Pneumonia (COVID-19): a Randomized, Open-Label, Parallel, Controlled Trial","Study for the effect of Moxibustion Guidance and Intervention based on internet for the discharged patients with novel coronavirus pneumonia (COVID-19)","Use of Defibrotide to Reduce Progression of Acute Respiratory Failure Rate in Patients With COVID-19 Pneumonia","Effect of pulmonary rehabilitation on pulmonary function, exercise capacity, activity of daily living and quality of life in survivors due to severe or critial novel coronavirus pneumonia (COVID-19)","Expressive Writing To Combat Distress Associated With The COVID-19 Pandemic In People With Inflammatory Bowel Disease","Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Gurin vaccination, a randomized controlled trial (COVID-19). - BCG-CORONA","Multi-Center Clinical Study on the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19) by Ebastine","A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection (COVID-19) - Phase II trial of inhaled anti-viral (SNG001) for SARS-CoV-2 infection","Efficacy and safety of Ma-Xing-Gan-Shi decoction in the treatment of novel coronavirus pneumonia (COVID-19)","Evaluation Danorevir sodium tablets combined with ritonavir in the treatment of novel Coronavirus Pneumonia (COVID-19): a randomized, open-label, controlled trial","The Efficacy and Safety of Bevacizumab in Severe or Critical Patients With COVID-19--a Multicenter Randomized Controlled Clinical Trial","Personalized Health Education Against the Health Damage of COVID-19 Epidemic in Hungary (PROACTIVE-19)","Effecacy and safty of extracorporeal blood purification therapy for severe patients with novel coronavirus pneumonia (COVID19): a prospective cohort study","Nitric Oxide Gas Inhalation Therapy for Severe Acute Respiratory Syndrome Due to COVID-19.","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells Secreting IL15 Superagonist and GM-CSF-neutralizing scFv for Therapy of COVID-19","Clinical application of inhaled acetylcysteine solution in the treatment of novel coronavirus pneumonia (COVID-19)","A single-center, single-arm clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","COVID-19 - ACE inhibitors or ARBs discontinuation for Clinical Outcome Risk reduction in patients hospitalized for the Endemic Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection: the randomized ACORES-2 study - ACORES-2","Efficacy and Safety of Escin as add-on Treatment in Covid-19 Infected Patients","Home treatment of elderly patients with symptomatic SARS-CoV-2 infection (COVID-19) : a multiarm, multi-stage (MAMS) randomized trial to assess the efficacy and safety\nof several experimental treatments to reduce the risk of hospitalization or death\n(COVERAGE trial) - COVERAGE","Clinical study for Celebrex in the treatment of novel coronavirus pneumonia (COVID-19)","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults - DisCoVeRy","A prospective, multicenter, randomized, parallel, double-blind, placebo-controlled phase IIb clinical trial to evaluate intravenous infusion of Defibrotide in the prevention and treatment of respiratory distress and cytokine release syndrome in patients with COVID-19. - DEFACOVID","A Pilot Study of Bevacizumab in the Treatment of Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)","An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID-19","Study for clinical effect of rehabilitation nursing program for patients with novel coronavirus pneumonia (COVID-19)","Interest in the administration of Dornase alpha aerosol in ARDS secondary to respiratory infection by the coronavirus SRASCoV-2 / COVID-19 - COVID19-COVIDornase","Pilot study to evaluate the efficacy and safety of mefloquine as prophylaxis in people exposed to the disease caused by the SARS-CoV-2 coronavirus (COVID-19) - MEFLOCOVID-19","Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. - PrEP_COVID","EC-COVID-RCT. Early CPAP in COVID Patients With Respiratory Failure. A Randomized Clinical Trial","Effectiveness and Safety of Respiratory Training Devices in the Prevention and Severity of COVID-19: A Randomized Controlled Clinical Trial","Efficacy and safety of Nintedanib esilate soft capsules in the treatment of pulmonary fibrosis in healed moderate to severe patients of novel coronavirus pneumonia (COVID-19): a single-center, randomized, placebo-controlled trial","An Open Clinical Trial to Evaluate Ganovo(Danoprevir ) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","A Study of Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)","A 6 Week Prospective, Open Label, Randomized, in Multicenter Study of, Oseltamivir Plus Hydroxychloroquine Versus Lopipinavir/ Ritonavir Plus Oseltamivir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine in Mild COVID-19 AND Lopipinavir/ Ritonavir Plus Oseltamivir Versus Favipiravir Plus Lopipinavir / Ritonavir Versus Darunavir/ Ritonavir Plus Oseltamivir Plus Hydroxychloroquine Versus Favipiravir Plus Darunavir and Ritonavir Plus Hydroxychloroquine in Moderate to Critically Ill COVID-19","Nitric Oxide Gas Inhalation Therapy in Spontaneous Breathing Patients With Mild/Moderate COVID-19: a Randomized Clinical Trial","A Trial of Ciclesonide Alone or in Combination With Hydroxychloroquine for Adults With Mild COVID-19","An open and controlled clinical study to evaluate the efficacy and safety of Ganovo combined with ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019-A Multicenter, Randomized and Controlled Clinical Trial Study","Tocilizumab (RoActemra) as Early Treatment of Patients Affected by SARS-CoV2 (COVID-19) Infection With Severe Multifocal Interstitial Pneumonia","High-dose intravenous zinc (HDIVZn) as adjunctive therapy in COVID-19 positive critically ill patients: A pilot randomized controlled trial","A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFN?) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection.","COUNTER-COVID - Oral imatinib to prevent pulmonary vascular leak in COVID-19  a randomized, single-blind, placebo controlled, clinical trial in patients with severe COVID-19 disease - CounterCovid Study","Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease","NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFECTION - NO-COVID-19","A randomized, double-blinded, placebo-controlled phase II clinical trial for Recombinant Novel Coronavirus (2019-nCOV) Vaccine (Adenovirus Vector) in healthy adults aged above 18 years","Efficacy and safety of lipoic acid injection in reducing the risk of progression in common patients with novel coronavirus pneumonia (COVID-19)","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic: A Unicentric, Double-Blinded Randomized Controlled Trial","Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","Effect of Vitamin D Administration on Prevention and Treatment of Mild Forms of Suspected Covid-19","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation","Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection","Dynamic Evaluation of COVID-19 Diagnostic Tests","Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment","Efficacy of Addition of Naproxen in the Treatment of critically ill Patients Hospitalized for COVID-19 Infection / Enacovid Study - ENACOVID","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo","A randomized parallel controlled trial for LIUSHENWAN in Treatment of Novel Coronavirus Pneumonia (COVID-19)","Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection","Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia","Chemoprophylaxis of SARS-CoV-2 infection (COVID-19) in exposed healthcare workers: a randomized double-blind placebo-controlled clinical trial - COVIDAXIS","Hydroxychloroquine for the Treatment of Mild COVID-19 Disease","IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizumab) versus standard of care in advanced or metastatic cancer patients with SARS-CoV-2 (COVID-19) infection\r\n\r\n - IMMUNONCOVID-20","Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Effectiveness and Safety of Chloroquine Phosphate in Combination With Telemedicine in the Reduction of Risk of Disease-related Hospitalization or Death, in Ambulatory Patients With COVID-19 at Particular Risk of Serious Complications","Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial","Dexamethasone and oxygen support strategies in ICU patients with Covid-19 pneumonia - COVIDICUS","PRAGMATIC, CONTROLLED, OPEN, SINGLE CENTER, RANDOMIZED, PHASE II CLINICAL TRIAL TO EVALUATE METHYLPREDNISOLONE PULSES AND TACROLIMUS IN HOSPITALIZED PATIENTS WITH SEVERE PNEUMONIA SECONDARY TO COVID-19 (TACROVID)","Use of therapeutic drug monitoring (TDM) to optimise oral/enteral hydroxychloroquine dosing in critically ill patients with COVID-19","Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19) - TCOVID","Allogeneic Adipose Tissue Derived Mesenchymal Stromal Cell Therapy for Treating Patients With Severe Respiratory COVID-19. A Danish, Double-blind, Randomized Placebo-controlled Study","Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes","Military COVID-19 Hydroxychloroquine Pre-exposure and Post-exposure Prophylaxis Study","Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM85","Prevention of SARS-CoV-2 (COVID-19) through Pre-Exposure Prophylaxis with Tenofovir disoproxil/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial controlled with placebo - EPICOS","A clinical study for the effect of remote monitoring exercise rehabilitation on the discharged patients with novel coronavirus pneumonia (COVID-19)","Efficacy and Safety of corticoids in patients with adult respiratory distress syndrome (ARDS) secondary to COVID-19. - Steroids In Coronavirus (SIC)","Clinical study for natural killer (NK) cells from umbilical cord blood in the treatment of viral pneumonia include novel coronavirus pneumonia (COVID-19)","Study on the prevention of COVID-19 with Chinese medicine regulating constitution","Blood Donor Recruitment During Epidemic of COVID-19 in Guangzhou, China","Efficacy of Chinese Herbal Tea in the Prevention of Novel Coronavirus Pneumonia (COVID-19) for Returning Workers in Wuhan: a Randomized Controlled Trial","Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","Pre-exposure Prophylaxis for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","Novel coronavirus pneumonia (COVID-19) emergency research project tackled by Shanghai University of Traditional Chinese Medicine","Dexamethasone associated with hydroxychloroquine vs. hydroxychloroquine alone for the early treatment of severe ARDS caused by COVID-19 : a randomized controlled trial - DHYSCO","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on Survival in Elderly Hospitalized Patients with VIDOC-19 : A Randomized, Multi-Centre, Adaptive, Blinded Study - COVID-Aging","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS): A Prospective Pragmatic Trial","A Randomized, Controlled, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Tocilizumab Combined with Pembrolizumab (MK-3475) in Patients with Coronavirus Disease 2019 (COVID-19)-Pneumonia Who Are Unresponsive to Standard Care - Tocilizumab plus Pembrolizumab in COVID-19  (COPERNICO Study)","Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals.","A Phase II Pilot Study of Quintuple Therapy to Treat COVID-19 Infection","COvid-19 and Vitamin D supplementation: a multicenter randomized controlled Trial of high dose versus standard dose vitamin D3 in high-risk COVID-19 patients - CoVitTrial","Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","Prospective, phase II, randomized, open-label, parallel group study to evaluate the efficacy of hydroxychloroquine together with baricitinib, imatinib or early lopinavir / ritonavir in patients with SARS Cov2 pneumonia (COVID-19 HUF) - COVID-19 HUF","Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19","Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System","Phase 2, randomized, open-label study to compare the efficacy and safety of siltuximab vs. corticosteroids in hospitalized patients with COVID19 pneumonia","Multicenter Study on the Efficacy and Tolerability of Tocilizumab in the Treatment of Patients With COVID-19 Pneumonia","Convalescent Plasma to Limit Coronavirus Associated Complications: An Open Label, Phase 2A Study of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19","Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive without radiological alteration and sars-cov-2 positive professionals without radiological alteration","Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive randoMizED Clinical Trial During the COVID-19 Pandemic (COVID MED Trial)","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the Emergency Department","Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals","suPAR-GUIDED ANAKINRA TREATMENT FOR VALIDATION OF THE RISK AND EARLY MANAGEMENT OF SEVERE RESPIRATORY FAILURE BY COVID-19: THE SAVE OPEN-LABEL, NON-RANDOMIZED SINGLE-ARM TRIAL","Open Randomized Single Centre Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With Severe Lung Injury Secondary to COVID-19","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial","Sedation with sevoflurane versus propofol in patients with Acute Respiratory Distress Syndrome caused by COVID-19 infection","Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With Symptoms of Confirmed or Probable COVID-19 Disease","Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial","Efficacy and Safety of Nintedanib Ethanesulfonate Soft Capsule in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID-9(COVID 19) : a Single-center, Randomized, Placebo-controlled Study","Randomised Controlled Trial of Problem Management Plus versus Enhanced Treatment as Usual on Anxiety and Depression in People Distressed by Covid 19","Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers: A randomised placebo-controlled trial","Safety and Effectiveness Study of Low Flow Extracorporeal Membrane Oxygenation(CO2 Removal) Driving by Continuous Hemofiltration Machine the Severe New Corovirus Pneumonia (NCP)","COVID 19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease Upon Hydroxychloroquine and Azithromycin Therapy in French Cancer Patients","Use of a respiratory multiplex PCR and procalcitonin to reduce antibiotic exposure in patients with severe confirmed COVID-19 pneumonia : a multicenter, parallel-group, open-label, randomized controlled trial - MULTI-COV","Randomized Double Blinded Monocentric Clinical Trial to Assess the Impact of Auricular Vagus Nerve Neuromodulation in COVID-19 Positive Inpatients Outcome.","The Danish Pre-HCQ Dialysis Study:\r\n Hydroxychloroquine for prevention of COVID-19 in dialysis-treated patients with end-stage renal disease -\r\nA multicenter parallel-group open randomized clinical trial\r\n - The Danish Pre-HCQ COVID19 Dialysis Study","A double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease (COVID-19) - PRAETORIAN-COVID","Evaluation of a Brief Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic: A Randomized Controlled Trial","Efficacy and safety of sarilumab in the early treament of hospitalized patients with mild-moderate neumonia and COVID19 infection versus standard of care - SARICOVID","Cord Blood Therapy to prevent progression of COVID-19 related pneumonia","Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19","Clinical study for Danggui Shaoyao Powder in the treatment of novel coronavirus pneumonia (COVID-19)","Randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts. COVID-19","Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy","Umbilical cord mesenchymal stem cells for the treatment of patients at high risk of novel coronavirus pneumonia  (COVID-19): a single-center, prospective, open clinical study","Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection.","Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency\n A Randomized, Open-Label, Phase II Trial - COVIPOC","COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)","Phase 1/2 clinical study to assess the feasibility, safety, tolerability and preliminary efficacy of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2, in patients with acute respiratory distress syndrome. (included patients COVID-19)","Randomized open-blind controlled trial to study the benefit of Colchicine in Patients with COVID-19 - COL-COVID","Randomized, controlled, blinded clinical trial for the evaluator, to evaluate the efficacy and safety of treatment with cyclosporine A (CsA) associated with standard treatment versus standard treatment only in hospitalized patients with confirmed infection by COVID-19 - FJD-COVID19-20-01","Corticodes au cours de la pneumonie virale Covid-19 lie  linfection par le SARS-Cov-2 - CORTI-Covid","Open labelled Randomised controlled trial to study the effect of Chloroquine in addition to standard therapy in COVID-19 patients","Random, controlled, open, one-site clinical trial in adult patients with COVID-19 severe pneumonia treated with immunomodulatory drugs","Double-blind, placebo-controlled phase I/II clinical trial to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSV-allo) in acute respiratory failure in patients with COVID-19 pneumonia.\r\n - Treatment of COVID.19 with allogeneic mesenchymal cells  (MSV).","An open labelled trial to evaluate safety and efficacy of SSV Formulation to boost immunity in quarantine patients of COVID-19","Two-center, randomized, controlled clinical trial with two treatment arms to evaluate the safety and efficacy of intravenous administration of expanded allogeneic adipose tissue adult mesenchymal cells in critically ill patients COVID-19.","Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19\n - COVIDSurgRCT_v1.0_20200330","Hydroxy Chloroquine, in open labelled, Randomised intervention for prevention of new infection and adverse outcomes following COVID-19 infection- A Tertiary Hospital based study - CORONA study","A single-center, open-label and single arm trial to evaluate the efficacy and safety of anti-SARS-CoV-2 inactivated convalescent plasma in the treatment of novel coronavirus pneumonia (COVID-19) patient","Recommendations for Diagnosis and Treatment of Influenza Patients in the Hospital of Chengdu University of Traditional Chinese Medicine Under the Raging of Novel Coronavirus Pneumonia (COVID-19)","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT)","A multicenter, open-label, randomized controlled trial to evaluate the efficacy and safety of inhaled ciclesonide for asymptomatic and mild patients with COVID-19 - RACCO trial","Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19)","Research for Traditional Chinese Medicine Technology Prevention and Control of Novel Coronavirus Pneumonia (COVID-19) in the Community Population","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of Chloroquine Phosphate and Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients in Lagos State","Clinical Application and Theoretical Discussion of Fuzheng Qingfei Thought in Treating Non-Critical Novel Coronavirus Pneumonia (COVID-19)","Therapeutic Pulmonary Telerehabilitation Protocol in patients affected by COVID-19, confined in their homes: Randomized Control Trial","Clinical Trial using N-acetylcysteine for treatment of 2019-nCoV Pneumonia","Favipiravir Combined With Tocilizumab in the Treatment of novel coronavirus pneumonia (COVID-19) - A Multicenter, Randomized, Controlled Trial","Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)","A Phase 1b Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Pharmacokinetics, and Anti-viral Effects of Galidesivir Administered Via Intravenous Infusion to Subjects With Yellow Fever or COVID-19","A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.","Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial","Clinical Application of Stem Cell Educator Therapy for the Treatment of Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","Exploratory Clinical Study to Assess the Efficacy of NestCell Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","Randomized, pragmatic, open study evaluating Hydroxychloroquine for prevention of Hospitalization and Respiratory Complications in outpatients with confirmed or presumptive diagnosis of Infection by (COVID-19)","COLCHICINE TO COUNTERACT INFLAMMATORY RESPONSE IN COVID-19 PNEUMONIA","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","Open and controlled trial of hydroxychloroquine and azytromicyn use to prevent complications in patients infected by new coronavirus (COVID-19): a randomized controlled trial - Brazil COVID Coalition I Trial","Comparative effectiveness of chloroquine and vitamin C prophylaxis in household contacts of confirmed COVID-19 patients","Household Transmission Investigation Study for Coronavirus Disease 2019 (COVID-19) in French Guiana","SOLIDARITY: AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL TO EVALUATE NON-LICENSED COVID-19 TREATMENTS IN ADDITION TO STANDARD OF CARE AMONG HOSPITALIZED PATIENTS","A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Oral Hydroxychloroquine for the Treatment of SARS-CoV-2 Positive Patients for the Prevention of Severe COVID-19 Disease.","Protective Role of Inhaled Steroids for Covid-19 Infection","Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by COVID-19: a Prospective, Randomized Controlled Trial","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19 in A Two Staged, Multicenter, Open Label and Randomized Trial","Treatment of Severe Acute Respiratory Syndrome Caused by COVID-19 With Ruxolitinib","A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Mild and Moderate COVID-19.","Efficacy and Safety of Corticosteroids in COVID-19: A Prospective Randomized Controlled Trails","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine Trial (HERO-HCQ Trial)","Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19","An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection","Clinical Investigation of Natural Killer Cells Treatment in Pneumonia Patients Infected With 2019 Novel Coronavirus","Accuracy and Inter-observer Variability of Lung Ultrasound in COVID-19 Pneumonia","A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection","COVID-19 Seroconversion Among Medical and Paramedical Staff in Emergency, ICU and Infectious Disease Services During the 2020 Epidemic","Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)","Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection","Effectiveness of Crisis Management Coaching on Faculty and Trainee Wellness During COVID-19 Crisis","Safety and Efficiency of Mesenchymal Stem Cell in Treating Pneumonia Patients Infected With COVID-19","Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19","Collection of COVID-19 Convalescent Plasma","Chemoprophylaxis With Hydroxychloroquine in Healthcare Personnel in Contact With COVID-19 Patients: A Randomized Controlled Trial (PHYDRA Trial)","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","Treatment of Non-severe Confirmed Cases of COVID-19 and Chemoprophylaxis of Their Contacts as Prevention Strategy: a Cluster Randomized Clinical Trial (PEP CoV-2 Study)","Non-contact Endoscopy at Covid-19 Outbreak","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial","The (Norwegian) NOR Solidarity Multicenter Trial on the Efficacy of Different Anti-viral Drugs in SARS-CoV-2 Infected Patients","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","Online Support for Psychosocial Stress in the Context of the COVID-19 Pandemic","Ayurveda Self-Management for Flu Like Symptoms in People Self-Isolated for 7 Days During the Coronavirus Disease 2019 (COVID-19) Outbreak","The Efficacy of Natural Honey in Patients Infected With Novel Coronavirus (COVID-19) : A Randomized, Controlled ,Single Masked , Investigator Initiated, Multi-center Trial","COVID-19-associated ARDS Treated With DEXamethasone: an Open-label, Randomized, Controlled Trial: CoDEX (Alliance Covid-19 Brasil III)","The Effect of Spironolactone on Oxygenation in Covid-19 ARDS Patients","Effects of a Mobile Meditation App on Stress During COVID-19 Pandemic in Outpatient Obstetrics and Gynecology Patients; a Randomized Controlled Trial","GO2 PEEP Study: The Use of a Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection","Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study","Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to SARS-Cov-2","An Open-label Randomized Multicenter Study to Evaluate the Efficacy of Early Administration of Tocilizumab (TCZ) in Patients With COVID-19 Pneumonia","Phase 2, Randomized, Open-label Study to Compare Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia","Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19","A Phase 2 Randomized, Open Label Study of Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19","Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)","Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19","A Randomized, Double-Blind, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)","Phase IIa Study Exploring the Safety and Efficacy of Convalescent Plasma From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment for Hospitalized Subjects With COVID-19 Infection","Dexamethasone Combined With Hydroxychloroquine Compared to Hydroxychloroquine Alone for Treatment of Severe Acute Respiratory Distress Syndrome Induced by Coronavirus Disease 19 (COVID-19): a Multicentre, Randomised Controlled Trial","Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center","Using Biovitals Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19","Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER","Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)","Randomized Phase II Clinical Trial of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.Ruxo-Sim-20 Clinical Trial.","Coronavirus Disease 2019- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ) Research Study A Randomized, Open Label Single Center Study","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial","Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection","Convalescent Plasma to Reduce Complications Associated With COVID-19 Infection: A Randomized Trial Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Standard Plasma in Hospitalized Patients With COVID- 19 Infection","Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","Clinical observation and evaluation of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19) in Hubei 672 Orthopaedics Hospital of Integrated Chinese&amp;Western Medicine","Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)","Clinical Study Evaluating the Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment","Randomized Trial of ACEIs in Treatment of COVID-19","Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms","Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial","A Phase II, Randomized, Open-label, Single-institution Study of the Effects of Povidone Iodine Oral Gargles and Nasal Rinses on Viral Load in Patients With COVID-19","Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial","Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia","COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial","Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 pneumonia_COVIDICUS","An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)","Administration of Chloropromazine as a Treatment for COVID-19","An Open-label, Randomized, Cross-over Interventional Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression","Investigation of the Effects of Exercise Using Telerehabilitation in Patients Diagnosed With Coronavirus (COVID-19) and Followed at Home","Investigation Of The Effectiveness Of Video-Based Exercise Program Applied To Adult Individuals Who Experience Social Isolation At Houses Due To The Coronavirus (COVID-19) Pandemic","Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm","Study for the therapeutic effect and mechanism of traditional Chinese medicine in the treatment of novel coronavirus pneumonia (COVID-19)","Feasibility, Safety and Early Efficacy Trial of Hydroxychloroquine as Primary Prevention of Corona Virus Disease 2019 in High Risk Health Care Providers","With Uncontroversial Honey And Nigella Sativa (WUHAN) Treatment for Novel Coronavirus Infection; Randomized, Controlled, Investigator Initiated Trial","A Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Patients With Moderate or Severe COVID-19","Convalescent Plasma to Limit Coronavirus Associated Complications: A Randomized Double-Blind, Phase 2 Study Comparing the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma vs. Placebo in Emergency Room Patients","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - CORIMUNO-CORIPLASM : EFFICACY OF CONVALESCENT PLASMA TO TREAT SARS-COV2 INFECTED PATIENTS","Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in SARS-Cov-2 Infected Patients With a Systemic Inflammatory Response Syndrome","Use of Convalescent Plasma Therapy for COVID-19 Patients With Hypoxia: a Prospective Randomized Trial","A Phase 2 Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","Two-treatment,Randomized, Controlled, Multicenter Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stromal Cells in Critically Ill Patients COVID-19","Feasibility of a Facebook delivered physical activity focused group lifestyle intervention for older adults during the COVID-19 pandemic","A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID 19 Infection","Assessment of COVID-19 IgM/IgG Self-testing Using Virtual Point-of-care","Plasma Rich Antibodies From Recovered Patients From COVID19","Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE","An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients With COVID-19","Phase IIb Prospective, Multi-center, Randomized, Parallel, Double Blind, Placebo Controlled Trial to Evaluate Defibrotide Intravenous Infusion in the Prevention and Treatment of COVID-19 Respiratory Distress and Cytokine Release Syndrome","A Phase II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for the Treatment of COVID-19 Infection","Clinical Study Evaluating the Efficacy of Faviprevir in COVID-19 Treatment","Impact of Zinc and Vitamin D3 Supplementation on the Survival of Institutionalized Aged Patients Infected With COVID-19","A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence","Efficacy and Safety of Favipiravir in Management of COVID-19","Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore: a Review of Process Feasibility, Safety, and Clinical Outcomes","Efficacy and Safety of Umifenovir as an Adjuvant Therapy Compared to the Control Therapeutic Regiment of Interferon Beta 1a, Lopinavir / Ritonavir and a Single Dose of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial","A Multi-Center, Adaptive, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.","IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)","Ayurveda for Flu-like Illness During the Covid 19 Outbreak: Non Randomised Single-blind Controlled Trial","Protecting frontline health care workers from COVID-19 with hydroxychloroquine pre-exposure prophylaxis: a randomized, placebo-controlled multi-site trial in Toronto, Canada","A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Mechanically Ventilated Intubated Patients With Respiratory Failure Due to COVID-19","RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)","ChemoPROphyLaxIs For covId-19 Infectious Disease (the PROLIFIC Trial)","Outpatient Treatment of Elderly People With Symptomatic SARS-CoV-2 Infection (COVID-19): a Multi-arm, Multi-stage (MAMS) Randomized Trial to Assess the Efficacy and Safety of Several Experimental Treatments to Decrease the Risk of Hospitalization or Death (COVERAGE Trial)","COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1","In adult patients with known or suspected COVID-19, does the use of Continuous Positive Airway Pressure (CPAP) or high-flow nasal oxygen (HFNO), compared with standard care reduce mortality or need for tracheal intubation?","COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses: Double-blind, Randomized, Placebo-controlled Clinical Study","The Effect of Camostat Mesylate on COVID-19 Infection in Ambulatory Patients: An Investigator-Initiated Randomized, Placebo-Controlled, Phase IIa Trial","Tocilizumab to Prevent the Progression of Hypoxemic Respiratory Failure in Hospitalized Non-Critically Ill Patients With COVID-19","Australasian COVID-19 Trial (ASCOT). A multi-centre randomised clinical trial to assess clinical, virological and immunological outcomes in patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care","A randomized double-blind placebo-controlled trial of intravenous plasma-purified alpha-1 antitrypsin for severe COVID-19 illness.","Investigation of efficacy and tolerability of the healing water Staatl. Fachingen STILL in patients for symptomatic treatment of heartburn in comparison to placebo\n - Healing water efficacy in heartburn","A Randomised, Double Blind, Placebo-Controlled Trial of the Efficacy of Hydroxychloroquine for the Community-Based Treatment of Adults With Diagnosed COVID-19\r\n","An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - Solidarity","Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia","Efficacy of Pulmonary Physiotherapy on Hospitalized Patients With Novel Coronavirus 2019 Pneumonia","A randomized, double-blind, placebo-controlled, multicentre clinical study on the improvement of novel coronavirus pneumonia (COVID-19) convalescent sleep mood disorder with shumian capsule","A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia","OUTPATIENT TREATMENT OF COVID-19 WITH EARLY PULMONARY CORTICOSTEROIDS AS AN OPPORTUNITY TO MODIFY THE COURSE OF THE DISEASE","A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period","A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers - A phase I/II trial of a candidate COVID-19 vaccine (COV001)","An open label single center randomized controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 - COVIDAM","COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS","Hydroxychloroquine Post Exposure Prophylaxis (PEP) for Household Contacts of COVID-19 Patients: A NYC Community-Based Randomized Clinical Trial","Pilot, double-blind clinical trial to evaluate the efficacy and safety of pre-exposure use of hydroxychloroquine versus placebo in the prevention of SARS-CoV-2 (COVID-19) infection in healthcare personnel. - PrevenCOVID-19","A multicenter, open, randomized, non-commercial study to evaluate the efficacy and safety of chloroquine phosphate in the outpatient treatment of COVID-19 in combination with telemedicine care for patients with SARS-CoV-2 infection with the risk of developing complications to reduce the risk of COVID-19-related hospitalization and death.","Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study.\n - Ruxolitinib Treatment in  Patients with Severe COVID-19 Infection.A Danish Safety and Efficacy Study","Automated Oxygen Titration - Monitoring and Weaning in Patients With Infectious Pneumonia Requiring Oxygen - Impact on the Number of Interventions for Healthcare Workers. An Innovative Device to Manage Patients With COVID-19 Pneumonia COVID Study (Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decreaseduring Pneumonia)","Plasma From Donors Recovered From New Coronavirus 2019 As Therapy For Critical Patients With Covid-19","An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19","Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial","A randomized, prospective, open label clinical trial on the use of convalescent plasma compared to best supportive care in patients with severe COVID-19 - Convalescent Plasma against COVID-19","A SINGLE-BLINDED RANDOMIZED, PLACEBO-CONTROLLED PHASE II TRIAL OF PROPHYLACTIC TREATMENT WITH ORAL AZITHROMYCIN VERSUS PLACEBO IN CANCER PATIENTS UNDERGOING ANTINEOPLASTIC TREATMENT DURING THE COVID-19 PANDEMIC","Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. - Antivirals for COVID-19    DAWN AZITHRO","A Prospective, Randomized, Open-label, Interventional Study to Investigate the Efficacy of Sargramostim (Leukine) in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 (Corona Virus Disease) Patients With Acute Hypoxic Respiratory Failure.","A Phase 2 Randomized, Single Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19","An Open Label, Dose-Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TAK-981 in Adult Patients With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019","Evaluation of the Safety and Clinical Efficacy of Hydroxychloroquine Associated With Azithromycin in Patients With Pneumonia Caused by Infection by the SARS-CoV2 Virus - Coalition COVID-19 Brasil II - Severely-ill Patients","A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study of Hydroxychloroquine in Outpatient Adults With COVID-19","A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","Sensor Based Vital Signs Monitoring of Patients With Clinical Manifestation of Covid 19 Disease During Home Isolation, a Randomized Feasibility Study","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","A Prospective, Randomized, Factorial Design, Interventional Study to Compare the Safety and Efficacy of Combinations of Blockade of Interleukin-6 Pathway and Interleukin-1 Pathway to Best Standard of Care in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure and Systemic Cytokine Release Syndrome","Mindfulness During COVID-19 - Remote Mindfulness Sessions","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients","Multi-Center, Randomized, Controlled, Phase II Clinical Efficacy Study Evaluating Nitric Oxide Releasing Solution Treatment for the Prevention and Treatment of COVID-19 in Healthcare Workers and Individuals at Risk of Infection","Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia (The SCOPE Trial)","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)","The Mechanism, Clinical Outcome and Therapeutic Intervention of Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive","A Randomized, Controlled, Open Label, Multicentre Clinical Trial to Explore Safety and Efficacy of Hyperbaric Oxygen for Preventing ICU Admission, Morbidity and Mortality in Adult Patients With COVID-19","Open, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Single Donor Banked Bone Marrow Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure: A Pilot Study","Anti COVID-19 Convalescent Plasma Therapy","Convalescent Plasma for Patients With COVID-19: A Pilot Study","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","An Open Label Phase II Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Symptoms","An Open Label Phase 1 Trial of Losartan for Worsening Respiratory Illness in COVID-19","EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","A Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Immunogenicity of the bacTRL-Spike Oral Candidate Vaccine for the Prevention of COVID-19 in Healthy Adults","A Partially Nested RCT to Evaluate the Effectiveness of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together (SPIN-CHAT) Program to Reduce Anxiety Among At-Risk Scleroderma Patients","A Randomized Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalized Subjects With Confirmed SARS-CoV-2","Renin Angiotensin System - CoronaVirus","Birth Experience During COVID-19 Confinement (Confinement and Fostering Intrapartum Care)","The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019","Adjuvant Use of Ivermectin To Hydroxychloroquine and Azithromycin in Patients With Covid19: A Novel Double Blind Placebo Controlled Pilot Study","Efficiency in Management of Organ Dysfunction Associated With Infection by the Novel SARS-CoV-2 Virus (COVID-19) Through a Personalized Immunotherapy Approach: the ESCAPE Clinical Trial","The Role of Resistant Starch in COVID-19 Infection","PATCH 2 &amp; 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) An Open Label Multi-arm Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19","A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda vs. Standard Supportive Care in Subjects Infected With COVID-19","Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)","Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (EVICT-CORONA-ALI)","Multicenter Randomized Controlled Trial of the Efficacy of Melatonin in the Prophylaxis of SARS-coronavirus-2 Infection Among High Risk Contacts.","A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19.","A Multicenter, Randomized, Active Controlled, Open Label, Platform Trial on the Efficacy and Safety of Experimental Therapeutics for Patients With COVID-19 (Caused by Infection With Severe Acute Respiratory Syndrome Coronavirus-2)","Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial","DAS181 for COVID-19: A Phase II/III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study","Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia","A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19","Cohort of Patients Infected With SARS-CoV2 or Suspected of Being (COVID-19 in Ile-de-France)","A Pilot Study of Ruxolitinib to Combat COVID-19","Study of Immune Response During SARS-CoV-2 Infection","A Randomized, Double-Blinded, Placebo-Controlled, Phase ?/? Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Off Label Study to Evaluate the Efficacy of HCQ for Pre-exposure Prophylaxis (PrEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Health Care Workers (HCWs) Who Are at High Risk of Occupational Exposure to SARS-CoV-2","Value of Early Treatment With Polyvalent Immunoglobulin in the Management of Acute Respiratory Distress Syndrome Associated With SARS-CoV-2 Infections","Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Trial","A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.","Tozumab combined with adamumab(Qletli) in the treatment of severe and critically ill patients with novel coronavirus pneumonia (COVID-19):A prospective, single-center, randomized, parallel controlled trial","An Open-Label Study to Compare the Efficacy, Safety, and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to \"no Treatment\" in Hospitalized Patients Suffering From a Mild or Moderate SARS CoV 2 Virus","Efficacy of Captopril Nebulization in Covid-19 Patients Suffering of SARS CoV-2 Pneumonia. A Randomized Phase II Study","Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial","Randomized Open Pilot Study to Evaluate the Efficacy of Subcutaneous Sarilumab in Patients With Moderate-severe COVID-19 Infection","Open Label, Randomized, Controlled Phase 2 Proof-of-Concept Study of the Use of Favipiravir v. Standard of Care in Hospitalized Subjects With COVID-19","Clinical trial for umbilical cord blood CIK and NK cells in the treatment of mild and general patients infected with novel coronavirus pneumonia (COVID-19)","Assesment of Usefulness of Ventil Device for Mechanical Ventilation in ICU Patients","Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Plasma From Patients Cured of COVID-19 Compared to the Best Available Therapy in Subjects With SARS-CoV-2 Pneumonia","Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS A Single-arm, Open-label, Proof of Concept Study","An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19","Efficacy and Safety of Azithromycin Compared to the Base Therapeutic Regiment of Hydroxychloroquine in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial","Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial","Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia: A Pragmatic Randomized Controlled Trial","Efficacy and safety of Lopinavir and Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19)","Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia: a Randomized Controlled Double-blind Study From the Skip-icu Consortium","Single arm study for the efficacy and safety of GD31 in patients with novel coronavirus pneumonia (COVID-19)","A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia","Phase II Clinical Trial of Estradiol to Reduce Severity of COVID19 Infection in COVID19+ and Presumptive COVID19+ Patients","Comparative Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19 in Healthcare Personnel","Does a Systematic Phone-call by a Medical Student/General Practitioner Team in Patients Suffering From a Chronic Condition During the COVID-19 Containment Period Impact One-month Hospitalization's Rate in France? A Cluster Randomized Trial","Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact","Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19: a Randomized, Multicenter, Adaptative Study","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in mild/common patients with novel coronavirus pneumon (COVID-19)ia","A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID 19 Positive Patients Hospitalized But Not Critically Ill.","Keto-diet for Intubated Critical Care COVID-19 (KICC-COVID19)","Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19","A Randomized Controlled Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity","Avoiding High PEEP in COVID-19 Induced ARDS: a Multi-center Study","Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial (DISTANSE COVID-19 RCT)","Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic by Creation and Analysis of a Biological and Tissue Collection of Pregnancy Outcomes","Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)","A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers","A randomized, double-blind, parallel, controlled trial for comparison of phosphoric chloroquine combined with standard therapy and standard therapy in serious/critically ill patients with novel coronavirus pneumonia (COVID-19)","Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection in Medelln, Colombia, 2020","An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19","A Prospective, Randomized, Double-Masked, Placebo-Controlled Trial of High-Titer COVID-19 Convalescent Plasma (HT-CCP) for the Treatment of Hospitalized Patients With COVID-19 of Moderate Severity","Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design","Efficacy of an Online Cognitive Behavioral Therapy (CBT) Programme Aiming at Reducing the Stress of Health Workers Involved in the Care of Patients During the Covid-19 Epidemic: a Randomized-controlled Trial","Randomized Clinical Study of Local Thermotherapy for Patients With Moderate Symptoms of COVID-19","Do Respiratory Control Center Anomalies Explain the Lack of Respiratory Sensations Perceptions Observed in Patients Affected by COVID-19 ?","Impact of Multi-Denominational Prayer on Morbidity and Mortality of Patients Admitted to the Intensive Care Unite With Corona Virus Infection","Clinical Trial Evaluating Safety and Efficacy of Ivermectin and Nitazoxanide Combination as Adjuvant Therapy in COVID-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope","Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients","Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia","A Randomized-Control Pilot Study to Assess Hydroxychloroquine in Patients Infected With SARS-CoV-2 (COVID-19)","Multi-centre Randomised Controlled Trial of Chloroquine/Hydroxychloroquine Versus Standard of Care for Treatment of Mild Covid-19 in HIV-positive Outpatients in South Africa","Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial","A Single-center Registry and Embedded Interventional Study of the Effects of COVID-19 With and Without Treatment With AT-001 on Cardiac Structure and Function in Patients Hospitalized for Management of COVID-19 Infection","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia: a Prospective Randomized Clinical Trial","Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress","Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU","Evaluation of the Safety and Efficacy of Isotretinoin in Treatment of COVID-19: Clinical Study","Comparison of Two Methods to Airway Clearance in Patients Admitted to Intensive Care Unit for COVID-19: A Pilot Corssover Randomized Controlled Trial","Comparison of the Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR","A Randomized, Double-blind, Placebo-Controlled Trial to Evaluate the Efficacy of Ramipril to Prevent ICU Admission, Need for Mechanical Ventilation or Death in Persons With COVID-19","Testing the efficacy of a coping skills app to support emotional wellbeing in youth during the Covid-19 epidemic","Treatment of Serious and Critical Patients With COVID-19 With Tocilizumab","Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection: Prospective Randomized Controlled Trial","Hydroxychloroquine or Hydroxychloroquine Associated With Azithromycin for Inpatients With Moderate or Severe Lung Disease Due to SARS-CoV-2 (COVID-19)","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG)","Testing an early online intervention for the treatment of disturbed sleep during the COVID-19 pandemic (Sleep COVID-19)","A randomized, double-blind, controlled trial for Bu-Fei-Huo-Xue Capsule in the treatment of novel coronavirus pneumonia (COVID-19) convalescence patient with ''Fei-Pi-Qi-Xu zhen''","Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19","Study for using sulfate in the prevention and control of novel coronavirus pneumonia (COVID-19) in high and low prevalence communities","A randomised controlled trial of Nebulised Heparin in critically ill mechanically ventilated patients with COVID-19 to assess the effect on  the  duration of mechanical ventilation.","The efficacy and safety of Siddha Treatment in Symptomatic Participants with novel coronavirus infectious disease (COVID-19): A Multicenter, Randomized, Open-Label, Active-controlled Randomised Clinical Trial","A Pilot, Multiple Dose Study to Evaluate the Efficacy and Safety of MRx-4DP0004 in Hospitalised Patients With Symptoms of COVID-19 (SARS-CoV-2 Infection)","The influence of COVID-19 pandemic on cardiovascular patients","Effectiveness and safety of hydroxychloroquine sulfate in the preventive treatment of novel coronavirus pneumonia (COVID-19)","Cohort of Patients With Covid19: Constitution of Blood Samples Collections With Clinical Characterization","Chronic Fatigue Etiology and Recovery in Covid-19 Patients in Intensive Care Unit : the Role of Fatigability","A double-blind, randomized study versus placebo of avdoralimab (IPH5401), an anti-C5aR antibody, in patients with COVID-19 induced pneumonia\r\n - FORCE (FOR COVID-19 Elimination)","The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations","Efficacy of Pragmatic Same-day Ring COVID-19 Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland: an Open-label Cluster Randomized Trial","Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS)","Internet based Solution Focused Brief Therapy treating adolescent anxiety under the novel coronavirus pneumonia (COVID-19) outbreak: A randomized controlled trial","Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 - APN01-01-COVID19","Suspension of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Hospitalized Patients With Coronavirus Infection (COVID-19). A Randomized Trial","COVID 19: Experimental use of tocilizumab (Roactemra) in severe SARS-CoV-2 related pneumonia.","A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19","A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men","Evaluation of the safety and immunogenicity of inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) in healthy population aged 3 years and above: a randomized, double-blind, placebo parallel-controlled phase I/II clinical trial","A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia - TOC-COVID","Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function in SARSCoV2 Associated Acute Myocardial Injury and Hyperinflammation","Efficacy and Safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19)","Efficacy and safety of novel treatment options for adults with COVID-19 pneumonia. A double-blinded, randomized, multi-stage, 6-armed placebo-controlled trial in the framework of an adaptive trial platform - CCAP-RCT","Proactive Prophylaxis with Azithromycin and Hydroxychloroquine Patients Hospitalized with COVID - ProPAC-COVID","A Randomized Trial of Efficacy and Safety of an Early OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome: a Strategy to Prevent Hospitalization","MR-Evaluation of Renal Function In Septic Patients","Effects of Traditional Chinese Medicines (TCMs) on Patients With COVID-19 Infection: A Perspective, Open-labeled, Randomized, Controlled Trial","Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study - COV-ENOX","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19","Randomized Controlled Trial of Losartan for Patients With COVID-19 Requiring Hospitalization","A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial\n\n - Nebulised rtPA for ARDS due to COVID-19  The PACA trial","Effectiveness of an expressive writing intervention in the reduction of psychological difficulties during the COVID-19 pandemic","An Open-label, Randomized Controlled Trial of Hydroxychloroquine and Azitromicyn for COVID-19 Infection on Hospitalized, Noncritical Patients","A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Gurin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Workers.\r\nCOVID-BCG\r\n - COVID BCG","BCG Vaccination to Reduce the Impact of COVID-19 in Australian Healthcare Workers Following Coronavirus Exposure (BRACE) Trial","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers : A Randomized Double-blind Placebo-controlled Clinical Trial","Efficacy and safety of ANAkinra during Adult  COVID-19  with Aggravating respiratory symptoms: a multicenter open-label controlled randomized trial - ANACONDA-COVID-19","Preliminary evaluation of the safety and efficacy of oral LL-37 antiviral peptide (CAS001) in the treatment of novel coronavirus pneumonia","The ECLA PHRI COLCOVID Trial","Reducing Health Care Workers Absenteeism in COVID-19 Pandemic by Enhanced Trained Immune Responses Through Bacillus Calmette-Gurin Vaccination, a Randomized Controlled Trial.","A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)","Plasma turnover in patients with COVID-19 disease and invasive mechanical ventilation: a randomized study - REP-COVID","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis","Azithromycin for Prevention of Disease Progression in Patients With Mild or Moderate COVID-19","Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC in patients with acute respiratory distress syndrome secondary to infection by COVID-19 - COVIDMES","Open Label Single-Center Study of Emergency Hyperbaric Oxygen for Respiratory Distress in Patients With COVID-19","Lipid Ibuprofen Versus Standard of Care for Acute Hypoxemic Respiratory Failure Due to COVID-19: a Multicentre, Randomised, Controlled Trial","Pilot study of single-dose bevacizumab as a treatment for acute respiratory distress syndrome in patients with COVID-19","Phase 1 Study to Evaluate the Safety of Convalescent Plasma as an Adjuvant Therapy in Patients With SARS-CoV-2 Infection","Application of Iron Chelator (Desferal) to Reduce the Severity of COVID-19 Manifestations","Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo","A Phase II, randomized, openlabel study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill patients with COVID-19.","PRAETORIAN-COVID: A Double-blind, Placebo-controlled Randomized Clinical Trial With Valsartan for PRevention of Acute rEspiraTORy dIstress Syndrome in hospitAlized patieNts With SARS-COV-2 (COVID-19) Infection Disease","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19","A Phase-II Clinical Trial for First Line Treatment of Stage II/III Covid-19 Patients to Treat Hyperinflammation","Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment","Safety and Efficacy of Baricitinib for COVID-19","A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)","Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection","A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2","A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19","Efficacy and Safety of Injectable Methylprednisolone Sodium Succinate in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome Under the New Coronavirus (SARS-CoV2): a Phase IIb, Randomized, Double-blind, Placebo-controlled, Clinical Trial.","Convalescent Plasma in the Treatment of COVID 19","An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial","Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults","A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion in Patients With Severe COVID-19 Pneumonia","An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects Positive With SARS-CoV-2 With Mild Symptoms","The Results of COVID 19 Treatment: A Real-life Experience on Patients With COVID 19","The Impact of Camostat Mesilate on COVID-19 Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial","A Pilot Study to Explore the Efficacy and Safety of Rescue Theraphy With Antibodies From Convalescent Patients Obtained With Double -Filtration Plasmapheresis (DFPP) and Infused in Critically Ill Ventilated Patients With Coronavirus Disease 2019 (COVID-19)","Safety and Efficacy of Ruxolitinib for COVID-19","Preventing COVID-19-associated Thrombosis, Coagulopathy and Mortality With Low- and High-dose Anticoagulation: a Randomized, Open-label Clinical Trial","BHV3500-203: Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of Vazegepant (BHV-3500) Intranasal (IN) for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen","A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam","A Prospective Clinical Study of Hydroxychloroquine in the Prevention of SARS- CoV-2 (COVID-19) Infection in Healthcare Workers After High-risk Exposures","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients With Severe COVID-19 Infection","A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia","Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Real Time Polymerase Chain Reaction (RT-PCR) Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate","Low-flow Extracorporeal Carbon Dioxide Removal Using a Renal Replacement Therapy Platform for Correction of Hypercapnia in COVID-19-associated Acute Respiratory Distress Syndrome","Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020","CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers","Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate","Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients","Prospective, open-label, controlled, multicenter cohort study of long-acting interferon plus ribavirin in patients with COVID-19 infection","A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19","Seroprevalence and Antibody Profiling Against SARS-CoV2 in Children and Their Parents","Treatment With Inhaled Corticosteroids in Patients Hospitalized Because of COVID19 Pneumonia","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)","A Randomized Trial of Anticoagulation Strategies in COVID-19","A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Etoposide in Patients With COVID-19 Infection","A Pilot, Open Label, Phase II Clinical Trial of Nebulised Recombinant Tissue-Plasminogen Activator (Rt-PA)","COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)","Feasibility and Acceptability of Online Based Mindfulness Interventions to Relieve Distress During COVID-19 Outbreak in a Chinese Population: a Proof-of-concept Trial","Evaluation of Prone Position in Conscious Patients on Nasal High-flow Oxygen Therapy for COVID-19 Disease Induced Acute Respiratory Distress Syndrome","Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia in Grand Ouest Interregion France","Pragmatic Trial Exploring Impact of Patient Positioning in the Management of Patients Infected With COVID-19: Supine vs. Prone","Prospective, Phase II, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Hydroxychloroquine Together With Baricitinib, Imatinib or Early Lopinavir / Ritonavir in Patients With SARS Cov2 Pneumonia","Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial","A Phase 2, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19","PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill COVID-19 Patients Under Electric Impedance Tomography (EIT)","Double-blind Randomized Controlled Clinical Trial of Low-dose Lenalidomide in the Treatment of COVID-19 Disease","Bacillus Calmette-Guerin Vaccination as Defense Against SARS-CoV-2: A Randomized Controlled Trial to Protect Health Care Workers by Enhanced Trained Immune Responses","A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19","Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum During an Emergency Laparoscopy Conducted on Confirmed or Suspected COVID-19 Patients","Double Blind, Placebo-controlled, Phase II Trial to Evaluate Safety and Efficacy of Allogenic Mesenchymal Stromal Cells MSV_allo for Treatment of Acute Respiratory Failure in Patients With COVID-19 Pneumonia (COVID_MSV)","A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19","A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)","Administration of Colchicine Plus Standard Treatment vs. Standard Therapy, in Hospitalized Patients With COVID-19, Within the First 48 Hours, and no Severity Criteria.","the Efficacy and Safety of Favipiravir for novel coronavirusinfected pneumonia: A multicenter, randomized, open, positive, parallel-controlled clinical study","Remote Monitoring in Patients With Coronavirus Disease (COVID-19)","A Phase 1, Double-blind, Randomized, Placebo-controlled, Sponsor-open, SAD and MAD Study in Healthy Subjects to Evaluate the Safety, Tolerability, and PK of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19","A Prospective, Open-label, Randomized Pilot Study (Including a Control Group) of BACTEK-R (MV130), Administered Sublingually to Assess the Clinical Impact in Subjects With Mild Pneumonia Due to COVID-19","Efficacy and Safety of ANAkinra During Adult \" COVID-19 \" With Aggravating Respiratory Symptoms: a Multicenter Open-label Controlled Randomized Trial","COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19 (the COMBAT-COVID-19 Pilot Study)","Treatment of Acute Respiratory Syndrome Resulting From the Inflammatory Process of COVID-19 Infection Using Methotrexate-loaded Nanoparticles: A Phase I/II Study","Efficacy of Novel Agents for Treatment of SARS-CoV-2 Infection Among High-Risk Outpatient Adults: An Adaptive Randomized Platform Trial","Convalescent Plasma to Limit Coronavirus Associated Complications: a Randomized Blinded Phase 2 Study Comparing the Efficacy and Safety of Anti-SARS-CoV2 Plasma to Placebo in COVID-19 Hospitalized Patients","A Phase 2, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-9 on Preventing Progression of COVID-19 in High-Risk Individuals","Clinical study of mesenchymal stem cells in treating severe novel coronavirus pneumonia (COVID-19)","PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention or Early Phase Treatment of Coronavirus Disease (COVID-19)","A Multicenter, Open-label, Pilot Study on Using Hydroxychloroquine (HCQ) and Azithromycin (AZ) Prophylaxis for Healthcare Workers With a Potential Risk of Exposure to COVID-19 Patients","Prediction of Acute Heart or Kidney Injury With Cardiovascular-renal Biomarkers in Patients Hospitalised for Severe or Critical Covid-19 Infection","The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients","Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients With Acute Respiratory Distress Syndrome (ARDS)","DETERMINATION OF THE DOSE AND EFFECTIVENESS OF CONVALESCENT PLASMA IN SEVERELY AND VERY SEVERELY ILL PATIENTS BY COVID-19","A Randomized, Double-Blind, Placebo-Controlled, Phase 1/2 Study Evaluating AVM0703 in Patients With COVID-19","Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic: An Open Pilot Trial","Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection: A Phase 2a Clinical Trial","Use of a Medical Device, Kerecis Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa","Multicentric Study to Assess the Effect of Consumption of Lactobacillus Coryniformis K8 on Healthcare Personnel Exposed to COVID-19","Phase I / II Multicentre, Randomized and Controlled Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection","Mesenchymal Stem Cell Therapy for Acute Respiratory Distress Syndrome in Coronavirus Infection: A Phase 2-3 Clinical Trial","Oxygen-Ozone as Adjuvant Treatment in Early Control of Disease Progression in Patients With COVID-19 Associated With Modulation of the Gut Microbial Flora","Plasma Adsorption in Patients With Confirmed COVID-19","Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib","The RESCUE 1-19 Trial: Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19","PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study)","A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19","Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients: Comparison of 40 mg o.d. Versus 40 mg b.i.d. A Randomized Clinical Trial","Phase I / II Clinical Trial, Multicenter, Randomized and Controlled, to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19","Psychological Impact of the Lockdown on Patients Giving Birth During the COVID-19 Epidemic","COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19","Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic","Comparison of Intraosseous Versus Intravenous Access in Suspected/Confirmed COVID-19 Patient in Prehospital Setting","Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)","Hydroxychloroquine as Primary Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)","The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19: Validation of a New Online Treatment","A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Serology COVID-19 From the Cornwall Hospital Union","Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19","Host-pathogen Interactions, Immune Response, and Clinical Prognosis at COVID-19 - the CoVUm Trial","The Impact of a Barrier Enclosure on Endotracheal Intubation Duration and First Pass Attempt - A Randomized Controlled Trial","Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization","Repurposing of Chlorpromazine in Covid-19 Treatment","An Open, Prospective/Retrospective, Randomized Controlled Cohort Study to Compare the Efficacy of Different Hormone Doses in the Treatment of 2019-nCoV Severe Pneumonia","Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) in Adult Patients With COVID-19","Clinical Study of Tetrandrine Tablets Adjuvant Treatment With COVID-19","A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M Adjuvant In Healthy Subjects","A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome","Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness (BREATH): an RCT for Frontline Hospital and Long-term Care Home Staff Managing the COVID-19 Pandemic","Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","A Phase 2/3 Study to Assess the Safety and Efficacy of MultiStem Therapy in Subjects With Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease (COVID-19)","Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients","A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe Pneumonia of COVID-19:a Single-center, Prospective, Randomised Clinical Trial","A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)","Tocilizumab in Hospitalized Cancer Patients With Coronavirus 2019 (SARS-CoV-2) and Severe Complications of Coronavirus Disease 19 (COVID-19)","The Clinical Trial of Application of Methylene Blue Vial for Treatment of Covid-19 Patients","Exploring Provider Burnout During the COVID-19 Pandemic","Platelet Inhibition With GP IIb/IIIa Inhibitor in Critically Ill Patients With Coronavirus Disease 2019 (COVID-19). A Compassionate Use Protocol","Mesenchymal Stem Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome","COVID-19 Health Messaging to Underserved Communities","A multicenter, single-blind, randomized controlled clinical trial for chloroquine phosphate in the treatment of 2019 novel coronavirus-infected pneumonia","Blood Innate Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients","Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019","A Telerehabilitation Approach to Improve Long-term Physical Ability and Quality of Life in Patients With Severe Acute Respiratory Syndrome Coronavirus (SARSCoV-2, COVID-19) Immediately After Hospitalization. The ATHLOS Study","Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients: Randomized Controlled Trial: MG-COVID","Hydroxychloroquine to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE): A Parallel Randomized Controlled Trial","COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie","A Repeated Measures Trial of Temporary Automated Manual Ventilation Versus Noninvasive Oxygenation or Conventional Ventilation for the Treatment of COVID-19 ARDS","The treatment and diagnosis plan of integrated traditional Chinese and Western medicine for novel coronavirus pneumonia (COVID-19)","A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)","Efficacy of Based MRI Contrast Media Against Covid-19","Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT)","Doxycycline Versus Placebo in COVID-19 + Patients Without Hospitalization Criteria: Prospective, Multicenter, Randomized, Double-blind Study","An adaptive phase 2/3, randomized, double-blind, placebo-controlled, study assessing efficacy and safety of sarilumab for hospitalized patients with COVID19","Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With SARS-CoV-2","A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting","Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial","A Retrospective Cohort Study to Evaluate the Efficacy and Safety of Traditional Chinese Medicine as an Adjuvant Treatment for Patients With Severe COVID-19","Utilisation de Soins Pendant la Crise Covid-19 : Recours, Report et Renoncement (US3R)","Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS","Antithrombotic Therapy to Ameliorate Complications of COVID-19","Prolonged Low Doses of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic","Evaluating the clinical impact of routine molecular point-of-care testing for COVID-19 in adults presenting to hospital: a prospective, interventional, non-randomised pre and post implementation study (CoV-19POC)","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia","Effects of a single session internet-delivered cognitive behavioral therapy for Acute Insomnia during the pandemic of novel coronavirus pneumonia (COVID-19)","To Study the Effectiveness of Ivermectin With Standard of Care Treatment Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study","A Pilot Study of Duvelisib to Combat COVID-19","Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-18","Application of non-invasive multichannel cardiopulmonary monitoring cloud management platform in patients with Novel Coronavirus Pneumonia (COVID-19)","Unplanned Shifting the Traditional Classroom-Based to Online Distance Learning as a Result of (COVID-19) Social Distancing Measures: Nursing Students' Perception and Achievement","An Open-Label, Phase II of Antiviral Therapy Combined With Baricitinib in Moderate and Severe Patients With COVID-19","An Open-label, Prospective, Randomized, Comparative Clinical Trial to Evaluate the Efficacy and Safety of ENKORTEN as an Immunomodulatory Therapy, Within the Usual Therapeutically Established Protocol, for the Treatment of Patients With Moderate to Severe COVID-19 Infection","A Study to Evaluate Health Behavior and Access Impacts Due to COVID-19 and for Community Engagement of Stakeholders Surrounding Scarce Resource Allocation Policy.","Utilizing Home Pulse Oximetry for Patients With COVID-19 To Monitor Disease Progression","The efficacy  of convalescent plasma in patients with critical novel coronavirus pneumonia (COVID-19): a pragmatic, prospective cohort study","Evaluation Of Efficacy Of COVID-19 Convalescent Plasma Versus Standard Plasma In The Early Care Of COVID-19 Patients Hospitalized Outside Intensive Care Units.","A Research Platform to Screen Patients in Oncology and Assess Impact - RESPONSE","Interventional Study to Evaluate the Efficacy of Therapeutic Plasma Exchange (TPE) Alone or in Combination With Ruxolitinib in COVID-19 Positive Patients With PENN Grade 2, 3, 4 Cytokine Released Syndrome (CRS)","Human Ab Response &amp; immunoMONItoring of COVID-19 Patients","Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial","Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","Comparison of the Efficacy and Safety of Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune) Plasma Among Outpatients With Symptomatic COVID-19.","Efficacy and Safety of High-Titer Anti-SARS-CoV-2 (COVID19) Convalescent Plasma for Hospitalized Patients With Infection Due to COVID-19 to Decrease Complications: A Phase II Trial","Randomized, Multi-arm Phase II Trial of Novel Agents for Treatment of High-risk COVID-19 Positive Patients","Moxibustion Plus Cupping in Convalescent Patients With COVID-19: A Randomized Clinical Trial","Efficacy and Safety of Early Anti-SARS-COV-2 Convalescent Plasma in Patients Admitted for COVID-19 Infection: a Randomized Phase II Trial","Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19","Evaluation of  the safety and efficacy for human umbilical cord mesenchymal stem cells in COVID-19 induced pulmonary fibrosis","Verification of Alternative Do-it-yourself Equipment Respirators","A Phase II Trial to Promote Recovery From COVID-19 With Ivermectin or Endocrine Therapy","Phase II Study of N-acetylcysteine in Severe or Critically Ill Patients With Refractory COVID-19 Infection","RCT in Asymptomatic Volunteers With COVID-19 Comparing Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone vs Standard of Care Without Antibiotics","HOPE Intervention for COVID-19","A Phase II, Open Label, Randomized Controlled Trial to Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications","Early transfusIon of COVID-19 Convalescent Plasma in Elderly COVID-19 Patients to Prevent Disease Progression.","Protecting Frontline Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Multi-Site Trial in Toronto, Canada","Uno studio randomizzato multicentrico in aperto per valutare lefficacia della somministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID-19. - TOCI-RE","Effects of a Mobile App on Health and Well-being During COVID-19 Pandemic in House Staff at Banner University Medical Center Phoenix","Hydroxychloroquine in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients: A Pilot, Multicenter Randomized Open-Label Trial","Treatment With COLchicine of Patients Affected by COVID-19: a Pilot Study","An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults &amp; Adolescents With Non-Tuberculous Mycobacteria, Burkholderia Spp, Aspergillus Spp and Corona-like Viral (Sub-Study) Infections","A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection","Treatment of Patients Hospitalized for COVID-19 Infection and Pulmonary Distress With Ibrutinib","Host-pathogen Interactions During Paediatric and Adult SARS-CoV-2 Infection (COVID-19)","London's Exogenous Surfactant Study for COVID19","Efficacy of Therapist Guided e-Therapy Versus Self-Help Therapy on Psychological Distress Among Individuals in Oman During COVID-19 Pandemic: An Open-Label 12 - Weeks Randomized Controlled Trail","Nitric Oxide Gas Inhalation for Prevention of COVID-19 in Healthcare Providers","Norwegian Coronavirus Disease 2019 Study: An Open Labeled Randomized Controlled Pragmatic Trial to Evaluate the Antiviral Effect of Chloroquine in Adult Patients With SARS-CoV-2 Infection","A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Efficacy and Safety of Otilimab IV in Patients With Severe Pulmonary COVID-19 Related Disease","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","Effectiveness of Hydroxychloroquine in Covid-19 Patients: A Single Centred Single-blind RCT Study","Low-dose Computed Tomography in COVID-19 Pneumonia: a Prospective Moscow Study","Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19)","Comparison of the Efficacy and Safety of Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19. A Prospective Randomized Controlled Phase II Trial","Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses","Fluoxetine to Reduce Intubation and Death After COVID19 Infection","Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS","CONCOR-KIDS: A Randomized, Multicentered, Open-label Phase 2 Clinical Trial of the Safety and Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children","A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection","Incidence of Covid-19 in School Children During the Pandemic Period in Nice","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia : a Multicenter, Parallel-group, Open-label, Randomized Controlled Trial","Home telerehabilitation for people with COVID-19: Implementing telehealth approaches to care and its effect on reintegration into the community","Randomised controlled trial of an app-based intervention, Anchored, to support the mental health of Australians recently unemployed due to COVID-19.","Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19)","Safe Return to Regular Clinical Operation After COVID-19 Pandemic; (Oncology Center, Prospective Cohort)","CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19","The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation","The Possible Effect of Quercetin on Prophylaxis and Treatment of COVID-19","Therapies to prevent progression of COVID-19, including Hydroxychloroquine, Azithromycin, Zinc, Vitamin D, Vitamin B12 with or without Vitamin C, a multi-centre, international, randomized trial: The International ALLIANCE Study","Effects of Hydrogen/Oxygen Mixed Gas Inhalation for Patients With Coronavirus Disease 2019 (COVID-19) Who Had Dyspnea: A Multicenter, Open-label Clinical Trial","A Randomized, Open-Label Trial of Therapeutic Anticoagulation in COVID-19 Patients With an Elevated D-Dimer","Mindfulness Training for Older Adults During the COVID-19 Pandemic","A Study of Trans Crocetin in Patients With Acute Respiratory Distress Syndrome Due to COVID-19 Disease","Efficacy and safety of high-dose vitamin C combined with traditional Chinese medicine in the treatment of moderate and severe novel coronavirus pneumonia (COVID-19)","Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients","A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection in UK","Reducing Morbidity and Mortality in Health Care Workers Exposed to SARS-CoV-2 by Enhancing Non-specific Immune Responses Through Bacillus Calmette-Gurin Vaccination, a Randomized Controlled Trial","Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses","The School Opening in the Age of Pandemic (SOAP) study: a cluster-randomised re-introduction of school activities in Norway","A Prospective, Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19","SUNLIGHT Study: Online Support Groups for Multiple Sclerosis (MS) to Address COVID-19","Prospective Randomized Open-label Trial of Atorvastatin as Adjunctive Treatment of COVID-19","An International, Multicenter, Randomized, Double-blind, Adaptive Placebo-controlled Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe SARS-CoV-2 Infection (COVID-19)","Assessment of the Clinical Effect of Dialyzable Leukocyte Extracts in Individuals With Acute Respiratory Infection (Suspected or Confirmed Cases of COVID-19) (FUTURE-T)","Randomized evaluation of COVID-19 therapy","Single-center, Phase II, Randomized Double-blind, Placebo-controlled Study of Hydroxychloroquine Compared to Placebo as Treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection","Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease","Single-center, Prospective, Open-label, Comparator Study, Blind for Central Accessor to Access the Efficacy, Safety, and Tolerability of Inhalations of Low-doses of Melphalan in Patients With Pneumonia With Confirmed or Suspected COVID-19","Development and application of TCM body regulating protection scheme for the convalescent population of novel coronavirus pneumonia (COVID-19)","A Randomized Placebo-Controlled Safety and Dose-Finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection","Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19: Multi-central Prospective Study","The Impact of Quarantine and the Effectiveness of Telerehabilitation in Patients With Chronic Pain During COVID-19 Pandemic.","Emergency Ventilator Splitting Between Two or More Patients Using a Single Ventilator to Address Critical Ventilator Shortages During a Pandemic","ReCOVER (Remote COVID-19 Evaluation and Response): a prospective non-randomised controlled trial to evaluate the effect of a novel smartphone application-centric model of care for the remote monitoring of COVID-19 patients in the community, on avoidable hospital presentations..","High dose intravenous vitamin C might be used as an important rescue therapy for aggravation of severe and critical novel coronavirus pneumonia (COVID-19) patients","A clinical study for effectiveness and safety evaluation for recombinant chimeric COVID-19 epitope DC vaccine in the treatment of novel coronavirus pneumonia","COVID-19 - Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease upon Hydroxychloroquine and Azithromycin Therapy in French Cancer patients - ONCOVID","REDUCING HOSPITAL ADMISSION OF ELDERLY IN SARS-CoV-2 PANDEMIC VIA THE INDUCTION OF TRAINED IMMUNITY BY BACILLUS CALMETTE-GURIN VACCINATION, A RANDOMIZED CONTROLLED TRIAL","Continuous positive airway pressure in severe Covid-19 pneumonia: a feasibility and physiological end-point study","EFFICIENCY IN MANAGEMENT OF ORGAN DYSFUNCTION ASSOCIATED WITH INFECTION BY THE NOVEL SARS-CoV-2 VIRUS (COVID-19) THROUGH A PERSONALIZED IMMUNOTHERAPY APPROACH: THE ESCAPE CLINICAL TRIAL - PERSONALIZED IMMUNOTHERAPY FOR SARS-CoV-2 ASSOCIATED ORGAN DYSFUCTION","Sleep position related to hospital length of stay in admitted COVID-19 patients","Lessening Organ Dysfunction With VITamin C (LOVIT)","A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Human Mesenchymal Stem Cells in Combination With Standard Therapy in the Treatment of COVID-19 Patients With Severe Convalescence","An open label randomized controlled trial of chloroquine, hydroxychloroquine or only supportive care in patients admitted with moderate to severe COVID-19\n","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients With Severe SARS-CoV-2 Pneumonia: An Open-Label, Multicenter Sequential and Cluster Randomized Trial","Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study","The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial","Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19)  hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","A Single Arm Open-label Clinical Study to Investigate the Efficacy and Safety of Ruxolitinib for the Treatment of COVID-19 Pneumonia","Preliminary randomized controlled trial of poractant alfa (Curosurf) by fiberoptic bronchoscopy-directed endobronchial administration in acute respiratory distress syndrome (ARDS) due to COVID-19 viral pneumonia. - CAARDS-1","A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease - RECOVER","Effectiveness of Video-Based Exercises on Physical and Emotional Well-Being During COVID-19 Induced Social Isolation","Can a sinus rinse and mouth wash reduce viral load in COVID-19 positive individuals? - SINUS WASH pilot study","CLINICAL TRIAL OF THE USE OF ANAKINRA (ANTI IL-1) IN CYTOKINE STORM SYNDROME (CSS) SECONDARY TO COVID-19 - ANA-COVID-GEAS","\"STUDY OF THE EFFICIENCY OF NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE\" GERONIMO 19\n - GERONIMO19","A Multi-center, Randomized, Parallel-Controlled Clinical Trial of the Application of A Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 - STOP-COVID19: Superiority Trial Of Protease inhibition in COVID-19","Single-center, randomized, open-label clinical trial on the efficacy of tocilizumab in modifying the inflammatory parameters of patients with COVID-19","A Phase 2, Randomized, Open-label Clinical Trial comparing the Safety and Efficacy of Hydroxychloroquine, and Standard of Care to a Combination of Masitinib, Isoquercetin, and Standard of Care for the Treatment of Hospitalized Moderate and Severe COVID-19 Patients.","A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection","A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Patients With COVID-19-Moderate Type","A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - \"PANAMO\" - Panamo","EARLY TREATMENT OF PNEUMONIA COVID-19 WITH GLUCOCORTICOIDS.\r\nRANDOMIZED CONTROLLED CLINICAL TRIAL - CORTIVID","ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients - ACCORD 2-Treatment of COVID 19 in Hospitalised Patients","EFFICACY OF INTRAVENOUS ALMITRINE IN REDUCING THE NEED FOR MECHANICAL VENTILATION IN PATIENTS WITH HYPOXEMIC ACUTE RESPIRATORY FAILURE DUE TO COVID-19-RELATED PNEUMONIA:  A RANDOMIZED CONTROLLED DOUBLE-BLIND STUDYFROM THE SKIP-ICU CONSORTIUM - AIRVM COVID","Low dose hydrocortisone in patients with COVID-19 and severe hypoxia  the COVID STEROID trial \n - COVID-STEROID trial","A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe &amp; Azithromycin &amp; Zinc vErsEs Standard CaRe - PIONEER","CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection. - CATALYST - An Early Phase Platform Trial in COVID-19","Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19","Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection ILIAD 7 trial - ILIAD","REDUCING ABSENCE FROM WORK OF HEALTHCARE WORKERS DUE TO COVID-19 INFECTION BY BCG (BACILLUS CALMETTE-GURIN) VACCINATION - BACH (BCG Against COVID-19 in Hunga","Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in patients with COVID-19 induced respiratory failure  a multicentre randomized, placebo-controlled, blinded, investigator-initiated trial","Exploratory Studies of the Effect of Tranexamic Acid Treatment on the Progression of COVID19 in Outpatients","Ruxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts - RAVEN - RAVEN","ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL","Stopping ACE-inhibitors in COVID-19 - a randomized, controlled clinical trial","Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care Due to Coronavirus Disease 2019 (COVID-19)- Randomised Controlled Trial","Impact of the use of low molecular weight heparins (LMWH), at prophylactic versus intermediate doses, on SARS-CoV2 infection (COVID-19) - Heparin-SARS-CoV2","Phase 3 randomized, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of ruxolitinib in patients with COVID-19 associated cytokine storm (RUXCOVID) - RUXCOVID","Randomized Controlled Trial of Hydroxychloroquine Versus Placebo for the Treatment of Adult Patients With Acute Coronavirus Disease 2019 - COVID-19","PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE IN SANITARIES HIGHLY EXPOSED TO COVID-19. (COVIDNA) - COVIDNA","A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOPING SEVERE PULMONARY COMPLICATIONS ASSOCIATED WITH CORONAVIRUS SARS-CoV2 PNEUMONIA (COVID-19) - COLCHI-COVID","The use of a simplified negative pressure cuirass style ventilator under COVID-19 pandemic conditions in support of critically overwhelmed healthcare systems","Pilot study to evaluate the potential of ivermectin to reduce COVID-19 transmission","Adapting the Decathlon Group Easybreathe snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection.","A Multicenter, Randomized, Open-label Parallel Group Pilot Study to Evaluate Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Patients with Mild/Moderate COVID19","Virucidal pilot study of Nasodine Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.","A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects with COVID-19.","The design of a modifed N95 respirator and its protective effects against facial pressure injuries","Effecacy and Safety of Hyperbaric Oxygen Therapy to patients with novel coronavirus pneumonia (COVID-19)","Clinical Research on Treatment of Novel Coronavirus Pneumonia  with ''Guangdong Pneumonia NO.1''","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule /Granule in the treatment of novel coronavirus pneumonia (COVID-19)","A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of suspected novel coronavirus pneumonia (COVID-19)","Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization - PanCOVID19","ChemoPROphyLaxIs For covId-19 infeCtious disease (the PROLIFIC trial) - PROLIFIC Trial (COVID-19)","Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (COVID-19) - REMAP-CAP","A prospective, randomized, open-label, interventional study to investigate the efficacy of sargramostim (Leukine) in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure. - SARPAC","A prospective multi-center open trial to evaluate the safety and efficacy of favipiravir in patients infected with COVID-19.","A prospective multi-center open trial to evaluate the safety and efficacy of triple combination therapy of  lopinavir , ritonavir and hydroxychloroquine sulfate in patients infected with COVID-19.","Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial (COVID-19)","A Single-center,Open-label,Dose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Baricitinib Combined With Antiviral Therapy in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID: A Randomized, Placebo-controlled Double-blinded Trial Evaluating Treatment With Azithromycin and Hydroxychloroquine to Patients With COVID-19","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","A Pragmatic Adaptive Open Label, Randomized Phase II/III Multicenter Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","Investigation Of The Effectiveness Of The Telerehabilitation Applied To Individuals Over The Age Of 65 Who Experience Social Isolation At Houses Due To The Coronavirus (Covid-19) Pandemic","Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection","CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection, Nested In The CORIMUNO-19","Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19- A Cluster Randomized Controlled Trial (SHARP COVID-19 RCT)","Hydroxychloroquine for Outpatients With Confirmed COVID-19","Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlled Clinical Trial","Aspirin, Losartan and Simvastatin in Hospitalised COVID-19 Patients: a Multinational Randomised Open-label Factorial Trial","Pyridostigmine in Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2 Infection","An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection","Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia. A Double-blinded, Randomized, Multi-stage, 6-armed Placebo-controlled Trial in the Framework of an Adaptive Trial Platform","Multi-center, Randomized Clinical Trial of Convalescent Plasma Therapy Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients","A Randomized, Controlled Clinical Trial of the Safety and Efficacy of Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients","Safety and Efficacy of Intravenous Infusion of Bone Marrow-Derived Mesenchymal Stem Cells in Severe Patients With Coronavirus Disease 2019 (COVID-19): A Phase 1/2 Randomized Controlled Trial","Prophylactic Hydroxychloroquine vs Vitamin C in Healthcare Workers at Risk of COVID-19: A RCT","The Randomized, Open, Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19","The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol","Open Label Randomized Controlled Trial of Ultraprotective Ventilation Without Extracorporeal Circulation in Patients With COVID 19 Pneumonia and Moderate to Severe ARDS","Prospective Study of the Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection","An Open-label Randomized Controlled Trial on Interferon -1b and Hydroxychloroquine Combination Versus Hydroxychloroquine Alone, as Treatment for COVID-19 Infection","Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19","High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19","Impact of a Minimal Psychoeducational Intervention Versus Standard of Care on Anxiety Among Hospitalized COVID-19 Patients in Denmark: a Randomized Clinical Trial","Clinical Study Evaluating the Efficacy of Chloroquine in COVID-19 Treatment","Randomized Trial Evaluating Effect of Outpatient Hydroxychloroquine on Reducing Hospital Admissions in Pregnant Women With SARS-CoV-2 Infection: HyPreC Trial","Multi-Site, Randomized, Open-Label, Parallel-Group, Placebo-Controlled Study to Assess the Chemoprophylactic Efficacy of Chloroquine Against SARS-CoV-2/COVID-19 in Healthcare Workers at High-Risk of Exposure","Impact of high intensity interval training and aerobic training in on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain: a randomized controlled trial.","Effectiveness of Prophylactic Hydroxychloroquine on incidence of COVID-19 infection in Front-line Health and Allied Health Care Workers: The COVID-SHIELD Trial","A reusable personalised ventilation hood for care of patients with suspected or confirmed COVID-19 in the intensive care, emergency and respiratory healthcare settings: A phase 1 safety study of a new device (McMonty).","the efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomize, controlled trial","Xiaoyao capsule improves COVID-19 convalescence sleep mood disorder in a randomized, double-blind, placebo-controlled, multicenter clinical study","Rqesearch on the Application of Traditional Chinese Medicine Traditional Techniques to Prevent and Control New Coronary Pneumonia","Lingnan Fire-Needle Therapy Improves the Quality of Life in General Population Under the Pandemic of novel coronavirus pneumonia (COVID-19): A Prospective, Randomized Controlled Trial","A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension","Study for efficacy and safety of Jie-Xing-Jun-Zi granules in the Treatment of convalescent patients of novel coronavious pneumonia (COVID-19)","A multicenter, randomized, open, controlled trial for the efficacy and safety of oral kolimycin in the treatment of patients with new coronavirus pneumonia (CoVID-19)","Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE)","Inhaled Nitric Oxide Gas Therapy in Mechanically Ventilated Patients with Severe Acute Respiratory Syndrome in COVID-19 - NOSARSCOVID19","COVID-19: addition of azithromycin to chloroquine treatment - CO VOR IT","COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents  a randomized controlled trial - COVID-19 PREVENTION","Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.","Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19","Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare\r\npersonnel with high risk of infection.","Clinical trial of Sarilumab in adults hospitalized with COVID-19 presenting cytokine release syndrome","Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019  COVID-19","A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. - COV-AID","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting; a Randomised, Placebo-controlled Prophylaxis Study (COPCOV)","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","Early Prone Positioning Combined With High-Flow Nasal Cannula Versus High-Flow Nasal Cannula in COVID-19 Induced Moderate to Severe ARDS","A Prospective, Controlled, Randomized, Multicenter Study to Compare the Efficacy of a Chloroquine Analog (GNS561), an Anti PD-1 (Nivolumab) and an Anti-interleukine-6 Receptor (Tocilizumab) Versus Standard of Care in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019-A Multicenter, Open, Randomized Controlled Study","A Multicenter, Randomized, Open-Label, Phase II Trial to Evaluate the Efficacy and Safety of Checkpoint Blockade in Patients With Coronavirus Disease 2019 (COVID-19)-Related Mild Acute Respiratory Syndrome Nonresponsive to Frontline Therapy","A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Treatment With Hydroxychloroquine vs Nitazoxanide + Hydroxychloroquine in Patients With COVID-19 With Risk Factors for Poor Outcome","CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort","Proof of Concept, Multicentre, Parallel, Randomized, Double-blind Clinical Trial to Assess the Safety and Efficacy of Nitazoxanide 600 mg Compared to Placebo in the Treatment of Hospitalized Patients With COVID-19 in Moderate Condition.","Open Label, Multicentric, Non Randomized, Exploratory Clinical Trial to Assess the Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Mild Acute Respiratory Syndrome (COVID-19) Caused by SARS-CoV-2 Virus","Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)","Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Open-label, Multicenter, Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19","An Open Label, Phase 2 Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection","Prevalence and Impact of SARS-COV-2 Infection in Pregnant Women, Fetuses and Newborns","Convalescent CoVID-19 Plasma in the Treatment of High Risk CoVID-19 Disease","Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial","Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial","COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma","Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19): a Diagnostic Accuracy Study","suPAR-guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE Open-label, Non-randomized Single-arm Trial","Clinical Trial of Sarilumab in Adults Hospitalized With COVID-19 Presenting Cytokine Release Syndrome","A Multi-center, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease","Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial","Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope","Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection - MARNEVO-Covid","Pilot Study on Cytokine Filtration in COVID-19 ARDS (CytokCOVID19)","Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial","A Randomized, Placebo-Controlled, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19","A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.","Povidone-Iodine Intranasal for Prophylaxis in Front-line Health-care Personnel and Inpatients During the Sars-CoV-2 Pandemic","Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study","\n                An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care\n","A Randomized Controlled Trial for the Effects of Low-Oxygen Consumption Instruction on the Prognosis of Patients with Novel Coronavirus Pneumonia (COVID-19)","A study for the mental health status of novel coronavirus pneumonia (COVID-19) convalescent patients and first-line medical staff and the intervention strategy of psychological crisis in Ningxia","Clinical study of novel coronavirus (SARS-Cov-2) infection treated with aerosol inhalation (IFN-? plus anti-inflammatory factor TFF2)","Randomized control clinical trial of CIGB 2020 in contacts and SARS-CoV-2 infection suspects (COVID-19)","Evaluation of the effect and safety of HeberFERON versus Heberon alfa in patients infected with the SARS-CoV-2 coronavirus (COVID-19).","Pharmacodynamics and safety of recombinant interferon alfa 2b, by different routes of administration, in healthy volunteers (COVID-19).","Low dose of IL-2 In Acute respiratory DistrEss syndrome related to COVID-19  LILIADE-COVID\n - LILIADE-COVID","A randomized trial of efficacy and safety of an early OUTpatient treatment of COVID-19 in patients with risk factor for poor outcome : a strategy to prevent hospitalization : OUTCOV Study\n - OUTCOV","Phase I/II clinical trial to evaluate the safety and efficacy of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cells Expanded in patients with severe COVID-19 pneumonia","Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. - BCG-DENMARK-COVID","CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL - HOPE","The NOR Solidarity multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). - N-ReCOVID 19","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)","Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: A Pragmatic Randomized Clinical Trial","Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization","DAS181 for Severe COVID-19: Compassionate Use","A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","An Adaptive Phase 2/3, Randomized, Double-blind, Placebo Controlled Study Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With COVID19","An International, Multi-site, Bayesian Platform Adaptive,Randomised, Double-blind, Placebo-controlled Trial Assessing the Effectiveness of Varied Doses of Oral Chloroquine in Preventing or Reducing the Severity of COVID-19 Disease in Healthcare Workers","Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Antiviral Activity of BLD-2660 in Hospitalized Subjects With Recently Diagnosed COVID-19 Compared to Standard of Care Treatment","Use of Caption AI to Perform a Clinically Indicated Transthoracic Echocardiogram in Patients Being Evaluated for or Positive for COVID-19","Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study","A Quadruple Blind, Randomized Controlled Pilot Trial of Gargling Agents in Reducing Intraoral Viral Load Among Laboratory Confirmed COVID-19 Patients: GARGLES STUDY","Efficacy of Sarilumab + Azithromycin + Hydroxychloroquine, and Sarilumab Alone, for Adult Patients Hospitalized With Moderate to Severe COVID-19: a Multicenter Open-label 1:1 Randomized Controlled Trial","A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)","UPright Incline Positioning in COVID-19 Patients for Oxygen SATuration Improvement With Hypoxemic Respiratory Failure (UPSAT)","COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning","A Randomized Phase 2 Study of Anti-IL-8 Therapy Versus Standard of Care in the Treatment of Hospitalized Patients With Severe COVID-19","A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)","A Phase II, Open Label, Single-Center, Clinical Trial to Assess Efficacy of HB-adMSCs to Provide Immune Support Against Coronavirus Disease","Randomized Controlled Trial of Hydroxychloroquine Versus Placebo in Early Ambulatory Diagnosis and Treatment of Elderly COVID19 Patients","Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19","Isotretinoin in Treatment of COVID-19 (Randomized)","A Randomized Phase 2/3 Trial of Hydroxychloroquine In Covid-19 Kinetics","Open-label (Unblinded) Randomized Trial of Colchicine to Reduce Myocardial Injury in COVID-19 (COLHEART-19)","Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced Acute Respiratory Distress Syndrome (ARDS)","Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)","A Comparison of 3D and 2D Telemedicine: Communication During Covid 19","Impact of Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19","Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia. Multicentric, Comparative, Randomized Study","Leflunomide for the Treatment of Ambulatory Patients With Mild COVID-19","A Randomized, Controlled Clinical Trial to Test the Safety and Efficacy of Convalescent Donor Plasma to Treat COVID-19 in Hospitalized Adults","Azithromycin With Amoxicillin/Clavulanate Versus Amoxicillin/Clavulanate Alone in COVID-19 Patients With Pneumonia and Hospitalized in a Non-intensive Care Unit Ward (AziA): a Superiority Open-label Randomized Controlled Trial","VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)","Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment","Efficacy and Safety of Hydroxychloroquine for COVID-19 Post-Exposure Prophylaxis of Healthcare Workers in the Philippine General Hospital and UP Manila National Institutes of Health: A Randomized, Double-blind, Placebo-controlled Trial","NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression","Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial","Alpha-1 Adrenergic Receptor Antagonism to Prevent COVID-19 Cytokine Storm Syndrome and Acute Respiratory Distress Syndrome: A Randomized Study Comparing the Efficacy of Prazosin vs. Standard of Care for SARS-CoV-2 Infection","Protective Effect of Aspirin on COVID-19 Patients","Safety and Efficacy of Endotracheal Intubation by Paramedics in Suspected/Confirmed COVID-19 Patients Under Cardiac Arrest Using Vie Scope Laryngoscope","Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19","Phase II Clinical Trial to Explore the Efficacy of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With Severe Pulmonary Involvement by COVID-19","Intraosseous Versus Intravenous Access During COVID-19 Patients Performed by Paramedics Wearing Level C Personal Protective Equipment. A Multi-center Prospective Randomized Crossover Single-blinded Simulation Trial","Increasing Our Understanding of COVID-19: Minimal Invasive Autopsies to Investigate Clinical, Radiological, Microbiological and Histopathological Changes in Deceased COVID-19 Patients","Prevention and Treatment With Calcifediol of COVID-19 Coronavirus-induced Acute Respiratory Syndrome (SARS)","Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID)","Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus (\"TeleSLE\") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial","A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS","Management of Covid-19 Patients During Home Isolation","A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic","Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic","Trans Thoracic Manipulation of Ventilation/Perfusion: the V/Q Vest","C5a Receptor Expression in Circulating Myeloid Cells in ARDS Secondary to COVID-19","Efficacy and Safety of Hydroxychloroquine in Primary Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers at Risk of Exposure: Randomised Control Trial","Phase 2 Randomised Trial Using XPro1595 to Treat Participants With Pulmonary Complications From Coronavirus Disease (COVID-19)","A Multi-site, Randomized, Double-Blind, Multi-Arm Historical Control, Comparative Trial of the Safety and Efficacy of Hydroxychloroquine, and the Combination of HCQ and Famotidine for the Treatment of COVID-19","Recruit Blood Donors Via SMS With Different Contents During Epidemic of COVID-19","A Double-blind, Randomized Study Versus Placebo of Avdoralimab (IPH5401), an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia","Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19","Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19)","Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection","WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound: a Prospective, Multicenter, Randomized, Open-label, Parallel-group Clinical Trial","Development of a Novel Hood Shield to Enhance PPE Security and Minimize COVID-19 Transmission to Front-line Health Care Workers Performing High-risk Procedures","Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial","Inhalable Sodium Bicarbonate: A Possible Adjuvant Treatment of Patients With Novel COVID-19: A Feasibility Study","A Randomized, Open Label, Controlled Clinical Study to Evaluate the Recombinant Bacterial ACE2 Receptors -Like Enzyme 2 (rbACE2) in Adult Patients With COVID-19","18F-av6-binding-peptide PET/CT in Patients Post SARS CoV2 Infection","Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19","Evaluation of Safety and Efficacy of Hydroxychloroquine Plus Favipiravir Drug Regimen in Comparison With Hydroxychloroquine Plus Kaletra on the Need for Intensive Care Unit Treatment in Patients With COVID-19; a Randomized, Multicenter, Parallel Groups, Open Label Study","A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit)","A Phase II Study of IL-6 Receptor Antagonist Tocilizumab to Prevent Respiratory Failure and Death in Patients With Severe COVID-19 Infection","Safety and Pharmacokinetics of Human Convalescent Plasma in High Risk Children Exposed or Infected With SARS-CoV-2","Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-CoV-2: Predictive Interest in Short-term Evolution","Using Behavioral Nudges to Improve Preventive Health Behaviors That Limit COVID-19 Spread","A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19","Randomized Controlled Trial (RCT) to Evaluate the Efficacy of an Internet-based Self-help Program for People With Psychological Distress Due to Covid-19","Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia","Pulmonary and Motor Rehabilitation for People With COVID-19 in Intensive Care Units to Reduce Length of Stay in Hospital","Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)","A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).","A randomized,double blinded, parallel  controlled clinical trial for azvudine in the treatment of novel coronavirus pneumonia (COVID-19)","Clinical trial for the washed microbiota transplantation in the treatment of novel coronavirus pneumonia (COVID-19) patients suspected with gut microbiota dysbiosis","A randomized, double-blind, placebo, parallel controlled trial for Pien-Tze-Huang Capsules in treating  convalescent novel coronavirus pneumonia (COVID-19) patient with SARS-CoV-2 positive.","Volatile agents for sedation in patients with COVID-19-associated acute respiratory distress syndrome  a pilot study","Randomized controlled trial of Digital Cardiac Counseling in patients with delayed cardiac surgical treatment due to Covid-19 pandemic (DCC trial)","Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19)","The use of (social) media","Countering Lung Damage in COVID-19 infection (CounterCovid) study","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial","Efficacy of captopril nebulization in Covid-19 patients suffering of SARS-CoV-2 pneumonia.\nA randomized phase II study\n - CAPTOCOVID","WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY Finland","Losartan and spironolactone treatment for COVID-19 patients with acute respiratory failure in intensive care unit - COVIDANCE","Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).","Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CAN-COVID).","A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 - Investigating a Vaccine Against COVID-19 (COV002)","A multi-centre open-label two-arm randomised superiority clinical trial of Azithromycin versus usual care In Ambulatory COVID-19 (ATOMIC2) - ATOMIC2, Version 1.0","Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19","A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute respiratory syndrome coronavirus-2)\n\nACOVACT (Austrian CoronaVirus Adaptive Clinical Trial)","Effectiveness of Interleukin-6 Receptor Inhibitors in the Management of Patients with Severe SARS-CoV-2 Pneumonia: An Open-Label Multicenter Sequential Randomized Controlled Trial","Pre-emptive tocilizumab in hypoxic COVID-19 patients, a prospective randomized trial - PreToVid","USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION (GLUCOCOVID). Pragmatic trial inserted in real practice during a pandemic COVID-19 - USE OF CORTICOSTEROIDS IN PATIENTS WITH SARS-COV2 CORONAVIRUS INFECTION","RANDOMIZED CLINICAL TRIAL OF PARALLEL GROUPS TO COMPARE THE EFFICACY OF HYDROXYCHLOROQUINE VS. CYCLOSPORINE - HYDROXYCHLOROQUINE IN THE TREATMENT OF COVID-19 PNEUMONIA. - HYDROCYCLO STUDY"],[null,"China","China","China","China",null,"China",null,null,"China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China",null,"China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China",null,"China","China","China",null,"China","China","China",null,"China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China","China",null,"China","China","China","China","China",null,"China","China","China",null,"China",null,null,"China","China",null,"China","China","China","China","China","China","China","China","China","China","France;United States;Hong Kong;Taiwan;Belgium;Spain;Australia;Denmark;Germany;Italy;China;Korea, Republic of, Republic of",null,"China",null,"China","China","China","China",null,"China","China","China","France",null,"China",null,"China",null,null,"China","China","China",null,"China","China","China","China","Italy","China","China","China","China","China","China","China","China","China","China","China","China","Belgium","China","China","China","China","Korea, Republic of, Republic of","China","China","China","China","China",null,"China",null,"China","China","China","China","China","China","China","China","China","China","Italy","China",null,"China","China","China","China","China","China","China","China","China","China","Japan","France","France","China","China","China","United States","China","China",null,"China",null,"China","China","United States","China","China","China",null,"China","Australia","Netherlands","China","United Kingdom","China","China","China",null,"China",null,"China","China","China","France","Italy","France","China","Spain","France;Belgium;Luxembourg;Netherlands;Germany;United Kingdom;Spain","Spain","China;Italy;China;Italy","United States","China","France","Spain","Romania","Spain",null,null,"China","China",null,"Thailand","United States",null,"China","United States","China","Italy","Australia","Italy","Netherlands","Iran","Norway","China","China","Spain","Spain","United Kingdom","Spain","United States","United States",null,null,"France","Iran","Netherlands","China",null,"China","France","Germany","France",null,"Israel","France","Spain","Australia","Spain","Denmark","United States","United States","Australia","Spain","China","Spain","China","China","China","China",null,"United States","China","France","France","United States","Spain","Spain","United States","France","Spain","China","Spain","China","China","Denmark","Spain","Italy","United States","Spain","United States","United States","Mexico","Greece","Spain","United States","Spain","Germany",null,"Greece",null,"Australia","New Zealand","China","France","France","France","Denmark","Netherlands","Sweden","Spain","Australia","France","China","Spain","Spain","China","Spain","Denmark","Spain","Spain","Spain","Spain","France","India","Spain","Spain","India","Spain","Ghana;Nigeria;South Africa;United Kingdom;India","India","China","China","United States;KOREA;Japan","Japan","China","China","Nigeria","China","Spain","Brazil","China","Egypt","Brazil","China","Nigeria;Nigeria",null,"Brazil","Brazil",null,"Spain","Brazil","Thailand","French Guiana","India;Iran;Thailand;Spain;Norway;Switzerland;South Africa;Argentina;Peru;Bahrain","Canada","France","China",null,"Mexico","China","China",null,"Thailand","Hong Kong","China","Belgium","United States","France","Mexico","United States","United States","China","China","United States","Mexico","Canada","Spain","China","France",null,"Norway",null,"France","Germany","United Kingdom","Egypt","Brazil","Turkey","United States","United States","United States","United States","Colombia","Italy","Spain","Belgium","United States","Germany","United States",null,"United States","France","United States","Hong Kong","France","Greece","Spain","United States","France","France","United States","United States","Iran","China","France","Egypt","Egypt","Poland","Brazil","United States","United States","Colombia","United States","France","Russian Federation","Egypt","Malaysia",null,null,"Puerto Rico","China","United States","Pakistan",null,"United States","France","Belgium","Bahrain","Spain",null,"Australia","India","United States","Egypt","Ireland","United States","Spain",null,"Egypt",null,null,"Egypt","United States","Iran","United States",null,"United Kingdom","Canada","United States",null,null,"France",null,"United Kingdom",null,null,"United States","Australia;New Zealand","Ireland","Germany","New Zealand","Spain;Thailand;Indonesia;Italy;Switzerland;Canada;Argentina;Brazil;Iran;Peru;South Africa;Germany;Norway","Slovenia","Iran","China","China","Spain","China","United Kingdom","Belgium","Austria","United States","Spain","Poland","Denmark","Canada","Italy","France;Hungary;Czech Republic;Denmark;Germany;United Kingdom","Canada","Germany","Austria","Belgium","Belgium;Italy","United States","United States","Brazil","United States;France;Netherlands;France;Netherlands;United States","United States","United States;Canada;Spain;Canada;Spain;United States","Norway","United States","Belgium","United States","Canada",null,"United States","France","China",null,"Brazil","United States",null,"Colombia","Colombia","United States","United States",null,"United States","Canada","Canada",null,"France","France","United States","Iraq","Greece",null,"United States","United States","France","United States",null,null,"Austria","Austria;Germany;Austria;Germany","Italy","France","Saudi Arabia","France","United States","France","China","United States","France","United States","France","China","Israel","France","United States","Spain","United States","China","Poland","Mexico",null,null,"Iran","Iran","Colombia","China","France","China",null,"United States",null,"France","Italy","France","China",null,null,null,null,"China","Canada","France","Italy",null,"China","Colombia","Netherlands",null,"United States",null,null,null,null,null,"United States","United States","United States","South Africa","Iran","United States","China","France","France",null,null,"Belgium",null,"New Zealand","Mexico","Turkey","Brazil",null,"United Kingdom","China",null,"China","Australia","India",null,"China","China","France","France","France",null,"Switzerland","Spain","China","Austria;Denmark","Brazil","Belgium",null,"United States","China","Germany","United States","China","Denmark","Denmark","France","Sweden","China","France","United States;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States","United States","United Kingdom","Serbia","Brazil","United States;Denmark;Germany;Greece;Japan;Korea, Republic of, Republic of;Mexico;Singapore;Spain;United Kingdom;Denmark;Germany;Greece;Japan;Korea, Republic of, Republic of;Mexico;Singapore;Spain;United Kingdom;United States","Gibraltar","France","Australia","France","France","China","Argentina","Netherlands","Canada","Spain","United States","United States","United States","Spain","United States",null,"Spain","Mexico","Iran","Spain","Spain","Netherlands","United States","Germany","United States","United States;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;China;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of, Republic of;Netherlands;Singapore;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;Iran","United States","United States","Netherlands","United States","United States","United States","Brazil","United States","Iran","France;Luxembourg;France;Luxembourg","United States","United States","Egypt","Denmark","Italy",null,"Switzerland","United States","Vietnam","United States","United States;Austria;France;Israel;Spain;United Kingdom;Austria;France;Israel;Spain;United Kingdom;United States","United States","Pakistan","Germany","Pakistan","Switzerland","Austria;Denmark;Germany;Austria;Denmark;Germany","United States","Pakistan","Canada","China",null,"France","Spain","United States","Israel","United States",null,"United Kingdom","France","Hong Kong","France",null,"United States","Spain","India","United States",null,"Spain","United States","United States","France","Spain",null,"Canada","Spain","China","United States","United Kingdom",null,"France","United States","Brazil","United States","United States",null,"China","Italy","Jordan","France","Italy","United States","Mexico",null,"Israel",null,"Iceland","Spain","Spain","Iran","Italy","United States","France","United States","France","United Kingdom","Italy",null,"France",null,"France","Poland","United States;Spain;United Kingdom;Spain;United Kingdom;United States","United States","Belgium",null,"France","France","Sweden",null,null,"France","China","United States","China","China","Australia",null,"Canada","United States","Brazil","Jordan","United States","France","Spain","China","Spain",null,"Iran","United States","Italy","United States",null,"China","France","China",null,null,"Canada","France",null,"China","United States",null,null,"France","France;Canada;Spain;Russian Federation;Israel;Germany;Japan;Italy","France","United States",null,"China",null,"France","Canada","Italy","Canada","United Kingdom",null,"China","India","United States","United States","China","Egypt","United States","Bosnia and Herzegovina",null,"United States","China","France","Canada",null,"France","Canada","Spain",null,"United States","United States",null,"Chile","Turkey","China","Belgium","United States","United States","United States","United States","India","Italy","Canada","Italy","United States","Jordan","Italy","Canada","China",null,"France",null,null,null,"Norway",null,"Germany","Pakistan","Russian Federation","Italy",null,"United States","United States","Canada","United States",null,"Germany","Canada","United States",null,"France","France","Australia","Australia",null,"Saudi Arabia",null,"Israel","Turkey","Australia;United States of America;Germany","China",null,"United States","France","China",null,null,"South Africa","Brazil","Norway",null,"United States",null,"Russian Federation","Mexico","United Kingdom","United States","United States","United States","Russian Federation","China","United States","Spain","Greece","United States","Australia","China","China","France","Netherlands","Netherlands","Greece","Netherlands","Canada","China","Netherlands","Denmark","France;Monaco;France;Monaco","Ireland","France",null,"Canada","France","Germany","Turkey","United Kingdom","Spain","France","China","United Kingdom","Spain","France","United States;Spain;Austria;Israel;Italy;United Kingdom;India;France;Canada;Belgium;Malaysia;Australia;Germany","Italy","Netherlands;Germany","Spain","United Kingdom","France","Denmark","United Kingdom","United Kingdom","Spain","United States;France;Spain;Belgium;Italy;United Kingdom","Hungary","Denmark","United States","United Kingdom","Greece","Austria",null,"Spain","United States;France;Spain;Germany;United Kingdom;Italy","Germany","Spain","Spain","Australia","Spain","Australia","Spain","Australia","Spain","China","China","China","China","China","Spain","United Kingdom","Portugal;Greece;Finland;Spain;Ireland;United Kingdom;France;Czech Republic;Hungary;Belgium;Romania;Croatia;Australia;Denmark;Netherlands;Germany;New Zealand","Belgium","Japan","Japan","United Kingdom","China","Italy","Denmark",null,"Netherlands","Turkey","United States",null,null,"United States","Brazil","Nigeria;Pakistan;Nigeria;Pakistan","Mexico","China","Denmark","Spain","United States","China",null,null,"United States","France","France","Hong Kong","Egypt","United States",null,"Egypt",null,"Australia","Spain","Australia","Australia","China","China","China","China","China","China","China","United Kingdom","United States;Austria;China","Netherlands","Denmark","Spain","Spain","Spain","Spain","Germany","Belgium",null,"United States;Israel;United States","United States;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States","United States","France","China","Spain","China","Mexico","France","Brazil","Brazil","United States","Canada",null,null,"United States","Argentina","Switzerland","Mexico","Italy","Greece","Spain",null,null,null,null,"Spain","United States","United States",null,"Italy","United States",null,"Indonesia;Iran;Ireland;Israel;Italy;Kenya;Lebanon;Malaysia;Norway;Peru;Philippines;Qatar;Saudi Arabia;South Africa;Spain;Switzerland;Thailand;Argentina;Brazil;Canada;Germany;Honduras;India",null,"China","China","Cuba","Cuba","Cuba","France","France","Spain","Denmark","Greece","Norway","China","United States;Canada;United States","United States","China","United Kingdom","Canada;France;Germany;Israel;Italy;Japan;Russian Federation;Spain;Canada;France;Germany;Israel;Italy;Japan;Russian Federation;Spain","United States;Canada;Ireland;South Africa;United Kingdom;Zambia;Canada;Ireland;South Africa;United Kingdom;United States;Zambia;Australia","United States","United States","United States",null,"France","United States",null,"United States","United States","United States","United States","Germany","Denmark","Egypt","United States","United States","France","Egypt","United Kingdom","Egypt","Tunisia","United States","United States","France","United States",null,null,null,"France","United States","China","Poland","United States","Spain","Poland","Belgium",null,"United States",null,"United States","Egypt","Austria",null,"United States","France",null,null,"United States","China","France","Israel",null,null,"France",null,null,"Egypt",null,"United States","Egypt","Iran","Tunisia","United States",null,"France",null,"United States","Switzerland","Indonesia","Italy","Sweden","Russian Federation","China","China","China","Netherlands","Netherlands","Netherlands","Netherlands","Netherlands","Netherlands","France","Finland","France","United States;France;Spain;Germany;United Kingdom;Italy","United States;France;Spain;Germany;Italy;United Kingdom","United Kingdom","United Kingdom","Spain","Austria","Denmark","Netherlands","Spain","Spain"],["Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid","Case series:Treated with conventional treatment combined with Chloroquine Phosphate;","experimental group:standardized comprehensive treatment combined with convalescent plasma treatment;control group:standardized comprehensive treatment;","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment;control group :western medicine symptomatic treatment  ;","control group:Western Medicine;experimental group:Integrated Traditional Chinese and Western Medicine;","Experimental group:Conventional treatment+Anti-aging Active Freeze-dried Powder Granules;Control group:Conventional treatment;","Experimental group:TCM based on symptomatic treatment;Control group:Placebo TCM based on symptomatic treatment;","Other: basic treatment;Drug: Arbidol","Drug: Intravenous Immunoglobulin;Other: Standard care","TCM Group:herbal medicine and conventional treatment;QFPD decoction group:QFPD decoction and conventional treatment;SFJD capsuale group:SFJD capsuale and conventional treatment;control group:conventional treatment;","control group:Standard treatment;experimental group:Standard treatment and methylprednisolone for injection;","experimental group:Truncation and Torsion Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","Drug: Arbidol;Drug: Lopinavir and Ritonavir Tablets","experimental group:Polyinosinic-Polycytidylic Acid Injection and conventional therapy;control group:conventional therapy;","Control group:Health education+Basic treatment of western medicine;Experimental group:Health education+Basic treatment of Western medicine+Dialectical?treatment of traditional Chinese medicine;","General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;","control group :Conventional treatment ;Experimental group :conventional treatment combined with umbilical cord mesenchymal stem cell conditioned medium group;","Drug: lopinavir/ritonavir group;Drug: ASC09/ritonavir group","experimental group :Traditional Chinese medicine compound granules + western medicine symptomatic treatment ;control group:western medicine symptomatic treatment ;","Experimental group:chloroquine;control group:conventional management;","experimental group:Chloroquine Phosphate;control group:Lopinavir / Ritonavir;","Conventional treatment group:The conventional treatment group will be treated according to the guidance of the Diagnosis and Treatment Scheme of COVID-19 published by the National Health Commission.;Experimental group:conventional treatment combined with Chloroquine Phosphate.;","experimental group:conventional standardized treatment and Lopinavir-Ritonavir;control group:Conventional standardized treatment;","control group:western medical therapies;Experimental group:Conventional medicine + TCM;","experimental group:Truncated Torsion' Formula and Routine treatment of Western Medicine;control group:Routine treatment of Western Medicine;","Case series:Conventional standardized treatment and vMIP atomized inhalation;","Group 1:TCM syndrome differentiation treatment+ Western medicine treatment;Group 2:Western medicine treatment;","Experimental group:Carrimycin;Control group:Lopinavir and Ritonavir Tablets;","control group:basic western medical therapies;experimental group:Reduning injection combined with basic western medical therapies;","Chinese traditional medicine group 1:Traditional Chinese medicine qingfei prescription treatment;Chinese traditional medicine group 2:Traditional Chinese medicine clear lung prescription and compound houttuynia mixture treatment;Control group:Conventional treatment;","Experimental group:Regulating intestinal flora + conventional treatment;Control group:conventional treatment;","Experimental Group:Combined Treatment of Chinese medicine and western medicine;Control Group:Western medicine treatment;","Treatment group:Integrated Traditional Chinese and Western Medicine;","Experimental group:Oral administration of 5 tablets of 1mg Azvudine tablets daily;Control group:According to the \"Pneumonia Diagnosis and Treatment Plan for New Coronavirus Infection (Trial Version 5)\" issued by National Health Commission of People's Republic of China, the subjects were given corresponding treatment.;","Experimental group:honeysuckle decoction;Control group:placebo;","Experimental group:umbilical cord mesenchymal stem cells;control group:convention treatment;","(ordinary) Western medicine group:Use the (ordinary)  western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(ordinary) Chinese and Western Medicine Group:Use the (ordinary)   TCM clinical prescription combined with the western medicine  treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Western medicine group:Use the (severe) TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;(severe) Chinese and Western Medicine Group:Use the(severe)TCM clinical prescription combined with the western medicine treatment plan in \"the diagnosis and treatment plan of new coronavirus infection pneumonia\" issued by the National Health Commission of the fourth edition.;","treament group:Chinese medicine decoction;placebo group:placebo;","Control group:Routine treatment (Pure western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection;Investigation group:(Integrated Chinese and western medicine): Lopinavir-ritonavir tablet combined with recombinant human interferon alpha 2b injection(routine treatment)+Qing-Wen Bai-Du-Yin formula granules;","Experimental group:Conventional Treatment &amp; Tanreqing Capsules (oral, 3 capsules at a time, 3 times a day);Control Group:Conventional Treatment;","experimental group:Traditional Chinese Medicine+psychological intervention;\t Control group:Traditional Chinese Medicine;Control group:psychological intervention;","Experimental group:Traditional Chinese medicine soup;Control group:Western antiviral;","Experimental group:Conventional treatment + take Ba-Bao-Dan;Control group:Conventional treatment;","Thymosin treatment group:Thymosin for injection 1.6 mg sc qd for 5 days;PD-1 treatment group:Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion;Conventional treatment group:Conventional treatment;","Two groups:Different stem cell doses;","experimental group \t:TCM decoctions+basic western medical therapies ;control group :basic western medical therapies ;","Experimental group:Routine treatment + Babaodan 6 capsules, bid orally;Control group:Conventional treatment;","Control group:Western medicine basic treatment;Experimental group:Western medicine basic treatment combined with traditional Chinese medicine;","1:Simplify cognitive behavior;2:Supportive psychotherapy;","experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;","Control group :Western medicine routine treatment plan;Intervention group :Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","Psychological Intervention Group:\"Intelligent Psychosomatic Regulation System\" Intervention;Control Group :General Treatment ;","control group:conventional therapy;Experience group:conventional  therapy+tocilizumab;","Experimental:Conventional treatment and Shenfu injection;control:Conventional treatment;","experimental group:TCM and general treatment;control group:general treatment;","Case series:FNC;","Experimental group:TCM+Routine treatment of Western Medicine;Control group:Routine treatment of Western Medicine;","experimental group:Xiyanping injection;control group:alpha-interferon;","Experimental group:Arbidol tablets + basic treatment;Control group:Basic treatment;","Experimental group:Traditional Chinese Medicine;control group:Basic treatment of modern medicine;","1:inhalate the mycobacterium vaccae for injection;2:inhalate  Physiological saline;","mild-moderate chloroquine group:oral chloroquine phosphate;mild-moderate Lopinavir/ritonavir group:oral Lopinavir/ritonavir;mild-moderate combination group:chloroquine phosphate plus Lopinavir/ritonavir;severe-chloroquine group :oral chloroquine phosphate  ;severe- Lopinavir/ritonavir group:oral Lopinavir/ritonavir;","Experimental group:Hydrogen-Oxygen Nebulizer;Control group:Oxygen concentrator;","Experimental group:rhG-CSF, 5ug/kg, combinated with standard treatment;Control group:standard treatment;","experimental group A:Conventional treatment followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations;control gorup A:Conventional treatment;Experimental Group B1:Artificial liver therapy+conventional treatment;Experimental Group B2:Artificial liver therapy followed by Intravenous infusion of Human Menstrual Blood-derived Stem Cells preparations+conventional treatment;Control Gorup A:Conventional treatment;","Ganovo / ritonavir group:Ganovo/ ritonavir oral;Pegasys group:Pegasys injection;Novaferon group:Novaferon  intramuscular injection+Spray inhalation;Coriolus group:Coriolus  oral;Comparator:TCM+Spray inhalation;","Low dose group:Shuanghuanglian 2 bottles/time, 3 times a day; Routine treatment.;Medium dose of group:Shuanghuanglian 4 bottles/time, 3 times a day; routine treatment.;High dose of group:Shuanghuanglian 6 bottles/time, 3 times a day; routine treatment.;Control group:Routine treatment;","Experimental group:Health Guidance + Guixi Regulating Lung Gong Method + Shenling Baizhu Powder + Moxibustion Treatment;Control group:Health Guidance + Guixi Regulating Lung Gong Method ;","doctors group:Psychological intervention;nurses group:Psychological intervention;suspected cases group:Psychological intervention or drug intervention;cases group:Psychological intervention or drug intervention;","Experimental group:Conventional standardized treatment and ASC09/Ritonavir;Control group:Conventional standardized treatment and Lopinavir/Ritonavir;","experimental group:routine treatment and Kangbingdu granules;control group:routine treatment ;","single arm:Chinese medicine treatment combined with western medicine treatment;","hydroxychloroquine group:oral intake hydroxycholoroquine 0.2 twice a day;control group:conventional therapy;","A:BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.BaloxavirMarboxil:80mg on day1,80mg on day4;and 80mg on day7 as neccessary. No more than 3 times administration in total.;B:Favipiravir: 600 mg tid with 1600mg first loading dosage for no more than 14 days.;C:Lopinavir-Ritonavir: 2# (200mg/50 mg), twice daily, for 14days.;","experimental group:TCM decoctions+basic conventional therapy;Control group:basic conventional therapies;","Experimental group:health education, follow-up condition management by team of family doctors, Chinese medicine treatment;Control group:health education, follow-up condition management by team of family doctors;","experimental group:shadowboxing +conventional treatment;Control group:conventional treatments;","Group A:alpha-Interferon atomization;Group B:Lopinavir and Ritonavir + alpha-Interferon atomization;Group C:Favipiravir + alpha-Interferon atomization;","experimental group:Pulmonary rehabilitation+Conventional treatment;control group:Conventional treatment;","control group:Conventional treatment;experimental group:conventional treatment combined with umbilical cord blood mononuclear cells group;","Case series:Add 500ml of 5% glucose injection or 0.9% sodium chloride injection into Tanreqing injection, intravenous drip, control the number of drops no more than 60 drops per minute, 1-2 times a day; the dosage is determined by the doctor,but no more than 80ml / day, 40ml / day is recommended.;","control group:basic western medical therapies;experimental group:TCM standard decoctions+basic western medical therapies;","experimental group 1:Hydroxychloroquine 0.1 oral 2/ day;experimental group 2:Hydroxychloroquine 0.2 oral 2/ day;Placebo control group:Starch pill oral 2/ day;","Control group:Conventional integrated traditional Chinese and western medicine treatment and western medicine psychological intervention treatment;Experimental group:Conventional integrated traditional Chinese and western medicine treatment, western medicine psychological intervention therapy and traditional chinese medicine psychological intervention therapy;","Group 1:Xuebijing Injiection;Group 2:Conventional treatment;","Experimental group 1:current antiviral treatment+Baloxavir Marboxil  tablets;Experimental group 2:current antiviral treatment+fabiravir tablets;Control group:current antiviral treatment;","DRV/c group:DRV/c (800mg/150mg QD) + Conventional treatment containing thymosin (1.6 mg SC QOD) ;LPV/r group:LPV/r (400mg/100mg bid) + Conventional treatment containing thymosin (1.6 mg SC QOD);other group:Conventional treatment containing thymosin (1.6 mg SC QOD) ;","A:Critical Treatment in Critical Period + Ankylosaurus;B:Critical Treatment in Critical Period + Ankylosaurus+M1 suppression therapy;C:Critical Treatment in Critical Period;","Biological: UC-MSCs","Experimental group:Syndrome differential treatment of Chinese Medicine + Western medicine basic treatment;Control group:Western medicine basic treatment;","experimental group:Lopinavir/litonavir (LPV/r)+ emtritabine (FTC)/ Tenofovir alafenamide Fumarate tablets (TAF) in combination;Historical Control:LPV/r;","severe NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;Acute exacerbation NCP group:Routine standard therapy + Jacketinib hydrochloride tablets (oral, the first 3 subjects were given a dose of 50mg Bid for 7 consecutive days; the current 3 subjects had no grade =3 drug-related adverse effects within D8 days). In the event, subsequent subjects were given 100 mg Bid for 7 consecutive;","Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;","Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;","Experimental group:enteral nutrition emulsion, tpf-t 200ml Bid;Control group:No intervention;","Routine treatment +  Jing-Yin Granule:Jing-Yin Granule 2 bags / time, 3 times a day \t;Routine treatment :Treat as prescribed in the sixth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Community exposure TCM intervention group:TCM intervention;Community exposure control group:Placebo;Hospital exposure TCM intervention group:TCM intervention;Hospital exposure control group:Placebo;Community suspected TCM intervention group:TCM intervention;Community suspected control group:Placebo;Hospital suspected TCM intervention group:TCM intervention;Hospital suspected control group:Placebo;","Humanistic care:Humanistic care+routine regimen;Control group:routine regimen;","Case series:Integration of traditional Chinese and Western Medicine;","Group A:traditional Chinese medicine treatment;Group B:Lopinavir / Ritonavir;Group C:traditional Chinese medicine treatment and Lopinavir / Ritonavir;","control group with common NCP:conventional treatment;experimental group with common NCP:conventional treatment combined with ozone therapy;experimental group with severe NCP:conventional treatment combined with ozone therapy;control group with severe NCP:conventional treatment;experimental group with critical NCP:conventional treatment combined with ozone therapy;control group with critical NCP:conventional treatment;","Experimental group:Exercise prescription;Control group:none;","Experimental Group:Conventional Treatment &amp; Low Dose  Recombinant Human Interleukin-2, i.m.(1 million IU per time, once another day, 3 times per week, 2 weeks);Control Group:Conventional Treatment+Placebo  i.m.(once another day, 3 times per week, 2 weeks);","Experimental group:Conventional treatent and adalimumab;Control group:conventional treatment ;","control group:conventional treatment;mild ill patients:conventional treatment and ozonated autohemotherapy;severe/critical ill patients:conventional treatment and ozonated autohemotherapy;","Experimental group:Iv injection of Wharton's Jelly mesenchymal stem cells (110^6/kg), cell suspension volume: 40ml;Control group:Iv 40ml saline;","Experimental group:Chloroquine phosphate;","Combination therapy group:Xiyanping injection+ conventional treatment;Conventional treatment group:Lopinavir / Ritonavir tablets, alpha-interferon;","Experimental group:Conventional treatent and hydroxychloroquine;Control group:Conventional treatment;","Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;","Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days a day ;Chloroquine phosphate gloup:The first dose of chloroquine phosphate was 1gx2 days, and the third day was 0.5gx12 days ;Control group:Recommended treatment plan for novel coronavirus pneumonia diagnosis and treatment plan ;","Drug: Carrimycin;Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate;Drug: basic treatment","Exercise prescription group:Exercise prescription;Control group:None;","Experimental group:conventional therapy with Infusion of convalescent plasma: 200-500ml, two infusions are recommended;control group:conventional therapy;","Experimental group :Oral leflunomide;Control group:Oral placebo;","Drug: PD-1 blocking antibody+standard treatment;Drug: Thymosin+standard treatment;Other: standard treatment","Intervention group 1:Oral antiviral oral solution (Xiangxue Pharmaceutical);Intervention group 2:Oral \"Wu-Zhi-Fang-Guan-Fang\" decoction;Control group:Routine quarantine measures;","Case series:mesenchymal stem cells therapy;","CRRT group:CRRT;Control group:Routine treatment, CRRT only when there are emergency indications;","Case series:diammonium glycyrrhizinate enteric-coated capsule combined with hydrogen-rich water;","Experimental group:ozonated autohemotherapy;Control group:Standard medical treatment;","Group 1:Traditional Chinese Medicine prescription No. 1 and 2;Group 2:Gankeshuangqing capsule;Group 3:Shuanghuanglian oral liquid;","Early corticosteroid intervention group:Early corticosteroid intervention;Middle-late corticosteroid intervention group:Middle-late corticosteroid intervention;Control group:No corticosteroid;","Experimental group:Basic treatment combined Triazavirin;Control group:Basic treatment combined Triazavirin placebo;","Control group:TCM + Conventional medicine treatment + conventional medicine's psychological intervention;Experimental group:Integrated Chinese and Conventional medicine treatment + conventional medicine's psychological intervention + TCM psychological intervention;","control group:conventional therapy;Experience group:conventional therapy and Tranilast;","Mild Group:probiotics;Severe Group:probiotics;","Group 2:SMO Assisted tracheal intubation;Group 1:Assisted tracheal intubation via nasal high-flow oxygen inhalation;","Experimental group:pulmonary training;control group:Conventional medication;","Chloroquine phosphate gloup:Chloroquine phosphate1.0gx2 days for the first dose, 0.5gx12 day from the third day   ; Hydroxychloroquine sulfate gloup:Hydroxychloroquine sulfate 0.2g bid x 14 days;Routine treatment group:Recommended treatment plan for novel coronavirus pneumonia severe and critical cases;","experimental group.:Recombinant Human Interferon a1b Eye Drops ;Control group:placebo drop;","Experimental group:Ruxolitinib combined with mesenchymal stem cell;control group:  Routine treatment;","experimental group:mesenchymal stem cells;control group:saline;","Experimental group:Chloroquine Phosphate;Control group:No;","Experimental group:Routine treatment + plasma treatment;Control group:Routine treatment;","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection;Drug: Lopinavir/ritonavir treatment","Experimental group:atic treatment medicines;Control group:Symptomatic treatment medicines;","Experimental group:ultra short wave  Electrotherapy;control:standard medical therapy;","A1:Hydroxychloroquine, small dose;A2:Hydroxychloroquine, high dose;B1:Abidol hydrochloride, small dose;B2:Abidol hydrochloride, high dose;","Control group:Treated according to the New Protocol for Diagnosis and Treatment of NCP(5th edition), without using traditional Chinese medicine;Experimental group 1:Basic treatment+Low dose of honeysuckle oral liquid 60ml each time, tid;Experimental group 2:Basic treatment + high dose of honeysuckle oral liquid 180 ml each time, tid;","experimental group:Routine treatment and Shenqi Fuzheng Injection;control group:Routine treatment ;","Device: Medical Mask;Device: N95 respirator","one group:Rehabilitation Lung Health Eight - Stage Exercise ;","Group 1:Eight lung exercises for rehabilitation;Group 2:Free activities;","Control group:Routine medicines and food;Experimental group:Taking Newgen beta-gluten probiotic composite powder;","Control group:Keep ritonavir/ritonavir treatment;Experimental group:Favipiravir;","Experimental group:Pirfenidone;Control group:Blank;","Case series:moxibustion;","Drug: Meplazumab for Injection","Drug: Xiyanping injection;Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet;Drug: N-acetylcysteine+Placebo","Drug: Fingolimod 0.5 mg","Pirfenidone group:Conventional standard treatment + Pirfenidone 400mg three times a day;Control group:Conventional standard treatment;","Case series:rehabilitation and Lung eight-segment exercise;Control group:Keep the initial life style;","Case series:Psychological intervention;","The experimental group:Wear a self-made \"gastroscope mask\" during gastroscopy;Control group:Without self-made \"gastroscope mask\" during gastroscopy;","Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;","Case series:Anti-2019-nCoV virus inactivated plasma;","High inflammation oXiris CRRT treatment group:oXiris CRRT treatment;High inflammation Conventional treatment group:Conventional treatment;Low inflammation conventional treatment group:Conventional treatment;","Case series:Suramin( IV.);","Exocrine group:Aerosol inhalation of exosomes;Control group:Blank;","Experimental group 1:Routine treatment + Kanguan No. 1;Control group (Mild patients):Routine treatment;Experimental group 2:Routine treatment + Kanguan No. 2;Control group (general patient):Routine treatment;Experimental group 3:Routine treatment + Kanguan No. 3;Control group (severe patients):Routine treatment;","Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;","Case series:conventional therapy+tocilizumab;","Experimental group:Conventional therapy and Pediatric Huatanzhike granules;Control group:Conventional therapy;","Experimental group:recombinant human interferon a1b spray;Control group:Blank;","Low-dose group:Low-dose hydroxychloroquine and conventional therapy;Medium-dose group:Medium-dose hydroxychloroquine and conventional therapy;High-dose group:High-dose hydroxychloroquine and conventional therapy;control group:conventional therapy;","Case series:Early initiation of blood purification;","Kesuting syrup group:conventional therapy and Kesuting syrup, p.o., 20ml, three times a day;Keqing capsule group:conventional therapy and Keqing capsule, p.o., three pills once, three times a day;control group:conventional therapy;","control group 1:Lopinavir / Ritonavir (Kaletra)  and IFN aerosol inhalation;control group 2:Abidol and IFN aerosol inhalation.;Experimental group:ASC09/ Ritonavir (ASC09F)  and IFN aerosol inhalation;","experimental group:routine treatment, Jinyebaidu granule, po, 1-2 bags once, 3 times a day;;control group:routinel treatment, treatment according to the fifth version  of the diagnosis and treatment protocol, no use of traditional Chinese medicine.;","Experimental group:Methylprednisolone, intravenous injection, 1-2mg/kgd for 3 days.;Control group:Without any glucocorticoid therapy;","arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;","Case series:Western medicine routine treatment plan plus TCM syndrome differentiation treatment;","ECMO group:ECMO therapy;the conventional treatment group:no;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;","experimental group:Ixekizumab and antiviral therapy;control group:antiviral therapy;","Control group:Conventional treatment;Experimental group:Conventional treatment +acupressure+Liuzijue qigong;","Biological: MSCs-derived exosomes","Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&amp;#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;","Control group:Conventional treatment;Experimental group:Conventional treatment pius Dao Yin;","Diagnostic Test: Standard screening strategy;Diagnostic Test: New screening strategy","Drug: pirfenidone","Experimental group:On the basis of routine treatment, add 100ml of normal saline and 50ml of Xuebijing injection twice a day;;Control group:conventional therapy;","Drug: T89","Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;","experimental group:dihydroartemisinin piperaquine tablets combined with antiviral treatment.;control group:antiviral treatment was selected as: a-interferon and Ardibdol;","Experimental group:Intravenous drip, 0.2 g (4 vials) once daily for adults; slow drip after dilution with 250 ml of 5% Glucose Injection or 0.9% Sodium Chloride Injection, not less than 120 minutes or 30-40 drops/minute. Continuous administration for 7 days, observation until 21 days or discharge;Control group:Conventional treatment, no control drug;","Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;","Experimental group:Lung rehabilitation training+Conventional treatment;Control group:Conventional treatment;","High dose group:High-dose NK cells (&gt;5x10^9)and mesenchymal stem cells(&gt;5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (&gt;3x10^9)and mesenchymal stem cells(&gt;3x10^9),Intravenous infusion once every week for a total of one time;","Experimental group:Conventional treatment followed by Intravenous infusion of  Umbilical Cord Blood Mononuclear Cells preparations;Control group:Conventional treatment;","treatment group1:HUMSCs: intravenous infusion, 5  10E7 cells / time, once / week, twice / course;treatment group 2:HUMSCs: intravenous infusion, 5  107 cells / time, 1 time / week, 2 times / course, a total of 2 courses;            Exosomes: intravenous administration, 180mg / time, 1 time / day, 7 days / course, 2 courses in total;control group:The control group was given the same amount of placebo (stem cell solvent);","Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;","Biological: Dental pulp mesenchymal stem cells","Control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan.;Experimental group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + Yiqi Huashi Jiedu Fang (same as above), decoction of decoction machine, 300mL;","Case series:cytokine removal therapy with Cytosorb;","Pirfenidone group:Support treatment with oral taken Pirfenidone capsule;Support treatment group:Support treatment ;","Case series:oXiris membrane;","Group 1:psychological support;Group 2:cognitive behavioral therapy;","Experimental group:normal treatment and auricular point pressing;control group:normal treatment;","group A:Arbidol Hydrochloride Tablets, Liushen Capsule, standard therapy;control group:standard therapy;","Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;","Control group:Conventional medicine;Experimental group:integrated Chinese and conventional medicine;","Treatment group:nebulization of recombinant super-compound interferon (rSIFN-co);Control group:nebulization of  interferon a;","&lt;br&gt;                Product Code: DAS181&lt;br&gt;                Pharmaceutical Form: Inhalation solution&lt;br&gt;                INN or Proposed INN: Farbefusp&lt;br&gt;                Current Sponsor code: DAS181&lt;br&gt;                Concentration unit: mg milligram(s)&lt;br&gt;                Concentration type: equal&lt;br&gt;                Concentration number: 4.5-&lt;br&gt;                Pharmaceutical form of the placebo: Inhalation solution&lt;br&gt;                Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Drug: Recombinant human interferon a1","intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;","Case series:dexmedetomidine;","Case series:Western medicine plus Qingfei Paidu decoction;","Experimental group:Anti-SARS-CoV-2 virus inactivated plasma;Control group:Ordinary plasma;","Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;","Group 2:Truncated Torsion' Formula and Routine treatment of Western Medicine;Group 1:Routine treatment of Western Medicine;","Case series:external diaphragmatic pacing;","High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);","control group:conventional therapy and placebo;Experience group:conventional therapy and ALA;","Experimental group:Immunoglobulin of cured patients;Control group:gama-Globulin;","&lt;br&gt;Trade Name: Plaquenil 200 mg, comprim pellicul&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","Group 1:mindfulness therapy;Group 2:cognitive behavioral therapy;Group 3:exercise therapy;Group 4:Without treatment, online assessment per two weeks;","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Drug: Huaier Granule","Biological: UC-MSCs;Other: Placebo","Drug: thalidomide;Drug: placebo","Drug: placebo;Drug: Thalidomide","Exocarpium Citri Grandis Group:Oral Administration of Exocarpium Citri Grandis Phlegm Cough Solution;Placebo Group:Oral Administration of Placebo;","Drug: Yinhu Qingwen Granula;Drug: Yin Hu Qing Wen Granula(low does);Other: standard medical treatment","Experimental group:Conventional treatent and Ulinastatin;Control group:Conventional treatent ;","Case series:Combination of Tocilizumab, IVIG and CRRT;","Case series:Traditional Mongolian Medicine;","Experimental group:chloroquine phosphate ;Control group:none;","Case series:CRRT;","Case series:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment;","Device: VivaDiag COVID-19 lgM/IgG Rapid Test","Control group:regular treatment;Experimental group:Compound amino acid combined with routine treatment;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;","Group 2:Western medicine conventional treatment;Group 1:TCM treatment;","Experimental group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment + acupoint application (Zusanli + Feishu);control group:Basic treatment of Western medicine + \"Baidu Duan Fang\" + routine nursing treatment;","eperimental group:Conventional treatment and convalescent plasma therapy;control group:conventional treatment;","Group A:Sevoflurane anesthesia maintenance, common extubation;Group B:Sevoflurane anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;Group C:Propofol anesthesia maintenance, common extubation;Group D:Propofol anesthesia was maintained, and the extubation strategy of \"circulatory induced respiration\" was adopted after the operation.;","Experimental group:On the basis of rehabilitation treatment, the subjects in the experimental group take Gu-Shen Ding-Chuan-Wan;Control group:standard treatment;","Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;","treatment group :Ba duanjin;","Positive drug control group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of Western medicine + Lianhua Qingwen Capsule (0.35 g per capsule) orally, 4 capsules each time;Compound Yuxingcao Mixture Group:Refer to the National Health Office Medical Letter (2020) 77 document \"Diagnosis and treatment plan for the novel coronavirus disease (trial version 5)\" general treatment plan. Based on the general treatment plan of western medicine + compound Yuxingcao mixture orally, 30mL each time, 3 times a day.;","Experimental group:PD-1 mAb + Standard treatment;Control group:Standard treatment;","&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;Product Name: itraconazole&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: ITRACONAZOLE&lt;br&gt;CAS Number: 84625-61-6&lt;br&gt;&lt;br&gt;","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*1071*108/kg body weight of NK cells each day.;control group:Sodium Potassium Magnesium Calcium and Glucose Injection.;","Two groups:Chinese massage versus control;","1:meditation+Standard treatment of traditional Chinese and Western Medicine;2:Standard treatment of traditional Chinese and Western Medicine;","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate","Experimental group:Combined standard therapy of chloroquine phosphate aerosol inhalation solution;control group:Water for injection atomization inhalation combined with standard therapy;","Experimental group:Conventional treatment and anti-SARS-CoV-2 virus inactivated plasma;Control group:Conventional treatment and Ordinary plasma;","Group 2:thymosin;Group 1:BaZhen soup;","Experimental group:High-dose Vitamin C;Control group:Routine treatment;","1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;","Experimental group :Conventional treatment followed by Intravenous infusion of Umbilical Cord Blood Plasma preparations;Control group:Conventional treatment ;","Group 1:Liuzijue exercise;Group 2:Respiratory muscle training;Group 3:Liuzijue exercise combined with respiratory muscle training;","Experimental group:Conventional treatment followed by Intravenous infusion of Cord Blood Mesenchymal Stem Cells preparations ;Control group :Conventional treatment ;","Biological: Pathogen-specific aAPC","experimental group:high-fow therapy by nasal cannulae (HFNC);control group:bag- valve mask oxygenation (SMO);","Mild Type Group A:antiviral therapy and Chinese medicine treatment;Mild Type Group B:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;Common and Heavy Type Group C:antiviral therapy and Chinese medicine treatment;Common and Heavy Type Group C:antiviral therapy, Chinese medicine treatment, and Novaferon atomization;","Experimental group:Danorevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;","Case series:The cell dose was 3*10^6 cells / kg. It was intravenously infused twice in a row, and the interval between each infusion was 1 week (+/-2 days). If the investigator considered it necessary, an additional infusion could be performed. Infusion interval 1 week (+/-2 days) from the last time.;","Intervention A:On the basis of routine medical treatment, the patients were given Novaferon Atomization inhalation, 20ug each time, twice a day, 7-14 days.;intervention B:On the basis of routine medical treatment, the patients were given lopinavir / ritonavir tablets (Kaletra) twice a day, twice each time, 7-14 days.;intervention C:On the basis of routine medical treatment, combined with Novafron and Kaletra, the usage and course of treatment are the same as above.;","experimental group:Toujiequwen Granules and basic treatment ;control group:basic treatment with or without antiviral therapy ;","Other: washed microbiota transplantation;Other: placebo","Drug: Abidol hydrochloride;Drug: Abidol Hydrochloride combined with Interferon atomization","Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo","Dietary Supplement: Vitamin C","Experimental group 1:the oral trial drug favipiravir tablets plus chloroquine phosphatetablets tablets group;Experimental group 2:the oral trial drug favipiravir tablets;Control group:the oral placebo treatment;","Drug: Hydroxychloroquine;Other: The control group will not receive hydroxychloroquine","Drug: Abidol hydrochloride;Drug: Oseltamivir;Drug: Lopinavir/ritonavir","Drug: ASC09F+Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: Oseltamivir","Experimental group:On the basis of the current clinical treatment of SNCP, NK cells and MSCs were increased;Control group:current clinical treatment of SNCP;","Experimental group:Conventional treatment &amp; Acupuncture;Control Group:Conventional treatment;","Experimental group:Conventional medication + Infusion of mesenchymal stem cells;Control group:Conventional medication;","Drug: Immunoglobulin of cured patients;Drug: ?-Globulin","Drug: YinHu QingWen Decoction;Drug: YinHu QingWen Decoction(low dose);Other: Chinese medicine treatment;Other: standard western medicine treatment","experimental group:Rabeprazole plus chloroquine;control group :Lopinavir + rabeprazole;","control group:None;Experimental group (mild and normal type in patients with new coronavirus pneumonia):3% hydrogen peroxide gargle;","Experimental group:oral hydroxychloroquine sulfate tablets;Control group:Conventional treatment meet the Guideline;","Immediate favipiravir arm: Favipiravir administered orally between Day 1 and Day 10, 1800 mg twice a day on Day 1 followed by 800 mg twice a day from Day 2&lt;br&gt;Delayed favipiravir arm: Favipiravir administered orally between Day 6 and Day 15, 1800 mg twice a day on Day 6 followed by 800 mg twice a day from Day 7","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Sulfate d'hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","Drug: Sildenafil citrate tablets","Group M:Play sleep-aid music on the cell phone at the same time as basic therapy, listen to it once every night at 22 o'clock, and the patient falls asleep with the music. A total of 2 weeks of treatment.;Group C:No music, the use of basic treatment, in accordance with the \"new coronavirus infection pneumonia diagnosis and treatment program\" trial fifth, sixth, seventh version of the provisions of the implementation.;","Drug: recombinant human interferon Alpha-1b;Drug: thymosin alpha 1","Device: bidirectional oxygenation mouthpiece","mindfulness intervention group:Mindfulness practice;control group:mind-wandering practice;","treatment group:combination of  Lopinavir/ritonavir (Kaletra) Tablets and interferon;control group:Routine medical treatment,;","","Biological: CAStem","Biological: high-titer anti-Sars-CoV-2 plasma;Other: oxygen therapy","Experimental group:Hua-Shi Bai-Du granules;control group:conventional treatment of western medicine;","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C","experimental group:TCM formula and general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);control group:general treatment based on \"Diagnosis and Treatment Program for COVID-19\" (trial version 6th);","hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day 1-3:500mg BID; Day 4-5:250mg BID;","1:Blank;2:Moxibustion treatment;","Drug: Defibrotide Injection","experimental group:Health education+ pulmonary rehabilitation;control group:Health educatio;","Expressive/gratitude writing intervention  This group will participate in the adapted evidenced-based 4-day writing program (Pennebaker 1997). Participants will meet with the facilitator (a researcher with a Psychology degree) using Zoom in a group format four times in one week for approx. 30 minutes (25 minutes of writing time). Daily e-mail reminders will be sent during the 4 days of writing. Session structure  1 min to complete the distress VAS measure (before), 5 minutes write any reflection from last session, 15 minutes spent writing about your thoughts and feelings, 5 minutes writing about the things you are grateful for, 1 min to complete the distress VAS measure (after). The instruction each day will be (adapted from Pennebaker): &lt;br&gt;Please write about your thoughts and feelings about your IBD and the recent situation with COVID-19. Try to select something that you had a strong reaction to  perhaps this was a thought that was challenging or unpleasant. Feel free to really let go and explore your very deepest emotions and thoughts. You might tie your topic to your relationships with others, including parents, lovers, friends or relatives, to your past, your present, your future, or to who you have been, who you would like to be, or who you are now. All of your writing will be completely confidential. Please dont worry about spelling, sentence structure, or grammar. Feel free to type or write by hand. &lt;br&gt;Participants will not be asked to share their writing with the study investigators, to ensure free expression.&lt;br&gt;","&lt;br&gt;Trade Name: BCG vaccine (BCG-Vaccin SSI [Nederlands VaccinStatens Serum Instituut]) Danish strain 1331.&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Concentrate and solvent for solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","experimental group:ebastine 10mg bid, nterferon-alpha aerosol inhalation 5million U bid and Lopinavir 200 mg, 2 capsules at a time, bid;control group:interferon-alpha aerosol inhalation 5million U  bid and Lopinavir 200 mg, 2 capsules at a time, bid;","&lt;br&gt;Product Name: Interferon beat-1a (IFN-1a)&lt;br&gt;Product Code: SNG001&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;Current Sponsor code: SNG001&lt;br&gt;Concentration unit: million IU million international units&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 6-&lt;br&gt;Pharmaceutical form of the placebo: Nebulisation solution&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","experimental group:Ma-Xing-Gan-Shi decoction and Conventional Western Medicine Treatment;control group:placebo and Conventional Western Medicine Treatment;","Case series:Danorevir sodium tablets,/ritonavir oral;","Drug: Bevacizumab","Behavioral: Personalized health education;Behavioral: General health education","Experimental group:Hemadsorption+conventional treatment;Control group:conventional treatment;","Drug: Nitric Oxide Gas","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Experimental group:Acetylcysteine inhaled via tracheal tube;Control group:Placebo (saline) inhaled via tracheal tube;","Azvudine Plus Symptomatic treatment:Azvudine Tablet: D1: 10 mg/day,QD; Starting from D2: 5 mg/day,QD. Symptomatic treatment:Subjects were treated corresponding treament plan in line with the release of a new coronavirus infection by the National Health and Medical Commission Diagnostic criteria for confirmed cases in the pneumonia diagnosis and treatment&amp;#32;","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","Drug: Escin;Drug: standard therapy","&lt;br&gt;Trade Name: PLAQUENIL 200 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib Teva 400 mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IMATINIB&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: AVIGAN 200mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: FAVIPIRAVIR&lt;br&gt;Other descriptive name: FAVIPIRAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: MICARDIS 20mg&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TELMISARTAN&lt;br&gt;CAS Number: 144701-48-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Experimental group:Celebrex capsules 200mg / time twice a day for 7 days;control group:routine treatment;","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Current Sponsor code: REMDESIVIR&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: Chloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Interfern b 1A&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: MYLAN&lt;br&gt;Product Name: lopinavir/ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;&lt;br&gt;Trade Name: REBIF&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Remdesivir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: DEFITELIO&lt;br&gt;Product Name: DEFITELIO&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: DEFIBROTIDE&lt;br&gt;CAS Number: 83712-60-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Drug: Bevacizumab Injection","Drug: Sarilumab;Drug: Placebo","Experimental group:Rehabilitation Nursing Program;Control group:Routine rehabilitation care;","&lt;br&gt;Trade Name: Pulmozyme 2500 U/2,5ml, solution pour inhalation par nbuliseur&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lariam&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: MEFLOQUINE&lt;br&gt;CAS Number: 53230-10-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Other: Tele-medicine platform","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine Sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Device: CPAP treatment","Device: Inspiratory training device;Device: Expiratory training device","Nintedanib group:Nintedanib;Control group:Placebo;","Drug: Ganovo+ritonavir+/-Interferon nebulization","Drug: Hydroxychloroquine as post exposure prophylaxis;Other: Others(No intervention)","Drug: Oral","Drug: Nitric Oxide","Drug: Ciclesonide Metered Dose Inhaler [Alvesco];Drug: Hydroxychloroquine","Experimental group:Ganovo/ ritonavir oral+conventional treatment;Control group:Conventional treatment;","Drug: Nitric Oxide Gas","Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab","Drug: Tocilizumab","COVID-19 symptomatic confirmed hospitalized adult patients will be enrolled as soon as possible after fulfilling the criteria for randomisation. Patients will be allocated in a 1:1 ratio to either the treatment group receiving intravenous zinc chloride (0.5mg/kg/d) or to control group, receiving saline placebo alone. &lt;br&gt;Pharmaceutical grade Zinc Chloride stock solution obtained from an Australian company (Phebra Pty Ltd) will be diluted in 250ml of normal saline and infused, resulting in a final dosage of 0.5mg/kg/d. Patients will be administered zinc for seven days. To standardise administration time, zinc infusions will commence around 9am but anywhere between 8am to 12pm in the morning is adequate. Zinc chloride will be administered via central venous or peripheral access over 3-6 hrs.&lt;br&gt;We will monitor fidelity to the intervention by review of nursing documentation in the intravenous fluid given section of the electronic fluid balance chart. Note will be made of what was given, time commenced, volume given, time completed.&lt;br&gt;","Biological: Emapalumab;Biological: Anakinra","&lt;br&gt;Trade Name: Imatinib mesilate &lt;br&gt;Product Name: Imatinib mesilate&lt;br&gt;Product Code: L01XE01&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Levamisole Pill + Budesonide+Formoterol inhaler;Drug: Lopinavir/Ritonavir + hydoxychloroquine","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulfate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;","Lipoic acid group:Routine Therapy and administration of Lipoic acid injection;Blank control group:Routine Therapy and administration of placebo;","Drug: Hydroxychloroquine;Drug: Placebos","Drug: Tocilizumab;Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Aspirin 75mg;Drug: Clopidogrel 75mg;Drug: Rivaroxaban 2.5 MG;Drug: Atorvastatin 40mg;Drug: Omeprazole 20mg","Dietary Supplement: Vitamin D","Drug: Mavrilimumab","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF);Device: Centricyte 1000;Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution;Drug: Liberase Enzyme (Roche);Drug: Sterile Normal Saline for Intravenous Use","Diagnostic Test: COVID-19 diagnostic test","Drug: Hydroxychloroquine;Drug: Oseltamivir;Drug: Azithromycin","&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: NAPROXEN&lt;br&gt;Other descriptive name: NAPROXEN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","Biological: Convalescent Plasma","&lt;br&gt;Product Name: IFX-1&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: -&lt;br&gt;CAS Number: -&lt;br&gt;Current Sponsor code: IFX-1&lt;br&gt;Other descriptive name: -&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","Control group:Coventional Treatment;Experimental group:Conventional treatment+LIUSHENWAN;","Drug: Camostat Mesilate;Drug: Placebo;Drug: Hydroxychloroquine","Biological: UC-MSCs;Other: Placebo","&lt;br&gt;Trade Name: Lopinavir/Ritonavir&lt;br&gt;Product Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine;Drug: Placebo","&lt;br&gt;Product Name: GNS561&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Not available&lt;br&gt;CAS Number: 1914148-72-3&lt;br&gt;Current Sponsor code: GNS561&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 50 - 200-&lt;br&gt;&lt;br&gt;Trade Name: Opdivo&lt;br&gt;Product Name: Nivolumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: NIVOLUMAB&lt;br&gt;CAS Number: NIVOLUMAB&lt;br&gt;Current Sponsor code: ET17-093&lt;br&gt;Other descriptive name: NIVOLUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;","Drug: Chloroquine phosphate;Other: Telemedicine","Drug: Piclidenoson","&lt;br&gt;Trade Name: Dexamethasone 20 mg/5mL&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: DEXAMETHASONE&lt;br&gt;CAS Number: 50-02-2&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Medicinal Oxygen&lt;br&gt;Product Name: Medicinal Oxygen&lt;br&gt;Pharmaceutical Form: Medicinal gas, liquefied&lt;br&gt;INN or Proposed INN: Medicinal Oxygen&lt;br&gt;Other descriptive name: Medicinal Oxygen&lt;br&gt;Concentration unit: % (V/V) percent volume/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Metilprednisolona&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-125&lt;br&gt;&lt;br&gt;Trade Name: Modigraf&lt;br&gt;Pharmaceutical Form: Powder for oral suspension&lt;br&gt;INN or Proposed INN: TACROLIMUS&lt;br&gt;CAS Number: 104987-11-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 0.1-0.2&lt;br&gt;&lt;br&gt;","Based on preclinical and non-randomised studies, the Royal Brisbane and Womens Hospital Intensive Care Unit clinical Consultant Medical Staff, in agreement with the Infectious Diseases Department and the Pharmacy Department, have decided that all patients admitted to the ICU with COVID-19 infection should receive hydroxychloroquine as standard care. Therefore, hydroxychloroquine is NOT considered a trial intervention for the purpose of this study.&lt;br&gt;&lt;br&gt;The dose of hydroxychloroquine used for COVID-19 infection is extrapolated from that in common use for malaria and other approved indications. However, the organ dysfuction that accompanies critical illness suggests dosing is likely to require adjustment. This study will adjust the dose of hydroxychloroquine using therapeutic drug monitoring (TDM) to a goal concentration known to be safe. The observation period for TDM will be a total of up to 10 days or until the time of ICU discharge, which ever is sooner.&lt;br&gt;&lt;br&gt;As is routine practice at the RBWH ICU, TDM will be led by the senior ICU pharmacist after initiation of therapy. Trough venous blood samples (3 ml) will be taken via an indwelling arterial cannula. The first TDM should ideally occur before the administration of the FIRST MAINTENANCE DOSE, provided the appropriate loading dose schedule has been completed. Sampling thereafter can occur every 24-48 hours to confirm the appropriateness of ongoing dosing as guided by the Pharmacy and Medical Team. Blood samples will be transported to Queensland Pathology on the Herston Campus for drug analysis. Prescribing of initial and ongoing/revised dosing will remain the responsibility of medical officers, whilst fidelity of the intervention will be maintained through pharmacy dosing adjustment notes which are subjected to","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 648-&lt;br&gt;&lt;br&gt;","Drug: Stem Cell Product","Drug: Linagliptin;Drug: Insulin regimen","Drug: Hydroxychloroquine;Dietary Supplement: Placebo","Study design: parallel group, wait list design, with treatment delayed by 3 months.&lt;br&gt;Open label OM85 one capsule (7.0mg) daily for 3 months with 3 months follow-up off treatment. &lt;br&gt;Adherence assessed by participant diary and blister pack return.","&lt;br&gt;Trade Name: Truvada&lt;br&gt;Product Name: Truvada&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE&lt;br&gt;CAS Number: 202138-50-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: EMTRICITABINE&lt;br&gt;CAS Number: 143491-57-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 245-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Experimental group:exercise rehabilitation under remote monitoring;Control group:patient education;","&lt;br&gt;Trade Name: Solu-Modern 1 g polvo y disolvente para solucin inyectable&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Metilprednisolona (como succinato de sodio)&lt;br&gt;CAS Number: 2375-03-3&lt;br&gt;Current Sponsor code: Pfizer, SL&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;","NK cell group:NK cells were injected by intravenous drip once a day for 2 to 3 times in total, each dose was 4 10^7 pieces /kg body weight,100ml normal saline suspension;Control group:100ml normal saline intravenous drip;","control group:General basic epidemic prevention measures;sachet group:General basic epidemic prevention measures + Traditional Chinese medicine sachet;Oral and nasal spray group:General basic epidemic prevention measures + Oral and nasal spray;Oral Chinese medicine group:General basic epidemic prevention measures + Traditional Chinese medicine for epidemic prevention in high risk groups;","Other: Questionnaire with precaution information;Other: Experimental: Questionnaire without precaution information","experimental group:Chinese herbal tea;control group:drinking water;","Biological: Anti- SARS-CoV-2 Plasma;Biological: SARS-CoV-2 non-immune Plasma","Drug: Hydroxychloroquine;Other: Placebo","In-hospital rehabilitation group: A. the patients took Qigong lung-nourishing exercise twice a day, once in the morning and afternoon, about 15 minutes each time. B, through online WeChat group patient communication, functional guidance, health counseling, psychological comfort.;Discharge follow-up rehabilitation group: A. the patients were given fitness Qigong lung-nourishing exercise twice a day, once in the morning and afternoon, about 15 minutes each time. B, through online one-to-one patient communication, functional guidance, health counseling, psychological comfort.;","&lt;br&gt;Trade Name: DEXAMETHASONE MYLAN 20mg/5mL &lt;br&gt;Product Name: DEXAMETHASONE&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: PLAQUENIL 200MG&lt;br&gt;Product Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Telmisartan EG&lt;br&gt;Product Name: Telmisartan&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine EG&lt;br&gt;Product Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: Curcumin C3&lt;br&gt;Product Name: Curcumin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine;Drug: Azithromycin","&lt;br&gt;Trade Name: KEYTRUDA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Pembrolizumab&lt;br&gt;Current Sponsor code: MK3475&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina Aristo&lt;br&gt;Product Name: Hidroxicloroquina sulfato&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: 81939&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine;Drug: Azithromycin;Dietary Supplement: vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","&lt;br&gt;Trade Name: ZYMAD 200 000 UI&lt;br&gt;Product Name: ZYMAD 200 000 UI&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;&lt;br&gt;Trade Name: ZYMAD 50 000 UI&lt;br&gt;Product Name: ZYMAD 50 000 UI&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ibuprofen&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: IBUPROFEN&lt;br&gt;CAS Number: 15687-27-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;Trade Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Other descriptive name: AZITHROMYCIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: Paracetamol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Paracetamol&lt;br&gt;CAS Number: 103-90-2&lt;br&gt;Other descriptive name: PARACETAMOL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","Biological: allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC);Other: Intravenous saline injection (Placebo)","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Dolquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Kaletra versus Aluvia&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Imatinib&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Imatinib&lt;br&gt;CAS Number: 152459-95-5&lt;br&gt;Other descriptive name: IMATINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-300&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Other descriptive name: Olumiant&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 4-2&lt;br&gt;&lt;br&gt;","Drug: Darunavir and Cobicistat","Drug: Hydroxychloroquine","Other: Surgical facial mask","&lt;br&gt;Trade Name: Sylvant&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 11-&lt;br&gt;&lt;br&gt;Trade Name: Urbason&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","Drug: Tocilizumab Injection","Biological: Convalescent Plasma","&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-800&lt;br&gt;&lt;br&gt;","Drug: lopinavir/ritonavir;Drug: Hydroxychloroquine Sulfate;Drug: Losartan;Drug: Placebos","Drug: Nitric Oxide Gas;Other: Inhaled Supplemental Oxygen","Drug: Hydroxychloroquine Sulfate;Drug: Bromhexine 8 MG","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;Trade Name: Bactrimel&lt;br&gt;Product Name: Sulfamethoxazole and Trimethoprim&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","Drug: Tacrolimus;Drug: Methylprednisolone","Drug: Hydroxychloroquine;Drug: Azithromycin","&lt;br&gt;Product Name: SEVOFLURANE&lt;br&gt;Pharmaceutical Form: Inhalation vapour, liquid&lt;br&gt;INN or Proposed INN: SEVOFLURANE&lt;br&gt;CAS Number: 28523-86-6&lt;br&gt;Other descriptive name: SEVOFLURANE&lt;br&gt;Concentration unit: ml millilitre(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 6-&lt;br&gt;&lt;br&gt;Product Name: PROPOFOL&lt;br&gt;Pharmaceutical Form: Emulsion for suspension for injection&lt;br&gt;INN or Proposed INN: PROPOFOL&lt;br&gt;Other descriptive name: PROPOFOL&lt;br&gt;Concentration unit: mg/kg/h milligram(s)/kilogram/hour&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;","Device: CytoSorb-Therapy","Other: telehealth applications","Drug: UNIKINON (Chloroquine phosphate) 200mg tablets","Drug: Nintedanib 150 MG;Other: Placebo","There are two arms to this trial. Arm 1: Problem Management Plus. Arm 2: Enhanced Treatment as Usual. Therapy is administered once-weekly 60 minute sessions by clinical psychologists over 6 weeks delivered via teleconferencing to groups of 4 people at a time. Problem Management Plus is a program developed by the World Health Organization. Across sessions the clinical psychologist will teach the following stress coping strategies: anxiety reduction, problem solving, behavioral activation, and accessing social support. This will occur will via educational sessions, group discussions via teleconference, and handouts. The duration of the study for any participant will conclude after a 2-month follow-up assessment, resulting in participation duration of 15 weeks.","Participants who are randomly assigned to the intervention group will  receive capsules containing the probiotic Lactobacillus rhamnosus HN001 (6X109 colony forming units). &lt;br&gt;&lt;br&gt;Participants will be instructed to take one capsule a day for a period of 12 weeks.&lt;br&gt;&lt;br&gt;Adherence will be assessed by asking participants to enter the number of remaining capsules they have in the bottle at the post-intervention data collection phase.","Device: Low flow ECMO driving by CVVH machine","Drug: Hydroxychloroquine;Drug: Azithromycin","&lt;br&gt;Trade Name: Antimicrobial therapy (antibiotics)&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;","Procedure: Auricular neuromodulation;Procedure: Control","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Valsartan or matched placebo&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: VALSARTAN&lt;br&gt;CAS Number: 137862-53-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 80-160&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Behavioral: Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Kevzara&lt;br&gt;Product Code: 1171196003&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: EU/1/17/1196/012&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Azitromicina&lt;br&gt;Product Name: Azitromicina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Trade Name: hidroxicloroquina&lt;br&gt;Product Name: Hidroxicloroquina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Cord blood therapy (expanded cord blood cells) + standard supportive management&lt;br&gt;5 million expanded umbilical cord blood cells (max -500 million cells) given intravenously over an hour by hospital staff under observation by research team&lt;br&gt;Single administration sourced from off the shelf CB units","&lt;br&gt;Trade Name: plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: azithromycin&lt;br&gt;Product Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;Other descriptive name: AZITHROMYCIN MONOHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","Case series :Western medicine plus Danggui Shaoyao Power ;","&lt;br&gt;Trade Name: CIRCADIN 2 mg&lt;br&gt;Product Name: CIRCADIN 2mg&lt;br&gt;Product Code: EMEA/H/C/000695&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CIRCADIN&lt;br&gt;CAS Number: 73-31-4&lt;br&gt;Other descriptive name: MELATONIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Case series:mesenchymal stem cells therapy;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Senicapoc&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINA SEID 0,5 mg comprimidos&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: COLCHICINE&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;Pharmaceutical form of the placebo: Coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: HCR040&lt;br&gt;Product Code: HCR040&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: HCR040&lt;br&gt;Current Sponsor code: HCR040&lt;br&gt;Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Concentration unit: million organisms million organisms&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-2&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINE&lt;br&gt;Product Name: COLCHIMAX&lt;br&gt;Product Code: M04AX&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: COLCHICINA&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: .5-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: DARUNAVIR&lt;br&gt;CAS Number: 206361-99-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: SPIRONOLACTONE&lt;br&gt;Other descriptive name: SPIRONOLACTONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: INTERFERON BETA-1B&lt;br&gt;CAS Number: 145155-23-3&lt;br&gt;Other descriptive name: INTERFERON BETA-1B&lt;br&gt;Concentration unit: g/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: prednisone&lt;br&gt;Product Name: prednisone&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: PREDNISONE&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.75-&lt;br&gt;&lt;br&gt;","Intervention1: Chloroquine phosphate: Chloroquine phosphate tablets will be given in the dose of 500 mg twice daily for 10 days to the patients who meets the inclusion criteria&lt;br&gt;Control Intervention1: No drug: Chloroquine will not be given to control group. These patients will be managed as per standard protocol.&lt;br&gt;","&lt;br&gt;Trade Name: Sandimmun&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-15&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 800-1200&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 75-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Clulas mesenquimales troncales adultas alognicas de mdula sea expandidas en suspensin&lt;br&gt;Product Code: MSV-allo&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: clulas mesenquimales troncales adultas alognicas de mdula sea expandidas mediante procedimiento IBGM&lt;br&gt;Current Sponsor code: MSV_allo&lt;br&gt;Concentration unit: U/ml unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10000000-&lt;br&gt;Pharmaceutical form of the placebo: Injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Intervention1: SSV Formulation Tablets: Each tablet of 500 mg to be consumed orally twice a day immediately after meals for 15 days.&lt;br&gt;Control Intervention1: Not Applicable: Not Applicable&lt;br&gt;","&lt;br&gt;Product Name: Allogeneic mesenchymal stromal cells isolated from adipose tissue&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Allogeneic adipose-derived mesenchymal stromal cells in vitro expanded&lt;br&gt;Other descriptive name: Allogeneic adipose-derived mesenchymal stem cells in vitro expanded&lt;br&gt;Concentration unit: million organisms/ml million organisms/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Lopinavir-Ritonavir &lt;br&gt;Product Name: Lopinavir-Ritonavir &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Lopinavir&lt;br&gt;Other descriptive name: Antiretroviral&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: Ritonavir&lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Hydroxychloroquine (Plaquenil) &lt;br&gt;Product Name: Hydroxychloroquine (Plaquenil) &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine sulfate&lt;br&gt;Other descriptive name: Antimalarial, Aminoquinoline&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;&lt;br&gt;","Intervention1: HCQS -MIMS Regimen: 300 mg daily x 1 wk followed by 300 mg weekly&lt;br&gt;Intervention2: Hydroxychloroquine: 300 mg daily x 7 days followed by 300 mg weekly x 7 weeks&lt;br&gt;Control Intervention1: Hydro Chloroquine(HCQ)-ICMR regimen: Group 2 : &lt;br&gt;400 mg bd for one day followed by 400 mg weekly for 7 weeks to be taken with meals (or until the epidemic stops) (ICMR Regimen)&lt;br&gt;Both groups will be advised to follow strict measures of self hygiene, social distancing and other routine protocols issued by IMA and Government bodies to prevent transmission. &lt;br&gt;&lt;br&gt;&lt;br&gt;","Case series:Anti-SARS-CoV-2 virus inactivated plasma;","Experimental group 1 (mild):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g,  tid,with warm water;Experimental group 1 (moderate):Compound Yinchai granules 15g, Qingqiao antiviral granules 15g, q4hwith warm water;","Dosing and Administration&lt;br&gt;Subjects will be randomized 1:1 to receive either active product or placebo. Initially, the trial will have 2 arms: &lt;br&gt;-Remdesivir will be administered as a 200 mg IV loading dose on Day 1, followed by a 100 mg once-daily IV maintenance dose for the duration of the hospitalization up to a 10 day total course. If a subject is no longer hospitalized, then infusions will no longer be given. &lt;br&gt;-A matching placebo will be given at an equal volume at the same schedule. &lt;br&gt;&lt;br&gt;Any dose that is delayed, but still the same study day, may be given. Any dose that is missed (not given that calendar day) is not made up.","Ciclesonide is inhaled three times a day at a dose of 400 microgram once a day for seven consecutive days.","Experimental group:Western medicine routine treatment combined with traditional Chinese medicine treatment;Control group:Western medicine routine treatment;","Experimental group:1. Jinhao Artemisia Antipyretic Granules 8g / time, bid, take it with warm water after meals; 2. Huoxiangzhengqi oral liquid 10ml / time, bid, orally after meals.;blank cntrol group:non-intervention;",";Chloroquine phosphate;Hydroxychloroquine sulphate;Placebo","Case series:traditional Chinese medicine and Western medicine treatment;","Group 1: Respiratory Exercise Program (REP) (n=33)&lt;br&gt;\tThe REP will consist of 10 exercises based on the recommendations made by the official Physiotherapy organizations at the institutional level (College of Physiotherapists of the Community of Madrid, Spain), with scientific evidence, consisting of exhalation and inspiration exercises, diaphragmatic reeducation and rib cage mobility. The REP will be taught to patients telematically in the first session, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. The REP will be reinforced by a physical therapist daily, through telematic control by videoconference with each patient.&lt;br&gt;&lt;br&gt;Group 2: Non-specific Toning Exercise Program (NTEP) (n=33)&lt;br&gt;\tThe NTEP will consist of 10 exercises based on the recommendations about toning exercises, general and functional muscle work of the lower and upper limb and trunk muscles, made by the official Physiotherapy organizations at the institutional level (College of Physiotherapists of the Community of Madrid, Spain), with scientific evidence. The NTEP will be taught to patients in the first session, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. and 12 a.m. The NTEP will be reinforced by a physical therapist daily, through telematic control by videoconference with each patient.&lt;br&gt;&lt;br&gt;Group 3: Sham Program (SP) (n=33)&lt;br&gt;\tThe Sham Program consists of 10 sedentary exercises based on sophrology and meditation, with mental exercises of visualization, concentration and mental activity. The SP will be taught to patients in the first session telematically, and it will be carried out once a day, for 21 days, at the patient's home, between 11 a.m. and 12 a.m. The SP will be reinforced by a physical therapis;Other;Exercise Therapy;Placebo Effect","Drug;Clinical Trial;Medical Examination;A total of 140 (one hundred and forty) patients diagnosed with severe acute respiratory syndrome will be invited to participate in the study, and, after signing the informed consent form, they will be randomized into two groups, which will be treated according to the protocol : Control Group (70 patients): will receive intravenous infusion in peripheral venous access of Placebo (Glucose 5% 100mL) in 20h (single dose). Intervention Group (70 patients): will receive intravenous infusion in peripheral venous access of N acetylcysteine in a total dose of 300 mg / kg, with the first dose being 200 mg / kg in 4 hours and the second dose 100 mg / kg in 16 hours ( Single dose). Serum tests (30mL of blood from peripheral venous access) and arterial blood gases will be collected from all patients. Patients will be monitored daily by reviewing medical records and clinical data will be recorded on a RedCap form.","Group 1:Favipiravir Combined With Tocilizumab;Group 2:Favipiravir;Group 3:Tocilizumab;",";Placebo;Measles Mumps and Rubella vaccine","Drug: Galidesivir;Drug: Placebo","Drug: Remdesivir;Drug: Remdesivir placebo",";IHP Detox tea;Placebo","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Biological: NestCell","Group 1 - Hydroxychloroquine, 400 mg 12/12h, oral, on the first day followed by Hydroxychloroquine, 400 mg once daily, oral for  6 days, totaling 7 days of treatment - 650 patients &lt;br&gt;&lt;br&gt;Grupo 2 - Control - 650 patients;Drug;Hydroxychloroquine","Drug: Colchicine","Drug: Dexamethasone","1. Control group - 210 participants&lt;br&gt;Control group will recieve proper COVID19 treatment but will not recieve hydroxychloroquine, chloroquine, azythromicyn or other macrolide.&lt;br&gt;&lt;br&gt;2. HCQA - 210 participants&lt;br&gt;HCQA group will recieve proper COVID19 treatment and hydroxychloroquine 400mg + azythromicyn 500mg once a day, oral, enteral or intravenous, for 7 days&lt;br&gt;&lt;br&gt;3. HCQ - 210 participants&lt;br&gt;HCQ group will recieve proper COVID19 treatment, and hydroxychloroquine 400mg once a day, oral, enteral or intravenous, for 7 days;Drug;Hydroxychloroquine;Azithromycin","Chloroquine 10 mg base/kg once a day on Day 1 and Day 8, Vitamin C 1000 mg once a day from Day 1 to Day 14","Procedure: Human biological samples","Group name:Standard of care Type of group;2 N of participants:200 Intervention(s) description:Standard of care that all patients with COVID recieve at the hospital. &lt;br&gt;Group name:Standard of care plus lopinavir with ritonavir plus interferon beta 1a Type of group;1 N of participants:200 Intervention(s) description:Standard care that is given to all COVID patients who come to this hospital / clinic plus Lopinavir with Ritonavir (orally twice a day for 14 days) plus interferon beta 1a (daily injection for 6 days). Lopinavir / Ritonavir is available from multiple manufacturers as fixed-dose thermostable tablets for oral administration: Lopinavir 200mg with Ritonavir 50mg per tablet. The oral solution for patients who cannot swallow is a light yellow to orange liquid containing 400 mg Lopinavir and 100 mg Ritonavir per 5 ml (80 mg Lopinavir and 20 mg Ritonavir per ml). Interferon beta 1a is supplied as a sterile solution that does not contain any preservative available in a pre-filled syringe. It is provided as a single dose pre-filled graduated syringe available in two strengths; either 44 micrograms per 0.5 ml or 22 micrograms per 0.5 ml (allowing a convenient supply of 44 ug doses for subcutaneous use). The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe. Contains the following inactive ingredients: Albumin (Human), Mannitol, Sodium Acetate, Water for Injection.&lt;br&gt;","Drug: Hydroxychloroquine","Drug: 2: Usual practice + SYMBICORT RAPIHALER;Other: 1: Usual practice","Drug: methylprednisolone therapy;Other: Standard care","Drug: chloroquine;Other: standard care","Drug: Ruxolitinib Oral Tablet","Drug: Remdesivir;Drug: Remdesivir placebo","Drug: Methylprednisolone","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","HA330 hemoperfusion&lt;br&gt;- HA330 hemoperfusion will be performed on a daily basis with a 6-hour duration per session until 1) 7 days, 2) IL-6 &lt;400 pg/mL, 3) clinically improved (defined by 3.1) PF ratio &gt;300 for at least 48 hours or 3.2) spontaneous respiration), whichever comes first.&lt;br&gt;, Usual care will be provided including antivirals, IV fluids, vasopressors, oxygenation and ventilatory support, steroid, antibiotics, IVIG","Drug: Lopinavir/ritonavir;Drug: Ribavirin;Drug: Interferon Beta-1B","Biological: NK Cells","Diagnostic Test: Lung ultrasound","Drug: Fluvoxamine;Drug: Placebo","Other: blood sample","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Device: Hyperbaric Oxygen Therapy","Behavioral: Crisis management coaching","Biological: MSCs","Biological: UC-MSCs;Drug: Placebo","Other: Plasma Donation","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Lopinavir/ritonavir","Drug: Treatment and prophylaxis;Other: Standard Public Health measures","Device: Non-contact MCE system","Drug: Tinzaparin or unfractionated heparin","Drug: Bevacizumab Injection","Drug: Hydroxychloroquine;Drug: Remdesivir;Other: (Standard of Care) SoC","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants;Dietary Supplement: isocaloric/isonutrigenous ONS","Drug: Sarilumab","Behavioral: Guided online support program;Behavioral: WHO recommendations (waiting condition)","Other: Individualised Ayurveda","Dietary Supplement: Natural Honey;Other: Standard Care","Drug: Dexamethasone","Drug: Spironolactone 100mg;Drug: Placebo oral tablet","Other: \"Calm\" is a mindfulness meditation mobile app","Device: GO2 PEEP MOUTHPIECE","Drug: Tradipitant;Drug: Placebo","Drug: Hydroxychloroquine Sulfate;Drug: Ascorbic Acid","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Tocilizumab","Drug: Siltuximab;Drug: Methylprednisolone","Other: Standard interface;Device: Double-Trunk Mask","Drug: Favipiravir;Other: Standard of care treatment","Procedure: ECMO Implantation","Other: Saline Nasal Irrigation;Other: Saline with Baby Shampoo Nasal Irrigation","Drug: Nitazoxanide;Drug: Placebo","Biological: Convalescent Plasma","Drug: Dexamethasone and Hydroxychloroquine;Drug: Hydroxychloroquine","Biological: anti-SARS-CoV-2 convalescent plasma","Device: BIOVITALS","Diagnostic Test: Serological tests will be applied on patients blood sampling","Drug: T3 solution for injection;Drug: Placebo","Drug: Ruxolitinib plus simvastatin;Other: Standard of Care","Dietary Supplement: Ascorbic Acid;Dietary Supplement: Zinc Gluconate;Dietary Supplement: Ascorbic Acid and Zinc Gluconate;Other: Standard of Care","Drug: Nivolumab Injection","Drug: Prednisone;Other: Control group","Biological: Convalescent Plasma;Biological: Standard Donor Plasma","Drug: Chloroquine;Drug: Placebo oral tablet","Drug: Interferon Beta-1A;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine","Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);","Procedure: Prone positioning","Drug: Chloroquine;Drug: Nitazoxanide;Drug: Ivermectin","Drug: ACEIs;Drug: Conventional treatment","Drug: Amiodarone;Drug: Verapamil","Behavioral: Tele-interventions related to diabetes management and mental well-being","Drug: Saline oral/nasal rinse;Drug: 0.5% Povidone/Iodine oral/nasal rinse;Drug: 0.12% Chlorhexidine oral/nasal rinse","Drug: Hydroxychloroquine;Drug: Azithromycin","Biological: Allogeneic NK transfer","Drug: Enoxaparin Prefilled Syringe [Lovenox]","Drug: Dexamethasone injection;Drug: placebo;Procedure: conventional oxygen;Procedure: CPAP;Procedure: HFNO;Procedure: mechanical ventilation","Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation.;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation;Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation","Drug: Chlorpromazine Injection","Drug: Tocilizumab;Drug: Methylprednisolone","Other: Telerehabilitation;Other: exercise brochure","Behavioral: Video based exercise","Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension","control group:Routine supportive treatment;experimental group:TCM decoction intervention + routine supportive treatment;","Drug: Hydroxychloroquine Sulfate (HCQ)","Drug: Honey;Drug: Nigella Sativa / Black Cumin;Drug: Placebos","Drug: Selinexor","Biological: Convalescent Plasma;Biological: Standard Plasma","Drug: Transfusion of COVID-19 convalescent plasma","Diagnostic Test: Cytokines dosage;Diagnostic Test: Complement dosage","Other: plasma therapy using convalescent plasma with antibody against SARS-CoV-2;Other: Routine care for COVID-19 patients","Drug: Acalabrutinib","Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells","This study will recruit older adults (aged 60 years and older) during the COVID-19 pandemic to a 6-week, group based physical activity promotion intervention delivered online through a private Facebook group. The group will allow members to receive information and contribute to weekly conversations on pre-specified topics related to physical activity eg. sedentary behaviour, goal setting, benefits of physical activity and support. Different topics will be covered each week with 2-3 Facebook posts on the topic each week. The content of each topic is designed specifically for this study but will also make use of existing videos, pictures and information sources. An exercise physiologists and dietitian will deliver the program. The purpose of the Facebook group is to facilitate social support and provide participants with a platform to exchange personal experiences including barriers and facilitators to commencing and maintaining a physical activity program. While discussion topics will be pre-determined, discussion will change weekly based on the participants posts for example someone may ask for examples of workouts or different ways overcome barriers. Participants will also be able to join a group video call via zoom two times per week. These calls will last for 20-30mins. The facilitator will lead the call and provide education on the topic for the week. This will also give the facilitator the chance to check in on participants and allow them to ask questions. The intervention itself will go for 6 weeks however there is the option for participants to remain in the Facebook group and continue to use it for support without the input from the facilitators. All 20 participants will be included in the one Facebook group and encouraged to check the Facebook weekly. The page","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Drug: Standard therapy of COVID-19","Diagnostic Test: COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support;Other: Telemedicine","Other: Antibody-Rich Plasma from COVID-19 recovered patients","Procedure: Prone Positioning;Procedure: Standard of care.","Drug: Dapagliflozin 10 MG;Drug: Placebo","Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days;Drug: Placebo 250 cc 24 hours continuous infusion for 15 days","Drug: Clazakizumab","Drug: Favipiravir;Drug: Placebos","Dietary Supplement: Zinc gluconate;Dietary Supplement: 25-OH cholecalciferol","experimental group:Xiangsha Liujun Pill;Control group:Placebo;","Drug: favipiravir;Drug: Standard of care therapy","Drug: Hydroxychloroquine","Drug: Umifenovir;Drug: Interferon- 1a;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine;Drug: Standards of Care","Drug: Gimsilumab;Drug: Placebo","Biological: Autologous Adipose MSC's","Dietary Supplement: Ayurveda;Other: Usual Care","&lt;br&gt;                Intervention: Hydroxychloroquine 400 mg orally once a day as pre-exposure prophylaxis against COVID-19.&lt;br&gt;                Control: Placebo.&lt;br&gt;                Randomization details: Fixed 1:1 allocation ratio produced by a computer-based random number generator. Randomly permuted blocks of varying size will be used to ensure equal allocation to each group, stratified by site.&lt;br&gt;","Biological: Multiple Doses of Anti-SARS-CoV-2 convalescent plasma","Drug: Nafamostat Mesilate;Drug: Placebo","Drug: Hydroxychloroquine - Daily dosing;Drug: Hydroxychloroquine - Weekly Dosing;Other: Matched Placebo Hydroxychloroquine","Dietary Supplement: Vitamins;Drug: Hydroxychloroquine;Drug: Imatinib;Drug: Favipiravir;Drug: Telmisartan","Drug: Nivolumab","&lt;br&gt;                Patients will be randomised in a 1:1:1 ratio to:&lt;br&gt;                Arm 1: Continuous positive airway pressure (CPAP), administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 2: High flow nasal oxygen (HFNO) will be administered according to local protocol/guidelines. Administration will be left to clinical discretion.&lt;br&gt;                Arm 3: Standard care. Standard oxygen therapy according to local protocol/guidelines.&lt;br&gt;","Device: mouthrinse with bta-cyclodextrin and citrox;Device: mouthrinse without bta-cyclodextrin and citrox","Drug: Camostat Mesilate;Other: Placebo","Drug: Tocilizumab;Drug: Placebos","Intervention 1&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir/ritonavir&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 2&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Hydroxychloroquine&lt;br&gt;Intervention Description: 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;Intervention 3&lt;br&gt;Intervention Type: Drug&lt;br&gt;Intervention Administration: Oral&lt;br&gt;Intervention Name: Lopinavir / ritonavir plus hydroxychloroquine&lt;br&gt;Intervention Description: Lopinavir (400mg)/ritonavir (100mg) twice daily for 10 days plus hydroxychloroquine 800mg twice a day (4x200mg administered 12 hours apart) on Day 1, followed by 400mg twice a day for 6 days&lt;br&gt;Intervention Adherence: direct supervision while in hospital. Once home, adherence will be monitored through daily phone calls&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Prolastin&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: HUMAN ALPHA1-PROTEINASE INHIBITOR&lt;br&gt;CAS Number: 9041-92-3&lt;br&gt;Other descriptive name: HUMAN ALPHA1-PROTEINASE INHIBITOR&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Staatl. Fachingen STILL&lt;br&gt;Product Name: Staatl. Fachingen STILL &lt;br&gt;Product Code: 6959688.00.00&lt;br&gt;Pharmaceutical Form: Oral liquid&lt;br&gt;INN or Proposed INN: Healing water&lt;br&gt;Other descriptive name: HYDROGEN CARBONATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2.769-&lt;br&gt;Pharmaceutical form of the placebo: Oral liquid&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Oral administration of Hydroxychloroquine capsules for five days. &lt;br&gt;Day 1: 800mg (4 capsules) Hydroxychloroquine stat&lt;br&gt;Days 2 - 5: 400mg (2 capsules) Hydroxychloroquine once daily&lt;br&gt;Adherence to trial treatment will be assessed through the study diaries which will require the participant to complete the time of administration and number of tablets taken each day. Participants will not be required to return used study treatments to the research office but encouraged to dispose of any unused medication via their community pharmacy or general practice.","&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;CAS Number: 1809249-37-3&lt;br&gt;Current Sponsor code: GS-5734&lt;br&gt;Other descriptive name: REMDESIVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Chloroquine difosfato&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Chloroquine difosfato&lt;br&gt;CAS Number: 54-05-7&lt;br&gt;Current Sponsor code: Clorochina&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Lopinavir/Ritonavir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Interfern b 1A&lt;br&gt;Product Name: Interfern b 1A&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Interferon beta-1a&lt;br&gt;CAS Number: 220581-49-7&lt;br&gt;Current Sponsor code: Interferon beta-1a&lt;br&gt;Other descriptive name: Interferon beta-1a&lt;br&gt;Concentration unit: g gram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 152-&lt;br&gt;&lt;br&gt;","Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet","Other: Pulmonary Physiotherapy Techniques","Experimental group:Shumian capsule;Control group:Shumian capsule placebo;","Experimental group:Shengmai Decoction;Control group:Shengmai Decoction simulant;","&lt;br&gt;Trade Name: Dacortin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Prednisone&lt;br&gt;CAS Number: NA&lt;br&gt;Current Sponsor code: NA&lt;br&gt;Other descriptive name: PREDNISONE&lt;br&gt;&lt;br&gt;","Control Group:Qimaifeiluoping Mixture Simulator + Respiratory Training + Rehabilitation Education Guidance;Experimental group:Qimaifeiluoping Mixture  + Respiratory Training + Rehabilitation Education Guidance;","&lt;br&gt;Product Name: ChAdOx1 nCoV-19&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Powder and solvent for solution for injection&lt;br&gt;Route of administration of the placebo: Intramuscular use&lt;br&gt;&lt;br&gt;Trade Name: Nimenrix&lt;br&gt;Product Name: Nimenrix&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Menveo&lt;br&gt;Product Name: Menveo&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Solnatide&lt;br&gt;Pharmaceutical Form: Powder for nebuliser suspension&lt;br&gt;INN or Proposed INN: Solnatide&lt;br&gt;CAS Number: 259206-53-06&lt;br&gt;Current Sponsor code: AP301&lt;br&gt;Other descriptive name: human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Solvent for...&lt;br&gt;Route of administration of the placebo: Inhalation use&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","&lt;br&gt;Trade Name: Dolquine&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Arechin&lt;br&gt;Product Name: Chlorine phosphate (Arechin) &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CHLOROQUINE PHOSPHATE&lt;br&gt;CAS Number: 50-63-5&lt;br&gt;Other descriptive name: CHLOROQUINE PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ruxolitinib (JAKAVI)&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ruxolitinib (phosphate)&lt;br&gt;CAS Number: 1092939-17-7&lt;br&gt;Current Sponsor code: INCB018424 phosphate&lt;br&gt;Other descriptive name: RUXOLITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 10-40&lt;br&gt;&lt;br&gt;","Other: Standard administration of oxygen flow;Device: Automated oxygen administration - FreeO2","Other: hyperimmune plasma","&lt;br&gt;Trade Name: PLAQUENIL 200 mg, comprim pellicul&lt;br&gt;Product Code: SAR390530&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: SAR321068&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","Drug: Azithromycin;Drug: Hydoxychloroquine or Chloroquine;Drug: Interferon-Beta","&lt;br&gt;Trade Name: Fresh frozen plasma (FFP) with marketing authorisation in Germany issued by PEI&lt;br&gt;&lt;br&gt;Product Name: For example \"Gefrorenes Frischplasma / Apherese DRK Blutspendedienst\"&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Zithromax&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;Current Sponsor code: OnCoVID19&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;Pharmaceutical form of the placebo: Capsule, hard&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;&lt;br&gt;Trade Name: azithromycine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;&lt;br&gt;Trade Name: azithromycine&lt;br&gt;Pharmaceutical Form: Syrup&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;&lt;br&gt;","Drug: Sargramostim;Other: Control","Drug: Peginterferon Lambda-1a;Other: Placebo","Drug: TAK-981;Drug: Standard of care","Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine SAR321068;Drug: Placebo","Drug: CD24Fc;Drug: Placebo","Drug: Colchicine;Drug: Placebo oral tablet","Device: Biosensors","Drug: INO-4800;Device: CELLECTRA 2000","Other: Usual Care;Drug: Anakinra;Drug: Siltuximab;Drug: Tocilizumab","Behavioral: Mindfulness session(s)","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate;Drug: Baricitinib (janus kinase inhibitor)","Drug: NORS (Nitric Oxide Releasing Solution);Drug: NORS (Nitric Oxide Releasing Solution)","Drug: Sirolimus;Drug: Placebo","Drug: Tocilizumab","Drug: Favipiravir","Drug: Hyperbaric oxygen","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets","Genetic: Mesenchymal Stromal Cells","Biological: anti-SARS-CoV-2 convalescent plasma","Drug: Plasma","Drug: Plasma;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin C;Dietary Supplement: Vitamin D;Dietary Supplement: Zinc","Drug: Losartan","Drug: Hydroxychloroquine and azithromycin treatment arm.;Drug: Hydroxychloroquine;Drug: Control arm","Drug: Hydroxychloroquine;Drug: Placebo","Biological: bacTRL-Spike;Other: Placebo","Other: SPIN-CHAT Program","Drug: Eicosapentaenoic acid gastro-resistant capsules","Other: blood draw","Other: Self-administered questionnaires","Other: Discontinuation of ARB/ACEI;Other: Continuation of ARB/ACEI","Drug: Ivermectine;Drug: Hydroxychloroquine Sulfate;Drug: Placebos;Drug: Azithromycin 500 mg","Drug: Anakinra;Drug: Tocilizumab","Drug: Dietary Supplement containing resistant starch;Dietary Supplement: Placebo Starch","Drug: Group A HCQ;Drug: Group B Control","Drug: Pegylated interferon lambda","Combination Product: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)","Drug: L-ascorbic acid;Other: Placebo","Drug: Melatonin 2mg;Drug: Placebo oral tablet","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Other: Placebo","Drug: Chloroquine or Hydroxychloroquine;Drug: Lopinavir/Ritonavir;Other: Best standard of care;Drug: Rivaroxaban;Drug: Thromboprophylaxis;Drug: Candesartan;Drug: non-RAS blocking antihypertensives;Drug: Clazakizumab;Drug: placebo for clazakizumab","Drug: ACE inhibitor, angiotensin receptor blocker","Drug: DAS181;Drug: Placebo","Drug: Hydroxychloroquine + placebo;Drug: hydroxychloroquine + azithromycin","Other: convalescent plasma from recovered COVID 19 donor","Other: blood samples","Drug: Ruxolitinib;Procedure: Peripheral blood draw","Other: blood sampling;Other: additional blood tubes","Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule;Biological: Two doses of placebo at the emergency vaccination schedule;Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule;Biological: Two doses of placebo at the routine vaccination schedule","Drug: Hydroxychloroquine (HCQ)","Drug: Human immunoglobulin;Drug: Placebo","Drug: Hydroxychloroquine Pre-Exposure Prophylaxis;Drug: Placebo oral tablet","Drug: Experimental drug","experimental group:Based on the standard treatment recommended in the guidelines, a combination of tozumab and adamumab was used;control group:Follow the guidelines for standard treatment;","Drug: hydroxychloroquine in combination with camostat mesylate;Drug: Hydroxychloroquine in combination of Azithromycin","Drug: captopril 25mg","Drug: L-ascorbic acid","Drug: Sarilumab;Other: Standar of care","Drug: Favipiravir + Standard of Care;Drug: Standard of Care","Control group:conventional therapy;CIK group:Umbilical cord blood CIK cells (1.610E8/kg) were injected twice every other day.;NK group:Umbilical cord blood NK cells (1.610E8/kg) were injected twice every other day.;","Device: Ventil - a gas flow divider","Biological: Plasma;Other: Best Available Therapy","Drug: Ruxolitinib administration","Drug: 50 mg/mL Virazole;Drug: 100 mg/mL Virazole","Drug: Hydroxychloroquine;Drug: Azithromycin","Drug: Favipiravir;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine;Drug: Lopinavir / Ritonavir Pill;Drug: Azithromycin;Other: Standard treatment","Experimental group:Lopinavir and Ritonavir Tablets;control group:Routine symptomatic support treatment;","Drug: Almitrine;Drug: Placebo","Case series:Routine treatment+GD31, GD31: D1: 200mg QD, dissolved in 100ml of saline, intravenous drip, about 60 minutes; D2 ~ 10: 100mg QD, dissolved in 100ml of saline, intravenous drip, 30 minutes.;","Drug: Recombinant human plasma gelsolin (Rhu-pGSN);Other: Placebo","Drug: Estradiol patch","Drug: Hydroxychloroquine Sulfate 200 MG;Other: Placebo","Behavioral: Phone-call screening and management by a medical student/general practitioner tandem","Drug: Baricitinib 4 MG Oral Tablet","Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Telmisartan","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);Placebo:2 tablets placebo BID, complicated with therapy recommended by New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5);","Drug: Suspension of heat killed (autoclaved) Mycobacterium w;Other: Placebo","Dietary Supplement: Ketogenic diet;Other: standard of care","Drug: Aviptadil (VIP);Drug: Placebo","Drug: Budesonide Nasal;Other: Physiological serum","Other: Gas exchanges at different PEEP;Other: lung mechanics at different PEEP;Other: Hemodynamics changes at different PEEP","Other: Cash transfer","Diagnostic Test: COVID 19 diagnostic test by PCR","Other: home care monitoring","Drug: Nitazoxanide;Drug: Placebo","Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by \"New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)\";Placebo:2 tablets placebo BID;","Biological: vaccine BCG;Other: Placebo","Drug: Chloroquine Sulfate;Drug: Hydroxychloroquine;Other: Standard supportive care","Biological: High-Titer COVID-19 Convalescent Plasma (HT-CCP);Biological: Standard Plasma (FFP)","Biological: SARILUMAB","Behavioral: Online cognitive behavioral therapy (CBT);Behavioral: Online bibliotherapy programme","Device: Electric pad for human external pain therapy","Other: hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint","Behavioral: prayer","Combination Product: Ivermectin plus Nitazoxanide;Other: Standard Care","Drug: Telmisartan 40mg;Drug: Placebo","Drug: FT516","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Chloroquine or hydroxychloroquine","Drug: Colchicine Tablets","Drug: AT-001","Drug: VC;Drug: Sterile Water for Injection","Other: prone position","Other: Doppler Echo","Drug: Isotretinoin Only Product in Oral Dose Form","Procedure: Chest physiotherapy using a non-invasive oscillating device","Other: samling of oropharynx and nasopharynx","Drug: Ramipril 2.5 MG Oral Capsule;Drug: Placebo oral capsule","The app includes seven modules that can be completed within a week to learn evidence-based coping skills based on CBT, psychoeducation and positive psychology techniques. The seven modules are: (1) identifying and rating emotions, (2) relaxation, (3) self-compassion, (4) gratitude, (5) staying connected, (6) physical care, and (7) goal setting. The app uses short videos and interactive activities to allow participants to practice the coping strategies that are taught in each module (e.g. a relaxation technique). Participants are asked to complete one module per day and to complete the modules in one week. Each module takes approximately 15 minutes to complete. Participants will be asked to complete module 1 first, but the other modules can be completed in any order. Adherence will be assessed via app analytics and also using self-report.","Drug: Tocilizumab","Other: Rehabilitation","Drug: Hydroxychloroquine Sulfate;Drug: Hydroxychloroquine Sulfate + Azythromycin","Drug: Therapeutic Anticoagulation","&lt;br&gt;                This is an interventional study where good sleepers will be recruited as a wait-list control, where they will receive the treatment after a delay of one week. An additional group of good sleeper participants will be recruited who will not receive the intervention. An equal number of participants will be recruited to each group and healthy good sleepers and individuals with sleep problems will be recruited at a 2:1 ratio (estimated n = 40:20 participants).&lt;br&gt;&lt;br&gt;                The study is single-centre and the study will be run entirely online.&lt;br&gt;&lt;br&gt;                Participants who are in the two intervention groups (poor sleep and wait-list control good sleepers) will be provided with an online version of a self-help leaflet. A printed version of this leaflet has been used in previous treatment studies conducted by our research group. Briefly, this self-help leaflet aims to improve sleep by identifying and addressing sleep-related dysfunctional thinking by providing education about sleep, providing techniques to distract from intrusive worrisome thoughts at night, and providing guidelines for sleep-related stimulus control.&lt;br&gt;&lt;br&gt;                The duration of treatment will be one week and the follow-up period is at the end of the treatment period. Participants will be randomised using online software (where good sleepers will be randomised to treatment or no treatment).&lt;br&gt;","Control:conventional therapy;Experimental group:Bufei Huoxue Capsule, 1.4g/day, three times a day, three months of treatment;","Drug: Anakinra;Drug: Normal saline","Experimental group:Administration of hydroxychloroquine sulfate;control group:Placebo given;","Nebulised (Vibrating mesh nebuliser) heparin sodium 25,000 IU in 5 ml 6-hourly to day 10 while invasively ventilated in addition to standard care.&lt;br&gt;The medication will be prescribed and administration documented in the medical record.&lt;br&gt;","&lt;br&gt;                The study consists of the following periods/assessments for participants in both the intervention and control arms.&lt;br&gt;                1. Screening period: -3 to -1 days. This will involve taking informed consent, assessing eligibility and comorbidity (e.g. Hypertension, Diabetes, Cardiovascular disease, etc.) through taking a medical and surgical history, smoking history, previous medication history, demographic history, physical examination, serology, 12-lead ECG, and vital signs.&lt;br&gt;                2. Treatment period: 0 to 14 days&lt;br&gt;                3. Follow-up period: 0 to 28 days. Patients will attend five study assessments at 0 (baseline assessment), 2, 8, 15 and 29 days. If nasal swabs taken at 15 days are negative participants will be invited to return 24 h later on day 16 for a second swab.&lt;br&gt;                4. Safety Follow-up assessment: 28 days after the last dose of the Siddha treatment was received in the event of early termination&lt;br&gt;&lt;br&gt;                The patients selected for participation will be assigned randomly to one of the two treatment groups, Siddha treatment regimen + Standard of Care, or Standard of Care only, in 1:1 ratio balancing the stratification factor of co-morbidity status.&lt;br&gt;&lt;br&gt;                The stratified permuted block randomization design will be used to randomize the patients in 1:1 ratio among the two treatment groups.&lt;br&gt;&lt;br&gt;                Siddha treatment regimen + Standard of care will involve Siddha treatment with Kabasura kudineer and Brammanandha bairavam where indicated in addition to standard care as per local/government guidance. Kabasura kudineer will be given in the dose of 60 ml, twice a day for 7 days taken 90 minutes before food. Brammanandha bairavam will be given in the dose of 100 mg, three times a day for 7 days, ta","Drug: MRx-4DP0004;Drug: Placebo","Case series:Nil;","Experimental group vs control group:Hydroxychloroquine versus Placebo;","Biological: Biological test","Other: Questionnaires;Biological: blood test;Other: Maximal effort test;Device: actigraphy;Device: Neuromuscular evaluation","&lt;br&gt;Product Name: avdoralimab&lt;br&gt;Product Code: IPH5401&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: avdoralimab&lt;br&gt;CAS Number: 2226393-85-5&lt;br&gt;Current Sponsor code: IPH5401&lt;br&gt;Other descriptive name: NNC0215-0384&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Drug: Aspirin 81 mg;Dietary Supplement: Vitamin D","Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil];Drug: Lopinavir/ritonavir","&lt;br&gt;Trade Name: Hidroferol 0,266 mg cpsulas blandas&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CALCIFEDIOL&lt;br&gt;CAS Number: 19356-17-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.266-&lt;br&gt;&lt;br&gt;","SFBT group:Internet based SFBT;Waiting Group:Wait ;","&lt;br&gt;Product Name: Recombinant human angiotensin-converting enzyme 2&lt;br&gt;Product Code: APN01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: APN01 / GSK2586881&lt;br&gt;Other descriptive name: GSK2586881&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Other: Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors","&lt;br&gt;Trade Name: ROACTEMRA&lt;br&gt;Product Name: tocilizumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Current Sponsor code: TOCILIZUMAB&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Biological: CYNK-001","Drug: Progesterone 100 MG","Phase I A1:Low dosage;Phase I A2:Placebo;Phase I A3:medium dosage;Phase I A4:Placebo;Phase I A5:high dosage;Phase I A6:Placebo;Phase I F1:Low dosage;Phase I F2:Placebo;Phase I F3:medium dosage;Phase I F4:Placebo;Phase I F5:high dosage;Phase I F6:Placebo;Phase I G1:low dosage;Phase I G2:placebo;Phase I G3:medium dosage;Phase I G4:placebo;Phase I G5:high dosage;Phase I G6:placebo;Phase I H1:low dosage;Phase I H2:placebo;Phase I H3:medium dosage;Phase I H4:placebo;Phase I H5:high dosage;Phase I H6:placebo;Phase I M1:low dosage;Phase I M2:placebo;Phase I M3:medium dosage;Phase I M4:placebo;Phase I M5:high dosage;Phase I M6:placebo;phase II A1:low dosage;phase II A2:placebo;phase II A3:medium;phase II A4:placebo;phase II A5:high dosage;phase II A6:placebo;phase II B1:medium;phase II B2:placebo;phase II C1:medium dosage;phase II C2:placebo;phase II D1:medium dosage;phase II D2:placebo;phase II E1:high dosage;phase II E2:placebo;phase II F1:low dosage;phase II F2:placebo;phase II F3:medium dosage;phase II F4:placebo;phase II F5:high dosage;phase II F6:placebo;phase II G1:low dosage;phase II G2:placebo;phase II G3:medium dosage;phase II G4:placebo;phase II G5:high dosage;phase II G6:placebo;phase II H1:low dosage;phase II H1:placebo;phase II H3:medium dosage;phase II H4:placebo;phase II H5:high dosage;phase II H6:placebo;phase II M1:low dosage;phase II M2:placebo;phase II M3:medium dosage;phase II M4:placebo;phase II M5:high dosage;phase II M6:placebo;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Roactemra&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Roactemra&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Drug: Canakinumab Injection 600mg;Drug: Canakinumab Injection 300mg;Drug: Placebos","Experimental group: mild cases:Ulinastatin 300,000 IU, Q12H;Experimental group: severe or critical cases:Severe cases: 1 million IU of ulinastatin, Q8H; Critical cases: ulinastatin 1.6 million IU, Q8H;Control group: mild cases:conventional therapy;Control group: severe or critical cases :conventional therapy;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Product Name: Olumiant&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Kevzara&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Subcutaneous use&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Olumiant&lt;br&gt;Product Name: Olumiant&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: BARICITINIB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Azithromycin&lt;br&gt;Product Name: Azithromycin&lt;br&gt;Product Code: Azithromycin&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;Other descriptive name: AZITHROMYCIN MONOHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-500&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Product Code: Hydroxyghloroquine&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab","Drug: Ringer's Acetate","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules;Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","&lt;br&gt;Trade Name: Enoxaparine sodique&lt;br&gt;Product Name: enoxaparine sodique&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ENOXAPARIN SODIUM&lt;br&gt;CAS Number: 9041-08-1&lt;br&gt;&lt;br&gt;","Drug: Remdesivir;Drug: Standard of Care","Drug: Losartan;Other: Placebo","&lt;br&gt;Trade Name: Actilyse &lt;br&gt;Product Name: Actilyse &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: Alteplase&lt;br&gt;CAS Number: 0105857-23-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;                The participants are randomized across experimental and control groups and blinded for group allocation.&lt;br&gt;                Following recruitment, the researcher who was blind to participants identities and baseline assessment results performed randomisation into groups using random number generating software.&lt;br&gt;                Intervention: Expressive writing  (20 minutes, 5 sessions during 2 weeks), participants are instructed to write about any experiences and thoughts on their life during the pandemic.&lt;br&gt;                Control: Treatment as usual (TAU), i.e. informal support through families, friends, and networks (face-to-face, telephone and online) as well as support participants could get using available services in the community during the state of emergency (e.g. online counseling, hotlines, available self-help manuals)&lt;br&gt;","Drug: Hydroxychloroquine Oral Product;Drug: Hydroxychloroquine + azithromycin","Other: Placebo;Drug: Remdesivir","Drug: Colchicine;Drug: Standard treatment","&lt;br&gt;Trade Name: VACCIN BCG AJVaccines&lt;br&gt;Product Name: VACCIN BCG AJVaccines&lt;br&gt;Pharmaceutical Form: Powder and solvent for dispersion for injection&lt;br&gt;Other descriptive name: BCG VACCINE, FREEZE-DRIED&lt;br&gt;Concentration unit: CFU/ml colony forming unit(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2-8&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","Drug: BCG Vaccine","Drug: Hydroxychloroquine;Drug: Placebo of Hydroxychloroquine;Drug: Lopinavir and ritonavir;Drug: Placebo of LPV/r Tablets","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;&lt;br&gt;","Case series:oral CSA0001;","Drug: Colchicine;Other: Local standard of care","Drug: BCG Vaccine;Drug: Placebo","Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine;Drug: remdesivir","&lt;br&gt;Trade Name: Albutein 5% solutin for infusion&lt;br&gt;Product Name: Human Albumin&lt;br&gt;Product Code: B05AA01&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: HUMAN SERUM ALBUMIN&lt;br&gt;Other descriptive name: ALBUMIN NORMAL HUMAN SERUM&lt;br&gt;Concentration unit: g/ml gram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;Trade Name: Flebogamma DIF/100 Human Inmunoglobulin normal&lt;br&gt;Product Name: Human Immunoglobuline normal&lt;br&gt;Product Code: Flebogamma DIF 50 mg/ml solucin para perfusin&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Human normal immunoglobulin&lt;br&gt;Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine Sulfate 400 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg twice a day;Drug: Hydroxychloroquine Sulfate 600 mg once a day;Drug: Placebo oral tablet","Drug: Tocilizumab;Drug: Tocilizumab","Drug: Azithromycin;Drug: Placebos","&lt;br&gt;Product Name: XCEL-UMC-BETA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: EX VIVO EXPANDED WHARTON'S JELLY DERIVED MESENCHYMAL STEM CELLS&lt;br&gt;Current Sponsor code: XCEL-UMC-BETA&lt;br&gt;Other descriptive name: EX VIVO EXPANDED WHARTON'S JELLY DERIVED MESENCHYMAL STEM CELLS&lt;br&gt;Concentration unit: IU/kg international unit(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 700000-1000000&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Device: hyperbaric oxygen therapy (HBOT)","Drug: Ibuprofen","&lt;br&gt;Trade Name: Avastin&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: BEVACIZUMAB&lt;br&gt;CAS Number: 216974-75-3&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;","Biological: Convalescent Plasma","Drug: Deferoxamine","Drug: Emtricitabine/tenofovir disoproxil;Drug: Hydroxychloroquine;Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo;Drug: Placebo: Hydroxychloroquine","&lt;br&gt;Product Name: Vafidemstat&lt;br&gt;Product Code: ORY-2001&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: VAFIDEMSTAT&lt;br&gt;CAS Number: 1357247-95-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.2-2.4&lt;br&gt;&lt;br&gt;","Drug: Valsartan (Diovan);Drug: Placebo oral tablet","Combination Product: Hydroxychloroquine Sulfate + Azithromycin;Drug: Hydroxychloroquine Sulfate","Drug: Ruxolitinib","Biological: mRNA-1273","Drug: Remdesivir;Drug: Standard of Care","Drug: Baricitinib","Drug: TJ003234;Drug: Placebo","Biological: Convalescent plasma","Drug: PUL-042 Inhalation Solution;Drug: Placebo","Drug: PUL-042 Inhalation Solution;Drug: Placebo","Drug: LY3127804;Drug: Placebo","Drug: Methylprednisolone Sodium Succinate;Drug: Placebo solution","Biological: Convalescent Plasma","Drug: Hydroxychloroquine;Drug: Lopinavir / Ritonavir;Drug: Interferon Beta-1A;Drug: Interferon Beta-1B","Drug: Remdesivir;Drug: Lopinavir/ritonavir;Drug: Interferon Beta-1A;Drug: Hydroxychloroquine;Other: Standard of care","Drug: CM4620-Injectable Emulsion","Drug: Hydroxychloroquine;Drug: Indomethacin;Drug: Zithromax Oral Product","Drug: Chloroquine;Drug: Favipiravir;Drug: Nitazoxanide;Drug: Ivermectin;Drug: Niclosamide;Drug: Other drugs","Drug: Camostat Mesilate;Drug: Placebo oral tablet","Biological: Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients","Drug: Ruxolitinib","Drug: Enoxaparin","Drug: Vazegepant (BHV-3500);Drug: Placebo","Drug: Chloroquine phosphate","Drug: Hydroxychloroquine","Drug: Selinexor;Other: Placebo","Biological: Lenzilumab;Drug: Standard of Care","Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Chloroquine;Drug: Placebo","Device: ECCO2R","Other: convalescent plasma","Drug: Tocilizumab (TCZ);Drug: Placebo","Drug: RhACE2 APN01;Drug: Physiological saline solution","Drug: Povidone-Iodine 2%;Drug: Povidone-Iodine 0.5%;Drug: Isotonic saline 0.9%","Drug: Hydroxychloroquine Sulfate Regular dose;Drug: Hydroxychloroquine Sulfate Loading Dose;Drug: Chloroquine;Drug: Placebo","Device: Control group;Device: SLEDD with a L-MOD","A:Long-acting interferon alpha-2a (135ug) + ribavirin;B:Abidol + ribavirin;","Drug: Hydroxychloroquine (HCQ);Drug: Azithromycin (Azithro);Drug: Placebo for Hydroxychloroquine;Drug: Placebo for Azithromycin","Biological: serology test;Diagnostic Test: NG Biotech;Biological: nasopharyngeal swab;Biological: rectal swab;Biological: saliva sample","Drug: Inhaled budesonide","Drug: Clazakizumab 25 mg;Drug: Clazakizumab 12.5 mg;Other: Placebo","Device: Hyperbaric oxygen therapy;Device: Normobaric oxygen therapy","Drug: Enoxaparin Higher Dose;Drug: Lower-dose prophylactic anticoagulation","Drug: Etoposide","Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA)","Drug: cholecalciferol 200,000 IU;Drug: cholecalciferol 50,000 IU","Behavioral: online mindfulness group","Other: Prone decubitus","Drug: Prednisone;Drug: Hydrocortisone","Other: Prone;Other: Usual Care","Drug: Hidroxicloroquine;Drug: Lopinavir/ritonavir;Drug: Imatinib tablets;Drug: Baricitinib Oral Tablet","Drug: Convalescent Plasma Transfusion;Other: Supportive Care;Drug: Random Donor Plasma","Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma);Biological: Non-convalescent Plasma (control plasma)","Procedure: alveolar recruitment","Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.;Drug: Placebo","Biological: BCG Vaccine;Biological: Placebo Vaccine","Drug: HB-adMSCs;Drug: Placebos","Other: Collection of samples","Biological: Mesenchymal Stromal Cells;Other: Placebo","Device: COVSurf Drug Delivery System;Other: Standard of Care","Other: Convalescent plasma","Drug: Colchicine Tablets;Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.","Experimental group:Farpiravir tablets;Control group:Abidole tablets;","Diagnostic Test: VitalConnect Vital Sign Patch","Drug: TD-0903;Drug: Placebo","Biological: Bactek-R","Drug: Anakinra plus oSOC;Drug: oSOC","Drug: Colchicine;Drug: Usual Care","Drug: Methotrexate;Drug: Methotrexate;Drug: Methotrexate","Drug: Ascorbic Acid;Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin;Drug: Folic Acid","Biological: Convalescent Plasma;Biological: Lactated ringer's solution or sterile saline","Drug: Stannous protoporphyrin (90mg);Drug: 0.9% sodium chloride (normal saline)","1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;","Drug: Hydroxychloroquine","Drug: HCQ &amp; AZ","Procedure: Biological samples specific to research;Procedure: Clinical examination;Procedure: Telephone follow-up","Drug: Sitagliptin","Biological: Umbilical Cord Mesenchymal Stem Cells;Other: Standard of Care","Biological: convalescent plasma","Drug: AVM0703;Drug: Placebo;Drug: hydrocortisone","Behavioral: Attention Bias Modification (ABM)","Drug: Alteplase 50 MG [Activase];Drug: Alteplase 100 MG [Activase]","Device: Kerecis Oral and Nasal Spray;Other: Placebo","Dietary Supplement: Probiotic;Dietary Supplement: Control","Biological: Hyperimmune plasma;Drug: Hidroxicloroquina + Azitromicina o Lopinavir/ritonavir + Interferon -1b + Hidroxicloroquina","Biological: Cell therapy protocol 1;Biological: Cell therapy protocol 2","Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care;Dietary Supplement: SivoMixx (200 billion);Drug: Azithromycin;Drug: hydroxychloroquine","Device: Plasma Adsorption Cartridge","Drug: Anakinra alone (stages 2b/3);Drug: Anakinra and Ruxolitinib (overcome stage 3);Other: Standard of care","Radiation: Low Dose Radiation Therapy","Behavioral: 1: Prone positioning;Behavioral: 2: No instruction regarding positioning","Drug: Dornase Alfa Inhalation Solution [Pulmozyme]","Drug: Enoxaparin","Drug: ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS","Behavioral: psychological assessment","Drug: Intermediate dose thromboprophylaxis;Drug: Standard of Care thromboprophylaxis","Diagnostic Test: Saliva collection","Device: NIO (Intraosseous access);Device: Standard of Care (Intravenous access)","Drug: Canakinumab;Drug: Placebo","Drug: Hydroxychloroquine;Drug: Placebo","Behavioral: Behavioral: OCAT-sham;Behavioral: Behavioral: OCAT;Other: psycho-education video","Drug: Clazakizumab;Drug: Placebo","Biological: Serological test;Biological: Serum test","Procedure: blood sampling","Procedure: Extended sampling and procedures","Device: COVID-19 barrier box","Behavioral: Intermittent prone positioning instructions;Behavioral: Usual care positioning with no instructions","Drug: CHLORPROMAZINE (CPZ);Combination Product: Standard of Care (SOC)","Drug: Methylprednisolone;Drug: Methylprednisolone","Device: Control swab;Device: Prototype swab","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Drug: Tetrandrine","Biological: SARS-CoV-2 rS;Other: Matrix-M Adjuvant;Other: NSS Saline Placebo","Biological: Ravulizumab;Other: Best Supportive Care","Other: Sudarshan Kriya Yoga (SKY);Other: Health Enhancement Program","Drug: Hydroxychloroquine (HCQ);Other: Pacebo: Calcium citrate","Biological: BCG;Biological: Placebo","Biological: WJ-MSCs","Biological: MultiStem;Biological: Placebo","Other: blood sample","Biological: Ozone auto-hemotherapy","hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;","Device: gammaCore (Vagus nerve stimulation)","Biological: Tocilizumab","Drug: MCN (Methylene blue, vitamin C, N-acetyl cysteine)","Behavioral: Coping strategies video","Drug: Tirofiban Injection;Drug: Clopidogrel;Drug: Acetylsalicylic acid;Drug: Fondaparinux","Biological: Remestemcel-L;Drug: Placebo","Behavioral: Messaging","Experimental treatment group:Oral chloroquine phosphate tablets (treatment group);control group:Oral placebo group (control group);","Other: blood sample","Drug: Oseltamivir;Drug: hormones;Device: oxygen therapy;Procedure: mesenchymal stem cells","Device: Telerehabilitation","Drug: Hydroxychloroquine and Azithromycin;Dietary Supplement: Azinc","Drug: Apo-Hydroxychloroquine;Drug: Matched Placebo","Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube)","Device: Mechanical ventilation with the automated BVM compressor","Suspected case treatment group:TCM formula 1 or TCM formula 2;Suspected case control group:null;Confirmed case  treatment group:Western medicine+(TCM formula 3 or TCM formula 4 or TCM formula 5 or TCM formula 6);Confirmed case control group:Western medicine;","Drug: Sirolimus 1 MG/ML;Drug: Placebo","Drug: SnPP Protoporphyrin;Drug: SnPP Protoporphyrin;Drug: SnPP Protoporphyrin;Drug: SnPP Protoporphyrin;Drug: SnPP Protoporphyrin;Drug: SnPP Protoporphyrin;Drug: Sulfonatoporphyrin(TPPS);Drug: Sulfonatoporphyrin(TPPS)","Drug: Hydroxychloroquine Sulfate","Drug: Doxycycline;Drug: Placebo","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Current Sponsor code: SAR153191&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Drug: Povidone-Iodine","Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Zinc Sulfate;Drug: Doxycycline","Other: Standard of care (SOC);Drug: Hydroxychloroquine;Drug: Association of diltiazem and niclosamide","Drug: Traditional Chinese Medicine Prescription","Other: Online questionnaire","Other: PSG","Drug: Heparin","Drug: Methylprednisolone;Other: standard care","Behavioral: Peer Resilience Champion;Behavioral: Enriched Survey Feedback","Patients will have a nose and throat swab collected and tested immediately using the QIAstat-Dx Respiratory n-CoV Panel. Results are available in one hour and will be communicated immediately to clinical and infection control teams. There is no patient follow up but clinical outcome data are collected retrospectively from case notes and hospital information systems for the duration of hospitalisation, up to 30 days post-intervention.","Drug: Placebo;Drug: Tocilizumab","Group 1:single-shot CBT-I;Group 2:Sleep Hygiene;","Drug: Ivermectin","Drug: Duvelisib;Procedure: Peripheral blood draw","Drug: Hydroxychloroquine;Drug: Lopinavir/ritonavir 400 mg/100 mg;Other: Placebo","Control:NA;Noninvasive cardiopulmonary monitoring group:Wear non-invasive multi-channel cardiopulmonary monitor;","Other: impliminting Online Distance Learning","Drug: Baricitinib;Drug: Hydroxychloroquine;Drug: Lopinavir/Ritonavir;Drug: Remdesivir","Drug: metenkefalin + tridecactide;Drug: The standard of care","Behavioral: Brief educational video","Device: Home Pulse Oximetry Monitoring","Group 1:Routine treatment + Infusion of convalescent plasma;Group 2:Routine treatment;","Drug: Transfusion of SARS-CoV-2 Convalescent Plasma.;Drug: Transfusion of standard Plasma.","Diagnostic Test: Nasopharyngeal (NP) swab","Procedure: Therapeutic Plasma Exchange;Drug: Ruxolitinib","Biological: Blood samples collection;Other: Saliva collection","Other: Olfactory retraining;Drug: corticosteroid nasal irrigation;Other: smell household Items;Other: Nasal Irrigation","Biological: Plasma exchange;Drug: Standar medical treatmen","Biological: SARS-CoV-2 convalescent plasma;Biological: Plasma from a volunteer donor","Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma","Drug: Hydroxychloroquine;Drug: Hydroxychloroquine and Azithromycin;Drug: Hydroxychloroquine and Ivermectin;Drug: Camostat Mesilate","Other: Moxibustion plus Cupping","Biological: COVID-19 convalescent plasma","Biological: Biological/Vaccine: Angiotensin peptide (1-7) derived plasma","Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;","Device: FFP2;Device: Facial mask;Device: MFS","Drug: Bicalutamide 150 Mg Oral Tablet;Drug: Ivermectin 3Mg Tab","Drug: N-acetylcysteine","Drug: Hydroxychloroquine sulfate &amp;Azithromycin;Drug: Placebo","Behavioral: HOPE intervention","Drug: Convalescent Plasma;Other: Standard Care Therapy","Biological: COVID-19 Convalescent Plasma","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 20 ml (400 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 10 ml (200 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Product Name: RoActemra 20 mg/mL concentrato per soluzione per infusione  flacone 4 ml (80 mg)&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","Device: Calm Meditation App","Drug: HCQ &amp; AZ vs HCQ+SIR","Drug: Colchicine 1 MG Oral Tablet","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Drug: DAS181;Drug: Placebo","Drug: Ibrutinib;Drug: Placebo","Biological: Blood sample;Biological: Low or upper respiratory tract sample;Biological: Stool collection or fecal swab;Genetic: Blood sample for whole genome sequencing;Other: phone call","Drug: Bovine Lipid Extract Surfactant","Behavioral: Therapist Guided E-Therapy;Behavioral: Self-Help Therapy","Drug: Inhaled nitric oxide gas","Drug: Hydroxychloroquine Sulfate","Biological: Otilimab;Biological: Placebo;Drug: Standard of care","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber);Device: vv-ECMO only (no cytokine adsorption)","Drug: Hydroxychloroquine 200 Mg Oral Tablet;Drug: Azithromycin 500Mg Oral Tablet;Dietary Supplement: Glucose tablets","Diagnostic Test: Low-dose Chest CT","Radiation: Single fraction whole lung radiotherapy","Drug: Tocilizumab 180 MG/ML;Drug: Methylprednisolone Sodium Succinate","Behavioral: Computer task questionnaires","Drug: Fluoxetine","Biological: V-SARS","Drug: Placebo;Drug: Ruxolitinib","Drug: Angiotensin 1-7;Drug: Placebos","Biological: MSC","Biological: Convalescent plasma (CP)","Biological: NT-17;Drug: Placebo;Other: Supportive care;Procedure: Peripheral blood draw","Drug: Ciclesonide;Drug: Placebo","Diagnostic Test: RT-PCR Covid-19","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin;Other: Usual antibiotic treatment","The primary aim of this study is to evaluate the efficacy and efficiency of two telerehabilitation interventions. The intervention consists of a rehabilitation intervention which focuses more on participation in usual activities and is offered via a coaching model to a virtual group of people. The intervention components are: identifying patient goals with therapist (1:1); and participation in virtual groups (up to 4 participants per session) with physiotherapist and occupational therapists which focus on increasing participation in life roles and usual activities. &lt;br&gt;The 1:1 session will last for approximately 45 minutes and will be followed by commencement of group sessions within 5 days.&lt;br&gt;Groups adopt a coaching model where the therapist talks about common challenges, facilitates discussion and sharing of experiences and ideas and the group brainstorm and plan next steps together. The group sessions will last approximately 45 minutes and will be delivered 3 times per week for up to 4 weeks. &lt;br&gt;Adherence will be measured using attendance logs. &lt;br&gt;&lt;br&gt;","'Anchored' is a smartphone application-based intervention that includes therapeutic content centred on behavioural activation (BA), mindfulness, and cognitive behavioural tasks. It was adapted from HeadGear, an existing smartphone application designed for individuals working in male-dominated industries. Anchored is more broadly aimed at all adults, and has a more gender-neutral look and feel, achieved through use of colour scheme, imagery, font/typography, inclusion of male and female characters, and delivery of in-app content by both male and female presenters. The Anchored app is designed for self-directed use by an individual on a smartphone device. It features interactive content, delivered by on-screen text, audio, static and interactive image displays and videos. The app can be accessed by the participant on their smartphone at a time and location of their choosing. This app/intervention has been used previously in a pilot study: Pilot-testing of a mobile phone application to support the mental health of Australian workers (ACTRN12619000761167); and is being currently being evaluated in a large scale randomised controlled trial (ACTRN12620000178943). Due to the unexpected changes to the workforce brought about by COVID-19 (coronavirus) the present study seeks to evaluate the efficacy of the Anchored app in individuals who are unemployed as a consequence of COVID-19. &lt;br&gt;&lt;br&gt;The main therapeutic component of the Anchored app takes the form of a 30 day intervention in which users complete one challenge daily (5- 10 minutes per day). These 'challenges' feature a variety of evidence-based therapeutic techniques delivered using a range of formats including: psychoeducational videos (on coping skills and resilience, mindfulness, and behavioural activation); min","Experimental group:WeChat-based parenting education;Control groop:Electronic Manual + Teaching Plan;","Diagnostic Test: molecular testing for virus RNA using RT-PCR","Drug: DeltaRex-G","Drug: Tocilizumab","Dietary Supplement: Quercetin Prophylaxis;Dietary Supplement: Quercetin Treatment","2 trial arms:&lt;br&gt;1) Hydroxychloroquine plus zinc plus Vit D3/B12 plus azithromycin plus IV Vitamin C&lt;br&gt;2) Hydroxychloroquine plus zinc plus Vit D3/B12 plus azithromycin&lt;br&gt;&lt;br&gt;Dosing &lt;br&gt;Trial arm 1+2: &lt;br&gt;Hydroxychloroquine: 400mg oral tablet twice a day for 1 day, followed by 200mg oral tablet two times a day for 6 days&lt;br&gt;Azithromycin: 500 mg oral tablet on day 1 followed by 250 mg oral tablet once daily for 4 days &lt;br&gt;Zinc Citrate: 30mg elemental zinc oral tablet daily for 14 days&lt;br&gt;Vitamin D3: 5,000iu oral capsule daily for 14 days&lt;br&gt;Vitamin B12 (Methylcobalamin): 500mcg oral tablet daily for 14 days &lt;br&gt;&lt;br&gt;Plus Trial arm 2 only:&lt;br&gt;Inpatients: IV Vitamin C (Sodium Ascorbate) &lt;br&gt;50mg/kg every 6hrs on day 1 followed by 100mg/kg every 6hrs (4x day, 400mg/kg/day) for 7 days (average 28g.day; maximum dose of 50g/24hrs for those weighing more than 125kg). &lt;br&gt;Outpatients: Vitamin C (Sodium Ascorbate)&lt;br&gt;200mg/kg x1 IV, then 1 gram oral tablet three times per day for 7 days&lt;br&gt;&lt;br&gt;All treatments will be administered by medical staff briefed on the trial protocol. Adherence and fidelity will be assessed and recorded on the trial specific electronic data collection sheet by medical staff providing the trial treatment &lt;br&gt;","Device: Hydrogen Oxygen Generator with Nebulizer;Other: Standard-of-care","Drug: Enoxaparin","Behavioral: Mindfulness training (MT) Connect","Drug: LEAF-4L6715;Drug: LEAF-4L7520","Control group 1:western medicine treatment;Integrated traditional Chinese and western medicine treatment group 1:(2)traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of 5% glucose (control);Integrated traditional and western medicine treatment + high-dose vitamin C group 1:traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of high-dose vitamin C (control);Control group 2:western medicine treatment;Integrated traditional and western medicine treatment group 2:(5)traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of 5% glucose (control);Integrated traditional and western medicine treatment + high-dose vitamin C group 2:(6)traditional Chinese medicine treatment, western medicine treatment, and intravenous administration of high-dose vitamin C (control);","Device: Transcutaneous Auricular Vagus Nerve Stimulation","Drug: Interleukin-7;Drug: Placebos","Biological: Bacille Calmette-Gurin (BCG);Other: Placebo Comparator","Procedure: Robot Assisted Percutaneous Cardiovascular Intervention","&lt;br&gt;                ARM 1-schools: Will remain closed for 5-10 level pupils.&lt;br&gt;                ARM-2-schools: Will open for 5-10 level pupils.&lt;br&gt;                The study period will last 4 weeks. The primary outcome measure will include data from 2 weeks after the commencement of the trial, and until 4 weeks after the trial period. We plan to randomise through a simple transparent process, e.g. a televised draw. We will do this by stratified randomisation, with separate draws of schools for each municipality. Hence, half of the schools in each municipality will be allocated to opening for all grades (110), and the other half to remaining closed for 510 grade (partial closure).&lt;br&gt;&lt;br&gt;","Drug: IMU-838;Other: Placebo","Behavioral: Online support Group","Drug: Atorvastatin","Biological: RPH-104 80 mg;Drug: Olokizumab 64 mg;Drug: Placebo","Drug: Dialyzable Leukocyte Extract;Drug: Placebo oral","&lt;br&gt;                Current interventions as of 07/05/2020:&lt;br&gt;&lt;br&gt;                RECOVERY is a randomised trial among people hospitalised for COVID-19. Eligible patients are randomly allocated between several treatment arms, each to be given in addition to the usual standard of care in the participating hospital: No additional treatment vs lopinavir + ritonavir vs corticosteroids vs hydroxychloroquine vs azithromycin. The study allows a second randomisation for patients with progressive COVID-19 (evidence of hypoxia and a hyper-inflammatory state): No additional treatment vs Tocilizumab. For patients for whom not all the trial arms are appropriate or at locations where not all are available, randomisation will be between fewer arms.&lt;br&gt;&lt;br&gt;                RECOVERY has an adaptive trial design. The interim trial results will be monitored by an independent Data Monitoring Committee (DMC). The DMC will assess whether the randomised comparisons in the study have provided evidence on mortality that is strong enough (with a range of uncertainty around the results that is narrow enough) to affect national and global treatment strategies. In such a circumstance, the DMC will inform the Trial Steering Committee who will make the results available to the public and amend the trial arms accordingly. New trial arms can be added as evidence emerges that other candidate therapeutics should be evaluated.&lt;br&gt;&lt;br&gt;                Drug dosage and duration&lt;br&gt;                First (main) randomisation:&lt;br&gt;                1. Lopinavir 400 mg + ritonavir 100 mg: by mouth (or nasogastric tube) every 12 hours for 10 days or until discharge&lt;br&gt;                2. Corticosteroid in the form of dexamethasone: administered as an oral (liquid or tablets) or intravenous preparation 6 mg once daily for 10 days. In pregnancy or b","Drug: Hydroxychloroquine;Other: Placebo","Biological: Recombinant Interferon Alfa-2b;Drug: Rintatolimod","Drug: Sirukumab;Drug: Placebo;Other: Standard of Care (SOC)","Drug: Melphalan;Other: Standard of care","Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);","Drug: Clazakizumab;Other: Placebo","Radiation: Low-dose radiotherapy;Drug: Hydroxychloroquine Sulfate;Drug: Ritonavir/lopinavir;Drug: Tocilizumab Injection [Actemra];Drug: Azithromycin;Drug: Corticosteroid;Drug: Low molecular weight heparin;Device: Oxygen supply","Other: Exercise Group","Device: Emergency Ventilator Splitter","TCC-COVID is an app-based model of care which includes a smartphone app and a pulse oximeter that measures oxygen saturation, pulse rate and collects symptoms. &lt;br&gt;Patients place their index finger in the pulse oximeter to measure their oxygen saturation and pulse rate twice a day, which will take approximately 5 minutes each time. Patients then enter the results into the TCC-COVID app twice daily, and complete a symptom questionnaire via the TCC-COVID app once daily, which will take approximately 5 minutes. The symptom questionnaire was designed specifically for this study. The measurements and information are directly connected to a clinician interface (KIOLA database) which provides the data of all patients in aggregate and an easy to use responsive format with customisable alerts. The alerts identify if the oxygen saturation levels are low or the pulse rate is out of range. The alerts also identify if a measurement has not been completed in a timely manner and the central monitoring service will contact the patient to check on their safety or if they are experiencing any technical issues. The overall duration of participation will be 14 days.","severe group:high dose intravenous vitamin C;critical group:high dose intravenous vitamin C;","common type :Immunotherapy with recombinant chimeric DC vaccine;Latent period group:Immunotherapy with recombinant chimeric DC vaccine;Normal control group:Immunotherapy with recombinant chimeric DC vaccine;Blank vaccine control group:0.9%NS;","&lt;br&gt;Trade Name: Plaquenil 200mg&lt;br&gt;Product Name: hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;Trade Name: Azithromycine&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;&lt;br&gt;","BCG-vaccine","Three conditions are tested (each lasting 30 min, the measurement period): &lt;br&gt;1. Oxygen delivery via a nonrebreathing mask (current standard of care) with sufficient inflow of O2 (which does not create PEEP).  &lt;br&gt;2. Oxygen delivery via the face mask with zero PEEP in order to test the effect of the mask alone. &lt;br&gt;3. Oxygen delivery via the face mask with PEEP of 7.5 cmH2O in order to test effect of moderate PEEP.","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Anakinra&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;&lt;br&gt;","Prevent a supine position during sleep by the use of a Sleep Position Trainer, a small wearable device that trains patients to not sleep on their back by using gentle vibrations (1:1 randomization). In both groups sleep position will be continuously registered.","Drug: Vitamin C;Other: Control","Biological: MSCs;Biological: Saline containing 1% Human serum albumin(solution of MSC)","All treatment arms contain standard supportive care during hospital and:&lt;br&gt;1.\tChloroquine arm: loading dose 600mg as chloroquine base followed by 300mg 12 hours later followed by 300mg twice a day; total treatment duration 5 days (same dose as LCI guideline) &lt;br&gt;2.\tHydroxychloroquine arm: loading dose 400mg bid followed by 200mg twice a day; total treatment duration 5 days (same dose as LCI guideline)&lt;br&gt;3.\tNo antiviral treatment arm","Drug: RoActemra iv;Drug: RoActemra sc;Drug: Kevzara sc;Other: Standard medical care","Drug: Hydroxychloroquine;Drug: Placebo","Drug: Thiazide or Thiazide-like diuretics;Drug: Calcium Channel Blockers;Drug: ACE inhibitor;Drug: Angiotensin receptor blocker","&lt;br&gt;Trade Name: Enoxaparin (LOVENOX or other specialties)&lt;br&gt;Product Name: Enoxaparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: enoxaparin&lt;br&gt;CAS Number: 9005-49-6&lt;br&gt;Other descriptive name: ENOXAPARIN&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 14000-&lt;br&gt;&lt;br&gt;Trade Name: Tinzaparine (INNOHEP)&lt;br&gt;Product Name: Tinzaparine (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: Tinzaparin&lt;br&gt;Other descriptive name: TINZAPARIN SODIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 14000-&lt;br&gt;&lt;br&gt;Trade Name: Dalteparin (FRAGMINE)&lt;br&gt;Product Name: Dalteparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: dalteparin&lt;br&gt;Other descriptive name: DALTEPARIN SODIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 12500-&lt;br&gt;&lt;br&gt;Trade Name: Nadroparin (FRAXIPARINE)&lt;br&gt;Product Name: Nadropanine (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: NADROPARIN CALCIUM&lt;br&gt;Other descriptive name: NADROPARIN CALCIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 114000-&lt;br&gt;&lt;br&gt;Trade Name: Enoxaparin (LOVENOX or other specialities)&lt;br&gt;Product Name: Enoxaparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: ENOXAPARIN SODIUM&lt;br&gt;CAS Number: 9041-08-1&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 8000-&lt;br&gt;&lt;br&gt;Trade Name: Tinzaparin (INNOHEP)&lt;br&gt;Product Name: Tinzaparin (Low Molecular Weight Heparin)&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: Tinzaparin&lt;br&gt;Other descriptive name: TINZAPARIN SODIUM&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: up","Drug: Hidroxicloroquina;Drug: Control group","Drug: Ruxolitinib","&lt;br&gt;Trade Name: Curosurf&lt;br&gt;Pharmaceutical Form: Endotracheopulmonary instillation&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Rekonvaleszentenplasma COVID-19 Apherese (HD)&lt;br&gt;Product Code: CP COVID19&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;&lt;br&gt;","Other: Video based aerobic exercise","&lt;br&gt;Trade Name: Vedine/Betadine&lt;br&gt;Product Name: Vedine/Betadine&lt;br&gt;Pharmaceutical Form: Oromucosal solution&lt;br&gt;INN or Proposed INN: iodonated Povidone&lt;br&gt;CAS Number: 9003-39-8&lt;br&gt;Current Sponsor code: nil&lt;br&gt;Other descriptive name: betadine/videne&lt;br&gt;Concentration unit: % (V/V) percent volume/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Nasal wash&lt;br&gt;Route of administration of the placebo: Nasal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: ANAKINRA&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ANAKINRA&lt;br&gt;CAS Number: 143090-92-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: LOPINAVIR/RITONAVIR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR/RITONAVIR&lt;br&gt;Other descriptive name: LOPINAVIR/RITONAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 800-200&lt;br&gt;&lt;br&gt;Trade Name: AZYTHROMICINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN DIHYDRATE&lt;br&gt;Other descriptive name: AZITHROMYCIN DIHYDRATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Immunoglobulines Humaines Normales&lt;br&gt;Pharmaceutical Form: Solution for injection/infusion&lt;br&gt;&lt;br&gt;","Device: oxyhydrogen;Device: Oxygen","&lt;br&gt;Product Name: Brensocatib&lt;br&gt;Product Code: INS1007&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Brensocatib&lt;br&gt;CAS Number: 1802148-05-5&lt;br&gt;Current Sponsor code: INS1007&lt;br&gt;Other descriptive name: AZD7986&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Masitinib&lt;br&gt;Product Code: AB1010&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Masitinib mesilate&lt;br&gt;CAS Number: 790299-79-5&lt;br&gt;Current Sponsor code: AB1010&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Masitinib&lt;br&gt;Product Code: AB1010&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Masitinib mesilate&lt;br&gt;CAS Number: 790299-79-5&lt;br&gt;Current Sponsor code: AB1010&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Isoquercetin &lt;br&gt;Product Code: IQC950AN &lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;&lt;br&gt;Trade Name: Plaquenil 200 mg&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Current Sponsor code: SAR321068&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Selinexor&lt;br&gt;Product Code: KPT-330, XPOVIO&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Selinexor&lt;br&gt;CAS Number: 1393477-72-9&lt;br&gt;Current Sponsor code: KPT-330&lt;br&gt;Other descriptive name: SELINEXOR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Film-coated tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Favipiravir;Other: Placebo","&lt;br&gt;Product Name: IFX-1&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: IFX-1&lt;br&gt;CAS Number: 2250440-41-4&lt;br&gt;Current Sponsor code: IFX-1&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Methylprednisolone&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;CAS Number: 2375-03-3&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE SODIUM HEMISUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 125-&lt;br&gt;&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: LOPINAVIR/RITONAVIR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR/RITONAVIR&lt;br&gt;Other descriptive name: LOPINAVIR/RITONAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 400-100&lt;br&gt;&lt;br&gt;Trade Name: TOCILIZUMAB&lt;br&gt;Pharmaceutical Form: Powder and solvent for suspension for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Bemcentinib&lt;br&gt;Product Code: BGB324&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: bemcentinib&lt;br&gt;CAS Number: 1037624-75-1&lt;br&gt;Current Sponsor code: BGB324&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: MEDI3506&lt;br&gt;Product Code: MEDI3506&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;CAS Number: 2376858-66-9&lt;br&gt;Current Sponsor code: MEDI3506&lt;br&gt;Other descriptive name: human immunoglobulin (Ig) G1 monoclonal antibody (mAb)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;&lt;br&gt;Product Name: acalabrutinib&lt;br&gt;Product Code: ACP-196&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: acalabrutinib&lt;br&gt;CAS Number: 1420477-60-6&lt;br&gt;Current Sponsor code: ACP-196&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Zilucoplan&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: Zilucoplan&lt;br&gt;CAS Number: 1841136-73-9&lt;br&gt;Current Sponsor code: RA101495&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 40-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: VECTARION INJECTABLE, lyophilisat et solution pour prparation injectable&lt;br&gt;Product Name: Almitrine (DCI) bis msilate&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Solu-Cortef&lt;br&gt;Product Name: Solu-Cortef&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection/infusion&lt;br&gt;INN or Proposed INN: hydrocortisone&lt;br&gt;Other descriptive name: HYDROCORTISONE SODIUM SUCCINATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;Pharmaceutical form of the placebo: Infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;Trade Name: Isotonic Sodium Chloride (0.9%)&lt;br&gt;Product Name: Sodium Chloride&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Sodium Chloride&lt;br&gt;Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.9-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Favipiravir&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Favipiravir&lt;br&gt;CAS Number: 259793-96-9&lt;br&gt;&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;&lt;br&gt;Product Name: Azithromycin&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Azithromycin&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Mylotarg&lt;br&gt;Product Name: Mylotarg&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Gemtuzumab ozogamicin&lt;br&gt;CAS Number: 220578-59-6&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: STROMECTOL 3 mg&lt;br&gt;Product Name: STROMECTOL 3 mg&lt;br&gt;Product Code: 34009 352 388 5 6&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: CYT107 &lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intramuscular use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: SSI BCG powder and solvent for suspension for injection&lt;br&gt;Product Name: BCG vaccine (Danish strain 1331, SSI, Denmark)&lt;br&gt;Product Code: OGYI-T-9001/02&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ilomedin&lt;br&gt;Product Name: Ilomedin&lt;br&gt;Pharmaceutical Form: Concentrate and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: Iloprost&lt;br&gt;CAS Number: 78919-13-8&lt;br&gt;Concentration unit: g/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","Drug: Tranexamic acid tablets;Drug: Placebo oral tablet","&lt;br&gt;Trade Name: Jakavi tablets&lt;br&gt;Product Name: Jakavi Tablets&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Klaricid&lt;br&gt;Product Name: Clarithromycin&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;Pharmaceutical Form: &lt;br&gt;&lt;br&gt;","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo","&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ENOXAPARIN SODIUM&lt;br&gt;CAS Number: 9041-08-1&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Jakavi 5mg Tabletten&lt;br&gt;Product Name: ruxolitinib&lt;br&gt;Product Code: INC424&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ruxolitinib&lt;br&gt;CAS Number: 1092939-17-7&lt;br&gt;Current Sponsor code: INC424&lt;br&gt;Other descriptive name: RUXOLITINIB PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","Drug: Hydroxychloroquine Sulfate;Drug: Placebo","&lt;br&gt;Trade Name: HYDROXYCHLOROQUINE&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: Bq/mg becquerel(s)/milligram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: COLCHICINA&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: COLCHICINE&lt;br&gt;CAS Number: 64-86-8&lt;br&gt;Current Sponsor code: COLCHICINE&lt;br&gt;Other descriptive name: COLCHICINE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,5-&lt;br&gt;&lt;br&gt;","This study is an unblinded trial of a cuirass based negative pressure ventilator. &lt;br&gt;The device consists of a plastic casing (cuirass) placed over the thorax with negative pressure of -200cmH2O applied by a household vacuum cleaner.The negative pressure in the cuirass facilitates inspiration. The device cycles back to atmospheric pressure allowing expiration.&lt;br&gt;Following confirmation of fit by the research team, application of ANZCA standard monitoring (Australian and New Zealand College of Anaesthetists, 2017) and trial of the device in an awake volunteer, the study will use sedation to simulate an unwell patient.  &lt;br&gt;Baseline data before intervention will include AVPU level of consciousness, HR, SpO2 and Vt on room air, then HR and SpO2 on 4L/min via Hudson mask.  &lt;br&gt;The patient will be ventilated using the device with supplemental oxygen via Hudson face mask at 4L/min for one hour. Tidal volumes will be recorded every 15 minutes. The Hudson mask will be removed and a face mask connected to a GE Anaesthetic Machine running FiO2 at 30%, 4L/min will be used to record Vt for 3 consecutive breaths.  &lt;br&gt;Sedation will be provided by an accredited Consultant Anaesthetist and targeted to maintain an AVPU score of V, that is, rousable to command. The level of sedation will be targeted to not require direct airway intervention. Sedation will be provided using propofol and Total Intravenous Anaesthesia (TIVA) using the Marsh algorithm. An initial bolus of Lignocaine will be included with the propofol to minimise patient discomfort as per accepted practice. &lt;br&gt;An anaesthetic record will be maintained as per ANZCA Guidelines (Australian and New Zealand College of Anaesthetists, 2019). &lt;br&gt;The trial will be conducted in an operating theatre environment with full resuscitati","&lt;br&gt;Trade Name: Stromectol&lt;br&gt;Product Name: Ivermectina&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Ivermectin&lt;br&gt;CAS Number: 70288-86-7&lt;br&gt;Other descriptive name: IVERMECTIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 3-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","We are testing the feasibility and comfort of the use of a novel mask (the Decathlon group EasyBreathe snorkel mask) for the transport of patients between locations at our health service.&lt;br&gt;The Decathlon mask is a non-TGA approved device used for recreational snorkelling.  It has been adapted for use in COVID-19 patients by Italian engineers (see https://www.isinnova.it/easy-covid19-eng/)&lt;br&gt;In this trial we propose to apply the Decathlon mask in place of standard delivery systems for oxygen and positive airway pressure.  The Decathlon mask will be applied by clinicians in the hospital setting.&lt;br&gt;The mask is worn over the entire face and has advantages over conventional delivery methods in that it is thought to reduce the risk of virus aerosolization (a common problem with conventional delivery systems) and therefore increase safety for healthcare workers and other patients at the hospital.&lt;br&gt;We will test mask comfort and tolerability with daily questionnaires.&lt;br&gt;The mask will be applied to suspected or confirmed COVID-19 patients during transfer between the emergency department and other locations such as radiology department, ward and high dependency unit.&lt;br&gt;We anticipate the mask will be worn for several hours at a time depending on patient tolerability (early data from overseas suggests superior tolerability to conventional mask setups).  The mask may be used intermittently for the entire patient admission to hospital pending the clinical needs and preference of the patient. We anticipate, based on how conventional treatments are applied, that the patient will use the mask in 3 hour sessions with potential breaks in between to be determined by clinical need and patient tolerability.","&lt;br&gt;Trade Name: Flebogamma 5% DIF&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Human normal immunoglobulin (IVIg)&lt;br&gt;Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN (IV)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Flebogamma 10% DIF&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Human normal immunoglobulin (IVIg)&lt;br&gt;Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN (IV)&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","Intervention is an aqueous buffered solution of 0.5% povidone-iodine (PVP-I) contained in a 30 mL bottle closed with a traditional nasal spray pump.&lt;br&gt;Subjects will receive a single dose to their nasal passages, administered by the investigator. &lt;br&gt;The amount a subject receives consists of 6 x 140L pump actuations (3 into each nostril), being 0.84 mL total volume.","&lt;br&gt;Trade Name: Prolastina 1000 mg, polvo y disolvente para solucin para perfusin&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for infusion&lt;br&gt;INN or Proposed INN: Alpha1-Proteinase Inhibitor (Human)&lt;br&gt;Other descriptive name: HUMAN ALPHA1-PROTEINASE INHIBITOR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;","Two groups:modified respirator versus conventional respirator;","1.5ATA:1.5ATA HBO;2.5ATA:2.5ATA HBO;Control group:Routine treatment;","experimental group:''Guangdong Pneumonia NO.1''+basic treatment;\t control group:basic treatment and(or) antiviral therapy;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan, without using traditional Chinese medicine;","Routine treatment + Lianhua Qingwen Capsules/granules:4 capsules / time or 1 bag / time, 3 times a day;Conventional treatment:Treat as prescribed in the fourth edition of the diagnosis and treatment plan;","&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos.&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Buccal use&lt;br&gt;&lt;br&gt;Trade Name: azitromicina cinfa 500 mg comprimidos&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;Trade Name: Kaletra&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: Hydroxychloroquine&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 200-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: LEVOFLOXACIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: LEVOFLOXACIN &lt;br&gt;CAS Number: CAS 138199-7&lt;br&gt;&lt;br&gt;Product Name: HYDROCORTISONE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: HYDROCORTISONE&lt;br&gt;CAS Number: 50-23-7&lt;br&gt;&lt;br&gt;Product Name: CEFTRIAXONE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CEFTRIAXONE&lt;br&gt;CAS Number: 73384-59-5&lt;br&gt;&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AZITHROMYCIN&lt;br&gt;CAS Number: 83905-01-5&lt;br&gt;&lt;br&gt;Product Name: CLARITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;CAS Number: 81103-11-9&lt;br&gt;Other descriptive name: CLARITHROMYCIN LACTOBIONATE&lt;br&gt;&lt;br&gt;Product Name: ERYTHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ERYTHROMYCIN &lt;br&gt;CAS Number: 3847-29-8&lt;br&gt;&lt;br&gt;Product Name: AMOXICILLINE-CLAVULANTE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AMOXICILLIN &lt;br&gt;CAS Number: 34642-77-8&lt;br&gt;INN or Proposed INN: POTASSIUM CLAVULANATE&lt;br&gt;CAS Number: 61177-45-5&lt;br&gt;&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: AZITHROMYCIN MONOHYDRATE&lt;br&gt;CAS Number: 121470-24-4&lt;br&gt;&lt;br&gt;Product Name: CLARITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CLARITHROMYCIN&lt;br&gt;CAS Number: 81103-11-9&lt;br&gt;&lt;br&gt;Product Name: PIPERACILLIN-TAZOBACTAM&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: PIPERACILLIN&lt;br&gt;CAS Number: 66258-76-2&lt;br&gt;INN or Proposed INN: TAZOBACTAM &lt;br&gt;CAS Number: CAS 89785-84&lt;br&gt;&lt;br&gt;Product Name: ROXITHROMYCIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: ROXITHROMYCIN&lt;br&gt;CAS Number: 80214-83-1&lt;br&gt;Other descriptive name: ROXITHROMYCIN&lt;br&gt;&lt;br&gt;Product Name: CEFTAROLINE&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CEFTAROLINE FOSAMIL&lt;br&gt;CAS Number: 229016-73-3&lt;br&gt;Other descriptive name: CEFTAROLINE FOSAMIL&lt;br&gt;&lt;br&gt;Product Name: MOXIFLOXACIN&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: MOXIFLOXACIN &lt;br&gt;CAS Number: 186826-86-8&lt;br&gt;Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE&lt;br&gt;&lt;br&gt;Trade Name: Oseltamivir&lt;br&gt;Product Name: oselt","&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for nebuliser solution&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Leukine&lt;br&gt;Product Name: Leukine&lt;br&gt;Pharmaceutical Form: Powder for solution for infusion&lt;br&gt;INN or Proposed INN: SARGRAMOSTIM&lt;br&gt;CAS Number: 123774-72-1&lt;br&gt;Concentration unit: g microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","oral administration of favipiravir","oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir","Biological: Human umbilical cord derived CD362 enriched MSCs;Biological: Placebo (Plasma-Lyte 148)","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Drug: Baricitinib","Drug: Azithromycin;Drug: Hydroxychloroquine;Drug: Placebo oral tablet;Drug: Placebo oral tablet","Drug: 1: Naproxen;Drug: 2: Standard of care","Drug: Best supportive Care (BSC) + IFX-1;Drug: Best supportive care only","Other: Telerehabilitation","Drug: Atovaquone/Azithromycin","Drug: Anakinra","Drug: Hydroxychloroquine Sulfate 200 milligram (mg) Tab","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: Chloroquine Diphosphate;Drug: Placebo oral tablet","Drug: Aspirin;Drug: Losartan;Drug: Simvastatin","Drug: Pyridostigmine Bromide;Drug: Placebo","Drug: Danoprevir+Ritonavir","Biological: Convalescent anti-SARS-CoV-2 plasma;Drug: Sarilumab;Drug: Baricitinib;Drug: Hydroxychloroquine;Other: Injective placebo;Other: Oral placebo","Other: Blood and derivatives.;Drug: Standard of Care","Drug: Hydroxychloroquine","Biological: BM-MSCs;Biological: Placebo","Drug: Hydroxychloroquine;Other: Vitamin C","Drug: Clevudine;Drug: Hydroxychloroquine","Drug: Hydroxychloroquine, Azithromycin;Drug: Hydroxychloroquine, Doxycycline;Drug: Hydroxychloroquine, Clindamycin;Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.;Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.;Drug: Remdesivir;Drug: Tocilizumab;Drug: Methylprednisolone;Drug: Interferon-Alpha2B;Drug: Losartan;Drug: Convalescent Serum","Other: PROTECTIVE VENTILATION;Other: ULTRAPROTECTIVE VENTILATION","Drug: Treatment with Dexmedetomidine","Drug: Interferon Beta-1B;Drug: Hydroxychloroquine","Biological: intradermal injection of BCG Vaccine;Other: placebo","Drug: Hydroxychloroquine","Other: Psychoeducational intervention","Drug: Chloroquine","Drug: hydroxychloroquine sulfate 200 MG;Drug: Placebo oral tablet","Oral 500mg chloroquine phosphate tablets prophylactic weekly regimen against COVID-19 over 10 week trial period followed with plasma chloroquine levels.","A home-based intervention based on high-intensity interval training (HIIT). A physical therapist, with more than 5 years of experience, will provide a video session upload to YouTube. A WhatsApp message will individually send to each participant with a session link, that they will have to complete.&lt;br&gt;Frequency, duration of the sessions and overall duration of the intervention: 45 min of HIIT session, six days per week during all the self-isolation period (6 weeks estimated). &lt;br&gt;Each session will have: &lt;br&gt;1) A warm-up (10 min): Joint mobility exercises. &lt;br&gt;2) Main part: CORE, arms and legs exercises, with 10-12 sets of 30-90 seconds with 15-60 seconds of rest between sets (ie. push ups, squats, splits or dead lifts). All the exercises will be performed with their own weight. &lt;br&gt;3) Cold down: Flexibility exercises.&lt;br&gt;Adherences will daily be monitored through WhatsApp message.","a) Hydroxychloroquine or placebo to match will be administered orally once daily; 400mg (&gt;=65kg body weight) or 200mg (&lt;65kg body weight);&lt;br&gt;b) the duration of administration will be for 4 months total;&lt;br&gt;c) the mode of administration oral capsule;&lt;br&gt;d) adherence to medication administration will be done via a daily reminder text message. At the completion of the study, study drug accountability will be performed and blood analysis for  Hydroxychloroquine at baseline and completion.","Phase 1 medical device trial investigating the use of a personalised ventilation hood (McMonty hood device) for use by patients with suspected or proven infectious respiratory diseases (primarily COVID-19 suspected or confirmed patients).  This non-invasive device provides a physical barrier to droplet and aerosol spread, as well as utilising a ventilation system to reduce aerosol spread from COVID-19 or other infectious diseases.  The hood has a skirt that drapes down the sides of the bed and over the patients waist and does not seal around the patient. The hood relies upon air being drawn up the sides of the bed and from the front near the patients legs etc. up to the rear, i.e. away from the healthcare worker who is principally at the front/sides of the patient. The air passes through the fan and on through a High Efficiency Particulate Air (HEPA) filter, thereafter returning to the hospital air environment.  The device will be used continuously for 7 days or until the patient has been declared COVID-19 negative, is discharged from hospital, or elects to withdraw from the study.  Use of the device is entirely voluntary, and patients may elect to cease use of the device at any time either temporarily, or permanently.  Staff will be asked to complete simple data for each clinical shift about device compliance use.  In addition, measures to capture technical product adverse events and complaints will be captured by forms available to clinical staff and checked daily by the investigator team.  Technical product complaint data will be submitted to an independent data safety monitor team.","HDIVC group:100mg/kg/day;Control group:normal saline;","Control  group:xiaoyao capsule;Experimental group:xiaoyao capsule;","Group 2:Conventional treatment;Group 2:Conventional treatment plus liu-zi--jue exercisee therapy;","Intervention group:Lingnan Fire-Needle Therapy;Control:Health and life guidance;","Group 2:Aliskiren with Standard Care;Group 1:Nifedipine with Standard Care;","Experimental group:Jiexingjunzi granules ;control group:placebo;","Experimental group:Basic treatment + kolimycin;Control group:Basic treatment;","&lt;br&gt;                The trial will initially be two-arm, comparing usual care to usual care with hydroxychloroquine treatment.&lt;br&gt;&lt;br&gt;                The trial will be implemented in the first instance in practices that are already part of the RCGP RSC Network. Currently, over 500 practices are part of this network, with 100 already offering a sentinel viral swabbing service which is being scaled up and due to the pandemic, all practices in the UK have been asked to join the RCGP RSC Network.&lt;br&gt;&lt;br&gt;                A platform trial, in contrast to say a  traditional two-arm design, allows multiple arms to be considered simultaneously, and interventions can be dropped and replaced as evidence emerges for effectiveness or lack of it. The intent is to establish an on-going trial infrastructure within a master protocol that uses all the data already accumulated for the assessment of current and subsequently introduced interventions. New interventions will only be added after submission to the appropriate approval bodies.&lt;br&gt;&lt;br&gt;                The PRINCIPLE trial will begin as a 1:1 randomised trial of usual care plus study-specific medication (in the first instance hydroxychloroquine) versus usual care alone but the study design has the capability to add additional interventions over time. The evaluation of any new interventions will be governed by the master protocol, including adaptive and decision criteria. In addition, the inclusion of any new interventions will require supplementary appendices to the protocol and SAP.&lt;br&gt;&lt;br&gt;                The initial drug is hydroxychloroquine sulphate 200 mg tablets. The tablets are for oral administration. One tablet (200 mg) hydroxychloroquine to be taken twice daily for 7 days by mouth (14 tablets in total). This is the standard therapeutic dose for its n","&lt;br&gt;Product Name: Inhaled nitric oxide&lt;br&gt;Product Code: n.a.&lt;br&gt;Pharmaceutical Form: Inhalation solution&lt;br&gt;INN or Proposed INN: NITRIC OXIDE&lt;br&gt;CAS Number: 10102-43-9 &lt;br&gt;Other descriptive name: Nitrogen monoxide&lt;br&gt;Concentration unit: PPM part per million&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1-80&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: chloroquine&lt;br&gt;Product Code: RVG 106659&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: azithromycin&lt;br&gt;Product Code: RVG 117670&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Pharmaceutical Form: Solution for infusion in pre-filled syringe&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Anbinex&lt;br&gt;Product Name: HUMAN ANTITHROMBIN&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Antithrombin III&lt;br&gt;Other descriptive name: HUMAN ANTITHROMBIN&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: hidroxicloroquine&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-42-3&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 5-200&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kevzara 200mg&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 175-&lt;br&gt;&lt;br&gt;Trade Name: Kevzara 400mg&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;CAS Number: 1189541-98-7&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 175-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Quensyl&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;Pharmaceutical form of the placebo: Capsule&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Kineret&lt;br&gt;Product Name: Kineret&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: ANAKINRA&lt;br&gt;CAS Number: 143090-92-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: RoActemra&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled syringe&lt;br&gt;INN or Proposed INN: TOCILIZUMAB&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: SYLVANT&lt;br&gt;Product Name: SYLVANT&lt;br&gt;Pharmaceutical Form: Powder for concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Siltuximab&lt;br&gt;CAS Number: 541502-14-1&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;","Drug: Chloroquine or Hydroxychloroquine;Drug: Placebo","Drug: Aviptadil by intravenous infusion + maximal intensive care;Drug: Normal Saline Infusion + Maximal intensive care","Drug: Tocilizumab (TCZ);Drug: Placebo","Device: high flow nasal cannula (HFNC);Procedure: Prone positioning (PP)","Drug: Chloroquine analog (GNS651);Drug: Nivolumab;Drug: Tocilizumab;Other: Standard of care","Drug: Anluohuaxian","Drug: Tocilizumab;Biological: Pembrolizumab (MK-3475)","Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);Other: Placebo","Drug: Nitazoxanide 500 MG;Drug: Hydroxychloroquine","Drug: Eculizumab","Drug: Nitazoxanide Tablets;Drug: Placebo","Drug: Hydroxychloroquine Sulfate;Drug: Azithromycin Tablets","Device: Q-NRG Metobolic Cart Device;Device: MuscleSound Ultrasound;Device: Multifrequency Bioimpedance Spectroscopy","Drug: Peginterferon Lambda-1A","Biological: anti-SARS-CoV-2 convalescent plasma","Diagnostic Test: identify SARS-CoV-2 infection by serology;Biological: collection of biological samples","Biological: Convalescent COVID 19 Plasma","Drug: Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.","Drug: Sevoflurane;Drug: Intravenous drug","Biological: Convalescent plasma","Diagnostic Test: rapid salivary test","Drug: Anakinra;Drug: trimethoprim/sulfamethoxazole","Drug: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA];Drug: Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA];Drug: Best available treatment","Drug: HCQ;Drug: HCQ+AZT;Drug: Placebo","Drug: Dexamethasone injection;Drug: Placebos","Combination Product: Hydroxychloroquine plus Nitazoxanide;Other: Standard care","Biological: blood samples","Device: Cytokine Adsorption","Other: Best Practice;Biological: Tocilizumab","Drug: HB-adMSC;Drug: Placebo;Drug: HC;Drug: AZ","Drug: Tociliuzumab","Diagnostic Test: conjunctival swab","Drug: Povidone-Iodine Nasal Spray and Gargle;Drug: Povidone-Iodine Nasal Spray and Gargle","Biological: Blood plasma","&lt;br&gt;                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups:&lt;br&gt;                1. Local standard of care alone&lt;br&gt;                OR local standard of care plus one of&lt;br&gt;                2. Remdesivir (daily infusion for 10 days)&lt;br&gt;                3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)&lt;br&gt;                4. Lopinavir + ritonavir (orally twice daily for 14 days)&lt;br&gt;                5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon-beta (daily injection for 6 days)&lt;br&gt;&lt;br&gt;                Follow-up is until death or discharge from hospital.&lt;br&gt;                Randomization is performed at one central global location through an online portal.&lt;br&gt;","Experimental group:Treatment according to the seventh edition of the diagnosis and treatment guidelines + continuous implementation of health education and low oxygen consumption and rest behavior guidance for 5 days;Control group:Treatment according to the seventh edition of the diagnosis and treatment guidelines;","COVID-19 convalescent patients:Psychological crisis intervention;First-line medical staff:Psychological crisis intervention;","Group 1:Standard therapy plus aerosol inhalation for 3 times (once for every day);Group 2:Standard therapy plus aerosol inhalation for 3 times (once for every 2 days);Third group:Standard therapy;Fourth group:Standard therapy plus aerosol inhalation for 6 times (once for every day);","- Control Group: Conventional treatment Basic (conventional) treatment planned in the hospital for the management of contacts and suspects of SARS-CoV-2 infection.   - Experimental Group: Conventional treatment + CIGB 2020 vaccine Basic (conventional) treatment planned in the hospital for the management of contacts and suspects of SARS-CoV-2 infection. In addition, patients will receive treatment with the CIGB 2020 vaccine nasal (scheme 0-7-14 days) and sublingually (one daily dose for 14 days).","Group A: HeberFERON (Recombinant Interferon Alpha Gamma, 3.5 MUI), subcutaneously, twice a week for three consecutive weeks. Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b, 3.0 MUI), subcutaneously, three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra, chloroquine, azithromycin or rocefin, depending on the magnitude of respiratory symptoms.","Group I: Recombinant human interferon (IFN) alpha-2b, 1 drop (0.05 mL) in each nostril (0.5 MIU IFN alpha 2b), every 12 hours (2.0 MIU daily) for 5 consecutive days. Group II: Recombinant human interferon (IFN) alpha-2b, 3 drops (0.15 mL) sublingually (1.5 MIU IFN alpha 2b), every 12 hours (3.0 MIU daily) for 5 consecutive days. Group III: Recombinant human interferon (IFN) alpha-2b, 1 drop (0.05 mL) in each nostril (0.5 MIU IFN alpha 2b), every 6 hours (4.0 MIU daily) for 5 consecutive days. Group IV: Recombinant human interferon (IFN) alpha-2b, 5 drops (0.25 mL) sublingually (2.5 MIU IFN alpha 2b), every 12 hours (5.0 MIU daily) for 5 consecutive days. Group V: Recombinant human interferon (IFN) alpha-2b, 2 drops (0.1 mL) in each nostril (1.0 MIU IFN alpha 2b), every 8 hours (6.0 MIU daily) for 5 consecutive days. Group VI: Recombinant human interferon (IFN) alpha-2b, 12 drops (0.6 mL) diluted in 2 mL of water for injection, aerosolized (6.0 MIU IFN alpha 2b), every 12 hours (12.0 MIU daily) for 5 consecutive days.","&lt;br&gt;Product Name: Aldesleukin&lt;br&gt;Product Code: ILT101&lt;br&gt;Pharmaceutical Form: Concentrate for cutaneous solution&lt;br&gt;CAS Number: 110942-02-4&lt;br&gt;Current Sponsor code: ILT101&lt;br&gt;Other descriptive name: ALDESLEUKIN&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;Pharmaceutical form of the placebo: Concentrate for cutaneous solution&lt;br&gt;Route of administration of the placebo: Subcutaneous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: PLAQUENIL 200 MG CPR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Trade Name: KALETRA 200MG/50MG CPR&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Current Sponsor code: LOPINAVIR&lt;br&gt;Other descriptive name: LOPINAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Current Sponsor code: RITONAVIR&lt;br&gt;Other descriptive name: RITONAVIR&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: ZITHROMAX 250MG CPR&lt;br&gt;Product Name: AZITHROMYCIN&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: AZITHROMYCIN&lt;br&gt;CAS Number:  83905-01-5&lt;br&gt;Current Sponsor code: AZITHROMYCIN&lt;br&gt;Other descriptive name: AZITHROMYCIN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Product Code: CMTAd&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE&lt;br&gt;Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Concentration unit: Other&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 80000000-160000000&lt;br&gt;&lt;br&gt;Trade Name: Treatment according to clinical practice by COVID-19&lt;br&gt;Product Name: Treatment according to clinical practice (Hydroxychloroquine + Azithromycin or Lopinavir / ritonavir&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 118-42-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: not less then&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Product Name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED&lt;br&gt;Product Code: CMTAd&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;INN or Proposed INN: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE&lt;br&gt;Other descriptive name: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE&lt;br&gt;Concentration unit: DF dosage form&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 160000000-320000000&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: BCG Vaccine 'AJ Vaccines'&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Bacillus Calmette-Guerin&lt;br&gt;Other descriptive name: BACILLUS CALMETTE-GUERIN VACCINE&lt;br&gt;Concentration unit: CFU/ml colony forming unit(s)/millilitre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2 x 10_5-8 x 10_5&lt;br&gt;Pharmaceutical form of the placebo: Solution for injection&lt;br&gt;Route of administration of the placebo: Intradermal use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Product Name: UNIKINON Tablets 200mg/tab&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: CHLOROQUINE PHOSPHATE&lt;br&gt;Other descriptive name: CHLOROQUINE PHOSPHATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Plaquenil&lt;br&gt;Product Name: Plaquenil&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulphate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Other descriptive name: Remdesivir&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","Drug: Bromhexine Hydrochloride Tablets;Drug: Arbidol Hydrochloride Granules;Drug: Recombinant Human Interferon a2b Spray","Drug: Hydroxychloroquine;Other: Placebo","Drug: Losartan;Other: Placebo","Drug: DAS181","Biological: ChAdOx1 nCoV-19;Biological: MenACWY;Biological: ChAdOx1 nCoV-19 boost;Drug: Paracetamol","Drug: Sarilumab SAR153191;Drug: Placebo","Drug: Low-dose chloroquine;Drug: Mid-dose chloroquine;Drug: High-dose chloroquine;Drug: Placebo","Drug: BLD-2660","Device: Caption AI","Drug: Hydroxychloroquine - Daily Dosing;Drug: Hydroxychloroquine - Weekly Dosing;Other: Placebo oral tablet;Diagnostic Test: Monitoring Visit - Baseline;Diagnostic Test: Monitoring Visit - Week 4;Diagnostic Test: Monitoring Visit - Week 8;Other: Weekly Assessment","Drug: Gargle/Mouthwash","Drug: Sarilumab;Drug: Azithromycin;Drug: Hydroxychloroquine","Drug: Placebos;Drug: Leronlimab (700mg)","Other: Postural Positioning","Other: Self-prone position recommendation;Other: Usual care","Drug: BMS-986253","Drug: Placebos;Drug: Leronlimab (700mg)","Drug: HB-adMSCs","Drug: Hydroxychloroquine;Other: Placebo","Other: Discontinuation of ACEi/ARB;Other: Continuation of ACEi/ARB","Drug: Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment;Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment;Drug: Standard treatment","Drug: Hydroxychloroquine;Other: Placebo","Drug: Colchicine Tablets;Other: Current care per UCLA treating physicians","Drug: Dornase Alfa Inhalation Solution [Pulmozyme];Procedure: standard procedure","Drug: Measles-Mumps-Rubella Vaccine;Drug: Placebos","Other: 3D Telemedicine;Other: 2D Telemedicine","Drug: Levamisole;Drug: Isoprinosine;Drug: Levamisole and Isoprinosine","Drug: Tocilizumab Injection;Drug: Deferoxamine","Drug: Leflunomide","Biological: pathogen reduced SARS-CoV-2 convalescent plasma;Biological: Placebo","Combination Product: Azithromycin with amoxicillin/clavulanate;Drug: amoxicillin/clavulanate","Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Placebo oral tablet","Drug: Ascorbic Acid","Drug: Hydroxychloroquine plus standard preventive measures;Drug: Placebo plus standard preventive measures","Genetic: Whole Genome Analysis;Genetic: T-cell receptor (TCR) repertoire;Genetic: SARS-CoV-2 viral composition","Drug: Hydroxychloroquine and azithromycin treatment;Other: conventional management of patients","Drug: Prazosin;Other: Standard of care","Drug: Aspirin 100mg","Procedure: Direct laryngoscopy;Procedure: Vie Scope laryngoscopy","Drug: Naltrexone;Drug: Ketamine;Other: Placebo","Biological: Mesenchymal cells;Drug: Standard of care","Device: Intravenous access;Device: Intraosseous access","Procedure: CT-scan with minimal invasive autopsy","Drug: BAT + Calcifediol;Drug: BAT","Drug: Enoxaparin Prophylactic Dose;Drug: Heparin Infusion;Drug: Heparin SC;Drug: Enoxaparin/Lovenox Intermediate Dose","Other: Telemedicine;Other: Standard care","Biological: BNT162a1;Biological: BNT162b1;Biological: BNT162b2;Biological: BNT162c2;Other: Placebo","Device: Oxygen Therapy;Procedure: Physical Therapy","Drug: Azithromycin 500 milligram (mg) oral Tablet;Drug: Placebo","Behavioral: Meditation app usage","Device: V/Q Vest","Other: draw blood","Drug: Hydroxychloroquine;Drug: Placebo oral tablet","Drug: XPro1595","Drug: HCQ + Intravenous Famotidine;Drug: HCQ + Placebo","Behavioral: blood donation SMS","Biological: avdoralimab;Other: Placebo","Drug: Linagliptin 5 MG","Diagnostic Test: diagnostic tests for COVID-19 infection","Drug: Hydroxychloroquine;Dietary Supplement: Vitamin D","Diagnostic Test: CTUS examination","Device: current IPAC-UHN PPE;Device: modified IPAC-UHN PPE","Biological: BCG-Denmark;Biological: Saline","Drug: Sodium Bicarbonate","Drug: Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2)","Drug: 18F-av6-BP","Biological: exchange blood transfusion from normal donor;Biological: plasma from convalescent patients with COVID-19;Drug: Methylene Blue 5 MG/ML","Drug: Favipiravir;Drug: Hydroxychloroquine;Drug: Kaletra","Drug: Hydroxychloroquine;Drug: Hydroxychloroquine (placebo);Drug: Zinc;Drug: Zinc (Placebo)","Drug: Tocilizumab","Biological: Anti-SARS-CoV-2 Human Convalescent Plasma","Device: Volatile Organic Compounds analysis","Behavioral: Behavioral Nudges (BN)","Drug: Acalabrutinib","Behavioral: Internet-based self-help;Behavioral: Internet-based self-help after 3 weeks","Biological: Convalescent plasma;Drug: Standard of care","Other: Pulmonary and Motor Rehabilitation","Drug: Ciclesonide Inhalation Aerosol","Drug: azoximer bromide;Other: Placebo","Experimental Group:FNC+Standard of Care;Control Group:FNC dummy tablet+ Standard of Care;","Routine treatment group:Routine treatment;WMT group:Washed microbiota transplantation;","Control group:the basic treatment withThymosin enteric capsule  + Pien Tze Huang Capsules placebo;Experimental group:the basic treatment with Thymosin enteric capsule +Pien Tze Huang Capsules;","The administration of inhaled isoflurane for sedation, compared to intravenous sedation. In this pilot study, patients will intermittent receive inhaled or intravenous sedation, according to the randomisation scheme.","All participants will receive at the different time intervals through our custom-made Digital Cardiac Counselling platform different questionnaires related to the different known risk factors for the perioperative cardiac care and measured outcomes. Additional to above participants, the intervention group will receive through the Digital Cardiac Counselling platform different modules with E-counselling for risk factors evaluated in the questionnaires. Additional to known risk factors a Covid-19 module will be used as well.&lt;br&gt;Digital counselling&lt;br&gt;&lt;br&gt;The digital counselling modules for intervention group are described below:&lt;br&gt; &lt;br&gt;-Screening for reduced physical fitness. If there are signs for a decreased physical condition we will refer the patient, after consultation, for a digital intake with our physiotherapist. The patients then get access to a digital module with information and videos of physical exercise training. The patient gets a trainings schedule and we will contact the patient after about 1 and 3 weeks to check their progression and to give additional advice when needed. &lt;br&gt; &lt;br&gt;-Screening for smoking. If the patient smokes and is motivated to quit smoking, we will refer, after consultation, for a digital intake with one of our stop smoking nurses. Then, a digital and telephone supported counselling will start after an informed and shared decision making with the nurse. When needed, supportive medication can be prescribed. &lt;br&gt; &lt;br&gt;-Screening for malnutrition and obesity. If there are signs of malnutrition (MUST-score) or obesity (BMI &gt;30) we will refer the patient, after consultation, for a digital intake with a dietician. The patients then get access to a digital module with information about a healthy diet. We will contact the patient ever 2 weeks in case of malnutrition and","All COVID-19 patients with an indication for admittance to the ICU department will be included and will (after informed consent) be rondomised to receive a bolus of alkaline phosphatase of 1000iU, followed by 9000 iU the same day. For the 3 consecutive days 10.000iU/day on top of regular care.","Infotainment intervention with (social) media and influencers.","Imatinib or placebo","Patients in this study are treated with intravenous tociluzumab: 8 mg/kg (maximum dose 800 mg), which can be repeated at the same dose after 8 hours if the hypoxia has not improved. This is the approved dose for cytokine release syndrome.","&lt;br&gt;Product Name: CAPTOPRIL&lt;br&gt;Pharmaceutical Form: Concentrate for nebuliser solution&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: OXIKLORIN&lt;br&gt;Product Name:  OXIKLORIN&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: hydroxychloroquine sulphate&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;Product Name: Remdesivir&lt;br&gt;Pharmaceutical Form: Lyophilisate for solution for infusion&lt;br&gt;INN or Proposed INN: REMDESIVIR&lt;br&gt;Other descriptive name: Remdesivir&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: LOSARTAN ARROW 50 mg, comprim pellicul scable&lt;br&gt;Product Name: Losartan&lt;br&gt;Product Code: Losartan&lt;br&gt;Pharmaceutical Form: Pillules&lt;br&gt;INN or Proposed INN: LOSARTAN&lt;br&gt;CAS Number: 114798-26-4&lt;br&gt;Current Sponsor code: losartan&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: SPIRONOLACTONE ARROW 25 mg,&lt;br&gt;comprim pellicul scable&lt;br&gt;Product Name: SPIRONOLACTONE&lt;br&gt;Product Code: SPIRONOLACTONE&lt;br&gt;Pharmaceutical Form: Pillules&lt;br&gt;INN or Proposed INN: SPIRONOLACTONE&lt;br&gt;Current Sponsor code: SPIRONOLACTONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ilaris&lt;br&gt;Product Name: Canakinumab&lt;br&gt;Product Code: ACZ885&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: CANAKINUMAB&lt;br&gt;CAS Number: 914613-48-2&lt;br&gt;Current Sponsor code: CACZ885D2310&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Ilaris&lt;br&gt;Product Name: Canakinumab&lt;br&gt;Product Code: ACZ885&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: CANAKINUMAB&lt;br&gt;CAS Number: 914613-48-2&lt;br&gt;Current Sponsor code: CACZ885D2310&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 150-&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;","&lt;br&gt;Product Name: ChAdOx1 nCoV-19&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Nimenrix&lt;br&gt;Product Name: Nimenrix&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;Trade Name: Menveo&lt;br&gt;Product Name: Menveo&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Zithromax&lt;br&gt;Product Name: Zithromax&lt;br&gt;Pharmaceutical Form: Capsule&lt;br&gt;INN or Proposed INN: Azithromycin dihydrate&lt;br&gt;CAS Number: 117772-70-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: SMOFLIPID&lt;br&gt;Product Name: TPN with emulsions enriched with omega-3 fatty acid&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;INN or Proposed INN: aceite de soja, triglicridos de cadena media, aceite de oliva y aceite de pescado&lt;br&gt;CAS Number: 66581&lt;br&gt;Other descriptive name: LONG-CHAIN TRIGLYCERIDES&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: CLINOLEIC&lt;br&gt;Product Name: TPN with emulsions enriched with omega-3 fatty acid&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;INN or Proposed INN: Aceite de oliva purificado y aceite de soja purificado&lt;br&gt;CAS Number: 66971&lt;br&gt;Other descriptive name: LONG-CHAIN TRIGLYCERIDES&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;&lt;br&gt;Trade Name: OMEGAVEN&lt;br&gt;Product Name: TPN with emulsions enriched with omega-3 fatty acid&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;INN or Proposed INN: Acidos grasos omega-3&lt;br&gt;Other descriptive name: OMEGA-3-FATTY ACIDS 90&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Trade Name: NUTRIFLEX LIPID SPECIAL&lt;br&gt;Product Name: NUTRIFLEX LIPID SPECIAL&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Solucion de aminoacidos&lt;br&gt;CAS Number: 62987&lt;br&gt;Other descriptive name: ESSENTIAL AMINO ACIDS&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 56-&lt;br&gt;INN or Proposed INN: Solucion de glucosa anhidra&lt;br&gt;CAS Number: 62987&lt;br&gt;Other descriptive name: GLUCOSE ANHYDROUS PH EUR&lt;br&gt;Concentration unit: % (W/V) percent weight/volume&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 158-&lt;br&gt;INN or Proposed INN: Aceite de soja refinado y MCT&lt;br&gt;CAS Number: 62987&lt;br&gt;Other descriptive name: LONG-CHAIN TRIGLYCERIDES&lt;br&gt;Concentration unit: % (W/V) p","&lt;br&gt;Product Name: Quensyl&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Kaletra&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: LOPINAVIR&lt;br&gt;CAS Number: 192725-17-0&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: RITONAVIR&lt;br&gt;CAS Number: 155213-67-5&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;&lt;br&gt;Trade Name: Xarelto&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: RIVAROXABAN&lt;br&gt;CAS Number: 366789-02-8&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Candesartan&lt;br&gt;Other descriptive name: CANDESARTAN CILEXETIL&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 4-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: RoActemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Infusion&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Product Name: Tocilizumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: Tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 162-&lt;br&gt;&lt;br&gt;Trade Name: Kevzara&lt;br&gt;Product Name: Sarilumab&lt;br&gt;Pharmaceutical Form: Solution for injection in pre-filled pen&lt;br&gt;INN or Proposed INN: SARILUMAB&lt;br&gt;Other descriptive name: Kevzara&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Roactemra&lt;br&gt;Product Name: roactemra&lt;br&gt;Pharmaceutical Form: Injection&lt;br&gt;INN or Proposed INN: tocilizumab&lt;br&gt;CAS Number: 375823-41-9&lt;br&gt;Current Sponsor code: L04AC07&lt;br&gt;Other descriptive name: TOCILIZUMAB&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 8-16&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Urbason/Metilprednisolona&lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: METHYLPREDNISOLONE&lt;br&gt;CAS Number: 83-43-2&lt;br&gt;Current Sponsor code: -&lt;br&gt;Other descriptive name: METHYLPREDNISOLONE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 20-40&lt;br&gt;&lt;br&gt;","&lt;br&gt;Trade Name: Sandimmun Neoral 25 mg cpsulas blandas&lt;br&gt;Sandimmun Neoral 50 mg cpsulas blandas&lt;br&gt;Sandimun Neoral 100 mg cpsulas blandas&lt;br&gt;Pharmaceutical Form: Capsule, soft&lt;br&gt;INN or Proposed INN: CICLOSPORIN&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 25-100&lt;br&gt;&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Hydroxychloroquine&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;Trade Name: Dolquine 200 mg comprimidos recubiertos&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: HYDROXYCHLOROQUINE&lt;br&gt;CAS Number: 747-36-4&lt;br&gt;Other descriptive name: HYDROXYCHLOROQUINE SULFATE&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;&lt;br&gt;"],["Phase 4","N/A","0","N/A","0","0","0","Phase 4","Phase 2/Phase 3","0","0","0","Phase 4","4","0","4","0","N/A","N/A","4","4","N/A","0","4","4","0","0","4","0","N/A","0","0","0","0","0","0","0","0","0","0","0","0","4","N/A","N/A","0","0","N/A","N/A","0","N/A","0","4","4","N/A","N/A","N/A","0","4","0","4","4","N/A","0","0","4","4","N/A","0","0","4","0","4","0","0","0","0","0","0","0","4","0","4","N/A","4","0","N/A","0","Phase 2","N/A","N/A","0","0","2","0","4","0","0","New Treatment Measure Clinical Study","0","0","N/A","0","4","0","0","4","4","4","4","0","Phase 4","N/A","N/A","3","Phase 2","New Treatment Measure Clinical Study","N/A","0","0","N/A","N/A","4","3","N/A","4","0","N/A","0","4","4","0","1-2","4","New Treatment Measure Clinical Study","N/A","0","N/A","0","4","4","N/A","1","N/A","N/A","0","0","0","Phase 1/Phase 2","N/A","Phase 2","Phase 2","0","0","0","N/A","N/A","0","0","0","0","0","N/A","2","4","4","4","N/A","4","0","4","N/A","N/A","N/A","Retrospective study","N/A","2","0","0","Phase 1","4","0","N/A","Phase 3","0","N/A","0","4","0","0","N/A","0","0","N/A","4","Early Phase 1","0","0","0","0","N/A","0","0","0","0","0","\n                Human pharmacology (Phase I): no\n                Therapeutic exploratory (Phase II): no\n                Therapeutic confirmatory - (Phase III): yes\n                Therapeutic use (Phase IV): no\n","Early Phase 1","N/A","0","N/A","N/A","N/A","4","1","New Treatment Measure Clinical Study","4","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","Phase 1/Phase 2","Phase 2/Phase 3","N/A","Phase 2","Phase 2","4","Phase 2/Phase 3","4","0","N/A","4","N/A","0","N/A","0","0","0","0","N/A","0","0","4","4","1","0","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","4","0","0","0","Phase 2","0","N/A","N/A","N/A","4","0","0","0","Phase 1","N/A","4","N/A","0","4","N/A","N/A","Phase 4","Phase 2/Phase 3","N/A","2-3","Early Phase 1","Phase 4","Phase 3","1","0","1","N/A","Phase 2/Phase 3","0","0","4","2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","N/A","Phase 3","N/A","N/A","Retrospective study","0","Phase 1/Phase 2","Phase 1","N/A","4","Phase 4","N/A","4","0","Phase 2","0","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","N/A","N/A","N/A","0","Phase 2","Phase 1/Phase 2","4","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Phase 2/Phase 3","1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","N/A","4","Phase 4","Phase 3","Phase 3","Phase 2","Phase 2","N/A","Phase 2","N/A","Phase 2","Phase 1 / Phase 2","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","2","4","Phase 3","Phase 2","N/A","N/A","Phase 2","Early Phase 1","N/A","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","Phase 4","Phase 1/Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Human pharmacology (Phase I): \nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): \nTherapeutic use (Phase IV): no\n","Phase 4","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1/Phase 2","Phase 4","Phase 2","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","0","N/A","N/A","Phase 2","Phase 3","0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 1/Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 3","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Phase 2","Early Phase 1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","N/A","N/A","Phase 2","Phase 2","Not Applicable","Not Applicable","N/A","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","N/A","N/A","3","2","N/A","N/A","Phase-3","0","N/A","N/A","4","Not Applicable","Phase 1","Phase 3","Not Applicable","Phase 2","Phase 1","3","Phase 2","Phase 4","3","Phase 4","N/A","0","Phase 3","Phase 3","Phase 2/Phase 3","Phase 2/Phase 3","Phase 1/Phase 2","Phase 3","N/A","Phase 3","N/A","Phase 2","Phase 1","N/A","Phase 2","N/A","Phase 3","N/A","N/A","Phase 1","N/A","N/A","Phase 3","Phase 3","Phase 3","N/A","Phase 2","Phase 2","Phase 2/Phase 3","Phase 4","Phase 2/Phase 3","N/A","N/A","Phase 3","Phase 3","Phase 4","N/A","N/A","Phase 3","Phase 2/Phase 3","Phase 3","Phase 2","Phase 2","N/A","Phase 2","N/A","N/A","Phase 3","Phase 2","Phase 3","Early Phase 1","N/A","N/A","Phase 2","Phase 2","N/A","Phase 2","Phase 2","Phase 1/Phase 2","Phase 2","Phase 4","1","N/A","Phase 2/Phase 3","Phase 3","Phase 2/Phase 3","N/A","Phase 2","Phase 3","Phase 1/Phase 2","Phase 2","N/A","Phase 3","Phase 1/Phase 2","Phase 3","N/A","N/A","Phase 2","0","Phase 2","Phase 3","Phase 2","Phase 2","Phase 2","N/A","N/A","Phase 2","Phase 2","Not Applicable","N/A","N/A","N/A","N/A","Phase 3","Phase 2","Phase 2","Phase 2/Phase 3","N/A","N/A","Phase 3","Phase 2","Phase 4","Phase 2","Phase 1","N/A","Phase III","Early Phase 1","Phase 2/Phase 3","Phase 3","Phase 3","Phase 2","Not Applicable","N/A","Phase 2","Phase 3","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 4","N/A","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","N/A","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2/Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 4","Phase 2","Phase 1","Phase 3","Phase 1","Phase 3","Phase 3","N/A","Phase 1","Phase 3","N/A","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Phase 2/Phase 3","Early Phase 1","Early Phase 1","Early Phase 1","Phase 2","Phase 2/Phase 3","Phase 2","Phase 1","Phase 3","Phase 3","Phase 1","N/A","Phase 3","N/A","N/A","N/A","Phase 1","Phase 2","Phase 3","Phase 2","Phase 2","Phase 2/Phase 3","Phase 2","Phase 2/Phase 3","Phase 3","Phase 2/Phase 3","Phase 4","Phase 2/Phase 3","Phase 2/Phase 3","Phase 2","N/A","Phase 2","N/A","Phase 1/Phase 2","Phase 2","Phase 3","Phase 3","Phase 2","4","Phase 3","Phase 2","Phase 1/Phase 2","Phase 2","Phase 2","0","N/A","Phase 2","Phase 2","Phase 1","Phase 4","Phase 4","Phase 2/Phase 3","0","Phase 3","1-2","Phase 2","Phase 2","Phase 2","N/A","Phase 2/Phase 3","Phase 3","4","Phase 3","N/A","Phase 2/Phase 3","Phase 3","N/A","N/A","N/A","N/A","Phase 3","4","Phase 3","Phase 4","Phase 3","Phase 2","N/A","N/A","N/A","N/A","Phase 2/Phase 3","Phase 2","Phase 1","Phase 4","Phase 3","Phase 2","Phase 2","Phase 2","N/A","N/A","Phase 3","N/A","N/A","Phase 2","Not Applicable","Phase 2","N/A","Phase 3","Phase 3","Not Applicable","0","Phase 3","4","Phase 3","Phase II","Phase 2","N/A","N/A","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1/Phase 2","Phase 1","1-2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","N/A","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Not Applicable","Phase 3","Phase 3","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","0","Phase 3","Phase 3","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 2","Phase 3","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Phase 4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 1","Phase 1/Phase 2","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 4","Phase 2","Phase 2","Phase 1","Phase 3","Phase 2/Phase 3","Phase 1/Phase 2","Phase 2/Phase 3","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 2","Phase 3","Phase 2","Phase 1/Phase 2","Phase 2/Phase 3","Phase 1/Phase 2","N/A","Phase 2/Phase 3","Phase 3","Phase 2/Phase 3","Phase 2","Phase 2","Phase 2","Phase 3","Phase 4","N/A","N/A","Phase 2","Phase 2","Phase 1/Phase 2","Phase 4","Phase 1","N/A","Phase 2","N/A","Phase 4","Phase 2","N/A","Phase 3","Phase 2","Phase 2","Phase 3","N/A","N/A","Phase 3","N/A","Phase 2","Phase 2","Phase 2","N/A","Phase 4","Phase 4","Phase 2","N/A","Phase 2","N/A","Phase 3","Phase 3","0","N/A","Phase 1","Phase 3","Phase 3","Phase 2","Phase 1/Phase 2","Phase 2/Phase 3","Phase 2","Phase 2","N/A","Phase 2","N/A","N/A","Phase 3","Phase 1/Phase 2","Phase 1/Phase 2","Phase 1/Phase 2","N/A","Phase 2","N/A","N/A","Phase 1/Phase 2","Phase 2/Phase 3","Phase 2","N/A","Phase 2","Phase 1/Phase 2","N/A","Phase 2","Phase 3","Phase 1/Phase 2","N/A","Phase 4","N/A","N/A","Phase 3","Phase 3","N/A","Phase 2","N/A","N/A","N/A","N/A","N/A","Phase 3","Phase 4","N/A","N/A","Phase 4","Phase 1","Phase 3","Early Phase 1","Phase 2","Phase 4","Phase 1","Phase 2/Phase 3","N/A","Phase 3","N/A","N/A","Phase 2","Phase 1","N/A","Phase 2","Phase 3","N/A","2","N/A","Early Phase 1","N/A","Phase 3","Phase 3","N/A","N/A","0","Phase 1","Phase 1","N/A","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 2","Phase 4","Phase 3","Phase 3","N/A","N/A","N/A","Phase 2/Phase 3","N/A","Not Applicable","Phase 3","N/A","N/A","Phase 2","Phase 2","N/A","N/A","Phase 2","Phase 2/Phase 3","N/A","N/A","0","Phase 3","N/A","Phase 2","N/A","Phase 4","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Phase 2","N/A","2","N/A","Phase 2","Phase 2","Phase 2","N/A","Phase 2","Phase 2/Phase 3","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","N/A","Phase 2","Phase 2","Phase 2","Phase 2","N/A","Phase 1/Phase 2","Phase 3","Phase 2","Phase 4","Phase 2","N/A","Phase 3","N/A","N/A","Phase 2","N/A","Phase 4","Phase 1/Phase 2","Phase 3","Phase 2/Phase 3","Phase 2","Phase 2","Phase 1","Phase 3","N/A","N/A","Not Applicable","Not Applicable","0","N/A","Phase 1/Phase 2","Phase 4","N/A","Not Applicable","N/A","Phase 2","N/A","Phase 1/Phase 2","N/A","N/A","Phase 2","Phase 3","N/A","Not Applicable","Phase 2/Phase 3","N/A","Phase 2","Phase 2/Phase 3","Phase 2","Phase II/III","Phase 2","Phase 1/Phase 2","Phase 2","Phase 2","0","Phase 2","N/A","N/A","N/A","Not Applicable","Retrospective study","1-2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n",null,null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n",null,"Phase 3","Phase 2",null,"Phase 2","Phase 3","Phase 4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 4","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","N/A","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 2","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Phase 3","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Not Applicable","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Phase 0","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","0","0","N/A","4","4","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","2","2","Phase 1/Phase 2","Phase 1","Phase 2/Phase 3","Phase 2","Phase 3","Phase 2/Phase 3","N/A","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2","Phase 3","Phase 2/Phase 3","Phase 4","Phase 3","Phase 2","Phase 3","Phase 1/Phase 2","Phase 2","Phase 2","Phase 2/Phase 3","N/A","Phase 4","Phase 2","Phase 3","Phase 1","N/A","Phase 2/Phase 3","Phase 2","Phase 4","Not Applicable","Phase 2 / Phase 3","Not Applicable","New Treatment Measure Clinical Study","N/A","N/A","0","0","0","0","Phase III","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Phase 2","Phase 3","N/A","Phase 2","N/A","Phase 2","Phase 2","Phase 4","Phase 2","N/A","Early Phase 1","N/A","Phase 2","Phase 2","N/A","Early Phase 1","Phase 2","Phase 3","Phase 2","N/A","Phase 2","Phase 2","Phase 3","Phase 2","Phase 2/Phase 3","N/A","N/A","Phase 3","Phase 2","Phase 2","N/A","Phase 2","N/A","Phase III","N/A","0","0","1-2","2","1","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): yes\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","N/A","Phase 3","Phase 2","N/A","Phase 1/Phase 2","Phase 2/Phase 3","Phase 3","Phase 2","N/A","Phase 3","N/A","Phase 2/Phase 3","Phase 2","N/A","N/A","Phase 2","Phase 2","Phase 2","Phase 2/Phase 3","N/A","Phase 3","Phase 2/Phase 3","Phase 2","Phase 3","Phase 3","N/A","Phase 3","Phase 3","Phase 1","Phase 3","Phase 3","Phase 3","Phase 2","Phase 3","N/A","Phase 3","Phase 2","Phase 2/Phase 3","N/A","Phase 2","Phase 2","N/A","N/A","Phase 2","Phase 4","N/A","Phase 1/Phase 2","N/A","Phase 2","N/A","N/A","N/A","N/A","Phase 2","Phase 3","N/A","Phase 2","Phase 3","N/A","Phase 3","N/A","N/A","Phase 3","Early Phase 1","Phase 1","Early Phase 1","Phase 2","N/A","Phase 3","Phase 2","Phase 1","N/A","N/A","Phase 2","N/A","Phase 2/Phase 3","N/A","Phase 2","Phase 2/Phase 3","N/A","0","0",null,null,null,null,null,null,"Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): yes\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): yes\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): no\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n","Human pharmacology (Phase I): no\nTherapeutic exploratory (Phase II): no\nTherapeutic confirmatory - (Phase III): no\nTherapeutic use (Phase IV): yes\n"],[0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,null,null,0,null,0,0,null,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,null,null,null,null,null,null,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,null,null,0,null,0,0,null,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,null,null,null,null,null,null,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,null,null,1,null,0,1,null,1,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,null,null,null,null,null,null,1,0,1,0,0,1,1,0,1,1,1,0,0],[0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,null,null,0,null,1,0,null,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,null,null,null,null,null,null,0,1,0,1,1,1,0,0,0,0,0,0,0],[1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,null,null,0,null,0,0,null,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,null,null,null,null,null,null,0,0,0,0,0,0,0,1,0,0,0,1,1],[0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,null,null,0,null,0,0,null,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,null,null,null,null,null,null,0,0,0,0,0,0,0,0,0,0,0,0,0],[4,null,0,null,0,0,0,4,3,0,0,0,4,4,0,4,0,null,null,4,4,null,0,4,4,0,0,4,0,null,0,0,0,0,0,0,0,0,0,0,0,0,4,null,null,0,0,null,null,0,null,0,4,4,null,null,null,0,4,0,4,4,null,0,0,4,4,null,0,0,4,0,4,0,0,0,0,0,0,0,4,0,4,null,4,0,null,0,2,null,null,0,0,2,0,4,0,0,null,0,0,null,0,4,0,0,4,4,4,4,0,4,null,null,3,2,null,null,0,0,null,null,4,3,null,4,0,null,0,4,4,0,2,4,null,null,0,null,0,4,4,null,1,null,null,0,0,0,2,null,2,2,0,0,0,null,null,0,0,0,0,0,null,2,4,4,4,null,4,0,4,null,null,null,null,null,2,0,0,1,4,0,null,3,0,null,0,4,0,0,null,0,0,null,4,1,0,0,0,0,null,0,0,0,0,0,3,1,null,0,null,null,null,4,1,null,4,0,3,0,2,3,null,2,2,4,3,4,0,null,4,null,0,null,0,0,0,0,null,0,0,4,4,1,0,0,2,4,0,0,0,2,0,null,null,null,4,0,0,0,1,null,4,null,0,4,null,null,4,3,null,3,1,4,3,1,0,1,null,3,0,0,4,2,3,4,3,null,3,null,null,null,0,2,1,null,4,4,null,4,0,2,0,null,4,4,2,0,null,null,null,0,2,2,4,0,3,3,3,0,4,3,2,3,3,1,3,3,null,3,null,null,4,4,3,3,2,2,null,2,null,2,2,3,2,3,4,2,4,3,2,null,null,2,1,null,3,3,null,3,0,4,2,3,3,2,4,2,3,2,null,2,2,4,2,3,3,null,3,0,0,null,null,2,3,0,3,3,2,2,4,2,3,3,2,2,3,3,null,2,2,2,2,3,2,1,2,3,3,4,null,null,2,2,null,null,null,2,4,null,3,2,null,3,null,3,null,4,4,1,2,2,3,2,3,4,2,null,4,2,3,2,3,3,null,null,3,2,null,null,3,0,null,null,4,null,1,3,null,2,1,3,2,4,3,4,null,0,3,3,3,3,2,3,null,3,null,2,1,null,2,null,3,null,null,1,null,null,3,3,3,null,2,2,3,4,3,null,null,3,3,4,null,null,3,3,3,2,2,null,2,null,null,3,2,3,1,null,null,2,2,null,2,2,2,2,4,1,null,3,3,3,null,2,3,2,2,null,3,2,3,null,null,2,0,2,3,2,2,2,null,null,2,2,null,null,null,null,null,3,2,2,3,null,null,3,2,4,2,1,null,null,1,3,3,3,2,null,null,2,3,3,2,3,2,3,4,null,null,null,4,null,2,2,2,3,3,4,2,null,null,3,3,2,2,2,4,2,1,3,1,3,3,null,1,3,null,2,2,2,2,null,3,1,1,1,2,3,2,1,3,3,1,null,3,null,null,null,1,2,3,2,2,3,2,3,3,3,4,3,3,2,null,2,null,2,2,3,3,2,4,3,2,2,2,2,0,null,2,2,1,4,4,3,0,3,2,2,2,2,null,3,3,4,3,null,3,3,null,null,null,null,3,4,3,4,3,2,null,null,null,null,3,2,1,4,3,2,2,2,null,null,3,null,null,2,null,2,null,3,3,null,0,3,4,3,null,2,null,null,null,null,2,2,3,2,null,2,null,2,2,1,2,2,2,4,3,2,3,null,null,4,3,2,2,null,3,3,2,3,3,3,3,0,3,3,2,2,2,2,3,2,null,4,2,1,2,3,2,4,2,2,1,3,3,2,3,2,2,2,2,2,2,3,2,2,3,2,null,3,3,3,2,2,2,3,4,null,null,2,2,2,4,1,null,2,null,4,2,null,3,2,2,3,null,null,3,null,2,2,2,null,4,4,2,null,2,null,3,3,0,null,1,3,3,2,2,3,2,2,null,2,null,null,3,2,2,2,null,2,null,null,2,3,2,null,2,2,null,2,3,2,null,4,null,null,3,3,null,2,null,null,null,null,null,3,4,null,null,4,1,3,1,2,4,1,3,null,3,null,null,2,1,null,2,3,null,2,null,1,null,3,3,null,null,0,1,1,null,3,3,2,4,3,3,null,null,null,3,null,null,3,null,null,2,2,null,null,2,3,null,null,0,3,null,2,null,4,2,2,2,2,null,2,null,2,null,2,2,2,null,2,3,3,2,null,null,2,2,2,2,null,2,3,2,4,2,null,3,null,null,2,null,4,2,3,3,2,2,1,3,null,null,null,null,0,null,2,4,null,null,null,2,null,2,null,null,2,3,null,null,3,null,2,3,2,null,2,2,2,2,0,2,null,null,null,null,null,2,2,null,null,2,null,3,2,null,2,3,4,4,4,null,2,2,null,2,3,2,null,3,2,2,2,3,3,3,2,3,3,3,2,3,2,3,2,2,4,2,4,3,2,3,3,3,3,null,2,null,2,0,2,0,0,null,4,4,3,3,4,4,2,2,2,1,3,2,3,3,null,2,2,3,2,2,3,3,4,3,2,3,2,2,2,3,null,4,2,3,1,null,3,2,4,null,3,null,null,null,null,0,0,0,0,null,4,4,3,2,2,3,2,2,3,null,2,3,null,2,null,2,2,4,2,null,1,null,2,2,null,1,2,3,2,null,2,2,3,2,3,null,null,3,2,2,null,2,null,null,null,0,0,2,2,1,2,3,2,3,2,3,null,3,2,null,2,3,3,2,null,3,null,3,2,null,null,2,2,2,3,null,3,3,2,3,3,null,3,3,1,3,3,3,2,3,null,3,2,3,null,2,2,null,null,2,4,null,2,null,2,null,null,null,null,2,3,null,2,3,null,3,null,null,3,1,1,1,2,null,3,2,1,null,null,2,null,3,null,2,3,null,0,0,null,null,null,null,null,null,2,3,2,3,3,3,2,4,2,2,2,4,4],[0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,null,null,0,null,0,0,null,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,null,null,null,null,null,null,0,0,0,0,0,1,0,0,0,0,0,0,0],[1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1],[0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0],[1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0],[0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1],[0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0],[0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1],[0,0,1,1,1,1,1,0,0,1,0,1,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,0,0,1,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0],[0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0],[0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0],[0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>TrialID<\/th>\n      <th>Scientific title<\/th>\n      <th>Countries<\/th>\n      <th>Intervention<\/th>\n      <th>Phase<\/th>\n      <th>fase0<\/th>\n      <th>fase1<\/th>\n      <th>fase2<\/th>\n      <th>fase3<\/th>\n      <th>fase4<\/th>\n      <th>faseNULL<\/th>\n      <th>fase_maxima<\/th>\n      <th>multiplas_fases<\/th>\n      <th>grupo_drogas<\/th>\n      <th>grupo_outros_tratamentos<\/th>\n      <th>grupo_no_identificado<\/th>\n      <th>grupo_preveno<\/th>\n      <th>categoria_antivirais<\/th>\n      <th>categoria_antimalrico<\/th>\n      <th>categoria_plasma_de pessoas curadas<\/th>\n      <th>categoria_medicina_tradicional chinesa<\/th>\n      <th>categoria_no_identificado<\/th>\n      <th>categoria_outras_drogas<\/th>\n      <th>categoria_corticides<\/th>\n      <th>categoria_outras_formas de preveno<\/th>\n      <th>categoria_clulas-tronco<\/th>\n      <th>categoria_testes<\/th>\n      <th>categoria_ventilao_pulmonar<\/th>\n      <th>categoria_comportamental_ou atividade fsica<\/th>\n      <th>categoria_anti-inflamatrio<\/th>\n      <th>categoria_anticorpos_monoclonais<\/th>\n      <th>categoria_inibidores_de enzimas do tipo quinases<\/th>\n      <th>categoria_nk_cells<\/th>\n      <th>categoria_vacinas<\/th>\n      <th>categoria_antibiticos<\/th>\n      <th>categoria_imunomoduladores<\/th>\n      <th>substancia_arbidol_(umifenovir)<\/th>\n      <th>substancia_cloroquina_ou hidroxicloroquina<\/th>\n      <th>substancia_no_identificado<\/th>\n      <th>substancia_outras_drogas<\/th>\n      <th>substancia_corticides<\/th>\n      <th>substancia_lopinavir/ritonavir<\/th>\n      <th>substancia_outros_antivirais<\/th>\n      <th>substancia_azvudine<\/th>\n      <th>substancia_interferon<\/th>\n      <th>substancia_anti-inflamatrio<\/th>\n      <th>substancia_tocilizumab_ou sarilumab<\/th>\n      <th>substancia_favipiravir<\/th>\n      <th>substancia_inibidores_de enzimas do tipo quinases<\/th>\n      <th>substancia_outros_anticorpos monoclonais<\/th>\n      <th>substancia_remdesivir<\/th>\n      <th>substancia_anakinra<\/th>\n      <th>substancia_azithromycin<\/th>\n      <th>substancia_imunomoduladores<\/th>\n      <th>substancia_outros_antibiticos<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"Bfrtip","buttons":["csv","excel"],"columnDefs":[{"className":"dt-right","targets":[6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55]},{"orderable":false,"targets":0}],"order":[],"autoWidth":false,"orderClasses":false}},"evals":[],"jsHooks":[]}</script>
</div>
<div id="critrios-de-classificao" class="section level3">
<h3>Critrios de classificao</h3>
<div class="knitr-options" data-fig-width="576" data-fig-height="460">

</div>
<div id="htmlwidget-65b05ef460af5a83df68" style="width:100%;height:auto;" class="datatables html-widget"></div>
<script type="application/json" data-for="htmlwidget-65b05ef460af5a83df68">{"x":{"filter":"none","caption":"<caption>**regex** = regular expression (padres textuais); **variavel** = onde o padro  buscado: Intervention ou Scientific title+Intervention (\"concat\")<\/caption>","fillContainer":true,"data":[["1","2","3","4","5","6","7","8","9","10","11","12","13","14","15","16","17","18","19","20","21","22","23","24","25","26"],["Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Drogas","Outros tratamentos","Outros tratamentos","Outros tratamentos","Outros tratamentos","Outros tratamentos","Outros tratamentos","Preveno","Preveno","Preveno"],["Anticorpos monoclonais","Anticorpos monoclonais","Antimalrico","Antivirais","Antivirais","Antivirais","Antivirais","Antivirais","Antivirais","Anti-inflamatrio","Corticides","Antibiticos","Antibiticos","Inibidores de enzimas do tipo quinases","Imunomoduladores","Outras drogas","Outras drogas","Clulas-Tronco","Medicina Tradicional Chinesa","Plasma de pessoas curadas","Ventilao Pulmonar","NK cells","Comportamental ou atividade fsica","Vacinas","Testes","Outras formas de preveno"],["tocilizumab ou sarilumab","outros anticorpos monoclonais","cloroquina ou hidroxicloroquina","favipiravir","lopinavir/ritonavir","remdesivir","azvudine","arbidol (Umifenovir)","outros antivirais","Anti-inflamatrio","corticides","azithromycin","outros antibiticos","Inibidores de enzimas do tipo quinases","Imunomoduladores","Interferon","Anakinra",null,null,null,null,null,null,null,null,null],["concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","concat","Intervention","concat","concat","concat"],["(tocilizu|sarilu)mab","(bevacizu|Eculizu|Leronli|Siltuxi|Clazakizu|Mavrilimu|Meplazu|Nivolu)mab","(h[iy]drox[iy])?c(h)?loroquin[ea]","Favipiravir","Lopinavir(( )?/( )?| | and | + )Ritonavir","(remdezi|remdesi)vir","Azvudine","A(r)?bidol|Umifenovir","(Oseltami|daruna|danopre|tenofo|Galidesi)vir|antiviral|ASC(-)?09|TMC[ -]?310911|cobicistat|emtricitabine|Ganovo|Ribavirin","(Naprox|Ibuprof|Aspir)[ei]n|Colchicine|Xiyanping|Jakotinib|Glycyrrhizinate","(cortic|ster)oid(s)?|(Methylprednisol|Dexamethas)one","Azithromycin","(Amoxicill|Moxifloxac|Levofloxac)in","((Barici|Ruxoli|Acalabru|Ima|Tofaci)ti|Nintenda)nib","Immunomodul","Interferon","Anakinra","(stem|mononuclear) cell","TCM|traditional chinese|traditional medicine|herb(s|al)?|Tanreqing|ba(-)?bao(-)?dan|reduning|RDN|Qing-Wen|Bai-Du-Yin|Shuang-Huang-Lian|Huo-Shen|Xue-Bi-Jing","plasma|immunoglobulin","ventilat|intubat|oxid|Inhalation|nitric oxide|chlorine dioxide|oxygen|NORS","NK cell","behavior|mindful|exercise","vaccin(e)?","test|diagnos|detect","prevent"]],"container":"<table class=\"display fill-container\">\n  <thead>\n    <tr>\n      <th> <\/th>\n      <th>grupo<\/th>\n      <th>categoria<\/th>\n      <th>substancia<\/th>\n      <th>variavel<\/th>\n      <th>regex<\/th>\n    <\/tr>\n  <\/thead>\n<\/table>","options":{"scrollY":"100vh","dom":"tip","order":[],"autoWidth":false,"orderClasses":false,"columnDefs":[{"orderable":false,"targets":0}]}},"evals":[],"jsHooks":[]}</script>
<!-- ### Drogas EUA  -->
<!-- ```{r} -->
<!-- DT::datatable(drugs_grupos_count,   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ```    -->
<!-- ### Nomes de substncias UE -->
<!-- ```{r} -->
<!-- DT::datatable(eu_substance_count,   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ``` -->
<!-- ### Dados EUA -->
<!-- ```{r} -->
<!-- DT::datatable(eua, filter = "top",   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ```    -->
<!-- ### Dados China -->
<!-- ```{r} -->
<!-- DT::datatable(china, filter = "top", -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ``` -->
<!-- ### Dados UE -->
<!-- ```{r} -->
<!-- DT::datatable(eu_data, filter = "top",   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ```    -->
<!-- ### Dados OMS -->
<!-- ```{r} -->
<!-- DT::datatable(select(oms, -`Inclusion Criteria`, -`Exclusion Criteria`),  -->
<!--               filter = "top",   -->
<!--               extensions = 'Buttons', -->
<!--               options = list( -->
<!--                     dom = 'Bfrtip', -->
<!--                     buttons = c('csv', 'excel')) -->
<!--               ) -->
<!-- ``` -->
</div>
</div>

</div>

<script>

$(document).ready(function () {

  // add bootstrap table styles to pandoc tables
  $('tr.header').parent('thead').parent('table').addClass('table table-condensed');

  // initialize mathjax
  var script = document.createElement("script");
  script.type = "text/javascript";
  script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
  document.getElementsByTagName("head")[0].appendChild(script);

});
</script>

<script type="text/javascript">
$(document).ready(function () {
  FlexDashboard.init({
    theme: "cosmo",
    fillPage: true,
    orientation: "columns",
    storyboard: false,
    defaultFigWidth: 576,
    defaultFigHeight: 460,
    defaultFigWidthMobile: 360,
    defaultFigHeightMobile: 460
  });
});
</script>

</body>
</html>
